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Summary
Endocrine disruption can affect health and reproduction of humans and
wildlife and has therefore become a topic of high concern for authorities
and politicians alike. In environmental risk assessment, the current ap-
proach for the evaluation of endocrine disruption relies mostly on data
of long-term reproductive and animal intensive studies, which are time
consuming and cost intensive and ethically disputable. Thus, there is an
increasing demand for alternative testing approaches. This thesis intended
to examine the suitability of fish embryo tests as an alternative approach
to testing endocrine disruptive chemicals (EDC). Although fish embryos
still lack reproductive organs, disallowing that endocrine disruption spe-
cific effects can manifest morphologically, endocrine genes have been re-
ported to be responsive to endocrine disruptors already at the embryonic
stage. It was therefore hypothesized that gene expression analysis could
be a tool for the detection and evaluation of endocrine disruption in fish
embryos. To corroborate this hypothesis, several endocrine compounds
of known or suspected estrogenic or anti-androgenic mode of action were
tested on fish embryos to evaluate the impact on gene expression. Two com-
mon ecotoxicological fish species, zebrafish and medaka, were compared to
investigate species-specific differences in the responses and to elaborate
possible species-related advantages for EDC testing. For zebrafish, mi-
croarray technology was applied to analyse responses of the transcriptome
to estrogens and anti-androgens. Due to the unavailability of a compara-
ble microarray for medaka, the analysis was limited to the expression of
representative genes of the hypothalamic-pituitary-gonadal axis and addi-
tionally, for comparative reasons, of selected significantly changed genes as
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identified in the zebrafish microarray results. For 48hpf (hours post fer-
tilization) zebrafish embryos, clearly distinguishable transcriptome profiles
were found for the two reference compounds 17α-ethinylestradiol (EE2, es-
trogen receptor agonist) and flutamide (androgen receptor antagonist). In
particular, EE2 induced gene pathways related to developmental processes,
including growth promotion, Hox gene regulation and endocrine signaling,
specifically disruption of steroidogenesis and the induction of established
biomarkers vitellogenin and aromatase b. The response to flutamide expo-
sure was less pronounced in the zebrafish embryos than for EE2. Never-
theless, the induction of several endocrine relevant pathways was detected,
which were related mainly to the neuronal regulation of the hypothalamic-
pituitary-gonadal axis. For the other endocrine disruptors tested, the com-
parison of the transcriptome profiles to the reference compounds allowed
a categorization in acting chemicals. The gene response of bisphenol A
and propanil was predominantly estrogenic and anti-androgenic, respec-
tively. Genistein, linuron and prochloraz exhibited multiple modes of ac-
tions, revealing estrogenic as well as anti-androgenic mechanisms. Methyl-
paraben showed a contrary response to EE2 and was therefore assumed to
act anti-estrogenic. Apart from the induction of the biomarker aromatase
b (cyp19a1b) and vitellogenin 1 (vtg1 ), estrogenic mechanisms included
the expression of growth- as well as isoprenoid- and cholesterol synthesis
related genes, suggesting a possible marker function for these genes. The
regulation of neuroendocrine pathways in flutamide and the further tested
suspected anti-androgens linuron and prochloraz implied a potential anti-
androgenic marker function for related genes. Given the little pronounced
gene response to the anti-androgenic reference compound, the expression of
known endocrine marker and androgen signaling related genes in response
to flutamide was examined after a prolonged exposure to 96hpf, in order to
test whether a stronger anti-androgenic response can be retrieved in a later
developmental stage. Indeed the downregulation of the androgen receptor,
gonadotropin releasing hormone receptor 2 as well the upregulation of es-
trogen receptor 2a, cyp19a1b and vtg1 could be identified after 96h exposure
Summary xvii
to flutamide in zebrafish, favoring the use of 96hpf zebrafish embryos over
48hpf embryos for testing anti-androgenic disruptors. Next, the zebrafish
results were compared to medaka. The EE2 response was in mostly line
with the corresponding transcriptome data for zebrafish, despite of the reg-
ulation of the steroid receptors, which was different in medaka. Different
was also the response to flutamide. The same genes were found responsive
in medaka and zebrafish, but their regulation was opposite. In addition, the
regulation of established anti-androgenic marker 11β-hydroxylase (cyp11b)
and 3-beta-hydroxysteroid dehydrogenase (3β-hsd) was unique to medaka.
Thus, the use of both fish species elicited species- and exposure time-
specific variations in the response to flutamide. In conclusion, this thesis
has demonstrated how estrogenic and anti-androgenic disruption mani-
fests in fish embryos at the transcriptome level. Gene expression analysis
allowed not only the detection of endocrine disruption, but even provided
information on the particular mechanisms action of the tested compounds.
This enabled an assignment of the compounds to either estrogenic, anti-
androgenic or multiple endocrine modulating mechanisms. Zebrafish and
medaka proved both suitable and complementary for the purpose of testing
endocrine disruption. However, for zebrafish the test duration should be
extended to 96hpf, in order to induce a more endocrine mode of action
specific transcriptome response. Lastly, the results presented in this thesis
provide substantial evidence for the suitability of medaka and zebrafish em-
bryos as alternative models for endocrine disruption testing. They further
corroborate the hypothesis that gene expression analysis is an efficient tool
for the detection and evaluation of endocrine disruption in fish embryos.
xviii Zusammenfassung
Zusammenfassung
Endokrine Disruption kann die Gesundheit und Reproduktion von Men-
sch und Tier gefa¨hrden und ist daher ein wichtiges Thema in politischen
und beratenden Instanzen. Im Rahmen der Umweltrisikobewertung er-
folgt die derzeitige Evaluierung endokriner Disruption mittels Langzeit-
Reproduktionsstudien, welche nicht nur zeit- und kostenintensiv sind, son-
dern durch den Einsatz einer Vielzahl von Tieren auch ethisch umstritten
sind. Daher werden derzeit alternative Testmethoden zur Bewertung en-
dokrin disruptiver Chemikalien (EDC) gefordert. In der vorliegenden Ar-
beit sollte gepru¨ft werden, ob der Fischembryo Test als eine solche alterna-
tive Testmethode etabliert werden kann. Zwar besitzen Fischembryos keine
reproduktiven Organe, sodass endokrine Effekte sich nicht auf morphologis-
cher Ebene manifestieren ko¨nnen, jedoch ko¨nnen EDC-vermittelte Effekte
auf der Genebene sichtbar werden. Die Analyse der Genexpression er-
schien daher als ein geeignetes Mittel fu¨r die Detektion und Evaluierung en-
dokriner Disruption in Fischembryos. Um diese Hypothese zu u¨berpru¨fen,
wurde in dieser Arbeit die Wirkung ausgewa¨hlter EDCs, welche nachweis-
lich oder mutmaßlich eine estrogene oder anti-androgene Wirkweise be-
sitzen, auf die Genexpression in Fischembryos analysiert. Dabei wurde
auch ein Vergleich zwischen zwei bedeutenden o¨kotoxikologischen Modell-
Fischarten, dem Zebrafisch und dem Medaka, erstellt, um artenspezifis-
che Unterschiede in der Genantwort zu bestimmen sowie arten-bezogene
Vorteile im Hinblick auf die Testung von EDCs auszuarbeiten. Fu¨r den Ze-
brafisch wurde die Microarray Technologie verwendet, um die Auswirkun-
gen der getesteten EDCs auf das Transkriptom des gesamten Fischembryos
zu untersuchen. Fu¨r den Medaka waren keine vergleichbaren Microarrays
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erha¨ltlich, sodass die Analyse sich auf die Expression ausgewa¨hlter Gene
beschra¨nkte, die zum einen fu¨r repra¨sentative Elemente der Hypothalamus-
Hypophysen-Gonaden-Achse (HPG) kodieren und zum anderen beim Ze-
brafisch, in den Microarray-Analysen, signifikant vera¨ndert worden sind.
Die Transkriptomprofile der 48hpf (Stunden nach Befruchtung) Zebrafis-
chembryos zeigten deutliche Unterschiede zwischen den beiden Referenz-
substanzen 17α-Ethinylestradiol (EE2, Estrogenrezeptor-Agonist) und Flu-
tamid (Androgenrezeptor-Antagonist). EE2 regulierte vor allem Gene,
die mit Entwicklungsprozessen, zum Beispiel Wachstum und Hox-Gen-
Regulation, sowie mit endokrinen Stoffwechselwegen wie Steroidgenese as-
soziiert sind, und induzierte zudem die etablierten Biomarker vitellogenin
(vtg1 ) und aromatase b (cyp19a1b). Das Transkriptomprofil von Flu-
tamid war im Vergleich zu EE2 weniger stark ausgepra¨gt. Dennoch zeigte
Flutamid Effekte auf endokrine Signalwege, vor allem auf solche, die an
der neuronalen Regulierung der HPG-Achse beteiligt sind. Der Vergle-
ich der Transkriptomprofile der weiteren Testsubstanzen mit denen der
Referenzsubstanzen ermo¨glichte eine Kategorisierung der Wirkweisen der
Testsubstanzen. Die Genantwort von Bisphenol A und Propanil war vor-
rangig estrogen beziehungsweise anti-androgen. Genistein, Linuron und
Prochloraz zeigten multiple Wirkweisen, die sowohl durch estrogene als
auch durch anti-androgene Mechanismen gekennzeichnet waren. Methyl-
paraben wurde aufgrund seiner kontra¨ren Wirkung zu EE2 als potentiell
anti-estrogen eingestuft. Neben der Induktion der Biomarker cyp19a1b
und vtg1, vera¨nderten alle als estrogen klassifizierten Substanzen die Ex-
pression von Wachstums- sowie Isoprenoid- und Cholesterol-assoziierten
Genen, welche deshalb als potentielle Marker fu¨r estrogene Disruption
in Frage kommen. Anhand des Expressionsmusters von Flutamid und
den anti-androgenen Testsubstanzen wurden Gene aus der neuroendokri-
nen Signalkaskade als mo¨gliche anti-androgene Marker identifiziert. Da
Flutamid eine relativ schwache Genantwort induzierte, wurde untersucht,
ob in spa¨teren Entwicklungsstadien eine sta¨rkere Genantwort erzielt wer-
den kann. Dazu wurde die Genexpression von endokrinen Markern und
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Genen aus der androgenen Signalkaskade nach einer verla¨ngerten Exposi-
tionszeit von 96 Stunden analysiert. Tatsa¨chlich konnte dann die Herun-
terregulierung des androgen receptor, sowie des gonadotropin releasing hor-
mone receptor sowie die Hochregulation des estrogen receptor 2a, cyp19a1b
und vtg1 nachgewiesen werden, was fu¨r eine Verla¨ngerung der Testzeit auf
96hpf spricht. Als na¨chstes wurden die Zebrafisch-Ergebnisse mit dem
Medaka-Modell verglichen. Die Genantwort zu EE2 war gro¨ßtenteils ver-
gleichbar mit dem Zebrafisch; lediglich die Steroidrezeptorregulation war
anders. Unterschiede gab es vor allem in der Genantwort zu Flutamid.
Teilweise sprachen in Zebrafisch und Medaka zwar die gleichen Gene an, je-
doch wurden sie gegensa¨tzlich reguliert. Außerdem konnte die Regulierung
der anti-androgenen Marker 11β-hydroxylase and 3-beta-hydroxysteroid de-
hydrogenase nur im Medaka nachgewiesen werden. Die Ergebnisse zeigten
somit Art- und Expositionszeit-abha¨ngige Unterschiede in der Genantwort
zu Flutamid. Zusammenfassend hat diese Arbeit gezeigt, wie sich en-
dokrine Disruption in Fischembryos auf molekularer Ebene manifestiert.
Die Genexpressionsanalyse ermo¨glichte nicht nur die Detektion endokriner
Disruption, sondern lieferte sogar Informationen u¨ber die einzelnen Mech-
anismen der Testsubstanzen, wodurch eine Klassifizierung der Substanzen
in entweder estrogene, anti-androgene oder multiple Mechanismen erfol-
gen konnte. Zebrafisch und Medaka erwiesen sich beide als geeignete
und komplementa¨re Fischmodelle fu¨r die Testung endokriner Disruption.
Jedoch sollte zuku¨nftig die Expositionszeit fu¨r den Zebrafisch auf 96hpf
verla¨ngert werden, um eine sta¨rkere endokrine Transkriptom-Antwort er-
fassen zu ko¨nnen. Schließlich bewiesen die in die Ergebnisse dieser Arbeit
die Eignung der Medaka- und Zebrafischembryos als alternative Modelle
fu¨r die Testung endokriner Disruption. Zudem untermauern sie die Hy-
pothese, dass die Genexpressionsanalyse ein effizientes Mittel fu¨r die De-
tektion und Evaluierung endokriner Disruption in Fischembryos eingesetzt
werden kann.
xxii Zusammenfassung
Chapter 1
Introduction and objectives of the
thesis
1.1 Endocrine disruption in fish
Endocrine disruption is a topic of high concern for environmental and hu-
man health, as this phenomenon has crucial health- and reproduction-
relevant effects in wildlife. Although the first cases of endocrine disruption
became evident in the early seventies, it took two decades until the topic
of endocrine disruption became popular and has since been addressed in-
tensely by many scientists [Tagasugi, 1976; Herbst and Bern, 1981; Gorski,
1979; Colborn et al., 1993; Colborn, 1994; Matthiessen et al., 1993, 1998;
Kavlock et al., 1996; Tyler et al., 1998]. Numerous studies have been con-
ducted to show that chemicals can have hormone-like activities and cause
reproductive effects in humans and wildlife, and especially for wildlife,
these effects have been linked to the exposure to environmental chemi-
cals [Jobling and Sumpter, 1993; Ashby et al., 1997; Swan, 1997; Sharpe
et al., 1995; Newbold, 1995; Jobling et al., 1996; Tyler et al., 1998; Des-
brow et al., 1998; Sumpter, 1998]. In 2002, the World Health Organization
released an official definition for endocrine disruption, in which an agent
causing endocrine disruption has been defined as “. . . an exogenous sub-
stance or mixture that alters function(s) of the endocrine system and conse-
quently causes adverse health effects in an intact organism, or its progeny,
or (sub)populations”[WHO, 2002]. Such endocrine disrupting chemicals
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(EDCs) can occur ubiquitously, and particularly in the aquatic environ-
ment critical concentrations of hormone mimics have been identified [Rudel
et al., 1998; Stumpf et al., 1999; Ternes et al., 1999; Belfroid et al., 1999;
Lintelmann et al., 2003]. There are many ways how endocrine disruptors
can enter the environment and subsequently affect humans and wildlife.
One source of EDCs in the environment are effluents of sewage treatment
plants, and even though the majority of the EDCs is removed during the
treatment process, minor concentrations remain and these low concentra-
tions can be sufficient to endanger aquatic populations [Chimchirian et al.,
2007]. Another source of EDCs in natural waters is untreated sewage con-
taining hormones derived from human excretion, such as the natural estra-
diol and testosterone of females and males, respectively, or synthetic hor-
mones, e.g. ingredients of contraceptive pills (17α-ethinylestradiol (EE2),
levonorgestrel) [Liu et al., 2009; Desbrow et al., 1998; Andersen et al.,
2003], directly released or accidentially spilled from households and indus-
trial plants or from sewer overflow events. The usage of biosolids (treated
sewage sludges) in agriculture can also be mentioned here [Pailler et al.,
2009]. Moreover, livestock farming contributes to considerable hormone re-
leases in the aquatic environment. Livestock excrete natural and synthetic
hormones, which are released via wastewater or via usage of manure as a
fertilizer on agriculture. Thus, animal derived hormones reach surface as
well as ground waters [Lange et al., 2002; Kolok and Sellin, 2008; Leet et al.,
2009; Lee et al., 2007]. Another contribution to endocrine disruptor release
is made by the application of pesticides and biocides, which reach natural
waters through run-off and leaching (reviewed in Lintelmann et al. [2003]).
Some have shown to posses endocrine activity. Aquatic organisms like fish
are particularly prone to exposure to endocrine disruptors, since they are
surrounded by water and subjected to steady uptake of chemicals via the
gills, skin or the diet [Van Der Kraak et al., 2001]. It has been shown that
the exposure to endocrine disruptors can have population-relevant impacts.
Since gonads of many fish species are bipotential throughout life time, even
after sexual differentiation, endocrine disruptors are able to induce sex re-
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versal or cause reproductive effects [Devlin and Nagahama, 2002]. Indeed,
various cases of disruption of reproduction caused by endocrine chemi-
cals have been observed in fish populations in laboratory (e.g. [Nash et al.,
2004; Coe et al., 2008; Sebire et al., 2008] and field studies [Van Aerle et al.,
2001; Kidd et al., 2007; Jobling et al., 1998]. In this context, particularly
(anti-)estrogenic and anti-androgenic chemicals are known to be responsi-
ble for the population-relevant effects [Desbrow et al., 1998; Jobling et al.,
2009]. Estrogenic substances have been reported to feminize male gonads,
cause intersex in males and induce sex ratio shifts from males to females.
In females, alterations in ovarian morphology, delayed sexual maturity and
altered gonad weights have been observed [Vos et al., 2000; Scholz and
Klu¨ver, 2009]. The attention for anti-androgenic disruption has also in-
creased in recent years, since adverse reproductive effects in fish have been
associated with anti-androgenic disruption, though the phenotypic effects
of antiandrogens are very similar to estrogen. For example, feminization
effects in males have been observed such as suppressed secondary charac-
teristics, disrupted spermatogenesis or intersex [Bayley et al., 2003; Panter
et al., 2004; Ankley et al., 2004; Kloas, 2002; Kiparissis et al., 2003; Top-
pari, 2008]. In summary, endocrine active compounds can be detrimental
to fish populations and therefore there is a need to regulate the release of
these EDCs.
1.2 Endocrine disrupting chemicals in current regu-
lation
Endocrine disruption has become an important criterion in the hazard
assessment of environmental chemicals and is considered in several leg-
islations. For example REACH (Directive 1907/2006/EEC on the Reg-
istration, Evaluation, Authorization and Restriction of Chemicals [EU,
2006]) categorizes endocrine disruptors as substances of very high con-
cern, provided there is weight of evidence for a population-relevant effect,
and therefore, demands regulation of such compounds. Further, the Eu-
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ropean directive for plant protection products (EC 1107/2009 [EU, 2009])
is in place, which demands a hazard based evaluation of endocrine prop-
erties. For this directive neither specific assessment guidance nor defined
evaluation criteria exist. For providing information about the endocrine
potential of a compound, regulatory testing methods and approaches have
been developed in conjunction with authorities like the US EPA (Environ-
ment Protection Agency) and organisations like the OECD (Organisation
for Economic Co-operation and Development) or the European Centre for
Ecotoxicology and Toxicology of Chemicals (ECETOC). The US EPA and
the 1996 founded EDSTAC (Endocrine disruptor’s Screening and Test-
ing Advisory Committee) in 1998 established the “Endocrine Disruptor
Screening Program” (EDSP), which is based on a two tier testing bat-
tery. Tier 1 comprises of complementary in vitro and in vivo screening
assays, e.g. steroid receptor binding-, aromatase-, steroidogenesis-assays
and fish screens, aimed at providing first information about an endocrine
activity of a substance. If tier 1 considers a substance as potentially en-
docrine active, tier 2 tests are applied for further proof [Borgert et al.,
2011]. Tier 2 tests are mostly long-term tests, like fish and mammalian
life cycle and multigenerational tests, examining the effects of a putative
endocrine compounds [US EPA, 2011] at population level. Also in 1996,
the OECD established a “Task Force on Endocrine disruptors Testing and
Assessment”(EDTA) to provide guidance for endocrine disruption testing.
Based on the guidance notes of the EDTA, specific in vitro and in vivo
tests were developed and validated, such as the Transcriptional ER assay
(OECD 455 [OECD, 2010]) and the H295R Steroidogenesis assay (OECD
456 [OECD, 2011b]), as well as the Fish Short Term Reproduction As-
say (OECD 229 [OECD, 2009a]) and the 21-day Fish Assay (OECD 230
[OECD, 2009b]), both assessing effects on reproduction and endocrine end-
points (e.g. biomarker and steroid level measurements), the Amphibian
Metamorphosis Assay (OECD 231 [OECD, 2009]), the Fish Sexual De-
velopment Test (OECD 234 [OECD, 2011a]), Repeated Dose 28-day Oral
Toxicity Study in Rodents (OECD 407 [OECD, 2008]) and bioassays for the
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evaluation of the estrogen and androgen receptor binding properties of test
compounds (Uterotrophic Bioassay in Rodents (OECD 440 [OECD, 2007])
and Hershberger Bioassay in rats (OECD 441 [OECD, 2009]), respectively).
Given the WHO definition of endocrine disruptors, the problem with high
number of test animals and long test durations necessary for endocrine
disruption testing was inevitable. This has in principle been acknowledged
by recent regulations and authorities. REACH considers the 3R’s princi-
ple (refinement, reduction, replacement of animal testing) and demands,
according to Directive 86/609/EEC, that “Experiments must not be done
if another that replaces, reduces or refines the existing test is reasonably
and practically available” [EU, 2006]. The OECD and US EPA also advo-
cate the 3R’s principle. Practically, however, reliable alternative methods
have not yet been established and decisions on the endocrine potential of
a compound still rely on animal testing. Due to the regulatory demands
and ethical responsibilities for animal protection, but also for economical
reasons, alternative testing methods are urgently needed.
1.3 Alternatives for endocrine disruption testing
In vitro testing appears as a attractive alternative for endocrine disruption
testing, as such procedures do not require animal use at all. Therefore,
several in vitro tests have been established for the identification of a hor-
mone mimicking potential: The Yeast Estrogen Screen (YES) is based on
genetically modified yeast cells, which express the estrogen receptor (of dif-
ferent origin) and thus can identify estrogen-receptor agonists [Routledge
and Sumpter, 1996]. Other receptor-based in vitro tests are the Estrogen-
/Androgen responsive chemical activated Luciferase gene expression tests
(ER/AR Calux), which use human estrogen and androgen receptor ex-
pressing cells for the detection of (anti-)estrogenic and (anti-)androgenic
properties of a compound [Legler et al., 1999; Van der Burg et al., 2010].
The Calux assays further comprise thyroid- and aryl hydrocarbon receptor
binding tests [Murk et al., 1996; Van der Linden et al., 2008]. Although
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these tests provide some information about the mode of action, they are
limited to the receptor binding and do not reflect the overall endocrine
response, thus disregard the complex biology of endocrine regulative path-
ways and metabolism present in a multicellular whole organism. In this
context, the H295R assay appears promising, since this method consid-
ers receptor-dependent and –independent effects on steroidogenesis [Hecker
et al., 2006]. In this assay, human female adrenocortical carcinoma cells
are used, which, in addition to steroid receptors, express steroidogenic en-
zymes and are able to synthesize steroids. Therefore, also disruption of
steroidogenesis, e.g. by alterations of aromatase activities or steroid pro-
duction, can be detected by this assay. The drawback of this test is the
low sensitivity a and weak endocrine disruptors may not be detected due
to the low basal steroid levels [Hecker et al., 2011]. Even though there is
progress in developing suitable in vitro tests, they cannot replace in vivo
tests.
A promising alternative in vivo approach is the Fish Embryo Toxicity
Test (FET). In Germany, it is already applied as an alternative for acute
fish toxicity in waste water screening (DIN EN ISO 15088, 2009 [DIN, 2009;
UBA, 2005]). The test is also considered by the OECD to be internation-
ally applied as an alternative to the Acute Fish Toxicity Test (OECD 203
[OECD, 1992]) and approval of a corresponding guideline is due in the very
near future. Although the method uses living fish embryos, the FET is e.g.
in Europe and the USA, legislatively not considered as animal test. Ac-
cording to the EU directive 2010/63/EU, fish embryonic and early larval
stages are not protected until the onset of active food uptake, because it is
assumed that these stages are not or only minor sensitive to pain [Stra¨hle
et al., 2012]. The stage of initial food uptake coincides with the deple-
tion of the yolk sac, which is approximately at 5 days post fertilization
(dpf) for zebrafish and 12dpf for medaka [Belanger et al., 2010]. However,
in medaka, the digestive system and the jaw are functionally developed
shortly after hatching and, in addition to nutrient uptake from the yolk
sac, these stages are likely to take up food actively [Axelrod and Shaw,
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1967; Douglas, 1991; Aihara et al., 2008]. Thus, for medaka, the test dura-
tion limit for the fish embryo test has still to be defined in order to comply
with the EU directive and until then, the test duration should not exceed
the hatching stage, i.e. 7 days. In this context, however, it has to be men-
tioned that the last OECD draft guideline for acute toxicity testing prefers
zebrafish over medaka and currently considers zebrafish only as the test
fish species [OECD, 2012a].
Compared to in vitro tests, fish embryos are whole-organisms and are
therefore predestined for analyzing integral in vivo biological processes.
In recent years, scientific research has taken advantage of this attribute of
the FET. In particular combined with so-called “omics” approaches, which
aim at elucidating the molecular response at the whole transcriptome, pro-
teome or metabolome level, the FET has increasingly been proposed for
the provision of information on the mechanistic effects of chemicals [Scholz
and Mayer, 2008]. Moreover, it is even being discussed whether molecu-
lar endpoints are suitable to indicate long-term phenotypic or population-
relevant effects [Ankley et al., 2010; Kramer et al., 2011]. In terms of
endocrine disruption, fish embryos have been shown to express e.g. es-
trogenic marker genes such as aromatase, a crucial enzyme for estradiol
synthesis, or vitellogenin, the yolk precursor protein produced only by fe-
males, but inducible upon estrogen exposure also in males [Kishida et al.,
2001; Rose et al., 2002; Arukwe and Goksøyr, 2003]. These endocrine
marker genes have also shown to be responsive to endocrine disruptors in
fish embryos [Muncke and Eggen, 2006] and thus, the FET appears suit-
able for the testing of endocrine disruption. Since the reproductive system
is not yet developed in fish embryos (see section 1.5.1.3), the integration
of molecular techniques is prerequisite to investigate impending reproduc-
tive effects. Furthermore, the endocrine signalling may differ in embryos
compared to adult fish since some steroid receptors are not expressed in
embryonic stages and the response may involve alternative pathways or be
absent in fish embryos. Another difference is the sensitivity in early and
adult life stages. The sexual differentiation in early life stages is a critical
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time window for an increased susceptibility to endocrine disruption [Koger
et al., 2000; Piferrer, 2001; Ankley et al., 2004; Devlin and Nagahama, 2002;
Maack and Segner, 2004]. Exposure to EDCs in these life stages have been
shown to affect sex ratios and secondary sex charesteristics [Nimrod and
Benson, 1997; Ankley et al., 2004; Scholz and Gutzeit, 2000; Orn et al.,
2003], even though in some cases the effects are reversible [Hill and Janz,
2003; Weber et al., 2003; Ankley et al., 2004]. Thus, in particular, medaka
embryos, where gonads are differentiated by hatch, are likely to be highly
sensitive to endocrine disruption. Besides, the role of steroid hormones
in early life stages is special in the embryo, since steroid hormones are
known to control developmental processes, which is not crucial in adults.
However, the mechanisms of steroid hormones in fish embryos are largely
unknown.
1.4 Fundamental background of endocrine disruption
1.4.1 Hypothalamic-pituitary-gonadal axis in fish
Regulation of sexual differentiation, gonad development, function and re-
production in fish is under control of the hypothalamic-pituitary-gonadal
(HPG) axis and the synthesis and release of endocrine hormones, which
in turn are regulated by feedback mechanisms. The mechanisms of these
steroid feedback regulations are described hereafter and illustrated in Fig-
ure 1.1. In response to sex steroids, the hypothalamus releases the go-
nadotropin releasing hormone, which binds to gonadotropin releasing hor-
mone receptors (GnRHR) in the pituitary resulting in the release of two
gonadotropins, i.e. follicle stimulating hormone (FSH) and luteinizing hor-
mone (LH) into the blood stream. In female gonads, FSH and LH control
the oocyte development in the ovary. They bind to their receptors in the
follicular theca- and granulosa cells and induce the production of testos-
terone in the theca cells as well as the upregulation of aromatase, which
converts testosterone to estradiol in the granulosa cells. In the testis, go-
nadotropins regulate the spermatogenesis and the testosterone synthesis.
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FSH binds to the receptor in Sertoli-cells and activates a cAMP pathway
which induces the transformation of germ cells to spermatoids. LH acts on
the Leydig cell membrane and causes, also via a cAMP dependent path-
way, the de novo testosterone synthesis from cholesterol. In contrast to
mammals, downstream enzymes, i.e. 11β -hydroxylase (11βH, encoded by
cyp11b) and 11β-hydroxysteroid dehydrogenase (11βHSD) further convert
testosterone to 11-ketotestosterone in fish, which is the major androgen in
fish [Kime, 1998]. The steroids produced in the gonads are then released
into the blood and act via negative or positive feedback on GnRH neurons,
regulating the gonadotropin production. Because GnRH neurons do not
express steroid receptors, this regulation occurs indirectly via kiss1 neurons
and neuropeptide Y (NPY) neurons, which do express steroid receptors.
Kiss1 neurons are located mainly in two hypothalamic areas, the arcu-
ate nucleus (ARC) and the anteroventral periventricular nucleus (AVPV),
whereas NPY neurons are present in the ARC, but not in the AVPV.
Steroid binding to those neurons leads to the secretion of the neurotrans-
mitter kisspeptin 1 and NPY.
Steroids can either stimulate (positive feedback) or inhibit (negative
feedback) the gonadotropin release. The negative feedback, required for
maintaining the gonadotropin and steroid balance, is triggered by both,
estrogen and androgen, and involves mainly the kiss1 and npy neurons in
the ARC nucleus. Estrogen and androgen receptors mediate the steroid
signalling on kiss1 neurons, which in turn secrete kisspeptin1 [Smith et al.,
2005; Irwig et al., 2004; Rometo et al., 2007; Smith et al., 2007; Garc´ıa-
Galiano et al., 2012]. Kisspeptin 1 can directly excite GnRH neurons and
it has also been shown to bind to the kiss1 receptor, expressed by npy neu-
rons resulting in NPY secretion which also contributes to GnRH neuron
stimulation [Kim et al., 2010]. The positive feedback is mainly required
for the induction of the preovulatory LH surge, taking place in the AVPV
and is mainly induced by estradiol in females. Although the kiss1 neurons
in the AVPV nucleus also express the androgen receptors, the estrogen re-
ceptors alpha and beta have been identified to mediate the feedback effects
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[Smith et al., 2005]. Testosterone is also able to activate kiss1 neurons in
the AVPV nucleus. However, since the AVPV is sexually dimorphic and
less kiss1 neurons are present in male AVPV nuclei than in females, the
androgen-driven positive feedback has been proposed to be rather irrele-
vant [Smith et al., 2005]. Apart from the spatial divergences, little is known
about the exact mechanism leading to either positive or negative feedback.
However, there is some evidence that molecular differences in steroid re-
ceptor signalling might contribute to the stimulating or inhibiting effect.
The negative feedback in the ARC involves steroid receptors, but does not
necessarily require classical gene signalling. In contrast, inhibition of the
classical signalling in the AVRV kiss1 neurons blocks the positive feedback
[Gottsch et al., 2009; Glidewell-Kenney et al., 2007].
Even though the gonads are not yet developed in embryos of zebrafish
and only gonadal precursors, the gonadal primordium, exist in medaka
[Nakamura et al., 2006], steroids are present in both and have a crucial
role for sexual differentiation. The steroids are mostly maternally derived
and are taken up from the yolk. At a later stage, some steroids are pro-
duced in the brain of fish embryos [Kishida et al., 2001; Iwamatsu et al.,
2006; Brooks et al., 1997; Hsu et al., 2002; Vosges et al., 2012; Pikulkaew
et al., 2010]. The presence of steroid receptors in embryos (section 1.5.1.3)
further underscore the relevance of steroids in early life stages [Pikulkaew
et al., 2010]. Thus, steroids elicit effects in fish embryos and endocrine pro-
cesses in the hypothalamus and pituitary regions are active and susceptible
to disruption at these developmental stages.
1.4.2 Mechanisms of endocrine disruption in brief
Endocrine active agents can disrupt the endogenous hormone balance in
many different ways. They can act as agonists or antagonists of steroid
receptors and thereby mimic or inhibit endogenous steroid hormone sig-
nalling or they can interfere with other sites of hormone synthesis or
metabolism. The main mechanisms are described in this chapter.
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Figure 1.1: Steroid feedback regulation The hypothalamic gonadotropin releasing hormone induces
the release of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH) in
the pituitary, which are transported to the gonads and stimulate the production of estrogen (E2) and
testosterone (T). E2 and T autoregulate their production by either positive or negative feedback for
enhancing or lowering the steroid levels, respectively. The negative feedback is triggered by both, E2
and T, and involves the kiss and npy neurons in the arcuate nucleus. In the absence of steroid signals,
kiss1 and NPY neurons secrete the neurotransmitter kisspeptin1 and neuropeptide X respectively, which
both excite gnrh neurons. Also, kisspeptin1 can indirectly enhance the gnrh production by stimulating
NPY neurons. Binding of E2 and T to cytosolic and membrane estrogen receptors as well as androgen
receptors in the kiss1 neurons inhibits this signalling cascade and leads to impaired steroid production.
The positive feedback is mainly induced by estrogen in females and involves kiss neurons located in the
AVPV. The estrogen receptors mediate the positive feedback effects and lead to an enhanced kisspeptin
production and therefore to gonadotropin release. Abbreviations: AR (androgen receptor); ER (estrogen
receptor); kiss1r (kiss 1 receptor); npyr (neuropeptide Y receptor); gnrhr (gonadotropin releasing hormone
receptor).
12 1. Introduction and objectives of the thesis
1.4.2.1 Receptor mediated signalling
Most endocrine disruptors are ligands of steroid receptors and activate
or suppress receptor signalling. In the classical, receptor-mediated sig-
nal transduction, steroids diffuse across membranes and bind to nuclear
steroid receptors, inducing the expression of steroid responsive genes. Prin-
cipally, ligand binding induces a conformational change of the receptor
leading to the dimerization of the receptors, which thereby become a nu-
clear transcription factor. The activated receptor then regulates gene ex-
pression by binding with its DNA binding domain to steroid responsive
elements in the promoter or enhancer regions of target genes or by recruit-
ing other transcription factors. This process is relatively slow and takes
at least several hours. Yet, steroids can also induce rapid actions, relying
on nongenomic pathways. Though the exact signalling mechanisms are
not fully understood yet, it is known that membrane bound steroid recep-
tors are mediating this process. One category of these plasma membrane
receptors are receptors identical to nuclear receptors, which translocate
from the nucleus to the cell membrane through posttranslational modifi-
cations [Razandi et al., 2003] or interaction with cytoplasmatic adaptor
molecules [Song et al., 2004, 2002]. Binding of ligands to such a mem-
brane bound steroid receptor initiates interaction with several signalling
molecules and induces the activation of mitogen-activated protein kinase
(MAPK) or phosphatidylinositol 3-kinase (PI3K)/Akt signalling cascades.
Another class of non-genomic signalling involves G-protein coupled recep-
tors, i.e. the GPR 30, which mediate the rapid actions of estradiol. This
signalling induces rapid cellular responses such as MAP kinase activation,
phosphoinositide 3-kinase (PI3K) activation, calcium flux elevations, el-
evated cyclic adenosine monophosphate (cAMP) concentrations and in-
creased c-fos oncogene transcription of oncogenes (e.g., c-fos) [Andersen
et al., 2003; Stra¨hle et al., 2012; Thomas et al., 2005; Albanito et al.,
2007; Filardo et al., 2000; Vivacqua et al., 2006; Li et al., 2010]. Notably,
apart from inducing cellular responses, some of these signalling cascades
can ultimately alter gene expression, despite being termed “non-genomic”
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[Picotto et al., 1999; Manavathi and Kumar, 2006; Boonyaratanakornkit
and Edwards, 2007; Shanle and Xu, 2011].
1.4.2.2 Receptor-independent mechanisms
Endocrine disruptors can also induce changes in hormone levels without
binding to steroid receptors. For example, they can interfere with steroido-
genic enzymes resulting in disruption of steroid biosynthesis. For example,
the phytoestrogen genistein is known to inhibit aromatase, and various pes-
ticides, e.g. prochloraz and propanil, target cytochrome dependent essen-
tial enzymes in steroidogenesis [Kao et al., 1998; Hofmeister and Bonefeld-
Jørgensen, 2004; Salazar et al., 2006]. Furthermore, some endocrine dis-
ruptors affect the transport of hormones by interacting with plasma mem-
brane proteins or they interfere with steroid metabolism [Kester et al.,
2000; Adlercreutz et al., 1993; Brouwer et al., 1998; Singleton and Khan,
2003]. Together, endocrine disruptors can act via various mechanisms, in-
cluding binding to different steroid receptors and cause transcriptional as
well as non-trancriptional cellular responses.
1.5 Key facts about zebrafish and medaka
The zebrafish (Danio rerio) is a tropical freshwater fish, native to India
and Burma, and belongs to the Cyprinidae family of the teleosts. The
zebrafish is a widely used model species in biology and has many advan-
tages for research. The husbandry of zebrafish is comparatively easy, since
the laboratory requirements are undemanding and due to their small size,
maintenance facilities require only little space [Westerfield, 2000]. Also,
they grow very rapidly and the generation cycle is only just over three
month. Zebrafish are continuous breeders and reproduce mainly in the
first hours after light onset throughout the year [Darrow and Harris, 2004],
even though spawning at further time points in the afternoon and a short
period before dusk can be also achieved in domesticated fish by condi-
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tioning [Baganz et al., 2005; Plaut, 2000]. Individual females can spawn
approximately every two days and produce 100-200 eggs a week [Eaton
and Farley, 1974]. The eggs are fertilized externally and can be harvested
easily by using mesh-covered spawning trays or similar collecting devices.
The fertilized embryos develop within 48 hours and the embryogenesis can
be visually inspected (or observed) due to the transparent chorion. The
small size of the fish embryos (approximately 1mm) is beneficial for molec-
ular technologies in the context of whole body analysis, as RNA/protein
can be easily extracted from the whole body and allows pooling of many
individuals. Also, the zebrafish genome is entirely sequenced and, with
the current release of the Zv9 assembly of the zebrafish sequencing project
(Sanger institute, 2010, announced in 2000 [Sanger Institute, 2000]), nearly
90% of the whole genome size are now annotated. Additionally, novel high-
throughput sequencing technologies, such as RNA sequencing, contribute
to a fast progress in genome annotation [Pauli et al., 2012; Collins et al.,
2012]. Thus, the vast genome data available for zebrafish makes it ideal
for various omics-analyses.
Medaka (Oryzias latipes) or Japanese rice fish is a freshwater to brack-
ish species and belongs to the Adrianichthyidae family of teleosts. The
origin of medaka lies in of Southeast Asia, Taiwan and Japan and the
preferred habitat are rice fields or shallow ponds [Kinoshita et al., 2009;
Wittbrodt et al., 2002]. Like zebrafish, medaka is a favored model in bi-
ology research. In terms of fish maintenance, medaka fish is more robust
than zebrafish and can equally be kept very easily at laboratory condi-
tions. The generation time is shorter than for zebrafish and takes about
two months. Medaka females can spawn up to 10-30 eggs daily, which
remain attached by filaments to the cloaca of the females until they get
stripped off [Wakamatsu et al., 2001]. To collect the eggs, they have to be
striping off the female’s body. Compared to zebrafish, the embryogenesis
in medaka takes 7-10 days until hatch [Kinoshita et al., 2009]. This can
be beneficial since embryonic developmental is staggered compared to ze-
brafish and allows the assignment of the observed effects to a particular
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developmental stage, which could hint a certain mode of action of a test
compound, i.e. in cases the detected effect coincides with the onset of
the development of a certain organ or the expression of indicative genes.
Beyond this, the longer embryonic development enables a longer exposure
duration and therefore allows the detection of longer-terms effects which
in particular are relevant for sub-chronic endocrine processes. However,
although the chorion is transparent, the attached filaments make the mor-
phological assessment of embryogenesis more difficult than in zebrafish,
unless the filaments are removed manually or by enzymatic digestion. In
terms of transcriptome or proteome based molecular techniques, medaka
embryos are as suitable as zebrafish embryos as RNA/protein can be easily
isolated from the whole body, allowing the analysis of molecular processes
in the entire embryo. Further, the genome is fully sequenced (Medaka1
assembly, National Institute of Genetics (NIG) and University of Tokyo
[NIG, 2002]), with 700Mbp the medaka genome is only half the size of the
zebrafish genome [Hinegardner and Rosen, 1972]. However, only limited
information on gene annotation is available for medaka so far.
1.5.1 Species- and embryo specific traits (or attributes)
For the application of zebrafish and medaka embryos for testing endocrine
disruption, there are species specific differences and special embryonic at-
tributes which need to be considered for the interpretation of results. In
this context, an important species specific difference addressed in the fol-
lowing subchapter is the different sexual differentiation in the two fish
species, which, in this study, is hypothesized to contribute to a diverging
molecular response to endocrine disruption withing both fish species. In
the same context, the next subchapter highlights the special role of the gene
encoding for aromatase, which is affected by estrogenic and anti-androgenic
substances and exerts species-specific roles in sex determination. Finally,
given steroid receptor binding is the prime mode of action of endocrine dis-
ruptors, the last subchapter describes whether and which steroid hormone
receptors are known to be present in the embryonic life stage and covers
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discrepancies between both fish species.
1.5.1.1 Sexual differentiation of zebrafish and medaka
The sexual determination in fish can be either genetically defined or plastic
and either way be influenced by environmental factors, such as tempera-
ture, pH or, although rarely, social relations [Kitano et al., 2000; Baroiller
and D’Cotta, 2001; Matsuda et al., 2002; Godwin, 2009]. Medaka is one of
the few fish species so far known to have defined sex chromosomes and to
be genetically sex determined [Devlin and Nagahama, 2002].
The sexual determination of medaka relies on the DMY (DM-domain
gene on the Y chromosome) or DMRT1 (DM-related transcription factor 1)
gene which is located on the Y chromosome [Matsuda, 2005; Matsuda et al.,
2002; Nanda et al., 2002]. In medaka, this genetic determination leads to
a differentiated gonad development, meaning that the gonads develop di-
rectly in either ovary or testis. Species with such a gonadal development
are termed differentiated gonochorists. The first gonad precursor, the go-
nadal primordium, appears at approximately 4 days post fertilization. This
coincides with the initial expression of DMY, the sex determining gene in
male gonadal cells. At the time around hatching, the female and male
gonadal primordium become distinguishable and the germ cells in females
start to increase in number. Around 10 days post hatch, sex dependent
genes begin to be expressed, initiating the proliferation of the gonadal cells.
DMRT1 and Sox9b (SRY-box containing gene 9b) regulate the testes de-
velopment whereas Cyp19a1a and Foxl2 (Forkhead box L2) are necessary
for ovary development. The gonadal morphogenesis becomes first appar-
ent at 20dph, the time at which ovarian follicles can be observed in female
medaka. Also at 20dph, steroidogenic enzymes start to be expressed, e.g.
Cyp17-lyase. Between 30dph and 50dph the gonad differentiation in both
sexes occurs.
The sexual determination and differentiation of zebrafish is different
from medaka, since no sex determining chromosomes or genes have been
identified so far. Besides the lack of a genetic sex determination, zebrafish
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is other than medaka an undifferentiated gonochorist, with a gonad devel-
opmental phase of originally described as juvenile hermaphroditism [Taka-
hashi, 1977]. During sexual differentiation, all individuals first develop an
ovary-like structure and then, either the ovary differentiates or apoptosis
of the oocytes occurs and the testis develops from the undifferentiated part
of the gonad precursor [Maack and Segner, 2003; Uchida et al., 2004; Hsiao
and Tsai, 2003; Tsai et al., 2003]. The first germ cells are developed at
11-14 days post fertilization and the onset of sex differentiation and the
development of sex specific gonads takes place between three and 4 weeks
post fertilization. At this time, the regulation of sex related genes initiates
the differentiation, and aromatase is downregulated and cyp11b and amh
(anti-Mullerian hormone) are upregulated in prospective males, whereas
the latter genes are downregulated in females.
1.5.1.2 Role of aromatase in sex differentiation
The sex determination of fish is dependent on several genes. One crucial
gene for sexual and especially the ovarian differentiation is cyp19, which
encodes for the aromatase, the enzyme converting testosterone to estradiol
[Kitano et al., 1999]. In fish, two aromatase gene isoforms exist, cyp19a1a
and cyp19a1b, which are translated into two different proteins and are
predominantly expressed in the gonads and in the brain, respectively. In
zebrafish, cyp19a1b is the most active form and is expressed early in the
development, long before the gonads appear. The embryonic expression
of cyp19a1b only initiates at 24hpf (hours post fertilization) and increases
sharply by 48hpf [Callard et al., 2001]. Although the expression of the
gonadal isoform cyp19a1a also starts at 24hpf, the expression levels are low
and increase only slowly during early life [Callard et al., 2001]. Cyp19a1b
is the key driver for the neuronal estrogen biosynthesis, which in turn is
crucial for sexual differentiation [Callard et al., 2001; Fenske and Segner,
2004; Menuet et al., 2005; Pellegrini et al., 2005; Le Page et al., 2006;
Pellegrini et al., 2007; Cheshenko et al., 2007; Diotel et al., 2010] and
affect the ontogeny of GnRH neurons.
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The role of cyp19a1b in sexual differentiation of medaka is different
from zebrafish. The onset of cyp19a1b and cyp19a1a expression is rela-
tively late compared to zebrafish, starting shortly before hatch (stage 39)
[Patil and Gunasekera, 2008]. This developmental stage coincides with the
start of germ cell proliferation in female medaka [Suzuki et al., 2004; Saito
et al., 2007; Patil and Gunasekera, 2008]. Levels of cyp19a1a are higher
in female medaka than in males, whereas the expression of cyp19a1b is
not sex specific before the onset of puberty [Patil and Gunasekera, 2008].
This suggests that cyp19a1a and not cyp19a1b initiates ovarian differenti-
ation in medaka. However, as a potential target to estrogenic disruption
in early life stages, cyp19a1b appears more sensitive due to the presence
of an estrogen-responsive element in its promoter. Also, cyp19a1b is quan-
titatively the more abundant isoform in zebrafish and in medaka embryos
[Callard et al., 2001; Pikulkaew et al., 2010]. Nevertheless, cyp19a1a con-
tains cAMP response elements, which make this gene susceptible for go-
nadotropin signalling and therefore also to endocrine disruption. In fact,
EDC induced sex reversal and altered sex ratios have been associated with
both, disrupted cyp19a1b and cyp19a1a expression [Uchida et al., 2004;
Fenske and Segner, 2004; Kuhl et al., 2005; Wong et al., 2006].
1.5.1.3 Sex steroid receptors in fish embryos
In medaka, two divergent androgen receptor (Ar) isoforms alpha and beta
exist due to genome duplication, whereas in zebrafish a loss of Ar-b has
occurred during evolution, resulting in one Ar-a gene only [Douard et al.,
2008]. Ar expression has been shown to be initiated in embryogenesis. In
zebrafish, the ar -expression starts at 24 hpf and is located particularly in
pronephros and olfactory placodes [Gorelick et al., 2008]. During later de-
velopment, the ar expression in zebrafish rises and dramatically increases
after 16dph; the highest level of ar expression is then found at 22dph, coin-
ciding with the early onset of bipotential gonad differentiation [Jørgensen
et al., 2008]. For medaka, the expression profile of the Ars during devel-
opment has not been determined yet, but it has been shown that Ars are
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already active during embryogenesis [Ogino et al., 2009].
Three estrogen receptor (Er) isoforms are described for medaka and
zebrafish, the Ers 1, 2a and 2b (formerly estrogen receptor alpha, beta2
and beta1, respectively) and most of them are already expressed in early
embryonic stages. In medaka, esr1 and esr2b are expressed at low levels
during embryogenesis whereas the expression of esr2a increases drastically
between 6-8 dpf, but only in females. In males the esr2a expression is as
low as the esr1 and esr2b expression during embryogenesis. The esr2a is
the predominant estrogen receptor gene in juvenile and adult medaka and
is mainly expressed in brain, heart, liver and gonads. The expression of
esr2b is restricted to testis and remains low in all stages, even decreasing
after 20dph. In contrast, the expression of esr1 increases after 50dph
and is widely expressed in many tissues, i.e. brain, heart, liver, gonads,
kidney and intestine, but the expression levels are still lower than of esr2a
[Chakraborty et al., 2011].
In zebrafish, estrogen receptor expression can also be detected in early
embryogenesis. In the first 6.5h only maternal esr2a mRNA is present,
and embryonic expression initiates at 12hpf and increases until 72hpf, with
a sharp increase at 48hpf [Bardet et al., 2002]. The expression of esr2b
follows the same pattern as esr2a [Bardet et al., 2002]. The expression
of esr1 starts only at 24hpf and sharply increases at 72hpf, becoming
the most abundant receptor isoform at this stage. During embryogenesis,
esr2a and esr2b are expressed in the telencephalon, the preoptic area,
hypothalamus, but also in the epidermis, pectoral fin buds and hatching
gland [Tingaud-Sequeira et al., 2004; Mouriec et al., 2009]. In addition, the
expression of esr2a and esr2b has been deteceted in neuromasts at 3dpf
[Tingaud-Sequeira et al., 2006]. In contrast, esr1 is expressed in the brain
only in adult stages [Anglade et al., 1994; Menuet et al., 2002], and in
embryos only in the liver [Mouriec et al., 2009]. In addition to the typical
estrogen receptors, three so-called orphan receptors, the estrogen receptor-
related receptors, Err α,δ, γ, exist in zebrafish [Gigue`re et al., 1988; Hong
et al., 1999; Xie et al., 1999; Bardet et al., 2004] and five Errs have been
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determined in medaka, with the corresponding genes erra, errb1 and errb2
as well as erry1 and erry2 [Zhang and Hu, tted; Zhang and Teng, 2000;
Zhang et al., 2008b]. No ligands have been identified for these receptors
yet, but they are structurally similar to the other estrogen receptors, and
interactions between the orphan and classical receptors have been reported
[Yang et al., 1996; Vanacker et al., 1999; Zhang and Teng, 2000; Kraus
et al., 2002].
Further, a membrane estrogen receptor isoform, the G-protein-coupled
estrogen receptor 30 (Gpr30/Gper), has been identified to mediate estro-
genic effects in zebrafish and is believed to be important for normal em-
bryonic development [Pang et al., 2008; Pang and Thomas, 2009; Chung
et al., 2011]. Initially, Gpr30 mRNA is maternally derived, followed by
a zygotic expression after 26hpf. In embryonic stages, gpr30 is expressed
in various tissues, including brain, neuromasts, heart and the pharyngeal
region [Jayasinghe and Volz, 2012]. In medaka, such a G-protein-coupled
receptor isoform has not been detected.
1.6 Objectives
Currently, evaluating endocrine disrupting chemicals (EDCs) relies on costly
long-term and animal intensive reproductive studies. Therefore, it was
aimed at establishing a much needed alternative testing approach for EDCs
using fish embryos. Fish embryos lack a functional reproductive system,
thus, molecular endpoints were targeted to assess endocrine disruption.
Firstly, this thesis intended to address the question whether endocrine dis-
ruption is detectable in fish embryos at the molecular level, and, secondly,
to gain insight into the underlying molecular mechanisms. In addition,
the question whether different modes of action are distinguishable on the
molecular level was addressed by focussing the investigations on two im-
portant modes of endocrine disruption, estrogenic and the anti-androgenic
disruption. The steps for approaching the central questions of the the-
sis are illustrated in figure 1.2. First, the transcriptome response of 48hpf
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zebrafish embryos to estrogenic and anti-androgenic reference and test com-
pounds was analysed by the use of microarray technology. This analysis
provided broad information on the two modes of actions of endocrine dis-
ruption in zebrafish embryos, which is described in chapter 3. Next, a
comparison of the zebrafish results to medaka was deemed important be-
cause the assessment of inter-species variation is important for a reliable
prediction of adverse effects from a short-term test like the FET. Thus, the
expression of selected genes, which appeared indicative of endocrine disrup-
tion in zebrafish, and common endocrine marker genes was investigated in
medaka (chapter 4). Another key goal of this thesis was the identification of
molecular markers for endocrine disruption which allow the reliable detec-
tion of endocrine disruption and the prediction of a certain endocrine mode
of action in fish embryos. The results of these investigations, i.e. potential
estrogenic and anti-androgenic marker, are presented in chapter 3 for ze-
brafish and in chapter 4 for medaka. In a proof-of-principle approach, an
in-depth analysis of genistein was conducted, since this compound does not
exclusively act estrogenic, but reportedly also show estrogen-independent
effects. The identified molecular mechanisms of genistein in fish embryos is
described in chapter 5. The same chapter takes up the issue of inter-species
variation and, in this context, further demonstrates the complementarity
of the two fish species. Together, the goal of this thesis was to evaluate
the suitability of fish embryos for the detection of endocrine disruption,
using the example of estrogenic and anti-androgenic compounds. With
this thesis it was aimed at providing substantiating knowledge for the im-
plementation of an alternative, fish-embryo based molecular approach for
endocrine disruption testing.
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Figure 1.2: Thesis workflow
Chapter 2
Material and methods
2.1 Fish maintenance and exposure
Fish maintenance
Adult zebrafish (wild-type) were maintained in 200 l glass aquaria under
flow-through conditions, with a 14:10 h light:dark photoperiod. Tap wa-
ter was charcoal- and particle-filtered, UV-sterilized, pre-heated to 26 ±
2◦C and aerated a 400 l storage tank before entering the aquaria. Fish
were kept in large spawning groups at a male to female ratio of approxi-
mately 2:1. The eggs were collected in metal-mesh-covered glass spawning
trays, equipped with artificial plants, and harvested from the aquaria one
hour after light onset. Before testing, the eggs were rinsed in 1:5 diluted
ISO (International Organization for Standardization) medium, prepared
according to the Annex 2 of the OECD Guideline 203 (ISO 6341-1982)
[OECD, 1992].
Medaka fish (wild-type carbio) were maintained in the same water con-
ditions as zebrafish. However, they were kept in smaller spawning groups
of six fish by tank dividers at a male to female ratio of 1:2. Each aquaria
devision was equipped with Ceratophyllum submersum as spawning sub-
strate. Medaka eggs were striped from the females between one and two
hours after light onset, placed into ISO medium and freed from attachment
filaments using tweezers.
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Chemicals
Chemicals were purchased from Sigma-Aldrich (Munich, Germany) (17α-
ethinylestradiol E4876, flutamide F9397, bisphenol A 239658, linuron 36141,
genistein G6649, propanil 45639, methylparaben 47889, prochloraz 45631).
Stock solutions for all chemicals, except bisphenol A and prochloraz, were
prepared in acetone (ROTIPURAN R© , purity = 99.8%, p.a., Carl Roth,
Karlsruhe, Germany).
Fish Embryo Toxicity Test (FET)
The Fish Embryo Toxicity Test (FET) was conducted following the draft
OECD Guideline for the testing of chemicals (OECD 2006). For prochlo-
raz and bisphenol A, the test solutions were prepared by directly dissolving
the chemicals in 200 ml pre-aerated ISO water. For all other substances,
the chemicals were dissolved in acetone (100%) and dilutions for each con-
centration prepared in 2 ml of acetone each. These 2 ml-acetone stocks
were transferred to 250 ml screw-cap glass bottles (SCHOTT c© , Mainz,
Germany) evenly spread onto the inner surface of the bottle. The acetone
was then allowed to evaporate completely and the bottles were filled with
200 ml pre-aerated ISO water. All test solutions were stirred at 26◦C for
several hours. A solvent control was prepared accordingly, using acetone
only.
For the tests, wells of U-bottom 96-well plates (Greiner Bio-One, Frick-
enhausen, Germany) were filled with 200µl of test solution each. Plates
were saturated overnight and refilled with new test solutions before test
start. Subsequently, unfertilized eggs were sorted out from freshly col-
lected eggs using a stereo microscope. Tests were only conducted if the
fertilization rate exceeded 80%. Prior to the placement to the final testing
well plates, fertilized eggs were first transferred to petri dishes containing
the final test solutions in order to guarantee quick and even exposure of
embryos and avoid dilutions of test solutions.
Zebrafish eggs entered the test solutions no later than 2 hours post-
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fertilization (hpf) by using a plastic pipette. Due to the slower development
and lower transparency, medaka embryos could be sorted at 3-4hpf only;
in order to correspond to the initial exposure time of zebrafish embryos
(32-64 cell stage), medaka embryos were subjected to test solutions using
tweezers by 4hpf.
From the petri dishes, 24 zebrafish and medaka embryos for each concen-
tration and replicate were placed individually into the wells of one plate and
incubated at 26◦C ± 1◦C for 48h or 96h (zebrafish) and 7d (medaka). Test
solutions were refreshed every two days in case of the extended zebrafish
test and the medaka test. Two replicates and at least five concentrations,
with a maximal constant spacing factor of 2.2, were used to establish a
concentration response relationship. For this purpose, all lethal and non-
lethal morphological endpoints (Annex Table B), were recorded after 48
hours and 7 days for zebrafish and medaka, respectively.
From the concentration response curves, the cumulative effect concen-
trations EC10 and EC20 were derived by probit analysis (ToxRat
R© Profes-
sional 2.10) and applied to further gene expression experiments. For the
extended zebrafish test, the same concentrations were used as retrieved
from the 48h dose-response. Microarray experiments were conducted with
four replicates per treatment whereas three replicates were used for quan-
titative PCR experiments. After exposure, the embryos were collected for
RNA extraction and thus, each replicate group of 24 fish embryos pooled
together in 1.5 ml Eppendorf-tubes, snap-frozen over dry ice and stored at
–80◦C.
2.2 RNA extraction and reverse transcription
Total RNA was isolated from frozen, pooled embryos by homogenization
in TRIreagent (Sigma-Aldrich, T9424) using motor-driven plastic pistils
followed by a centrifugation step, RNA extraction with chloroform and
ethanol and final purification using RNeasy Mini Spin Columns (QIA-
GEN, Hilden, Germany) according to the manufacturers’ protocols. RNA
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was then stored at -80◦C until further analysis. RNA and cRNA con-
centrations were measured by using a NanoDrop 1000 spectrophotometer
(Thermo Fisher Scientific, Schwerte, Germany). For the microarray anal-
ysis, RNA quality was verified on an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, USA). All further processed RNA samples had
RNA integrity numbers between 8.8 and 9.8 and a 260/280 absorbance
between 1.8 and 2.2. For cDNA synthesis, RNA was treated with DNAse
(Sigma-Aldrich, AMP-D1) and reverse transcribed using SuperScript III
Reverse Transcriptase (Invitrogen, Carlsbad, USA). A negative cDNA con-
trol sample, without added reverse transcriptase, was included in all qPCR
measurements.
2.3 Quantitative real-time PCR
Quantitative real-time PCR (qPCR) was used for the initial validation of
zebrafish microarray data (i.e. for genistein array data) and as a method for
gene expression analysis of the extended fish embryo zebrafish test (96hpf)
and of the medaka tests.
The iQ5 real-time PCR detection system (BioRad
TM
, Hercules, USA)
and SYBR R©GreenER qPCR SuperMix (Invitrogen, Carlsbad, USA) were
used for most qPCR experiments. Since medaka gene expression analyses
were partly conducted in an external lab (Prof. John Giesy, University
of Saskatchewan, Canada), the Applied Biosystems 7300 Real-time PCR
system with SYBR R©Green qPCR Master Mix was used for those samples
(genistein, prochloraz, linuron and bisphenol A medaka samples).
Specific primers were designed using the web-based NCBI PrimerBlast
tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast). Zebrafish
primer are listed in Annex Table A-1. For medaka, primer were selected
from the medaka HPG PCR array collection developed by Zhang et al.
[2008a], which comprise a broad range of genes involved in the hypothalamic-
puitary-gonadal axis. Additional primer sets were designed for target genes
found to be differentially expressed in zebrafish. The complete medaka
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primer set is listed in Annex Table A-2.
For zebrafish microarray validation and gene expression analysis of the
extended FET, only cDNA from the EC20 exposure were used. After in-
cubating for 2 min at 50◦C and for 10 min at 95◦C, targets were amplified
at 95◦C for 15 s, 59◦C for 30 s and 72◦C for 30 s (40 cycles), together with
the two reference genes, β-actin and rpl13, used to normalize the expres-
sion values. Identical RNA samples were used for the microarrays and the
qPCR.
Using the Applied Biosystems 7300 Real-time PCR system and the
SYBR R©Green qPCR Master Mix, target sequences were incubated for 10
min at 95◦C and amplified at 95◦C for 15 s, 59◦C for 30 s and 72◦C for
30 s (40 cycles). The data was normalized using two reference genes, 16S
rRNA and rpl7.
For both, medaka and zebrafish, 40 ng cDNA were used as starting tem-
plate. Two technical replicates and a negative control were integrated in
each experiment. Relative gene expression ratios were calculated by the
comparative Ct method (ddCt) [Pfaffl, 2001]. For zebrafish data, a stu-
dent’s test was used for testing significant differences between the EC20
conditions and the solvent control. As the medaka qPCR analysis com-
prised three conditions (control, EC10 and EC20), one-way ANOVA with
subsequent Dunnett’s multiple comparison test were selected for the sta-
tistical evaluation.
2.4 Microarray analysis
2.4.1 Microarray processing
Microarray experiments for each chemical were carried out using Zebrafish
(V2) Gene Expression Microarrays 4X44K (Agilent Technologies, Santa
Clara, USA). Each array contained 43,604 oligonucleotide probes repre-
senting 16,865 different genes (partly in duplicates, and additional non-
annotated genes) and was hybridized with 500 ng of total RNA accord-
ing to the Agilent one-color microarray hybridization protocol (One-Color
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Microarray-Based Gene Expression Analysis, version 5.7, Agilent Tech-
nologies). RNA quality was verified using a Bioanalyzer 2100, only samples
with a RNA Integrity Number (RIN) of above 9 were further processed.
We carried out cDNA synthesis, cRNA Cy3 (Cyanine 3) labeling, amplifi-
cation and hybridization according to the manufacturer’s protocols (Quick
Amp Labeling Kit; Agilent Technologies). Briefly, RNA was reverse tran-
scripted using the MMLV-RT (Moloney Murine Leukemia Virus Reverse
Transcriptase). cDNA was then transcribed to cRNA by T7 RNA Poly-
merase and a nucleotide mix containing Cy3 labeled cytodine triphosphate.
Subsequently, the labelled cRNA was fragmented in order to enhance hy-
bridization (by reducing size and overcome secondary and tertiary struc-
tures). After hybridization at 65◦C for 17 hours, the slides were washed
and microarrays were scanned with the Agilent Microarray Scanner (Agi-
lent Technologies). Data were extracted using Agilent Feature Extraction
Software (Agilent Technologies). During this preprocessing, single pixels
are summarized, defined as feature or background population and quanti-
fied as intensity signals. Further, background subtraction is performed and
outlier are detected and flagged. The extracted data were then normalized
using GeneSpring Software GX (Agilent Technologies). To this end, inter-
array normalization was performed by setting the raw signal threshold to
five and shifting the values of all probes to the 75th percentile. The ra-
tionale of this common normalization method is the assumption that half
of the genes on the array are not differentially expressed and, thus, be-
long to the background noise; the 75th percentile is therefore the median
of the remaining half of the genes. The 75th percentile values are thus
aligned in all arrays, ensuring equal normal distributions. Subsequent,
a within-replication normalization was carried out, performing a baseline
transformation to the median for each gene in a replicate. Flags previously
determined by the Agilent Feature Extraction software were then filtered.
For statistical evaluation, a one-way ANOVA was carried out for each gene,
asymptotic p-values were computed and the Benjamini-Hochberg False Dis-
covery Rate was applied to correct for multiple testing, resulting in q-values
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for each gene. Further, to determine the gene regulation, expression ratios
were calculated between the normalized intensity values of the treatment
and control group.
2.4.2 Functional analysis
As final evaluation step, functional analysis of the microarray data was car-
ried out. Two different methods were applied for this purpose: the single
enrichment analysis and the gene set analysis. The reason for the choice
of two analyses methods was the different intention of the manuscripts. In
chapter 5 the key mechanisms of action of a single substance, genistein,
were investigated and thus, a more restrictive method was chosen in order
to focus on the most affected pathways. This method, i.e. the single en-
richment analysis, is based on extracting most significant genes, building
clusters of genes with similar expression ratios and screening for overrepre-
sented genes in these clusters. Contrary, in chapter 3, the aim was to find
intersections of pathways and a pattern of signalling, demanding a more
sensitive and less restrictive method for analysis. To this end, a ranked
list of all genes, without setting a p-value cut-off, was subjected to gene
set analysis which determined enriched gene sets in a particular partition
of the gene list and elucidated significantly affected pathways.
Single Enrichment Analysis
For single enrichment analysis, only genes with a corrected p value below
0.01 and a fold change above 2 were selected. Tukey Honestly Significant
Difference (Tukey HSD) was chosen for post-hoc testing which determined
the particular differences between the conditions. Differentially expressed
genes were then clustered using the Self Organizing Map (SOM) algorithm,
which uses the K-means calculation to create clusters of similarly-expressed
genes and produce a two-dimensional grid to show the affinity between clus-
ters. The Manhattan function was chosen for distance measurement. In the
resulting clusters, entities lacking annotations were removed and excluded
from further analysis. The final clusters were then matched to the KEGG
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Pathway, Gene Ontology (GO) and InterPro databases using FatiGO, a
web-based tool for functional gene enrichment analysis, on the babelomics4
platform (http://www.fatigo.org). To this end, each cluster was tested
for overrepresented genes compared to the rest of the zebrafish genome,
applying Fisher’s exact test and setting the p value cut-off to 0.05.
Gene Set Analysis
For subsequent gene set analysis (GSA), all genes were ranked by their log-
transformed q-value, where the most significant upregulated genes were in
the top of the list and the most significant downregulated genes in the
bottom of the list. Only genes with annotations were used. The ranked
list was then subjected to GSA, performed with FatiGO (http://www.
fatigo.org, Al-Shahrour et al. [2007]) a web-based tool on the babelomics
platform [Al-Shahrour et al., 2005]. A Fisher exact test based partitioning
algorithm, Fatiscan, was selected to find regulated KEGG pathways, Gene
Ontology (GO) and InterPro terms in the top and the bottom of the list,
respectively. Odd’s ratios for each KEGG pathway and GO-, InterPro
term were calculated by FatiGO, reflecting the probability for pathway-
associated genes to be overrepresented in the identified part of the list.
The adjusted p-value cut-off was set to 0.1.
2.4.3 Visualization of gene set analysis
For the visualization of GSA results, the Multiple Array Viewer (MeV)
was used. All identified pathways significantly regulated by the reference
chemicals ethinylestradiol and flutamide were ranked by their odd’s ratios.
For the non-reference substances, only the significant pathways that were
also found regulated by the reference chemicals were taken into account
and visualized.
For the visualization of the most relevant GO Terms related to the
EE2 and flutamide exposures, we used REVIGO (http://revigo.irb.hr,
Supek et al. [2011]), a web-based open source tool for the visualization and
summarization of GO term lists. REVIGO reduces the redundancy of
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GO terms occurring due to the hierarchical GO structure, which results
in many child/parent- or sibling relationships. REVIGO builds groups
of similar GO terms, by taking into account the neighbourhood of the
GO terms, the adjusted p-value retrieved from functional analysis for each
GO term, and by avoiding general terms at the top of the hierarchy. A
further algorithm, the SimRel semantic similarity measurement, a default
in REVIGO, determines the diversity of the list. Four values (0.4, 0.5, 0.7
and 0.9) can be selected; the smaller the value the more condensed the
resulting list will be. We used the small value 0.5 for summarizing the
EE2 GO term list, and due to the small number of affected GO-terms the
medium value 0.7 was selected for flutamide.
The resulting parameters were exported and visualized using the Cy-
toscape 2.2 software [Shannon et al., 2003; Smoot et al., 2011]. Further,
where possible, cross links between InterPro and GO terms were manually
incorporated into the GO visualization. In this visualization, the rectangu-
lar and hexagonal shapes illustrate the identified GO and InterPro terms,
respectively. The node color indicates the regulation, with blue and yellow
color reflecting down- and upregulation, respectively. The odd’s ratio is
indicated by the node size whereas the value of the corresponding adjusted
p-value is visualized by the node opacity (opacity increases with increasing
p-values). The width of the line between the nodes signifies the degree of
similarity between the terms and is determined by the SimRel semantic
similarity measurement algorithm calculated by REVIGO.
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3.1 Abstract
Exposure to environmental chemicals known as endocrine disruptors (EDs)
is in many cases associated with an unpredictable hazard for wildlife and
human health. The identification of endocrine disruptive properties of
chemicals certain to enter the aquatic environment relies on toxicity tests
with fish, assessing adverse effects on reproduction and sexual develop-
ment. The demand for quick, reliable ED assays favored the use of fish
embryos as alternative test organisms. We investigated the application of
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a transcriptomics-based assay for estrogenic and anti-androgenic chemicals
with zebrafish embryos. Two reference compounds, 17α-ethinylestradiol
and flutamide, were tested to evaluate the effects on development and the
transcriptome after 48h-exposures. Comparison of the transcriptome re-
sponse with other estrogenic and anti-androgenic compounds (genistein,
bisphenol A, methylparaben, linuron, prochloraz, propanil) showed com-
monalities and differences in regulated pathways, enabling us to classify the
estrogenic and anti-androgenic potencies. This demonstrates that different
mechanisms of ED can be assessed already in fish embryos.
3.2 Introduction
Endocrine disruption is of high environmental concern since it affects the
reproductive health of aquatic vertebrates. For this reason, endocrine dis-
ruption has been in the focus of the hazard assessment of substances occur-
ring in the environment. Since 2007, with the implementation of REACH,
every environmental relevant substance produced by the industry has to
be tested for its endocrine potential. To this end, regulatory authorities
like the US EPA (United States Environmental Protection Agency) or the
OECD (Organisation of Economic Co-operation and Development) pro-
posed testing strategies, which also include in vitro and in vivo studies for
fish [OECD, 2006b; US EPA, 2009]. Although promising efforts have been
made to promote in vitro testing, the final decision for a substance to be
classified as endocrine active relies on in vivo data from tests with adult
animals. In order to reduce the number of animals used for, e.g., life-cycle
studies, which are regarded as a standard for assessing reproduction related
and thus considered endocrine disrupting effects for fish, alternative test
guidelines for short-term screening assays were published by the OECD
and the OPPTS (Office of Prevention, Pesticides, and Toxic Substances)
in 2009. Although these test guidelines (TG) (i.e., TG OECD 229 and
230, OPPTS 890.135) comply with the 3R’s concept of animal testing (re-
placement, reduction and refinement) by reducing the number of animals
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[Russell and Burch, 1959] and minimizing the duration of suffering from
several months to 21 days, neither of these tests replaces animals fully.
Alternative testing methods to further reduce the number of animals and
to replace current standard tests for endocrine disruption are therefore of
urgent need.
In this context, the zebrafish embryo emerged as a potential alternative
model because according to the revised European directive on the protec-
tion of animals used for scientific purposes (Directive 2010/63/EU), fish
embryos are excluded from protection. Zebrafish embryos represent whole
organisms and offer many advantages including a rapid embryonic develop-
ment (the majority of the organs develop within the first 48 hours post fer-
tilization (hpf) of the embryonic phase), small size, transparency and easy
handling. However, with regard to endocrine disruption, a disadvantage is
that any morphological effects occurring in the embryos due to exposure
cannot be associated with endocrine or reproductive disruption. In juve-
nile and adult fish, endocrine disruption is conventionally demonstrated
by impairment of sexual organs and diminished reproductive performance,
thus characteristics which are not yet developed in an embryo. Yet, by
adding gene expression analysis to the testing procedure, this problem can
partially be overcome. Previous studies have shown that omics-based ap-
proaches, which aimed at elucidating molecular responses at transcriptome,
proteome or metabolome level could provide significant information on the
mechanistic effects of chemicals [Scholz and Mayer, 2008]. Moreover, it
is being discussed whether molecular endpoints are suitable to even in-
dicate long-term phenotypic or population-relevant effects [Ankley et al.,
2010; Kramer et al., 2011]. For zebrafish, it has been reported that certain
marker genes are affected by endocrine disruptors already in zebrafish em-
bryos [Kishida et al., 2001; Muncke and Eggen, 2006]. With our study, we
now wanted to obtain more in-depth knowledge on the mechanistic effects
of endocrine disruptors in the developing embryo. To this end, we analysed
the transcriptome response of whole 48hpf zebrafish embryos after expo-
sure to the two model endocrine disruptors 17α-ethinylestradiol (EE2), an
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estrogen, and flutamide, an anti-androgen. Our aim was to elicit whether
the endocrine modes of action of these two compounds are distinguishable
at gene expression level and whether a specific expression pattern may al-
low the identification of further estrogenic or anti-androgenic substances.
We included in the analysis three additional compounds for each mode of
action, which are regarded as either mostly estrogenic or anti-androgenic.
The synthetic estradiol analogue EE2 was used as a model estrogen
due to its strong binding affinity to the estrogen receptor [Dickson and
Eisenfeld, 1981]. It is the main component of many oral contraceptive pills
and is known to be released into the aquatic environment via waste water
at concentrations harmful for aquatic vertebrates [Kuch and Ballschmiter,
2000; Purdom et al., 1994; Belfroid et al., 1999; Arukwe, 2001] and is
therefore of environmental concern.
We selected bisphenol A (BPA), genistein and methylparaben as further
estrogenic compounds. BPA is an industrial compound used to produce
polycarbonate and diverse other plastics [Staples et al., 1998]. It is known
to be released to the environment and to cause endocrine effects in aquatic
organisms [Alexander et al., 1988; Kang et al., 2007]. Due to its binding
affinity to estrogen receptors (ERs), BPA has been classified as a weak
estrogen [Krishnan et al., 1993; Ashby and Tinwell, 1998]. Genistein is a
plant-derived isoflavone with structural similarity to estradiol, which has
also been categorized as a weak estrogen [OECD, 2006b]. Further, we chose
methylparaben, which is widely used in many products for its preserving
properties [Soni et al., 2002]. Methylparaben has been reported to bind to
ERs and it has therefore been suggested to have estrogenic activity [Blair
et al., 2000; Routledge et al., 1998; Pugazhendhi et al., 2005], but there is
little data supporting its endocrine disruptive potency. Thus, we included
this rather unknown endocrine disruptor to challenge our study approach
and to test whether an estrogenic mechanism becomes apparent in the fish
embryos.
The non-steroidal compound flutamide was included as an anti-androgenic
reference since it has been used for this purpose in various validations of
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endocrine disruption assays (Hershberger Assay, Fish Sexual Development
Test OECD 234) [OECD, 2009, 2011a]. Flutamide acts as anti-androgen
by binding competitively to the androgen receptor (AR), resulting in the
inhibition of testosterone uptake and signalling and is therefore used in
prostate cancer therapy [Koch, 1984; Trump et al., 2001; Ankley et al.,
2004; Makynen et al., 2000]. In fish, this can result in morphological ef-
fects similar to those of estrogens, but despite some similarities, the mech-
anism of action at transcription level shows differences [Filby et al., 2007].
Further, it has been shown that flutamide shares more similarities with
DBT (dibenzothiophene), by not only blocking the androgen receptor, like
vinclozolin, which is a more specific AR-antagonist. This indicates a more
complex function of flutamide as expected. Despite abundant studies de-
scribing the phenotype of flutamide exposure [Panter et al., 2004; Bayley
et al., 2002], in general, only little information about the molecular mode
of action of anti-androgens and specifically flutamide, exists [Filby et al.,
2007; Martinovic´-Weigelt et al., 2011]. In this context, our study provides
supporting and complementary insight to the transcriptional effects of flu-
tamide. While flutamide itself is of low environmental concern, many other
anti-androgenic substances occur ubiquitously in the environment and may
cause reproduction-relevant effects in aquatic vertebrates. In particular,
many pesticides are known to have anti-androgenic activity and are thus
suspected to contribute to the observed reproductive effects in male or-
ganisms [Kelce et al., 1995, 1997; Orton et al., 2011; Kojima et al., 2004;
Orton et al., 2009; Kelce et al., 1998; Makynen et al., 2000; Sohoni et al.,
2001]. Given their potentially high environmental concern, we chose three
pesticides for our study, prochloraz, linuron and propanil, which have been
reported to possess anti-androgenic properties. Prochloraz is a fungicide of
the imidazole family used worldwide. Its action is based on the inhibition
of steroidogenesis [Maertens, 2004; White and Parker, 1998], but androgen
receptor antagonizing effects have also been identified for prochloraz [An-
dersen et al., 2002; Noriega et al., 2005; Vinggaard et al., 2002]. Linuron
is a urea-based and propanil an amide herbicide which have both been
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reported to competitively bind the androgen receptor [Wolf et al., 1999;
Lambright et al., 2000; Bauer et al., 1998].
Together, in this manuscript, we demonstrate the transcriptome re-
sponse to EE2 and flutamide to provide information on the mode of action
of estrogenic and anti-androgenic disruption in fish embryos. Moreover, the
transcriptome response to other estrogenic and anti-androgenic substances
will be compared to the ones of the reference compounds to extract en-
docrine pathways and anticipate a mode-of-action specific categorization
of the test compounds. With the results, we aim to show that fish embryos
are suitable for the testing of endocrine disruptive chemicals.
3.3 Material and methods
3.3.1 Fish maintenance and exposure
Adult zebrafish were maintained in 200 l glass aquaria under flow-through
conditions, with a 14:10 h light:dark photoperiod. Tap water was charcoal-
and particle-filtered, UV-sterilized, pre-heated to 26 ± 2◦C and aerated in
a 400 l storage tank before entering the aquaria. Fish were kept in large
spawning groups at a male to female ratio of approximately 2:1. The eggs
were collected in metal-mesh-covered glass spawning trays and harvested
from the aquaria one hour after light onset. Before testing, the eggs were
rinsed in 1:5 diluted ISO (International Organization for Standardization)
medium, prepared according to the Annex 2 of the OECD Guideline 203
(ISO 6341-1982) [OECD, 1992]. All animal experimental procedures were
conducted in accordance with local and international regulations. Guide-
lines on the protection of experimental animals by the Council of Europe,
Directive 2010/63/EU, which allows zebrafish embryos to be used up to the
onset of free-feeding (approximately 5 days after fertilization). The Ger-
man Animal Welfare Act (TierSchG) of 18 May 2006 (BGBL. I S. 1206)
has not yet implemented the current EU regulation, but allows the use of
unhatched fish embryos in all Federal States of Germany. Since embryos
used here were no older than two days post-fertilization, no license was
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required approved by the ethics committee of the local Federal State of
North Rhine-Westphalia.
3.3.2 Chemicals
Chemicals were purchased from Sigma-Aldrich (Munich, Germany) (17α-
ethinylestradiol E4876; flutamide F9397; bisphenol A 239658; linuron 36141;
genistein G6649; propanil 45639; methylparaben 47889; prochloraz 45631).
Stock solutions were prepared in acetone.
3.3.3 Fish Embryo Test (FET)
The fish embryo exposures were conducted in accordance with the pro-
cedures described in the first draft Test Guideline of the “Fish Embryo
Toxicity (FET) Test” [OECD, 2006a]. For prochloraz and bisphenol A,
the test solutions were prepared by directly dissolving the chemicals in 200
ml pre-aerated ISO water. For all other substances, the chemicals were
dissolved in acetone (100%) and dilutions for each concentration prepared
in 2 ml of acetone. These 2 ml-acetone stocks were transferred to 250 ml
screw-cap glass bottles (SCHOTT c©, Mainz, Germany) and evenly spread
onto the inner surface of the bottle. The acetone was then allowed to evap-
orate completely and the bottles were filled with 200 ml pre-aerated ISO
water. All test solutions were stirred at 26◦C for several hours. A solvent
control was prepared accordingly, using acetone only.
For the tests, wells of U-bottom 96-well plates (Greiner Bio-One, Frick-
enhausen, Germany) were filled with 200µl of test solution each. Plates
were saturated overnight and refilled with new test solutions before test
start. Subsequently, 24 freshly fertilized zebrafish embryos for each con-
centration and replicate were placed individually into the wells of one plate
(eggs entered the test solutions no later than 2hpf) and incubated for 48h
at 26◦C ± 1◦C. Two replicates and at least five concentrations were used to
establish a concentration response relationship. For this purpose, all lethal
and non-lethal morphological effects were recorded after 48 hours and plot-
ted as percentage total effects occurring against the exposure concentra-
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tions. A list of effects recorded is provided in the Annex Table B. From
the concentration response curves, the cumulative total effect concentra-
tions EC10 and EC20 were derived by probit analysis (ToxRat
R© Professional
2.10). The EC10 and EC20 of each chemical were used in the microarray ex-
periments. Accordingly, newly fertilized embryos were exposed for 48 hours
to 0.65 mg/l (EC10) and 0.8 mg/l (EC20) of 17α-ethinylestradiol (EE2), 1.2
mg/l (EC10) and 1.4 mg/l (EC20) of flutamide, 8.0 mg/l (EC10) and 8.5
mg/l (EC20) of bisphenol A (BPA), 0.8 mg/l (EC10) and 1.1 mg/l (EC20)
of propanil, 19.8 mg/l (EC10) and 24.4 mg/l (EC20) of methylparaben, 1.2
mg/l (EC10) and 1.3 mg/l (EC20) of linuron and 1.7 mg/l (EC10) and 2.0
mg/l (EC20) of prochloraz. ISO-water controls were included in all ex-
posures and acetone solvent controls were additionally included for EE2,
flutamide, propanil and linuron. All microarray experiments were con-
ducted with four replicates per treatment, with each replicate comprising
24 fish embryos. After exposure, the embryos were collected for RNA ex-
traction and each replicate group of 24 fish embryos was pooled together,
snap-frozen over dry ice and stored at -80◦C. The use of EC10 and EC20 con-
centrations derived specific gene responses in previous embryo exposures
and was therefore well-founded. However, in order to corroborate this as-
sumption, a subsequent concentration-response experiment was conducted
to verify the expression of the established estrogenic marker genes esr1,
esr2a, vtg1 and cyp19a1b for EE2 exposure at concentrations below and
above the EC10 and EC20 level. The experimental procedure and the results
of this experiment are presented in the supplement 3.A-1.
3.3.4 RNA extraction
Total RNA was isolated from snap-frozen, pooled embryos by homogeniza-
tion in TRIreagent (Sigma-Aldrich, T9424) using plastic pestles driven by
a hand-held grinder motor, followed by extraction with chloroform and
ethanol and final purification using RNeasy Mini Spin Columns (QIA-
GEN, Hilden, Germany) according to the manufacturers’ protocols. RNA
was then stored at –80◦C until further analysis. RNA and cRNA con-
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centrations were measured by using a NanoDrop 1000 spectrophotometer
(Thermo Fisher Scientific, Schwerte, Germany). For the microarray anal-
ysis, RNA quality was verified on an Agilent 2100 Bioanalyser (Agilent
Technologies, Santa Clara, USA). All processed RNA samples had RNA
integrity numbers between 8.8 and 9.8 and a 260/280 absorbance between
1.8 and 2.2.
3.3.5 Microarray analysis
Microarray experiments for each chemical were carried out using Zebrafish
(V2) Gene Expression Microarrays 4X44K (Agilent Technologies, Santa
Clara, USA). Each array contained 43,604 oligonucleotide probes repre-
senting 16,865 different genes (partly in duplicates, and additional non-
annotated genes) and was hybridized with 500 ng of total RNA accord-
ing to the Agilent one-color microarray hybridization protocol (One-Color
Microarray-Based Gene Expression Analysis, version 5.7, Agilent Tech-
nologies). We carried out cDNA synthesis, cRNA Cy3 labeling, amplifica-
tion and hybridization according to the manufacturer’s protocols (Quick
Amp Labeling Kit; Agilent Technologies). Microarrays were scanned with
the Agilent Microarray Scanner (Agilent Technologies) and data were ex-
tracted using Agilent Feature Extraction Software (Agilent Technologies).
The data were normalized using GeneSpring Software GX (Agilent Tech-
nologies) by setting the raw signal threshold to five, shifting the values of
all probes to the 75th percentile and performing a baseline transformation
to the median for each gene. Flags previously determined by the Agilent
Feature Extraction software, were then filtered. For statistical evaluation,
a one-way ANOVA was carried out for each gene, asymptotic p-values
were computed and the Benjamini-Hochberg False Discovery Rate was ap-
plied to correct for multiple testing, resulting in q-values for each gene.
A Tukey Honestly Significant Difference (Tukey HSD) test was chosen for
post-hoc testing, determining the particular differences between the con-
ditions. Further, to determine the gene regulation, expression ratios were
calculated between the normalized intensity values of the treatment and
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control group (ISO or, where applicable, solvent control). For subsequent
gene set analysis (GSA), only genes with annotations were used. GSA does
not depend on significance levels of individual genes. It is a threshold-free
method to identify the co-expression of functionally related genes, therefore
no p-value or log-fold change cut-offs for individual genes were applied. All
genes were ranked by their log-transformed q-value, where the most signif-
icantly upregulated genes were in the top of the list and the most signifi-
cantly downregulated genes in the bottom of the list. The q-values refer to
the comparisons of the EC10 and EC20 conditions against the correspond-
ing ISO and the solvent controls, respectively. The ranked list was then
subjected to GSA, performed with FatiGO (http://www.fatigo.org/) a
web-based tool on the babelomics platform [Medina et al., 2010]. A Fisher
exact test based partitioning algorithm, Fatiscan, was selected to find reg-
ulated KEGG pathways, Gene Ontology (GO) and InterPro terms in dif-
ferent partitions of the upper and the lower half of the list, respectively.
A subsequent false discovery rate control after Benjamini Hochberg is im-
plemented in FatiGO to correct for multiple testing and derive adjusted
p-values. The adjusted p-value cut-off for GSA, i.e. for overrepresented
gene sets, was set to 0.1. Odds ratios for each KEGG pathway and GO-,
InterPro term were calculated by FatiGO. The ratios reflect the probabil-
ity for pathway-associated genes to be overrepresented in the particular
section of the list. The adjusted p-value cut-off was set to 0.1. Functional
analysis has been carried out for both conditions, EC10 and EC20, for each
substance to confirm a concentration-dependency and to test the sensitivity
of the transcriptome response. As expected, the EC20 conditions affected
more pathways than the EC10 conditions. To ensure the highest possible
degree of intersection between the treatments and chemicals, only the in-
formation richer EC20 conditions were processed further and presented at
this point.
Microarray data have been deposited in the NCBI Gene Expression
Omnibus GEO and can be accessed through GEO Series accession number
GSE44263 and GSE34616.
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3.3.6 Visualization of functional analysis
For the visualization of GSA results, the Multiple Array Viewer (MeV)
was used. All identified pathways significantly regulated by the reference
chemicals 17α-ethinylestradiol and flutamide were ranked by their odds
ratios. For the non-reference substances, only the significant pathways
that were found regulated also by the reference chemicals were taken into
account and visualized.
For the illustration of the most relevant GO Terms related to the EE2
and flutamide exposures, we used REVIGO (http://revigo.irb.hr/, Su-
pek et al. [2011]), a web-based open source tool for the visualization and
summarization of GO term lists. REVIGO reduces the redundancy of
GO terms occurring due to the hierarchical GO structure, which results
in many child/parent- or sibling relationships. REVIGO builds groups of
similar GO terms, by taking into account the neighborhood of the GO
terms, the adjusted p-value retrieved from functional analysis for each GO
term, and by avoiding general terms at the top of the hierarchy. A fur-
ther algorithm, the SimRel semantic similarity measurement, a default in
REVIGO, determines the diversity of the list. Between four values (0.4,
0.5, 0.7 and 0.9) can be selected; the smaller the value the more condensed
the resulting list will be. We used the small value 0.5 for summarizing the
EE2 GO term list, and due to the small number of affected GO-terms the
medium value 0.7 was selected for flutamide.
The resulting parameters were exported and visualized using the Cy-
toscape 2.2 software [Shannon et al., 2003; Smoot et al., 2011]. Further,
where possible, cross links between InterPro and GO terms were manually
incorporated into the GO visualization. In this visualization, rectangular
and hexagonal shapes illustrate the identified GO and InterPro terms, re-
spectively. The node color indicates the regulation, with blue and yellow
color reflecting down- and upregulation, respectively. The odds ratio is
indicated by the node size whereas the value of the corresponding adjusted
p-value is visualized by the node opacity (opacity increases with increasing
p-values). The width of the line between the nodes signifies the degree of
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similarity between the terms and is determined by the SimRel semantic
similarity measurement algorithm calculated by REVIGO. All terms sub-
grouped to a related category and therefore not appearing in the graph are
listed in Annex table 3.5
3.3.7 Intersection analysis of affected categories in non-reference
and reference compounds
For the calculation of the alignment proportion of affected categories be-
tween the test compounds (BPA, genistein, propanil, methylparaben, pro-
chloraz and linuron) and the reference compounds EE2 and flutamide, only
the categories significantly regulated by EE2 or flutamide were taken into
account; all further categories affected by the non-reference compounds
were excluded. Further, the list of categories affected by EE2 and flu-
tamide was condensed in order to avoid redundant categories and to include
functionally different categories as far as possible. To this end, functionally
closely related categories, which had direct parent/child GO- and InterPro-
relationships, were merged and only the parent term was included in fur-
ther calculations. The categories included in the intersection analysis are
listed in tables 3.6 and 3.7. The intersection analysis was applied to the
EC20 data only.
3.3.8 Quantitative real-time PCR
Differential expression was tested by qPCR using the iQ5 real-time PCR
detection system (BioRad
TM
, Hercules, USA) and SYBR R©GreenER qPCR
SuperMix (Invitrogen, Carlsbad, USA). Identical RNA samples were used
for the microarrays and the qPCR. For cDNA synthesis, RNA was treated
with DNAse (Sigma-Aldrich, AMP-D1) and reverse transcribed using Super-
Script
TM
III Reverse Transcriptase (Invitrogen, Carlsbad, USA). A negative
cDNA control sample, without added reverse transcriptase, was included
in all qPCR measurements. Only cDNA from the EC20 exposure and the
control groups were used for the validation. 40 ng cDNA were used as
starting template and two technical replicates and a negative control were
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integrated in each experiment. After incubating for 2 min at 50◦C and for
10 min at 95◦C, targets were amplified at 95◦C for 15 s, 59◦C for 30 s and
72◦C for 30 s (40 cycles), together with the two reference genes, β-actin
and rpl13, used to normalize the expression values. The target genes and
the primer sequences for all target and reference genes are listed in Annex
table 3.3. Relative gene expression ratios were calculated by the compara-
tive Ct method (ddCt) [Pfaffl, 2001]. A student’s test was used for testing
significant differences between the EC20 conditions and the controls. For
the EE2 concentration-response study (see Annex 3.A), qPCR data were
subjected to one-way ANOVA with subsequent Dunnett’s multiple com-
parison test.
3.4 Results
3.4.1 Morphological assessment and dose response relationships
Morphological effects were assessed after 48hpf exposure and ranged from
cardiac edema to cardiovascular effect, to head and tail- deformations and
to coagulation. The effects observed for each substance at EC10 and EC20
are summarized in Table 3.1. This table also lists the corresponding
cumulative EC10 and EC20 values retrieved from the concentration-response
relationships (which are shown in supplementary figure 3.A-2).
Table 3.1: Cumulative effect concentrations and corresponding prevailing morphological effects (3.3.3)
 
Chemical Cumulative effect 
concentrations in mg/l 
Morphological effects in EC10 and EC20 
concentrations 
EC10 EC20 
EE2 (17α-
ethinylestradiol)  
0.65 0.8 reduced blood circulation, edema, coagulation 
Flutamide 1.2 1.4 reduced blood circulation, edema, coagulation, 
malformation of tail, malformation of heart 
BPA (bisphenol A) 8.0 8.5 reduced blood circulation, edema, malformation 
of tail, growth retardation 
Genistein 2.2 2.4 reduced blood circulation, edema, malformation 
of tail, growth retardation 
Propanil 0.8 1.1 edema, malformation of tail 
Methylparaben 19.8 24.4 reduced blood circulation, edema, coagulation 
Linuron 1.2 1.3 edema, malformation of head, malformation of 
tail, growth retardation 
Prochloraz 1.7 2.0 edema, reduced blood circulation 
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3.4.2 Significance analysis of microarray data
All analysed array samples passed the performance evaluation by the fea-
ture extraction software and no replicates were discarded. Statistical anal-
ysis of the normalized data revealed only few significantly regulated genes
for the reference compounds. Applying a q-value cut-off of 0.05 resulted in
33 and 44 of differentially expressed genes for EE2 and flutamide, respec-
tively. The other test compounds significantly altered more genes, with
1095 genes affected by linuron, followed by 881 genes regulated by genis-
tein, 735 genes regulated by methylparaben and 469 genes for BPA. The
number of significant genes was smaller for propanil (260) and prochloraz
(120). The low number of genes regulated by the reference compounds
indicated a rather subtle biological effect. Therefore, gene set analysis was
applied to the data, which does not depend on p-values or fold changes
cut-offs, but focuses on the co-expression of functionally related genes.
3.4.3 Gene set analysis of microarray data
The heat map of Figure 3.1 depicts the results of the Gene Set Analysis
(GSA) and shows enrichment of affected genes for KEGG pathways and
GO- and InterPro terms (data shown for EC20 only). The GSA provides
a broad overview of the transcriptome response of fish embryos to the
reference compounds EE2 (0.8 mg/l) and flutamide (1.4 mg/l) compared
to the selected estrogenic and anti-androgenic test compounds bisphenol
A (8.5 mg/l), genistein (2.4 mg/l), propanil (1.1 mg/l), methylparaben
(24.4 mg/l), linuron (1.3 mg/l) and prochloraz (2.0 mg/l). The first two
lanes (or columns) on the left show the complete set of significantly af-
fected pathways (p-value <0.1), according to the affected KEGG-, GO-
and InterPro- categories, for EE2 and flutamide; the categories are ranked
by their odds ratios. The reference compound flutamide provoked a rel-
ative weak transcriptome response (17 affected pathways) compared to
EE2, which affected a considerably larger number of pathways (60 path-
ways). For the non-reference compounds, the heat map shows only those
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affected pathways, which were also affected by either of the reference com-
pounds, i.e. the gene sets of the intersections. Overall, the non-reference
compounds affected more pathways (see Annex Tables C-1-C-8). Genis-
tein caused the strongest alterations in gene expression with 711 affected
pathways, followed by linuron, prochloraz, BPA and propanil with 251,
228, 196 and 182 pathways, respectively, and methylparaben showed the
weakest response, with 101 regulated pathways.
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Figure 3.1: Estrogenic and anti-androgenic pathways in 48hpf zebrafish embryos. Overview of
affected pathways after exposure to 17α-ethinylestradiol (EE2), flutamide and comparison to bisphenol
A (BPA), propanil, genistein, methylparaben, linuron and prochloraz. All significantly altered (p-value
<0.1) and therefore overrepresented KEGG-, GO- and InterPro-terms for EE2 and flutamide are shown
in the left two lanes (data were obtained from gene set analysis processed at the Babelomics 4 platform
(http:www.fatigo.org). For the other substances, only the equivalent pathways and their regulation
are shown. The color illustrates the odds ratios of the pathways, reflecting the probability for pathway-
associated genes to be overrepresented in the identified part of the list; yellow fields indicate pathways
containing upregulated genes, whereas blue color indicates downregulated pathways (3.3.6).
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Reference compounds A distinctive transcriptome pattern was retrieved
for the model estrogen EE2 and the model anti-androgen flutamide (Fig-
ure 3.1), clearly emphasizing that the modes of action of EE2 and flutamide
are different in the fish embryos. Apart from one InterPro term, no similar-
ities were found between the transcriptome responses of the two reference
compounds. Figure 3.2 provides a summarized view of the affected GO
and InterPro annotations as well as of the relationships between the single
categories for EE2 (Figure 3.2a) and flutamide (Figure 3.2b), respectively.
In the EE2 condition, growth related pathways, such as regulation of cell
growth and insulin-like growth factor binding were strongly upregulated,
showing the highest odds ratios (4.5 and 4.8, respectively) and signifi-
cance values (0.003 and 0.002). Highly significant was also the induction
of transcription related pathways, including biosynthesis, DNA binding
and genes associated with homeodomain-like family. Further, genes asso-
ciated with early steroid synthesis, e.g. isoprenoid synthesis, and steroid
metabolism, e.g., sulfotransferase activity, were upregulated. Response to
xenobiotic stimulus was another upregulated GO process, with the estro-
genic biomarker aromatase b and vitellogenin 1 among the affected genes.
Fewer pathways were downregulated by EE2. However, several GO terms
related to protein metabolism were downregulated, indicating a decreased
protein-turnover after EE2 exposure. Compared to EE2, the gene response
to flutamide was less diverse and affected fewer pathways and molecular
processes. The flutamide data suggest hormone activity, which is sup-
ported by the induction of the related molecular functions “receptor bind-
ing” and “neurotransmitter receptor activity” (Figure 3.2b). Further, in-
duction of genes associated with the zona pellucida sperm-binding protein
(IPR001507) (see Figure 3.1) implied an endocrine response in flutamide
exposed fish embryos.
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Figure 3.2: Visualization of estrogenic and anti-androgenic mode of actions in zebrafish em-
bryos after 48h exposure to 17α-ethinylestradiol (EE2) and flutamide. The figure shows the main affected
GO categories (biological processes, molecular functions and cellular components, depicted in rectangu-
lar shapes) and InterPro-terms (hexagonal shapes) to EE2 (A) and flutamide (B), as summarized by
REVIGO (http://revigo.irb.hr/revigo.jsp). Blue and yellow colored nodes depict downregulated
and upregulated pathways, respectively, with the node size reflecting the value of the odds ratio. The
node opacity reflects the corresponding adjusted p-value (opacity increases with increasing p-values). The
width of the line between the nodes increases with the degree of similarity between the terms (determined
by the SimRel semantic similarity measurement algorithm in REVIGO). Visualization of GO and Inter-
Pro terms was performed with Cytoscape. Terms, which were sub-grouped into a functionally related
category, do not appear in the graph, but are listed in tables 3.4 and 3.5 in the Appendix (3.3.6).
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Non-reference compounds Figure 3.1 shows also those affected pathways
of the non-reference substance, which were concordantly affected by either
EE2 or flutamide. The entire gene expression profile of each individual sub-
stance is provided in the Annex (C-1-C-8). The heat map demonstrates
that all tested non-reference substances regulated endocrine pathways. The
numbers of affected estrogenic and anti-androgenic pathways as well as
the commonalities with each reference substance, however, differ between
the substances. After calculating the ratio between the sum of estrogenic
and anti-androgenic pathways (regulated by a test compound) and the
sum of all pathways regulated by EE2 and flutamide (all pathways, which
are presented in Figure 3.1, were included in the calculation), the broad-
est endocrine responses were found for genistein, linuron and prochloraz.
They showed respectively 69%, 30% and 43% of pathway regulation agree-
ment with EE2 and flutamide. BPA and propanil affected fewer estrogenic
and anti-androgenic pathways (29% and 20%). Methylparaben showed the
weakest endocrine response with only 12% of pathways shared with the
reference compounds. The proportion of alignment of affected categories
between the test compounds and EE2 or flutamide is depicted in Figure 3.3.
Based on the number of concordantly affected pathways, a categorization
as predominantly estrogenic or anti-androgenic was achievable for BPA (es-
trogenic) as well as for propanil, linuron and prochloraz (anti-androgenic).
Most of the BPA affected endocrine pathways were in agreement with the
ones regulated by EE2. However, the anti-androgenic responses of linuron
and especially prochloraz were ambiguous as they shared many pathways
with EE2, implying other endocrine mechanisms of actions in addition to
the anti-androgenic activity. For methylparaben, all pathways were regu-
lated contrary to EE2, suggesting a predominantly anti-estrogenic activ-
ity. Genistein affected proportionally more anti-androgenic than estrogenic
pathways. However, the large overlap with flutamide and EE2, suggested
a dual or multiple mode of action for genistein. Therefore, genistein can be
considered as an anti-androgenic as well as an estrogenic acting compound.
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Figure 3.3: Pathway intersections between bisphenol A (BPA), genistein, propanil, linuron or prochlo-
raz and the reference compounds 17α -ethinylestradiol (EE2) and flutamide. For each substance, the per-
centage reflects the ratio of the number of equally and differently regulated GO-, KEGG- and InterPro-
pathways, compared to the number of all pathways affected by the reference compounds. Functionally
closely related pathways (i.e. direct parent/child GO-and InterPro relationships) were merged prior to
the calculation of the ratios (3.3.7). The pathways included in the calculation are listed in Tables 3.6 and
3.7.
Estrogenic and anti-androgenic transcriptome patterns When comparing
the expression profiles of the estrogenic substances EE2, BPA and genis-
tein, an intersection of commonly affected pathways became apparent. All
substances induced the GO category “response to xenobiotic stimulus”,
which comprises also the estrogenic biomarker genes cyp19a1b and vtg1.
The upregulation of these genes has been confirmed by qPCR for EE2,
BPA and genistein (data not shown for EE2 and BPA; for genistein, the
validation has been published in Schiller et al. [2013]). Further, all sub-
stances regulated terpenoid backbone pathway genes, a KEGG analogue to
the GO biological process “isoprenoid synthesis”. The regulation for BPA,
however, was opposite to EE2 and genistein. Moreover, growth related
categories, such as “regulation of growth” and “growth factor binding”
were induced by the estrogens. Among the corresponding gene sets, regu-
lation affected genes encoding for proteins of the IGFBP superfamily, such
as ctgf (connective tissue growth factor) and igfbp1 (insulin-like growth
factor binding protein 1 ), which were upregulated by BPA, genistein and
EE2. The regulation of hox genes was also identified for the estrogenic
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compounds, with EE2 and BPA showing up- and genistein downregulation
of these genes. Lastly, our data suggest some alterations of the energy
metabolism since an enrichment of downregulated genes of the ATP bind-
ing category was found for all estrogenic substances.
The expression profiles of propanil, linuron, prochloraz and genistein
showed commonalities with the anti-androgen flutamide. Like flutamide,
linuron and prochloraz upregulated genes associated with neurotransmit-
ter receptor activity, which included several neuropeptide y receptor iso-
forms (npy1r, npy4r, npy7r) as well as kisspeptin receptors (kiss1b for
prochloraz and flutamide and kiss1ra for linuron). In addition, prochloraz
and flutamide induced hormone activity related genes, such as gnrh (go-
nadotropin releasing hormone) (flutamide and genistein), lhbeta 1 (luteiniz-
ing hormone beta 1 ) (flutamide) and fshb (follicle stimulating hormone
beta (prochloraz), and linuron and prochloraz induced genes associated
with the zona pellucida sperm-binding protein domain. Propanil shared
affected pathways with flutamide, which are related to amino acid and
purine metabolism as well as hydrolase activity.
Validation of microarray results For the validation of the microarray re-
sults, gene expression analysis of selected genes for all tested compounds
was performed by quantitative real-time PCR (qPCR). For genistein, the
validation has previously been shown and described in Schiller et al. [2013].
For all other substances, genes were selected for validation, which showed
an adjusted p-value below 0.05 in the microarray significance analysis and,
if possible, appeared in the gene sets retrieved by GSA. QPCR was also
applied to evaluate a concentration-dependency of established estrogenic
marker genes after exposure to EE2. The qPCR validation confirmed the
microarray results for the selected genes in terms of significant up- or down-
regulation. On the other hand, a concentration-dependency could not be
established for the expression of esr1, esr2a, vtg1 and cyp19a1b, verifying
the suitability of the EC10 and EC20 concentration levels for the analysis
of compound specific gene regulation, exclusive of systemic toxicity effects.
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The corresponding data are available from the supplementary material in
Annex 3.A and 3.A-3.
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3.5 Discussion
We performed microarray analyses with eight substances known to have
an endocrine disruptive potential. The selection of those substances was
based on existing data from the literature suggesting either an estrogenic
and/or an anti-androgenic mode of action. Two substances were used as
reference compounds for estrogenicity and anti-androgenicity, i.e. the es-
trogen receptor agonist 17α-ethinylestradiol (EE2) and the androgen recep-
tor antagonist flutamide. We focused our analysis on the gene expression
profiles of the reference substances to firstly, characterize typical estrogenic
and anti-androgenic transcriptome effects in developing fish embryos, and
then, secondly, to discriminate these features in the transcriptome response
of other substances suspected to have a similar endocrine mode of action.
To extract the endocrine related features from the non-reference transcrip-
tome responses, we compared the affected pathways with those regulated
by the reference substances and based on these comparisons, the chemi-
cals were categorized as either estrogenic or anti-androgenic. Afterwards,
we compared the gene expression results with existing data for adult ze-
brafish or, where not available, for other fish species, exposed to the same
chemicals. The aim was to find coherences between the alterations in gene
expression and the regulatory relevant apical effects defining the endocrine
disruptive potency. The key question we aimed at answering was whether
the results from the zebrafish embryos may be used to extrapolate to later-
on effects in adult fish, and consequently, render fish embryos as suitable
alternative models for testing endocrine disruption.
Even though the statistical analysis of single genes revealed only few
significantly regulated genes at low EC10 and EC20 level exposures to EE2
and flutamide, the gene set analysis showed many affected pathways, giving
a broad insight into the mechanistic effects of these two endocrine disrup-
tors in developing fish embryos. The transcriptome patterns of EE2 and
flutamide were very specific and distinct with only one pathway equally af-
fected. This reflected a mechanistic specificity of the reference substances.
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Furthermore, it also demonstrated the potential of transcriptome analy-
ses to identify different modes of endocrine action in fish embryos. By
comparing the regulated estrogenic and anti-androgenic pathways of the
test substances with those affected by the reference compounds, a general
classification of these substance as either predominantly estrogenic or anti-
androgenic was possible. A clear categorization of the tested non-references
compounds to a specific endocrine mode of action, however, was not pos-
sible. This is not surprising since the evidences in the literature suggest
rather ambiguous endocrine activities for these compounds [Gordon et al.,
2004; Hofmeister and Bonefeld-Jørgensen, 2004; Salazar et al., 2006; Rime
et al., 2010], which would certainly reflect upon the transcriptome response.
Estrogenic and anti-androgenic transcriptome responses in fish embryos EE2
exposure induced terpenoid backbone pathways in fish embryos. Since ter-
penoids (synonymous with isoprenoids) are required for the de novo syn-
thesis of cholesterol, which is a component of plasma membranes and a
precursor for steroid hormones, induction of this pathway may indicate an
enhanced steroidogenesis. Together with an increased sulfotransferase ac-
tivity, pointing to an increased sulfonation of estrogens [Ohkimoto et al.,
2003], and the induced “response to xenobiotic stimulus,” which involves
the regulation of the estrogenic marker aromatase and vitellogenin, our
data provide multiple evidence of an estrogenic response at gene expres-
sion level for EE2. Furthermore, the transcriptome response of the embryos
showed induction of genes involved in growth regulation, with related tran-
scription pathways like “regulation of cell growth and insulin-like growth
factor binding protein” induced accordingly. In this context, the upregu-
lation of Hox genes can likely be attributed to the stimulation of growth.
Hox genes have a key function in embryonic development and thus, are
likely to be affected when growth is stimulated. Few pathways were down-
regulated, among which was “ATP binding”, indicating alterations of the
energy metabolism. The identified gene set comprised 454 genes, what
would suggest a considerable impact of EE2 on ATP binding.
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Other than EE2, flutamide impacted only few pathways. However,
an endocrine effect was apparent since genes related to neurotransmitter
and hormone activity, including members of the hypothalamic-pituitary-
gonadal axis (e.g. gh, gnrh3, lhbeta, npy1r) were induced. Further indi-
cation for endocrine disruption was provided by the upregulation of genes
associated with the estrogenic marker zona pellucida sperm binding pro-
tein. Zona pellucida proteins are part of the chorion and are essential for
the sperm-oocyte interactions. Our data now demonstrate that these genes
can be regulated by anti-androgenic compounds in fish embryos.
Together, our data show that estrogenic and anti-androgenic compounds
induce distinctive transcriptome responses in 48hpf embryos. When com-
paring our data to EE2 microarray studies conducted with adult zebrafish
(Table 3.2), an intersection of pathways affected both in embryos and adults
became apparent, among which were IGF signalling, hox gene regulation,
steroid biosynthesis and sulfotransferase activity. Flutamide exposure of
adult zebrafish and medaka altered hormone activity and zona pellucida
gene regulation [Filby et al., 2007; Haut, 2005], in coherence to our fish
embryo results. Despite of the not yet developed reproductive system in
fish embryos, our data provide some evidence that estrogenic and anti-
androgenic exposure related effects at gene expression level are already
similar to adult fish.
The gene response patterns of estrogens BPA and genistein induced similar
regulative pathways and genes as EE2. The fact that BPA showed most
commonalities with EE2 and shared only a few pathways with flutamide, is
in accordance with the literature, which mostly evidenced estrogenic prop-
erties [Krishnan et al., 1993; Ashby and Tinwell, 1998; Andersen et al.,
1999; Fisher et al., 1999], and only a few indications for an anti-androgenic
mechanism of BPA are given [Haubruge et al., 2000; Hatef et al., 2012].
The response pattern of genistein indicating equally estrogenic and anti-
androgenic properties also reflects existing evidence of its ambiguous mode-
of action, ranging from estrogenic [Scholz et al., 2004; Zhang et al., 2003;
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Table 3.2: Comparison of embryonic and adult gene response to EE2
GO annotation 48hpf
zebrafish
embryos (48h
exposure,
800 ng/l)
Martyniuk et al.
[2007]: Adult
males (21d
exposure to
10 ng/l EE2)
Hoffmann et al.
[2006]: Adult females
(24h or 168h exposure
to 15, 40, 100 ng/l
EE2)
IGF signalling up up up (all concentrations)
Hox gene regulation up up -
ATP binding down ATPase down -
DNA replication and
proteolysis
down down -
Growth up - down (24h, 100 ng/l)
Sulfotransferase ac-
tivity
up - up (168h, 100 ng/l)
Peroxisome down - down (24h, 100 ng/l)
Isoprenoid synthesis up - sterol biosynthesis,
up (24h, 40 and 100 ng/l)
Cellular biosynthesis up - up (24h: 15, 40, 100 ng;
168h: 100 ng)
Sassi-Messai et al., 2009; Schiller et al., 2013], anti-estrogenic [Fritz et al.,
2002; Dang et al., 2006], androgenic [Bektic et al., 2004], to anti-androgenic
[Rosenberg Zand et al., 2000] and even thyroidal [Sosic´-Jurjevic´ et al.,
2010]. In this context, the inclusion of additional endocrine mode of action
specific reference compounds would have facilitated the elucidation of the
full spectrum of endocrine mechanisms of genistein. However, our data cor-
roborate a principally estrogenic effect of genistein, since genes associated
with the biological process “response to xenobiotic stimulus” were specif-
ically induced, which was unique to genistein and the estrogens EE2 and
BPA. The corresponding GO term included genes encoding for markers
of estrogenic disruption [Sumpter and Jobling, 1995; Kishida et al., 2001;
Tseng et al., 2005; Scornaienchi et al., 2010], like the yolk precursor pro-
tein vitellogenin and aromatase b (cyp19a1b), the testosterone converting
iso-enzyme, as well as for the metabolizing enzymes cyp1 and cyp3a65.
The induction of the estrogenic biomarkers vtg1 and cyp19a1b in zebrafish
embryos is in accordance with other studies [Kishida et al., 2001; Muncke
and Eggen, 2006] and substantiates the evidence that fish embryos already
express endocrine biomarker genes, which can be regulated by estrogenic
exposure. A pathway upstream of steroidogenesis, the terpenoid backbone
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synthesis, was regulated by all three estrogenic substances. For EE2, this is
consistent with previous in vitro and in vivo studies reporting elevated ter-
penoid and cholesterol synthesis in response to EE2 [Cypriani et al., 1988;
Sharpe et al., 2007]. It is also in line with observations in adult zebrafish
showing upregulated genes involved in cholesterol biosynthesis [Hoffmann
et al., 2006]. For genistein, induction of steroid hormone synthesis has
been reported for adult fish [Zhang et al., 2002; Kiparissis et al., 2003] as
well. Contrary to EE2 and genistein, BPA downregulated steroidogenic
genes. However, this is in accordance with other studies showing that
BPA reduces steroidogenic enzymes and cholesterol uptake in the mito-
chondria of fish and mammals [Peretz et al., 2011; Ye et al., 2011]. Since
steroid hormones regulate sexual development and function and secondary
sex characteristics in fish, alterations of steroidogenesis can have severe
reproductive effects [Brantley et al., 1993]. It has been shown that disrup-
tion of steroidogenesis in fish embryos can affect early gonad development
in zebrafish [Thorpe et al., 2004; D’Amico et al., 2007]. Early effects can
manifest in adult fish through e.g., gonadal abnormalities as demonstrated
for exposures to estrogens [Van den Belt et al., 2003; Kawamura et al.,
2002; Kiparissis et al., 2003; Fenske et al., 2005]. Growth related path-
ways were induced by the estrogenic compounds and in particular, ctgf,
igfbp1 and further members of the Igfbp superfamily were enriched in the
appropriate gene sets. Due to their Igfbp homology domain, the proteins
encoded by those genes can bind to Insulin-like growth factor (IGF) and
modulate its action. IGF is an important factor for growth regulation
and cell differentiation [Jones and Clemmons, 1995] and has already been
suggested to mediate growth related effects of estradiol and EE2 in fish
[Yager et al., 1994; Kelley et al., 2002; Shepherd et al., 2007; Kamangar
et al., 2006; Shved et al., 2008; Norbeck and Sheridan, 2011]. Our data
are even consistent with studies reporting increased igfbp1 expression after
EE2 exposure of adult zebrafish [Hoffmann et al., 2006; Martyniuk et al.,
2007]. The interaction between the IGF system and estrogens might be
mediated by membrane localized estrogen receptors, since ctgf and cyr61
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(cysteine-rich, angiogenic inducer, 61 ) were identified as important target
genes of gper (g-protein-coupled estrogen receptor, synonymous to gpr30 )
signalling in nuclear estrogen receptor negative breast cancer cells [Pandey
et al., 2009]. Further, induction of ctgf mediated by gper signalling [Pupo
et al., 2012] was specifically reported for BPA. Altogether, our data indi-
cated a growth promoting effect of the estrogenic compounds. However,
rapid growth stimulation in embryos may result long-term in growth retar-
dation, as suggested by some studies [Yager et al., 1994; Hoffmann et al.,
2006].
In accordance with other studies, genes such as hoxa9, hoxa11, hoxb4a,
hob4b and hoxc6 were regulated by EE2, BPA and genistein. These genes
are required for the differentiation of female primary sex characteristics and
are relevant for the reproductive function [Taylor et al., 1998, 1999; Daf-
tary and Taylor, 2006]. Hoxa9 and hoxa11 are known to be regulated in an
ER-dependent manner by estradiol as well as BPA and genistein [Daftary
and Taylor, 2006; Taylor et al., 1999]. A study with adult zebrafish demon-
strated hox gene regulation after EE2 exposure [Martyniuk et al., 2007].
Genistein downregulated hox genes, probably due a strong proapoptotic
effect previously reported by us [Schiller et al., 2013] and other authors
[Schmidt et al., 2008; Ding et al., 2003; Kim et al., 2009; Sassi-Messai
et al., 2009], which superimposes the estrogenic activity thereby inhibiting
hox expression. Nevertheless, our findings suggest that sex steroids play a
role in hox gene regulation in fish embryos, which in turn could potentially
impact on the development of the reproductive system.
Genes related to the molecular function “ATP binding” were decreased
in EE2, BPA and genistein exposed embryos. For example, genes encoding
for diverse ATPases were overrepresented in this gene set (e.g atp1a1a.4,
atp1a1a.5 atp1a2a, atp1a3a, encoding for polypeptides of Na+/K+ trans-
porting ATPase or atp2a1, encoding for Ca2+ transporting ATPase). AT-
Pases hydrolyze ATP to ADP in order to provide energy to the cell. A
decreased ATPase activity affects all energy consuming processes like os-
moregulation, DNA replication or proteolysis. For EE2, a disruption of
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these processes and also of sperm cell activity through ATPase inhibition
has been shown earlier at gene expression [Perkins and Diffley, 1998; Her-
big et al., 1999; Petersen et al., 2001; Martyniuk et al., 2007; Montgomery
et al., 2012; Hashimoto et al., 2009; Lerner et al., 2007] as well as protein
level [Miccio et al., 1989; Simon et al., 1996]. BPA and genistein showed
impaired gene regulation of ATP turnover, too. Instead of downregulating
ATPases, BPA rather causes mitochondrial dysfunction and ATP depletion
by reducing oxidoreductase activity [Nakagawa and Tayama, 2000], as also
indicated by our data showing downregulation of “oxidoreductase activity”
and of genes encoding mitochondrial components. In fish, ATP-depleting
effects of BPA have been associated with reduced sperm count and sperm
motility [Haubruge et al., 2000; Hatef et al., 2012]. The decreased ex-
pression of ATP binding related genes by genistein can be related to the
inhibition of enzymes containing ATP binding sites [Barnes and Peterson,
1995; Polkowski and Mazurek, 2000]. In accordance with BPA and EE2,
ATP depletion by genistein may also affect sperm motility in fish [Green
and Kelly, 2008; Tao et al., 2009]. Overall, there is some evidence that a
decreased ATP level long-term may impair sperm function in adult fish,
and this would certainly affect population relevant endpoints.
Methylparaben is considered as an estrogen but the exact endocrine
mode of action of methylparaben is not yet well understood. Several studies
reported an estrogenic activity due to ER binding [Blair et al., 2000; Rout-
ledge et al., 1998; Pugazhendhi et al., 2005] or indicate interference with
estradiol homeostasis through inhibition of sulfotransferases [Prusakiewicz
et al., 2007; Tavares et al., 2009]. At the same time, androgenic activ-
ity (AR binding) [Leskinen et al., 2005], anti-androgenic properties [Chen
et al., 2007] as well as anti-estrogenic, i.e. aromatase inhibiting, effects
[Van Meeuwen et al., 2008] have been suggested for methylparaben. In
our study, methylparaben showed a relatively weak but exactly contrary
response to EE2. Corroborating the assumption of an anti-estrogenic activ-
ity, it has been shown that propylparaben, another member of the paraben
group, elicits anti-estrogenic gonadal effects in zebrafish, which were not
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ER mediated [Mikula et al., 2006, 2009]. However, to substantiate the
hypothesis of a primary anti-estrogenic mode of action in fish embryos,
the transcriptome response of methylparaben needs to be compared to ref-
erence anti-estrogens ancd androgens, like the ER antagonist fulvestrant
or AR agonist methyltestosterone, what we plan to do shortly. In sum-
mary, BPA and genistein shared many similarities in the gene response with
EE2, including pathways related to xenobiotic stimulus and growth, altered
steroidogenesis and induction of hox genes. Besides, ATP binding related
genes were downregulated. BPA mainly affected pathways classified pre-
dominantly estrogenic, which is consistent with numerous studies reporting
an estrogenic mode of action for BPA [Krishnan et al., 1993; Ashby and
Tinwell, 1998; Andersen et al., 1999; Fisher et al., 1999]. For genistein, the
upregulation of cyp19a1b and vtg1 evidenced an estrogenic impact but the
extent of similarities with flutamide also suggests an anti-androgenic com-
ponent in its activity. A multiple mode of action response of genistein was
anticipated from previous studies [Rosenberg Zand et al., 2000; Fritz et al.,
2002; Basak et al., 2008; Pihlajamaa et al., 2011] and indeed manifested in
the transcriptome response of the embryos. For methylparaben, our data
suggest a mode of action contrary to EE2, but to verify an anti-estrogenic
activity, further investigations are required.
The gene response pattern of antiandrogens The transcriptome responses of
the anti-androgenic substances prochloraz, linuron and propanil were less
defined than of the estrogens, with the molecular mechanisms obviously
differing between the compounds. The ambiguous response of genistein
has been discussed above. No regulated pathways were shared between
all of the anti-androgenic substances tested. However, the individual sub-
stances shared pathways with the reference compound flutamide, and rel-
atively more anti-androgenic pathways were affected than estrogenic. This
implies that an anti-androgenic mode of action was apparent in the fish
embryos. Similarly to flutamide, linuron, prochloraz and genistein induced
genes related to neurotransmitter activity. We found several members of
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neuropeptide y receptors (npy1r, npy4r, npy7r) as well as kiss1r recep-
tors in the identified gene sets. In fish and mammals, the stimulation of
neuropeptide Y (NPY) leads to the secretion of gonadotropin releasing
hormone, an essential hormone in the hypothalamus-gonadal axis, which
is also important for the neuronal development in fish embryos [Onuma
et al., 2011] and the release of the gonadotropic hormones LH and FSH
[Chen et al., 2009; Peng et al., 1994; Gaikwad et al., 2005; Ward et al.,
2009; Campos et al., 2010]. NPY is known to be stimulated by steroids in
fish, whereby androgens appear more effective than estrogens [Peng et al.,
1994]. This stimulation is part of a positive steroid feedback regulation
and is probably mediated by kisspeptin receptors [Seminara et al., 2003;
Kim et al., 2010; Mitani et al., 2010]. Since very little is known about
the impact of anti-androgens on neurotransmitter activity in fish, our data
provided new information on the mechanisms of anti-androgens. Anti-
androgens affect the signalling downstream of NPY, and flutamide e.g.,
demonstrated to alter GnRH expression in juvenile catfish after 50 day of
exposure [Chakrabarty et al., 2012; Rajakumar et al., 2012]. Prochloraz
showed a LH-like effect in rainbow trout [Rime et al., 2010], and the in-
duction of LH has been associated with the induction of genes required
for androgen biosynthesis, like cyp17 and 11βhsd. These genes were up-
regulated by flutamide also in adult fathead minnow [Filby et al., 2007].
These findings are in line with our results, which indicate the induction
of genes encoding for GnRH and gonadotropins within the GO category
“hormone activity”, for prochloraz and flutamide. We therefore hypothe-
size that the regulation of genes associated with the HPG axis is targeted
by anti-androgens in fish embryos. Given that the HPG axis is crucial
for reproduction, gene regulative impairments in the embryos may lead
long-term to reproductive and thus, population relevant effects. Common
between linuron, genistein and flutamide was the induction of genes associ-
ated with the InterPro domain zona pellucida (ZP) sperm binding protein
and its subfamily endoglin/CD105 antigen subgroup. In adult female fish,
ZP genes are expressed in liver and ovary, whereas in fish embryos, they
64 3. Transcriptome pattern in zebrafish
are maternally derived and can be detected until 3dpf [Onichtchouk et al.,
2003; Mathavan et al., 2005]. ZP proteins have been shown to be estrogen-
responsive [Del Giacco et al., 1998] in zebrafish and are known as estrogenic
biomarkers. Flutamide has shown to enhance zona pellucida homologues
(choriogenin L and choriogenin H) in medaka fish [Haut, 2005]. Alterations
in zona pellucida-sperm binding have been observed also after genistein ex-
posure [Furuya et al., 1994]. Besides, the zona pellucida domain is part of
other extracellular proteins, such as endoglin (or CD105), a co-receptor for
members of the TGFbeta (Transforming growth factor beta) family, e.g.
TGFbeta I and III [Barbara et al., 1999]. In this context, flutamide has
been reported to alter TGFbeta signalling in mammals and fish [Evangelou
et al., 2000; Jensen et al., 2004; Marie et al., 2005]. Although flutamide,
genistein and linuron may induce zona pellucida binding domain containing
genes, the zona pellucida genes in the embryos are still maternal, and the
upregulation should therefore not be interpreted as an embryonic endocrine
response.
Propanil and flutamide shared the induction of genes associated with
hydrolase activity and cellular amino acid processes. Both processes are
rather unspecific and therefore hard to link to any particular endocrine
mechanisms. Altogether, propanil, linuron, prochloraz and genistein share
regulated pathways with flutamide, and the degree of similar regulation of
between 20% and 56% for linuron, prochloraz and genistein was higher than
for propanil. As previously described for genistein, linuron, prochloraz and
propanil shared pathways with EE2, additionally to the commonalities with
flutamide. This is coherent with the current literature reporting apart from
anti-androgenic also estrogenic activities for prochloraz [Hofmeister and
Bonefeld-Jørgensen, 2004; Rime et al., 2010], linuron [Gordon et al., 2004]
and propanil [Salazar et al., 2006]. These herbicides are known to interfere
with several sites of steroidogenesis [Lambright et al., 2000; Salazar et al.,
2006; Skolness et al., 2011] and thus, can elicit effects similar to EE2,
like induced oocyte maturation or feminized male offspring as reported for
prochloraz [Rime et al., 2010; Kinnberg et al., 2007; Vinggaard et al., 2002].
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Altogether, our transcriptomics-based fish embryo test approach man-
aged to reveal estrogenic and anti-androgenic mechanisms in the responses
of the reference and the test compounds. The proportional alignment of
regulated pathways of the test compounds in comparison to the reference
compounds exposed the predominant mode of actions for each test com-
pound, but also elicited putative multiplicity in the molecular mechanisms.
The fact that our data widely reflected the modes of action described for
each test compound elsewhere in the literature underscores the strength
of our approach. Nevertheless, for some EDCs like genistein or methyl-
paraben, the inclusion of reference compounds of additional endocrine
modes of action, such as androgenic, anti-androgenic and thyroid mode
of action, is indicated to allow an inevitably reliable classification.
3.6 Conclusion
The present study provides convincing evidence that estrogenic and anti-
androgenic disruption manifests in fish embryos at the molecular level. The
transcriptome response patterns of the reference compounds EE2 and flu-
tamide were clearly discernible and highlighted specific endocrine disrupt-
ing activities. Exposure to the estrogen receptor agonist EE2 enhanced
estrogen-dependent gene pathways that are also relevant for the develop-
ment of the embryos. Whereas EE2 predominantly affected pathways re-
lated to growth promotion, disruption of steroidogenesis and hox gene reg-
ulation, flutamide characteristically influenced neuroendocrine pathways.
Besides, coherences between the gene expression changes in the embryos
and endocrine disruption related effects occurring in adult fish after ex-
posure to the same compounds strengthen our hypothesis that fish em-
bryos are suitable for the identification of endocrine disruption in fish. We
demonstrated that the transcriptome response profiles of the zebrafish em-
bryos allowed for a categorization of compounds as either estrogenic or
anti-androgenic when compared to the profiles of the references EE2 and
flutamide. This worked well for BPA and propanil. For genistein, es-
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trogenic as well as for anti-androgenic activities were demonstrated. Our
results for methylparaben confirmed the inconclusive and ambiguous find-
ings of the literature, but hint to an anti-estrogenic mode of action, which
we still have to verify. The expression profiles of prochloraz and linuron
reflected the ambiguous partly anti-androgenic as well as estrogenic mode
of action reported for these compounds in current literature. In conclusion,
we propose that zebrafish embryos at the prehatching stage of 48 hours are
suitable models for the detection of endocrine disruption. The combina-
tion of transcriptomics and fish embryo testing proved very promising for
the identification of either estrogenic or anti-androgenic activity of com-
pounds. It is therefore a very viable and sensible alternative to long-term
fish tests in the context of endocrine disruption. Evidently, further po-
tentially estrogenic and anti-androgenic compounds need to be tested to
validate the fish embryo transcriptomics approach. Besides, transferability
of this approach to the other endocrine modes of action, such as andro-
genicity, anti-estrogenicity or thyroid disruption has to be tested. For a
scientifically sound validation of the test method, the inclusion of additional
positive and negative reference compounds will be necessary to unequiv-
ocally discern mode of action specific patterns and to exclude substance
specific non-endocrine effects. Important to consider when this approach
should be applied as a rapid screening system, is to eventually replace also
the costly and analysis intensive microarrays. Instead, a set of genes rep-
resentative for endocrine mode of action specific marker pathways should
then be used and measured by quantitative PCR.
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3.A Appendix
Concentration-response to EE2
Methods: For the EE2 concentration-response experiment, five expo-
sure concentrations were applied in total, of which four were ranging from
0.8 – 800 µg/l EE2 divided by a spacing factor of 10 (i.e. 0.8, 8, 80 and
800 µg/l EE2) and one concentration corresponded to the EC50 value of
the previously established concentration-response relationship for EE2 (fig-
ure 3.A-2). The test was conducted using three replicates, comprising 24
individuals each. ISO-water and solvent controls were included accordingly.
The embryo collection and RNA extraction corresponded to the procedure
described for the microarray experiments.
Results: The exposure concentration-response relationship for EE2 did
not show any concentration dependency for aromatase b cyp19a1b, vitel-
logenin 1 vtg1, estrogen receptor 1 (esr1 ) nor estrogen receptor 2a (esr2a)
(3.A-1). Although upregulation of cyp19a1b and vtg1 were identified al-
ready in the lowest concentration tested (0.8 µg), the only significant up-
regulation was identified in the EC20 exposure (800 µg). The expression
profiles of the estrogen receptors esr1 and esr2a did not show any regulation
after EE2 exposure in any concentration. These results provide evidence,
for a chemical specific rather than a systemic toxicity-related effect on gene
expression testing at the EC10 and EC20 concentration level in case of EE2.
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Figure 3.A-1: Differential expression of cyp19a1b (aromatase b), vtg1 (vitellogenin 1 ), esr1 (estrogen
receptor 1 ) and esr2a (estrogen receptor 2a) after 48h exposure to 0.8, 8, 80, 800 and 1000 µg/l EE2 in
48hpf zebrafish embryos, determined by quantitative rtPCR. Expression ratios were calculated according
to the (2∆∆Ct) method [Pfaffl, 2001] method and normalized to solvent control references. Results
represent the mean ± standard error of the mean (SEM) of the expression ratio of three replicates
with each comprising 24 embryos per treatment. Error bars indicate SEM. P-values were determined
by one-way ANOVA with subsequent Dunnett’s multiple comparison test and are indicated by asterisks
(*=<0.05).
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Table 3.3: Target genes and primer sequences used in qPCR analysis
Gene Accession Primer Sense Primer Antisense
18s FJ915075.1 TCGCTAGTTGGCATCGTTTATG CGGAGGTTCGAAGACGATCA
rpl8 NM 200713.1 CCGAGACCAAGAAATCCAGAG CCAGCAACAACACCAACAAC
rxfp3 NM 001128788.2 ATGAGCGTCGCGAGATACTG CCTCGTTAGAAACCGTGGCT
gh1 NM 001020492.2 GCATCAGCGTGCTCATCAAG TGAGACTGGTCTCCCCTACG
ins NM 131056.1 ATCCACCATTCCTCGCCTCT TGCTTACACTGGACACGACC
npy8br NM 131436.1 CCTCTCATGCTCCGACATCC CTGCTACGGCCAGGTATGAG
gnrh2 NM 181439.4 GGCTGATGCTGTGTCTGAGT TGTTTCTTCCCTGCGGTCTC
oxtl NM 178291.2 GAAAGGCCTGCGGTTATGAG CTGTTGGCCGGTTGATTGAC
zp 3.1 NM 001109741.1 ACTGCAACAGTGTGGTGATG TAGTGGCACTGAACACCAAC
esr1 NM 152959.1 ACAAAGGAATGGAGCACTTA GTGTAGATGGAGGGTTTTTC
esr2a NM 180966.2 AGAGTCGACTTCAACAGAAC TCTCCTCTGTATCTGCTACC
cyp19a1b NM 131642.1 GCTCCAGACACGCTCTCCAT CATCCTCCAGAGACTGCCTCA
hmgcra NM 001079977.1 AAAGTCACATGACTCACAA ACTGATGTAAATGTACAGACTT
mvd NM 001007422.1 GCATCAAGATCACCTGAGAAC TATGGACCTTGTTGCTGACA
sc4mol NM 213353.1 CCACCGAGCTCTACATCATC AAGAGGGTGGGCATATTCTG
igfbp1a NM 173283 TAATAAAGAGAGCATGAAGG AGGTAGAATCTGGTCAATTT
igfbp1b NM 001098257 GTCTCACTATAGCCAGTTTT TATACACACATTAACCCAAC
cyr61 NM 001080987 ATGACTGTAGGTTTGTCTTT CGTATACAAGCGAGAGTCTA
hoxa10b NM 131155.1 AAGGGGGTCCACTGGCACCG TCGCCGTCAGCCAGTTAGCTG
hoxa11b NM 131147.1 GCGGCAGCAGCAATGGACAAAAG CGGTCAGTGAGGTTGAGCATTCTG
vtg1 NM 001044897.2 GCAGCCTTGCCATCTCAGAGGTCC TGGATTGATGGGAACAGCGACAGGA
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Figure 3.A-2: Concentration–response to 48h exposure of 17α-ethinylestradiol, flutamide, bisphenol A,
genistein, methylparaben, propanil, linuron or prochloraz in zebrafish embryos. Newly fertilized zebrafish
embryos were exposed to at least five concentrations of each test compound for 48h (3.3.3). The con-
centration x-axis is logarithmic. The graph shows data points (black points) depicting the mean±SD
percentage number of occurring effects (lethal and non-lethal) in each concentration, the calculated func-
tion (black full line) and the 95% confidence levels (dashed lines), referring to two replicates comprising
24 individuals each (function and confidence levels were retrieved by probit analysis, ToxRat R©).
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Table 3.4: EE2 REVIGO attributes: GO and InterPro terms (in italics) sub-grouped into a functionally
related category (in regular) (for visualization in Figure 3.2A)
Accession
term
Description Adjusted
pvalue
GO molecular function
GO:0003700 sequence-specific DNA binding transcription factor activity 0.00210185
GO:0004950 chemokine receptor activity 0.0484939
GO:0008146 sulfotransferase activity 0.0528342
GO:0005520 insulin-like growth factor binding 0.00232739
GO:0019838 growth factor binding 0.010987
GO:0019956 chemokine binding 0.0484939
GO:0003676 nucleic acid binding 0.000710134
GO:0005515 protein binding 0.00267521
GO:0016787 hydrolase activity 0.0573522
GO:0005524 ATP binding 0.0696629
GO:0001882 nucleoside binding 0.0696629
GO:0003677 DNA binding 0.0742797
GO:0043565 sequence-specific DNA binding 0.00210185
GO biological process
GO:0001503 ossification 0.064803729
GO:0001558 regulation of cell growth 0.003097419
GO:0040008 regulation of growth 0.003097419
GO:0016049 cell growth 0.006897632
GO:0008299 isoprenoid biosynthetic process 0.06095369
GO:0006974 response to DNA damage stimulus 0.065132838
GO:0009058 biosynthetic process 0.069055774
GO:0006259 DNA metabolic process 0.06095369
GO:0009059 macromolecule biosynthetic process 0.017885455
GO:0006139 nucleobase-containing compound metabolic process 0.065478693
GO:0044249 cellular biosynthetic process 0.069055774
GO:0016070 RNA metabolic process 0.000760501
GO:0006355 regulation of transcription, DNA-dependent 0.000143186
GO:0006351 transcription, DNA-dependent 7.21E+00
GO:0009889 regulation of biosynthetic process 0.000257691
GO:0030163 protein catabolic process 0.06095369
GO:0009410 response to xenobiotic stimulus 0.069055774
GO:0019538 protein metabolic process 0.013652117
GO:0048593 camera-type eye morphogenesis 0.069055774
GO:0006508 proteolysis 0.06095369
GO:0044267 cellular protein metabolic process 0.069055774
GO:0006464 protein modification process 0.092150989
Table continues on next page
72 3. Transcriptome pattern in zebrafish
Continued: EE2 REVIGO attributes
term description adjusted
pvalue
GO cellular component
GO:0030117 membrane coat 0.0085344
GO:0030118 clathrin coat 0.0565133
GO:0005938 cell cortex 0.0689058
GO:0005634 nucleus 0.0977404
Interpro
IPR000694 anenome neurotoxin 0.0731194
IPR001092 restriction/modification DNA-methylase 0.0059893
IPR000867 insulin-like growth factor-binding protein, IGFBP 0.0061675
IPR006208 cystine knot 0.0679742
IPR009057 homeodomain-like 0.0059893
IPR017970 homeobox, conserved site 0.0007053
IPR020479 homeobox, eukaryotic 0.0059893
IPR011598 helix-loop-helix DNA-binding 0.0059893
IPR000047 helix-turn-helix motif 0.001022
IPR001356 homeobox 0.0007053
IPR001827 homeobox protein, antennapedia type, conserved site 0.0860083
IPR000837 Fos transforming protein 0.0313681
IPR011616 bZIP transcription factor, bZIP-1 0.0547961
IPR011700 basic leucine zipper 0.0675961
IPR008917 eukaryotic transcription factor, Skn-1-like, DNA-binding 0.0675961
Table 3.5: Flutamide REVIGO attributes: GO and InterPro terms (in italics) sub-grouped into a func-
tionally related category (in regular) for visualization in Figure 3.2B (3.3.6)
Accession
term
Description Adjusted
pvalue
GO biological process
GO:0008652 cellular amino acid biosynthetic process 0.078059
GO:0006520 cellular amino acid metabolic process 0.036498
GO:0009308 amine metabolic process 0.083236
GO:0006164 purine nucleotide biosynthetic process 0.083236
GO:0006163 purine nucleotide metabolic process 0.083236
GO:0009165 nucleotide biosynthetic process 0.083236
GO molecular function
GO:0016820 hydrolase activity, acting on acid anhydrides, catalyzing
transmembrane movement of substances
0.060688
GO:0005102 receptor binding 0.001619
GO:0030594 neurotransmitter receptor activity 0.098169
GO:0005179 hormone activity 0.001619
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Table 3.6: Pathways included for the calculation illustrated in Figure 3.3 or sub-grouped to a functionally
related category (in italics) for EE2.
Nr Accession
term
Description
1 dre04140 regulation of autophagy
2 GO:0006259 DNA metabolic process
3 GO:0019538 protein metabolic process
GO:0030163 protein catabolic process
GO:0006508 proteolysis
GO:0044267 cellular protein metabolic process
GO:0006464 protein modification process
4 dre04146 peroxisome
5 GO:0006974 response to DNA damage stimulus
6 GO:0005524 ATP binding
7 GO:0001882 nucleoside binding
8 GO:0016787 hydrolase activity
9 GO:0006351 transcription, DNA-dependent
GO:0044249 cellular biosynthetic process
GO:0003677 DNA binding
GO:0005515 protein binding
GO:0009059 macromolecule biosynthetic process
GO:0003676 nucleic acid binding
GO:0016070 RNA metabolic process
GO:0009889 regulation of biosynthetic process
GO:0045449/
GO:0006355
regulation of transcription, DNA-dependent
GO:0043565 sequence-specific DNA binding
GO:0003700 sequence-specific DNA bindingtranscription factor activity
GO:0009058 biosynthetic process
GO:0005634 nucleus
GO:0006139 nucleobase-containing compound metabolic process
IPR011598 helix-loop-helix DNA-binding
IPR000047 helix-turn-helix motif
IPR001092 restriction/modification DNA-methylase
IPR011700 basic leucine zipper
IPR008917 eukaryotic transcription factor, Skn-1-like, DNA-binding
IPR011616 bZIP transcription factor, bZIP-1
10 IPR009057 homeodomain-like
IPR001356 homeobox
Table continues on next page
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Continued: EE2 pathways included in intersection calculations
Nr Accession
term
Description
IPR020479 homeobox, eukaryotic
IPR017970 homeobox, conserved site
IPR001827 homeobox protein, antennapedia type, conserved site
11 IPR000694 anenome neurotoxin
12 dre03040 spliceosome
13 GO:0048593 camera-type eye morphogenesis
14 GO:0009410 response to xenobiotic stimulus
15 GO:0001503 ossification
16 GO:0004950 chemokine receptor activity
GO:0019956 chemokine binding
17 dre00900 terpenoid backbone biosynthesis
GO:0008299 isoprenoid biosynthetic process
18 GO:0008146 sulfotransferase activity
19 GO:0019838 growth factor binding
GO:0016049 cell growth
GO:0040008 regulation of growth
GO:0001558 regulation of cell growth
GO:0005520 insulin-like growth factor binding
IPR006208 cystine knot
IPR000867 insulin-like growth factor-binding protein, IGFBP
20 IPR000837 Fos transforming protein
21 GO:0005938 cell cortex
22 GO:0030117 membrane coat
GO:0030118 clathrin coat
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Table 3.7: Pathways included for the calculation illustrated in Figure 3.3 or sub-grouped to a functionally
related category (in italics) for flutamide (3.3.7)
Nr Accession
term
Description
1 dre00260 glycine, serine and threonine metabolism
2 IPR013968 polyketide synthase, KR
3 GO:0006164 purine nucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0006163 purine nucleotide metabolic process
4 GO:0016820 hydrolase activity, acting on acid anhydrides, catalyzing trans-
membrane movement of substances
5 GO:0030594 neurotransmitter receptor activity
6 IPR000980 SH2 motif
7 GO:0005179 hormone activity
GO:0005102 receptor binding
8 IPR001507 zona pellucida sperm-binding protein
IPR017976 endoglin/CD105 antigen subgroup
9 GO:0009308 amine metabolic process
GO:0008652 cellular amino acid biosynthetic proces
GO:0008652 cellular amino acid biosynthetic process
10 dre00072 synthesis and degradation of ketone bodies
11 IPR000837 Fos transforming protein
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Figure 3.A-3: Microarray significance validation: Differential expression of a) cyp19a1b (aromatase b),
vtg1 (vitellogenin 1 ), sc4mol (sterol-C4-methyl oxidase–like gene), mvd (mevalonate (diphospho) de-
carboxylase), cyr61 (cysteine-rich, angiogenic inducer, 6 ) and hoxb4a after 48h exposure to 0.8 mg/l
EE2, b) gh1 (growth hormone 1 ), oxtl (oxytocin), rxfp3 (relaxin/insulin-like family peptide receptor
3 ) and zp3.1 (zona pellucida sperm-binding protein domain) after exposure to 1.4 mg/l flutamide, c)
cyp19a1b, vtg1, hoxa10b and sult1st5 (sulfotransferase family 1, cytosolic sulfotransferase 5 ) after expo-
sure to 8.5 mg/l BPA, d) hoxb5b, npy8br (neuropeptide Y receptor 8b), rxfp3, igfbp1a (insulin-like growth
factor binding protein 1a) and ins (preproinsulin) after exposure to 2.0 mg/l prochloraz, e) hmgcra (3-
hydroxy-3-methylglutaryl-coenzyme A reductase a) and mvd after exposure to 1.1 mg/l propanil, f) gnrh2
(gonadotropin-releasing hormone 2 ), npy8br, rxfp3, gpr74 (G-protein coupled receptor 74 ) and zp3.1 after
exposure to 1.3 mg/l linuron and g) hoxa10b, hoxa11b, igfbp1b (insulin-like growth factor binding protein
1b) after exposure to 24.4 mg/l methylparaben in 48hpf zebrafish embryos, determined by quantitative
rtPCR. Expression ratios were calculated according to the 2∆∆Ct method [Pfaffl, 2001] and normalized to
ISO or, where applicable, solvent control references. Results represent the mean ± standard error of the
mean (SEM) of the expression ratio of four replicates with each comprising 24 embryos per treatment.
Error bars indicate SEM. P-values were determined by Student’s t-test and are indicated by asterisks
(*=<0.05,**=<0.01,***=<0.001)
.
Chapter 4
The value of fish embryos as an
alternative test system for the
evaluation of estrogenic and
anti-androgenic disruptors,
considering differences between
medaka and zebrafish
submitted in Aquatic Toxicology
4.1 Abstract
Many regulations have been implemented to control the release of potential
endocrine disrupters into the environment. However, currently, these tests
rely on studies with adult fish and reliable alternatives have to be intro-
duced yet. In this context, evidence arises for the molecular fish embryo
test being such an alternative approach. With this manuscript we aimed
to compare two fish species, the zebrafish and medaka, in terms of their
specific suitability for testing estrogenic and anti-androgenic disruption.
To this end, the gene response to the estrogenic and anti-androgenic ref-
erence compounds 17α-ethinylestradiol and flutamide, respectively, as well
to further known or suspected estrogenic and anti-androgenic test com-
pounds, i.e. bisphenol A, genistein, prochloraz, linuron and propanil, was
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compared between medaka and zebrafish embryos. Further, the impact of
a prolonged exposure to 96h was analysed for zebrafish. Our data showed
that the estrogenic response is comparable in medaka and 48hpf as well as
96hpf zebrafish embryos, implying the suitability of both species for the
detection of endocrine disruption. However, the anti-androgenic response
differed in both fish species, providing complementary information about
the mechanism of anti-androgenic disruption in fish embryos. However,
an indicative anti-androgenic response could be assessed in 96hpf zebrafish
only, but not 48hpf, whereas testing at the prehatch stage was sufficient
for medaka. Together, the data suggests including both species, medaka
and zebrafish, in the implementation of a promising alternative testing
approach for endocrine disruption.
4.2 Introduction
Endocrine disruption is of high environmental concern since it can affect the
health and the reproduction of human and wildlife. In particular aquatic
animals are affected since, living in water, they are directly exposed to envi-
ronmental pollutants. Many regulations have therefore been implemented
to control the release of potential endocrine disrupters, i.e. according to
REACH, every chemical substance potentially entering the environment
has to be tested for its endocrine disruptive potential. Thus, high num-
bers of tests have to be conducted. Currently, these tests rely on studies
with adult fish, since reliable alternatives have not been introduced yet.
According to the 3 R’s principle, REACH regulations and social factors
demand that these animal tests need to be minimized and if possible, re-
placed. In this context, fish embryos are currently discussed to serve as
alternatives and to be integrated in endocrine disruption testing. Fish
embryos are beneficial, since they are non-protected animals (EU direc-
tive 2010/63/EU [EU, 2010]), serve as in vivo models, fully developed at
the end of embryogenesis and allow rapid testing procedures. In terms of
endocrine disruption fish embryos have a drawback since they lack devel-
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oped gonads and endocrine disruption cannot be assessed morphologically.
However, at transcriptome level fish embryos have been shown to express
endocrine marker, such as aromatase and vitellogenin [Kishida et al., 2001;
Muncke and Eggen, 2006] which can be regulated by endocrine compounds.
For an efficient application of fish embryos in endocrine disruption test-
ing, it is important to better understand the underlying mechanisms of en-
docrine disruption in the embryos and, in particular, to examine whether
different modes of action can be discerned at the molecular level. In this
study, we aimed at exploring the effects of two important mode of action
classes of endocrine disrupters, the estrogenic and anti-androgenic com-
pounds, on fish embryos and the expression of indicative genes. We de-
cided to compare two fish species, the zebrafish and the medaka. Zebrafish
embryos develop within 48hpf and thereby allow rapid testing. Medaka de-
velopment is slower, they hatch at 7-10dph, which, although prolonging the
test procedure, is beneficial in terms of detecting longer-term effects, which
in particular are relevant for sub-chronic endocrine processes. Another im-
portant difference between the two species is the sexual differentiation,
which is genetically determined for medaka only. The zebrafish is a ju-
venile hermaphrodite, meaning that in the larval stages ovary-like gonads
appear in both sexes and in half of the fish apoptotic processes lead to a
degeneration of the ovary and the development of testes. In this context
it is also important to note that at the prehatch stage, in medaka, but not
in zebrafish, gonad precursors are present. Therefore, we have essential
differences in the embryonic development, in the sexual differentiation and
in the gonadal status at the testing point, making zebrafish and medaka
complementary in endocrine disruption testing.
Previously, we described the transcriptome response of 48hpf zebrafish
embryos to estrogenic and anti-androgenic acting chemicals in detail. We
exposed the embryos to the reference compounds ethinylestradiol and flu-
tamide and identified specific transcriptome responses, which were com-
pared to those of several other estrogenic and anti-andorgenic chemicals.
These chemicals were bisphenol, genistein, methylparaben, prochloraz, lin-
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uron, and propanil. In the present study, we now want to compare the ze-
brafish data with the response of genes in medaka, exposed to the same es-
trogenic and anti-androgenic substances (except for methylparaben). Since
no commercial oligomicroarray was available for medaka, we examined the
alterations in gene expression for selected genes only. The aim of this
comparison was to show that endocrine disruption can be detected in the
embryos of both fish species and to elaborate species specific benefits for
zebrafish and medaka for testing endocrine disruption. In particular, we
anticipated specific differences due to the differing embryonic development,
the resulting difference in exposure duration, and due to the contrasting
mode of sexual determination and differentiation. We also compared two
developmental stages of zebrafish to examine the effects of a prolonged
exposure. Conclusively, this manuscript intended to proof the suitability
of fish embryos for the detection of endocrine disruption, to explore the
distinct effect of estrogenic and anti-androgenic compounds on gene ex-
pression in fish embryos, and to provide a decision basis for the selection
of one or, if medaka and zebrafish appear complementary, the inclusion
of both fish species, in order to long-term implement an alternative, fish-
embryo based molecular approach for endocrine disruption testing.
4.3 Material and methods
4.3.1 Fish maintenance and exposure
Adult wild-type zebrafish (Danio rerio), originally obtained from West
Aquarium GmbH (Bad Lauterberg, Germany) and continuously bred for
several generations in the Fraunhofer IME laboratories since, and Medaka
(Oryzias latipes) fish (wild-type carbio) were used for egg production. Fish
were maintained in 200 l glass aquaria either under flow-through condi-
tions, or attached to Eheim (Eheim, Deizisau, Germany) external biofilter
systems, in a temperature controlled room with a 14:10h light:dark pho-
toperiod. For water supply, tap water was charcoal- and particle-filtered,
UV-sterilized, pre-heated to 26 ± 2◦C and aerated in a 400 l storage tank
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before entering the aquaria. Zebrafish were kept in large spawning groups
at a male to female ratio of approximately 2:1. The eggs were collected in
metal-mesh-covered glass spawning trays and harvested from the aquaria
one hour after light onset. Medaka were separated into smaller spawning
groups of six fish of a male to female ratio of 1:2 by tank dividers at. Each
aquaria division contained Ceratophyllum submersumas as spawning sub-
strate. Medaka eggs were striped from the females between one and two
hours after light onset, placed into ISO medium and freed from attachment
filaments using tweezers. Before testing, all eggs were rinsed in 1:5 diluted
ISO (International Organization for Standardization) medium, prepared
according to the Annex 2 of the OECD Guideline 203 (ISO 6341-1982)
[OECD, 1992].
4.3.2 Chemicals
Chemicals were purchased from Sigma-Aldrich (Munich, Germany) (17α-
ethinylestradiol E4876; flutamide F9397; bisphenol A 239658; linuron 36141;
genistein G6649; propanil 45639; prochloraz 45631). Stock solutions were
prepared by dissolving the chemicals either in pure acetone (ROTIPURAN R©,
purity = 99.8%, p.a., Carl Roth, Karlsruhe, Germany) or, in case of suffi-
ciently high solubility in water (for bisphenol A and prochloraz), directly
in ISO medium.
4.3.3 Fish Embryo Toxicity Test (FET)
Fish Embryo Toxicity Tests (FET) were conducted with modifications fol-
lowing the draft OECD Test Guideline version of 2006 (OECD 2006) and
according to the recommendations of the background document of the Ger-
man Federal Environment Agency (UBA) [Braunbeck and Lammer, 2006].
For the preparation of test solutions, 17α-ethinylestradiol, flutamide,
bisphenol, linuron, genistein and propanil were dissolved at corresponding
concentrations in 2 ml of acetone (100 %) and these stock solutions were
further diluted to each test concentration also in 2 ml of acetone each. Each
2 ml-acetone solution was transferred to 250 ml screw-cap glass bottles
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(SCHOTT c©, Mainz, Germany) and evenly spread onto the inner surface
of the bottle. To remove the solvent, the acetone was allowed to evaporate
completely before the bottles were filled up with 200 ml pre-aerated ISO
water. Prochloraz and bisphenol A (BPA) were dissolved directly, in 200
ml pre-aerated ISO water without the aid of solvent. A 200 ml solvent
control solution was prepared accordingly, using acetone only. All test
solutions were stirred and aerated at 26◦C for several hours prior to use.
For the tests, U-bottom 96-well plates (Greiner Bio-One, Frickenhausen,
Germany) were filled with 200 µl per well of test solution each. All test
plates were saturated overnight with the corresponding test solution dilu-
tions and refilled with new solutions before test start. After egg harvest,
fertilization of the freshly collected eggs was evaluated using a stereo mi-
croscope and tests were only conducted at an estimated fertilization rate
of 80 %. Fertilized eggs were then immediately transferred to petri dishes
containing the final test solutions in order to guarantee earliest possible
exposure of the embryos. Zebrafish eggs entered the test solutions no later
than 1.5 hours post-fertilization (hpf), medaka embryos at 3-4hpf, but due
to the slower development this still corresponded to a 32-64 cell stage.
For each concentration replicate 24 zebrafish or medaka embryos were
transferred from the petri dishes individually to the wells of a 96 well plate.
Test plates were covered with transparent self-adhesive sealing film (mi-
croamp, Applied Biosystems R©) and incubated at 26◦C ± 1◦C for 48h/96h
(zebrafish) and 7d (medaka), respectively. Test solutions were refreshed
every two days in case of an extended exposure beyond 48h.
Previously, concentration response relationships of all chemicals were es-
tablished using two replicates and at least five concentrations, divided by
a maximal constant spacing factor of 2.2. For this purpose, all lethal and
non-lethal morphological effects occurring in the embryos (modified after
Braunbeck and Lammer [2006], described in detail in Schiller et al, submit-
ted 2013) were assessed after 24, 48 and 96 hours (zebrafish and medaka)
and 7 days (medaka only). From the concentration response curves (data
not shown), the 48h (zebrafish) and 7d (medaka) cumulative lethal and
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non-lethal effect concentrations and EC20 were derived after probit anal-
ysis (ToxRat R© Professional 2.10) and these concentrations applied in all
subsequent gene expression oriented experiments.
Microarray experiments were conducted in zebrafish for 48h with four
replicates per treatment (i.e., EC10, EC20, ISO- and acetone control), quan-
titative PCR experiments were run either for 48h or 96h (zebrafish) and
7 days (medaka), with three replicates only. After exposure, the embryos
were collected for RNA extraction, pooling each replicate group of 24 fish
embryos together in 1.5 ml eppendorf-tubes, then snap-frozen over dry ice
and stored at -80◦C.
4.3.4 RNA extraction and reverse transcription
Total RNA was isolated from frozen, pooled embryos by homogenization
in TRIreagent (Sigma-Aldrich, T9424) using a hand-held pestle grinder
motor adapter with plastic pestles followed by extraction with chloroform
and ethanol and final purification using RNeasy Mini Spin Columns (QIA-
GEN, Hilden, Germany) according to the manufacturers’ protocols. RNA
was then stored at –80◦C until further analysis. RNA and cRNA concentra-
tions were measured using a NanoDrop 1000 spectrophotometer (Thermo
Fisher Scientific, Schwerte, Germany). For the microarray analysis, RNA
quality was verified on an Agilent 2100 Bioanalyser (Agilent Technologies,
Santa Clara, USA). All further processed RNA samples had RNA integrity
numbers between 8.8 and 9.8 and a 260/280 absorbance between 1.8 and
2.2. For cDNA synthesis prior to qPCR, RNA was treated with DNAse
(Sigma-Aldrich, AMP-D1) and reverse transcribed using SuperScript III
Reverse Transcriptase (Invitrogen, Carlsbad, USA). A negative cDNA con-
trol sample, without added reverse transcriptase, was included in all qPCR
measurements III Reverse Transcriptase (Invitrogen, Carlsbad, USA).
4.3.5 Quantitative real-time PCR
Quantitative real-time PCR (qPCR) was applied to validate the zebrafish
microarray data, on the one hand, and as a method for gene expression
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quantification in medaka and 96h zebrafish embryos on the other hand.
The iQ
TM5 real-time PCR detection system (BioRad c©, Hercules, USA)
and the SYBR R©Green ER qPCR SuperMix (Invitrogen, Carlsbad, USA)
were used for the majority of qPCR experiments. Some medaka samples
were analysed in a collaborative laboratory in Saskatoon, Canada, where
an Applied Biosystems 7300 Real-time PCR system with SYBR R©Green
qPCR Master Mix was used. The respective system used is indicated in
the corresponding data Figures.
Specific primers were designed using the web-based NCBI PrimerBlast
tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The ze-
brafish primers are listed in Annex Table A-1. For medaka, primer se-
quences were taken from the medaka PCR array collection developed by
Zhang et al. [2008a], which comprises a broad range of genes involved in
the hypothalamic-puitary-gonadal axis. Additional primer sets were de-
signed for target genes found to be differentially expressed in zebrafish.
The complete medaka primer set is listed in Annex Table A-2.
On the the iQ
TM5, cDNA was incubated for 2 min at 50◦C and for 10
min at 95◦C, prior to target amplification at 95◦C for 15 s, 59◦C for 30 s
and 72◦C for 30 s (40 cycles). The two reference genes, β-actin and rpl13,
were run in parallel and used to normalize the expression values. Identical
RNA samples were used for the microarrays and the qPCR.
Using the Applied Biosystems 7300 Real-time PCR system and the
SYBR R©Green qPCR Master Mix, target sequences were incubated for 10
min at 95◦C and amplified at 95◦C for 15 s, 59◦C for 30 s and 72◦C for
30 s (40 cycles). The data was normalized using two reference genes, 16S
rRNA and rpl7.
For zebrafish, qPCR analysis was carried out with cDNA taken from
the EC20 exposures of selected 48h FETs and of 96h extended FETs. For
medaka, cDNA samples of all exposures were analysed by qPCR, only. For
both, medaka and zebrafish, 40 ng cDNA were used as starting template.
Two technical replicates and a negative control were integrated in each
experiment.
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Relative gene expression ratios were calculated by the comparative Ct
method 2∆∆Ct [Pfaffl, 2001]. A student’s test was used for testing signifi-
cant differences between the EC20 conditions and the solvent control.
4.3.6 Microarray analysis
Microarray experiments for each chemical were carried out using Zebrafish
(V2) Gene Expression Microarrays 4X44K (Agilent Technologies, Santa
Clara, USA), following the Agilent one-color microarray hybridization pro-
tocol (One-Color Microarray-Based Gene Expression Analysis, version 5.7,
Agilent Technologies). Each array contains 43,604 oligonucleotide probes
representing 16,865 different genes (partly in duplicates, and additional
non-annotated genes). The method is described in detail in chapter 3.
4.4 Results
4.4.1 Morphological effects
The morphological effects occurring in medaka and zebrafish at the EC20
level (Figure 4.4-1) differed by chemical and species. At the low EC20 con-
centration, the observed effects other than mortality were mostly confined
to those considered non-lethal, except for the lack of heart beat occurring in
zebrafish after exposure to flutamide. In zebrafish, the effects were in gen-
eral more diverse and ranged from coagulation, oedema, blood circulation
defects and yolk deformation to malformations of tail and head. Medaka
showed mainly effects at the cardiovascular system, i.e oedema and reduced
blood circulation. The effect composition was different for each substance,
but with little to no coherence between zebrafish and medaka. A chemical
specific morphological pattern could be suggested for flutamide, genistein
and linuron in zebrafish, but for medaka the effect composition of all chem-
icals was to unvarying and confined to three effect characteristics (i.e., co-
agulation, malformation of tail and oedema) to suggest specificity. Only
prochloraz and propanil showed a similar effect composition in zebrafish,
with oedema as predominant effect. Interestingly, the anti-androgen flu-
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tamide and the estrogen EE2 caused the same morphological effects in
medaka, but affected zebrafish very differently. In medaka, first effects
caused by EE2 occurred after 4 days and increased drastically thereafter.
Similarly for flutamide, where effects first appeared after 5 days. In ze-
brafish, first effects of EE2 and flutamide were already visible after 24hpf,
but increased significantly after 48hpf.
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Figure 4.4-1: Proportion of morphological effects at the EC20 level for zebrafish and medaka. The
morphological effects were assessed in the EC20 condition after 48h and 7d exposure to EE2, flutamide,
genistein, propanil, linuron and prochloraz in zebrafish and medaka, respectively. The results represent
data from three replicates comprising 24 fish embryos each (4.3.3).
The cumulative effect concentrations and confidence intervals for each
substance are listed in Table 4.1. For all chemicals but EE2 and BPA, ze-
brafish was significantly (confidence intervals were not overlapping) more
sensitive than medaka where higher concentrations were needed to get mor-
phological effects.
4.4.2 Gene expression analysis
Zebrafish We previously described the transcriptome response of 48hpf
zebrafish embryos after exposure to EE2, flutamide, bisphenol A (BPA),
linuron, prochloraz, methylparaben and propanil as retrieved by microar-
ray analysis (chapter 3, Schiller et al. submitted February 2013). Briefly,
clearly distinct transcriptome response patterns were identified for the
estrogenic reference compound EE2 and the anti-androgen reference flu-
tamide. Both reference compounds featured estrogen- respectively anti-
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Table 4.1: Mean effect concentrations and 95% confidence intervals (CI) for tested chemicals in zebrafish
and medaka embryos. Experiments were run in two replicates with 24 individual embryos each (4.3.3)
Table 1: Effect concentrations and 95% confidence intervals (CI) for tested chemicals in 
zebrafish and medaka embryos 
 
Chemical 
Zebrafish cumulative effect 
concentrations in mg/l (CI) 
Medaka cumulative effect 
concentrations in mg/l (CI) 
EC10  EC20  EC50 EC10 EC20 EC50 
Ethinyl- 
estradiol 
0.65  
(0.63-0.74) 
0.8  
(0.74-0.84) 
1.04  
(0.98-1.13) 
0.8  
(0.73-0.86) 
1.07 
(0.98-1.3) 
1.7  
(1.6-1.75) 
Flutamide 1.2  (1.01-1.23) 
1.4  
(1.2-1.42) 
1.75  
(1.65-1.86) 
5.6  
(4.3-6.2) 
6.2  
(5.0-6.6) 
6.93  
(6.4-7.8) 
Bisphenol A 8  (6.5-8.6) 
8.5  
(7.7-9.6) 
11.3 (10.3-
12.56) 
7 
(5.2-9.2) 
8 
(6.7-9.9) 
9.8  
(8.9-13.8) 
Genistein 2.2  (1.6-2.63) 
2.4  
(1.95-2.89) 
2.8  
(2.5-3.8) 6 (n.d) 10 (n.d) n.d. 
Propanil 0.8 (n.d) 1.1  (1.09-1.21) 
1.8  
(1.76-1.87) 
6 
 (5.0-6.7) 
9 
 (6.9-10.2) 
9.5  
(8.7-12.7) 
Linuron 1.2  (1.02-1.27) 
1.3 
(1.17-1.4) 
1.88  
(1.77-2.02) 6.5 (n.d) 7 (n.d) 8.2 (n.d) 
Prochloraz 1.7  (1.55-1.82) 
2  
(1.85-2.14) 
2.67  
(2.52-2.85) 
4.12  
(3.78-4.51) 
4.5  
(4.32-4.97) 
5.7 (5.45-
6.09) 
androgen-like characteristics in their response, according to previous stud-
ies describing the effects of estrogens and anti-androgens at molecular level
in sexually differentiated fish. EE2 induced various pathways associated
with isoprenoid synthesis, growth, and energy metabolism, and induced es-
trogenic markers such as aromatase b (cyp19a1b) and vitellogenin 1 (vtg1 ).
In agreement with EE2, the estrogenic substances BPA and genistein regu-
lated genes related to isoprenoid synthesis and also induced cyp19a1b and
vtg1. To confirm these microarray results, we validated the upregulation of
cyp19a1b as well of genes related to isoprenoid synthesis (mvd). Further,
as from the transcriptome data we concluded the regulation of cholesterol
synthesis, of a pathway downstream the isoprenoid synthesis, we addition-
ally confirmed the expression of cholesterol synthesis associated genes lss
and sc4mol, by quantitative PCR for EE2 (Figure 4.4-2) and genistein
(shown in 5, Schiller et al. [2013]). Vtg1 showed a high variation between
the replicates as well as general low expression with Ct values above 35
and thus, could not be shown to be regulated by qPCR. The microarray
results further indicated the lack of steroid receptor regulation, which was
confirmed by qPCR: No regulation was identified for esr1 in EE2 exposed
48hpf zebrafish embryos and the expression of esr2a was too low to assess
acceptable Ct values for qPCR calculation. Further, no androgenic genes
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(androgen receptor (ar), 11β-hydroxylase (cyp11b), 3-beta-hydroxysteroid
dehydrogenase (3β-hsd) have been regulated by EE2 at this stage.
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Figure 4.4-2: Gene response to EE2 and flutamide in 48hpf zebrafish embryos. Differential
expression of androgen receptor (ar), 11-beta-hydroxylase (cyp11b), aromatase b (cyp19a1b), vitellogenin
1 (vtg1 ), estrogen receptor 1 (esr1 ), estrogen receptor 2a (esr2a), gonadotropin-releasing hormone (type
2) receptor 2 (gnrhr2 ), 3β-hydroxysteroid-dehydrogenase D5-D4 isomerase (3β-hsd), lanosterol synthase
(lss), sterol-C4-methyl oxidase-like (sc4mol) and mevalonate (diphospho) decarboxylase (mvd) in ze-
brafish after 48h exposure to EC20 levels of 17α-ethinlyestradiol (EE2) and flutamide, determined by
quantitative PCR. Expression ratios were calculated according to the 2∆∆Ct method [Pfaffl, 2001], nor-
malized to solvent control (4.3.5). Results represent the mean ± standard error of the mean (SEM)
of the expression ratio of three replicates with each comprising 24 embryos per treatment(4.3.3). Er-
ror bars indicate SEM. P-values were determined by student’s t-test and are indicated by asterisks
(*=<0.05,**=<0.01,***=<0.001).
For the anti-androgenic reference and test compounds flutamide, linuron
and prochloraz microarray analysis showed neuroendocrine molecular ef-
fects. However, we could not verify individual genes by qPCR (data shown
for gonadotropin releasing hormone 2 (gnrhr2 ) in Figure 4.4-2, not shown
for neuropeptide y, kiss1 receptor a, kiss1 receptor b), and neither the an-
drogen receptor (ar) or downstream androgenic genes, such as 3β-hsd and
cyp11b were affected by flutamide exposure in 48hpf zebrafish embryos. For
linuron and prochloraz, microarray analysis did not show significant expres-
sion of these genes, neither, but this was not further analysed by qPCR.
Although no androgenic genes were affected by flutamide, it significantly
upregulated cyp19a1b and vtg1 in the microarray analysis and we con-
firmed this regulation for cyp19a1b by quantitative qPCR (Figure 4.4-2).
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Vtg1 regulation could not be validated due to the same reasons described
above. From the isoprenoid- and cholesterol-synthesis related genes, only
sc4mol was significantly altered by flutamide. Together, only a weak effect
of flutamide on the gene expression could be determined in 48hpf zebrafish
embryos and genes related to the androgen receptor signalling were not
regulated at this stage.
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Figure 4.4-3: Gene response to EE2 and flutamide in 96hpf zebrafish embryos. Differential
expression of androgen receptor (ar), 11-beta-hydroxylase (cyp11b), aromatase b (cyp19a1b), vitellogenin
1 (vtg1 ), estrogen receptor 1 (esr1 ), estrogen receptor 2a (esr2a), gonadotropin-releasing hormone (type
2) receptor 2 (gnrhr2 ), 3β-hydroxysteroid-dehydrogenase D5-D4 isomerase (3β-hsd) in zebrafish after 96h
exposure to EC20 levels of 17α-ethinylestradiol (EE2) and flutamide, determined by quantitative PCR.
Expression ratios were calculated according to the 2∆∆Ct method [Pfaffl, 2001], normalized to solvent
control (4.3.5). Results represent the mean ± standard error of the mean (SEM) of the expression ratio of
three replicates with each comprising 24 embryos per treatment (4.3.3). Error bars indicate SEM. P-values
were determined by student’s t-test and are indicated by asterisks (*=<0.05,**=<0.01,***=<0.001).
We therefore analysed the expression of genes of common androgenic
(and estrogenic) markers and steroid hormone receptors in 96hpf zebrafish
by quantitative qPCR, to see whether those genes are regulated in a later
developmental stage. The results are shown in Figure 4.4-3. Indeed, we
could identify the downregulation of the androgen receptor and gnrhr2 af-
ter exposure to flutamide, however, 3β-hsd and cyp11b, were not regulated.
Nevertheless, esr2a as well as cyp19a1b and vtg1 were found to be induced
after flutamide exposure. Apart from cyp19a1b and vtg1, which were also
induced in response to EE2, the molecular mechanism appears to be dif-
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ferent in flutamide and EE2 since, contrary to flutamide, in EE2, esr1 and
not esr2a was upregulated whereas the androgen receptor is not affected
in EE2. Together, in contrast to 48hpf, the prolonged 96h exposure led to
a regulation of steroid hormone receptors in zebrafish at gene expression
level and, despite some commonalities, a distinctive response was identified
for EE2 and flutamide (Figure 4.4-3).
Medaka First, in order to compare the effects of the reference compounds
on the gene response in zebrafish and medaka, we selected the same subset
of genes in medaka as analysed in 48hpf and 96hpf zebrafish embryos, i.e.
genes encoding for common estrogenic and androgenic markers, steroid re-
ceptors and genes related to isoprenoid and cholesterol biosynthesis, and
assessed alterations in gene expression after 7d exposure to flutamide and
EE2 in medaka. The qPCR results (depicted in Figure 4.4-4) revealed a
similar response to EE2 compared to zebrafish. EE2 induced the expres-
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Figure 4.4-4: Gene response to EE2 and flutamide in 7dpf medaka embryos. Figure shows
relative transcript levels to aromatase b (cyp19a1b), vitellogenin 1 (vtg1 ), estrogen receptor 2a (esr2a),
androgen receptor (ar), 11-β-hydroxylase (cyp11b), gonadotropin-releasing hormone (type 2) receptor
2 (gnrhr2 ), 3β-hydroxysteroid-dehydrogenase D5-D4 isomerase (3βhsd) after 7d exposure to 1.1 mg/l
EE2 and 6.2 mg/l flutamide. Expression ratios were calculated according to the 2∆∆Ct method [Pfaffl,
2001], normalized to solvent control (4.3.5). Results represent the mean ± standard error of the mean
(SEM) of the expression ratio of three replicates with each comprising 24 embryos per treatment (4.3.3).
Error bars indicate SEM. P-values were determined by student’s t-test and are indicated by asterisks
(*=<0.05,**=<0.01,***=<0.001).
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sion of the aromatase cyp19a1b, vtg1 and it upregulated isoprenoid and
cholesterol synthesis related genes lss, sc4mol, mvd, which corresponds
to the zebrafish data. EE2 further upregulated the estrogen receptor 2a,
which was unique to medaka. However, contrary to 96hpf zebrafish, the
expression of estrogen receptor alpha could not be detected by qPCR at
this stage in medaka. Further, Figure 4.4-4 shows the diverging estrogenic
and anti-androgenic responses in medaka embryos. The androgen receptor
was downregulated by EE2, but not by flutamide. Flutamide reduced the
expression of gnrhr2 as well as the androgenic genes cyp11b and 3β-hsd.
Additionally, flutamide repressed the estrogen receptor 2a and cyp19a1b.
Due to the low gene response in 48hpf zebrafish embryos, the comparison
can only be conducted with 96hpf embryos. The regulation of the estro-
genic genes cyp19a1b and esr2a was contrary to zebrafish, i.e. they were
downregulated instead of upregulated. Furthermore, the anti-androgenic
response to flutamide was more evident in medaka, since the androgenic
genes such as 3β-hsd and cyp11b were downregulated. However, a com-
monality was the downregulation of gnrhr2 in both fish species.
Then, we analysed the response to the further estrogenic test compounds
BPA and genistein to, first, determine whether the response features the re-
sponse to EE2 and, secondly, to compare the estrogenic response of medaka
to zebrafish. The gene regulation of medaka for those compounds was sim-
ilar to EE2 (Figure 4.4-5), since as in EE2, cyp19a1b, esr2a and lss were
induced by genistein and BPA and sc4mol and mvd were further induced
by BPA. This regulation of cyp19a1b and the isoprenoid and cholesterol
synthesis related genes is largely in agreement with the zebrafish tran-
scriptome data, however, in case of BPA there is a contrary response of
the isoprenoid and cholesterol related genes. Further, the regulation of
esr2a was unique to 7d medaka.
Finally, we compared the gene response to the anti-androgenic test com-
pounds linuron, prochloraz and propanil to the response to the reference
flutamide (Figure 4.4-6) in medaka. The response was very similar, given
that all substances downregulated cyp11b, 3β-hsd and gnrhr2. In addition,
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Figure 4.4-5: Gene response to estrogenic compounds in 7dpf medaka embryos. Figure shows
relative transcript levels to estrogenic marker aromatase b (cyp19a1b), vitellogenin 1 (vtg1 ), estro-
gen receptor 2a (esr2a) and steroidogenic genes lanosterol synthase (lss), sterol-C4-methyl oxidase-like
(sc4mol) and mevalonate (diphospho) decarboxylase(mvd) as well to the androgenic genes androgen re-
ceptor (ar), 11-β-hydroxylase (cyp11b), gonadotropin-releasing hormone (type 2) receptor 2 (gnrhr2 ),
3β-hydroxysteroid-dehydrogenase D5-D4 isomerase (3β-hsd), after 7d exposure to EC20 levels of EE2,
BPA and genistein. Expression ratios were calculated according to the 2∆∆Ct method [Pfaffl, 2001],
normalized to solvent control (4.3.5). Results represent the mean ± standard error of the mean (SEM)
of the expression ratio of three replicates with each comprising 24 embryos per treatment (4.3.3). Error
bars indicate SEM. For BPA and genistein, the gene expression of cyp19a1b, vtg1, esr2a, 3β-hsd, gnrhr2,
cyp11b and ar were measured on the Applied Biosystems 7300 Real-time PCR system, all other tests
were conducted using the BioRad R©iQTM5 real-time PCR detection system (4.3.5).
prochloraz and propanil downregulated cyp19a1b and prochloraz repressed
the androgen receptor. Since we did not further analyse the expression of
individual genes for the anti-androgenic test compounds in zebrafish em-
bryos by qPCR, no comparison can be conducted for those compounds
between the two fish species in this manuscript.
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Figure 4.4-6: Gene response to anti-androgenic compounds in 7dpf medaka embryos. Fig-
ure shows relative transcript levels to estrogenic marker aromatase b (cyp19a1b), vitellogenin 1 (vtg1 ),
estrogen receptor 2a (esr2a) as well to the androgenic genes androgen receptor (ar), 11-β-hydroxylase
(cyp11b), gonadotropin-releasing hormone (type 2) receptor 2 (gnrhr2 ), 3β-hydroxysteroid-dehydrogenase
D5-D4 isomerase (3β-hsd), after 7d exposure to EC20 levels of flutamide, prochloraz, linuron and propanil.
Expression ratios were calculated according to the 2∆∆Ct method [Pfaffl, 2001], normalized to solvent
control (4.3.5). Results represent the mean ± standard error of the mean (SEM) of the expression ra-
tio of three replicates, comprised of 24 embryos each (4.3.3). Error bars indicate SEM. For prochloraz,
linuron and propanil, the gene expression of cyp19a1b, vtg1, esr2a, 3β-hsd, gnrhr2, cyp11b and ar were
measured on the Applied Biosystems 7300 Real-time PCR system, all other tests were conducted using
the BioRad R©iQTM5 real-time PCR detection system (4.3.5).
4.5 Discussion
With this study, we compared fish embryo toxicity tests (FET) in com-
bination with gene expression endpoints, with either medaka or zebrafish,
to evaluate their suitability in terms of endocrine disruption. The key
questions we aimed at answering with this study were whether endocrine
disruption can be measured in fish embryos and whether the preference of
zebrafish for the FET is justified in the context of endocrine disruption.
To address these questions, medaka and zebrafish embryos were exposed
for 7 days and, initially, 48 hours, respectively, to different environmen-
tal chemicals either known or suspected for their estrogenic respectively
anti-androgenic activity. We chose EE2 and flutamide as estrogen recep-
tor agonist and androgen receptor antagonist reference compounds. BPA
and genistein were used as estrogenic, linuron, prochloraz and propanil as
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anti-androgenic test compounds. For zebrafish, the detailed results for the
test compounds have been previously described in chapter 3. The estro-
genic zebrafish transcriptome response revealed the expression of indicative
genes which have been validated by qPCR and thus have been used for
comparison to medaka in this study. The response to the reference anti-
androgenic flutamide, however, was weak in 48hpf zebrafish embryos, and
no individual genes could be selected for the anti-androgenic compounds
for comparison to medaka. Thus, we analysed the expression of known
endocrine marker and androgen signalling related genes in response to flu-
tamide in 48hpf embryos and 96hpf embryos, in order to test whether a
stronger anti-androgenic response can be retrieved in a later developmental
stage. The same subset of genes was then selected for the comparison to
the anti-androgenic response in medaka.
In terms of developmental toxicity, zebrafish was overall more sensi-
tive, since the effect threshold concentrations for morphological effects were
lower than for medaka. The exception was EE2 and BPA. The higher sen-
sitivity of 48hpf zebrafish for toxicity compared to medaka has already
been shown and discussed in Lammer et al. 2009 [Lammer et al., 2009],
and one possible reason to be taken into consideration here is the harder
chorion in medaka compared to zebrafish, which could result in impaired
permeability of some molecules [Donovan and Hart, 1982; Hart et al., 1984;
Wittbrodt et al., 2002; Furutani-Seiki and Wittbrodt, 2004]. Further, the
variety of morphological effects was larger in zebrafish and ranged from
head, tail and yolk sac deformations to growth retardation and reduced
blood circulation. In medaka, the effects were mainly limited to cardiovas-
cular defects, such as blood clots, reduced blood circulation and oedema.
The effects differed for each substance and suggested neither for zebrafish
nor for medaka, a mode of action specific effect pattern. Correspondence
of effects was however found for EE2 and flutamide in medaka, where re-
duced blood circulation was the only observed effect, and for prochloraz
and propanil in zebrafish with oedema as predominant effect. Due to the
extended developmental exposure in medaka compared to zebrafish, it was
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tentatively assumed that some of the morphological effects would perhaps
correlate to or show some coherence with the two modes of action of the
test chemicals. However, this could not be confirmed, and the oppositely
acting chemicals EE2 and flutamide even induced the identical phenotype.
These findings only underscore the difficulty to reliably identify endocrine
disruption by means of apical endpoints other than reproduction and sex-
ual differentiation. A viable alternative approach to endocrine disrupter
assessment in fish avoiding chronic reproductive exposures is via a molecu-
lar mechanism based testing method. For this reason, we investigated gene
expression analysis in combination with the FET as a method to elucidate
the endocrine response to different endocrine disruptors.
Embryonic gene response to estrogens Estrogenic disruption could be de-
tected after exposure to EE2, BPA and genistein in fish embryos. The
response was similar in zebrafish and medaka, and we could identify an
impact on the known estrogenic biomarkers cyp19a1b (aromatase b) and
vitellogenin as well as on genes associated with isoprenoid and cholesterol
synthesis. The induced aromatase b expression is in line with other stud-
ies conducted in early and adult life stages of fish and is an indicator for
estrogenic disruption (e.g. Kishida et al. [2001]; Fenske and Segner [2004];
Kiparissis et al. [2003]). In medaka, the induction of aromatase b is medi-
ated by the esr2a, since we detected an upregulation of this receptor after
estrogen exposure. We could not detect any esr1 expression in medaka
embryos and, thus, esr2a is likely to be the only active isoform in prehatch
medaka embryos. Although we did not measure esr2b expression, this hy-
pothesis is in line with the results from Chakraborty et al. [2011], since the
authors identified only low expression values for esr1 and esr2b in prehatch
medaka embryos and esr2a as the only receptor isoform responsive to 17β-
estradiol. The regulation of esr2a is probably specific to the embryonic
stage, given that in adult medaka, EE2 only affected esr1, and not esr2a
[Zhang et al., 2008a], implying that esr2a carries out the mediating role in
estrogen signalling in embryonic stages. In zebrafish, no esr1 and esr2a
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regulation could be detected at 48hpf. However, in 96hpf embryos, we
identified the upregulation of esr1 in response to EE2, implying that this
isoform is mediating cyp19a1b induction in posthatch zebrafish embryos.
In zebrafish, neither in 48hpf nor in 96hpf embryos AR inhibition could
be identified after EE2 exposure. In medaka embryos, however, we ob-
served a downregulation of the androgen receptor alpha, which is similar to
the response of medaka larvae and adult males reported elsewhere [Zhang
et al., 2008a; Mizukami-Murata and Kishi-Kadota, 2011]. Since androgens
are crucial for brain development, sexual differentiation and sexual behav-
ior in male fish, disruption of the androgenic signalling in adult and early
life stages causes severe reproductive effects in fish [Jobling and Tyler,
2003; Leo´n et al., 2008; Oshima et al., 2003]. Our results show that andro-
genic disruption becomes already evident on the molecular level in prehatch
medaka embryos.
The isoprenoid and cholesterol syntheses appeared as further targets of
the estrogens EE2, BPA and genistein in 48hpf zebrafish embryos. Iso-
prenoids are building blocks of cholesterol, which, in turn, is the starting
molecule for steroid hormone synthesis. The selected genes represent early
steps of steroid biosynthesis, and these genes were in fact strongly induced
also in medaka after exposure to especially EE2 and BPA. The regulation
of these genes was different for BPA in zebrafish, where they were downreg-
ulated. However, this is not contradictory to the literature, which reports
both, enhancing and repressing effects of BPA on steroidogenesis [Zhou
et al., 2008]. The induction of genes associated with isoprenoid and choles-
terol synthesis in fish embryos may hint to an enhanced neurosteroidoge-
nesis because in embryonic stages steroidogenesis predominantly occurs in
the brain [Kishida and Callard, 2001; Kishida et al., 2001; Menuet et al.,
2005; Diotel et al., 2011] and since the blood-brain-barrier is impermeable
to cholesterol, de novo cholesterol synthesis is required for steroid synthesis
in the brain. Estrogens have been shown to interfere with cholesterol syn-
thesis and neurosteroidogenesis in vitro and in in vivo fish studies [Smith
et al., 1978; Cypriani et al., 1988; Sinchak et al., 2003; Messa et al., 2005;
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Nagarajan et al., 2013] and, therefore, steroidogenesis is likely to be target
of estrogenic disruption already in the embryos. However, since 3β-hsd, a
gene encoding for a more downstream steroidogenic enzyme, was not af-
fected by EE2 in medaka in our study, and other genes directly involved in
the steroid hormone synthesis were found not to be estradiol-responsive in
larvae and adult stage medaka [Zhang et al., 2008a; Mizukami-Murata and
Kishi-Kadota, 2011], the influence of estrogen disrupters on steroidogenesis
is perhaps more complex. An enhanced cholesterol synthesis can be fur-
ther associated with the promotion of cell growth, as generally described
for estrogens [Quesney-Huneeus et al., 1979; Martini et al., 2010]. The
induction of growth related genes in 48h zebrafish embryos after exposure
to estrogenic substances, as demonstrated by our group (chapter 3) would
corroborate this hypothesis for fish embryos. The analysis of growth related
genes found regulated in zebrafish, such as igfbp1 and ctgf (chapter 3) is
still outstanding for medaka embryos, but a positive result is likely as it
has already been confirmed for EE2 in medaka larvae [Mizukami-Murata
and Kishi-Kadota, 2011].
Taken together, our data show that an estrogenic response is evident
in fish embryos and is similar for zebrafish and medaka. The response
is characterized by the upregulation of estrogenic marker genes and the
enhancement of genes of isoprenoid and cholesterol synthesis-related path-
ways.
Embryonic gene response to anti-androgens A response to anti-androgenic
exposure was detected for all tested substances and in both species. How-
ever, the responses differed between zebrafish and medaka and between
the different developmental stages of zebrafish. Previous microarray ex-
periments in 48hpf zebrafish have shown that the reference anti-androgen
flutamide induces predominantly neurosteroidogenic pathways, which com-
prised genes encoding for neuropeptide Y and kisspeptin receptors, as well
as gonadotropin releasing hormone receptor 2 and luteinizing hormone sub-
unit beta. However, the transcriptome response was overall weak and none
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of the neurosteroidogenic genes could be validated by qPCR. Androgen-
signalling associated genes such as androgen receptor, cyp11b or hsd3b were
neither affected at the 48hpf stage; however, the estrogenic genes cyp19a1b
and vtg1 were upregulated. In order to determine whether testing at a later
developmental stage would result in the regulation of common androgen
signalling related genes and steroid receptors, we performed a prolonged
exposure to 96h in zebrafish. After this prolonged exposure, cyp19a1b and
vtg1 still showed upregulation, but at the same time downregulation of
the androgen receptor ar and gnrhr2 as well as upregulation of esr2a were
identified. This response in zebrafish corresponds exactly to what is an-
ticipated for an initial androgen receptor antagonistic activity. The short-
term increased amount of testosterone caused by the competitive blocking
of the androgen receptor leads to an increased activity of aromatase, which
in turn results in an enhanced level of estradiol and the associated upreg-
ulation of the estrogen receptor. The depletion of testosterone was then
likely to trigger an inhibition of the AR-mediated signalling via a negative
feedback mechanism, which is indicated by the downregulation of gnrhr2
and ar. Medaka showed a contrary response, which might be explained
by the exposure time discrepancy to zebrafish. We found some genes like
esr2a and cyp19a1b affected oppositely to zebrafish, thus downregulated
instead of upregulated. This is in accordance with the response to flu-
tamide shown by Leo´n et al. [2008], who found downregulation of estrogen
receptor 2a and of aromatase in female medaka larvae at 7dph. The same
study further identified downregulation of gnrhr2 in male larvae, which we
confirmed for 7dpf medaka embryos.
Further, we observed downregulation of the androgenic genes down-
stream in the HPG cascade, i.e. 3β-hsd and cyp11b. 3β-hsd encodes
for a steroidogenic enzyme, mediating several steps in steroidogenesis and
in particular, the synthesis of androstenedione, the direct precursor of
testosterone. Cyp11b encodes for an enzyme converting testosterone to
11-ketotestosterone, which is the main androgen in fish [Young, 2005] and
crucial for male sexual differentiation and spermatogenesis [Miura et al.,
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1991; Kobayashi and Nakanishi, 1999], making cyp11b an important indi-
cator for disruption of androgen synthesis. Considering the complementary
information from both fish species, it is therefore likely that anti-androgens
first induce the upregulation of estrogenic genes, which is indicated by
the 48h zebrafish response. The decrease of testosterone then leads to a
negative feedback causing downregulation of androgen receptor and gnrhr2
which is apparent after the prolonged exposure in 96hpf zebrafish embryos.
Finally, the downregulation of genes encoding for steroidogenic enzymes af-
ter 7 days of exposure in medaka lets us seculate that that sooner or later
the steroid levels are depleted in the embryos. Apart from the time dis-
crepancy, another possible reason for the differential effects in zebrafish
and medaka could be the different modes of sexual differentiation. Other
than zebrafish, medaka is a differentiated gonochorist and differentiation
is direct and starts early during development. Thus, it is possible that ge-
netically determined male or female medaka embryos are more susceptible
to antiandrogens than the sexually still undetermined zebrafish embryos.
In medaka, gonadal precursors are already apparent around hatching and
start to proliferate in the females. To this, a sex specific response to flu-
tamide in the embryonic stage could be verified in future studies using
sex-determined medaka embryos.
For the anti-androgenic test compounds, prochloraz, propanil and lin-
uron, we reported the similarities to the response of flutamide in 48hpf
fish embryos in our previous study. However, due to the low response to
flutamide at this stage and the 96hpf data indicating a stronger response
at the posthatch stage, a transcriptome analysis at a later developmental
stage is still outstanding for the anti-androgenic substances. In medaka,
however, we could observe a similar response to the tested anti-androgens.
The response of the investigated genes indicated an anti-androgenic activ-
ity, with significant downregulation of gnrhr2, cyp11b, 3bhsd, and cyp19a1b.
In addition, esr2a was downregulated by flutamide and prochloraz, and fur-
thermore, a regulation of the androgen receptor could be identified after
exposure to prochloraz in medaka. Since the androgen receptor was not
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regulated by the other antiandrogens, another mechanism of action can
be anticipated apart from the competitive binding to androgen receptor,
but this remains to be clarified by further mechanistic studies. In general,
the prochloraz effect on gene expression in medaka fish embryos was very
similar to the observations in adult medaka [Zhang et al., 2008a]. Like-
wise, they found cyp19a1b and ar downregulated (in females and males)
and cyp11b, gnrhr2 and esr2a decreased (in females). Notable is the corre-
spondence of our data with the female medaka response, which provides an
target for future studies. Further, the medaka data strengthen the evidence
for an anti-androgenic mechanism of propanil by the downregulation of gn-
rhr2, 3β-hsd, cyp11b and cyp19a1b, which is in line with mammal studies
reporting androgen receptor antagonistic properties for propanil [Takeuchi
et al., 2008].
Together, anti-androgenic-like gene response could be identified in em-
bryos of both fish species. However, even though we observed an endocrine
response in 48hpf zebrafish embryos, a prolongation of exposure time up
to 96hpf for testing antiandrogenic substances reveals a broader response
which includes the regulation of steroid hormone receptors. The testing
of anti-androgens in 7dpf in medaka is sufficient for the induction of anti-
androgenic-like effects at the molecular level, which enables the testing
at the prehatch stage and therefore favours medaka. Further, comparing
the regulation of endocrine genes for the estrogenic and anti-androgenic
reference compounds, we could identify a discernible response in medaka
and 96hpf zebrafish embryos. However, with the upregulation of cyp19a1b
and vtg1, zebrafish showed more commonalities between the two modes
of actions than medaka, which showed contrary regulation of all tested
genes in flutamide and EE2 and the regulation of androgenic genes (3β-
hsd and cyp11b) in flutamide only. Apart from differences in test duration,
the different sexual determination and development of medaka might be
accounted for these effects and providing complementary information.
In conclusion, medaka and zebrafish proved to be both suitable for
the detection of endocrine disruption. Importantly, embryos of both fish
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species showed an endocrine response which was comparable to larval or
adult fish stages reported elsewhere [Zhang et al., 2008a; Leo´n et al., 2008;
Mizukami-Murata and Kishi-Kadota, 2011]. In our study, zebrafish em-
bryos were toxicologically more sensitive than medaka embryos and showed
a broader range of morphological effect. Gene expression analysis provided
new insights in the embryonic response to endocrine disruptors and elicited
similarities and differences in the tested fish species. Estrogenic response
was comparable in medaka and 48hpf as well as 96hpf zebrafish embryos
and included the regulation of the classical biomarker aromatase and the
induction of genes associated with isoprenoid and cholesterol syntheses. In
addition, regulation of estrogen receptor 2a and estrogen receptor 1 was
identified in medaka embryos and 96hpf zebrafish embryos, respectively.
Anti-androgenic response differed in both species: Whereas in zebrafish a
defined response could be induced after 96hpf only, testing at the prehatch
stage was sufficient for medaka. Further, the regulation of androgenic genes
such as cyp11b and 3β-hsd was medaka-specific and thus, medaka provided
a robust proof for androgenic disruption. Thus, medaka was beneficial in
terms of testing at the prehatch stage and showing a discernible gene re-
sponse to the two modes of action classes. The advantage of the zebrafish
was the easy handling and the rapid testing. However, testing of endocrine
disruption in zebrafish should be performed in a prolonged exposure to
96hpf, the stage where we could identify the regulation of steroid receptors
and a stronger response to the anti-androgen flutamide. It is likely that
transcriptome analysis of 96 hpf zebrafish embryos will reveal additional
markers for anti-androgenic disruption, which would then enable the mode
of action categorization of the different substance classes. Thus, the data
suggests that the use of two fish species provides complementary informa-
tion and thus we propose to include both, medaka and zebrafish in the
implementation of a promising alternative testing approach for endocrine
EDC testing.
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5.1 Abstract
Assessment of endocrine disruption currently relies on testing strategies in-
volving adult vertebrates. In order to minimize the use of animal tests ac-
cording to the 3R’s principle of replacement, reduction and refinement, we
propose a transcriptomics and fish embryo based approach as an alternative
to identify and analyse an estrogenic activity of environmental chemicals.
For this purpose, the suitability of 48h and 7d post fertilization zebrafish
and medaka embryos to test for estrogenic disruption was evaluated. The
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embryos were exposed to the phytoestrogen genistein and subsequently
analysed by microarrays and quantitative real-time PCR. The functional
analysis showed that the genes affected related to multiple metabolic and
signalling pathways in the early fish embryo, which reflect the known com-
ponents of genistein’s mode of actions, like apoptosis, estrogenic response,
hox gene expression and steroid hormone synthesis. Moreover, the tran-
scriptomics data also suggested a thyroidal mode of action and disruption
of the nervous system development. The parallel testing of two fish species
provided complementary data on the effects of genistein at gene expression
level and facilitated the separation of common from species-dependent ef-
fects. Overall, the study demonstrated that combining fish embryo testing
with transcriptomics can deliver abundant information about the mecha-
nistic effects of endocrine disrupting chemicals, rendering this strategy a
promising alternative approach to test for endocrine disruption in a whole
organism in vitro scale system.
5.2 Introduction
The endocrine system of vertebrates is susceptible to disruption by environ-
mental chemicals such as anthropogenic industrial products and byprod-
ucts as well as natural compounds. One example is genistein, a plant-
derived isoflavone that is categorized as a weak estrogen [OECD, 2006b].
Many studies have shown that genistein has estrogenic activity in humans,
rodents and fish. For example, Kausch et al. [2008] reported increased
vitellogenin gene expression in male zebrafish (Danio rerio) after 11 days
exposure to genistein, and similar results were observed in male medaka
(Oryzias latipes) [Scholz et al., 2004; Zhang et al., 2002]. Gonadal effects,
such as pre-ovulatory oocyte atresia and altered secondary sex characteris-
tics in females as well as intersex gonads in males were observed in medaka
after exposure to genistein for 100 days [Kiparissis et al., 2003]. Although
these studies provided important information about the effects of genistein
on aquatic vertebrates, they required the use of numerous animals, as do
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most of the current testing strategies for endocrine disruption, proposed
by regulatory authorities like the US EPA or as outlined in the conceptual
framework for the testing and assessment of potential endocrine disrupters
of the OECD [OECD, 2006b; US EPA, 2009]. Whilst there are consid-
erable efforts within the EDC (endocrine disruptive chemicals) screening
programs of US EPA and OECD to increasingly include in vitro and other
animal test free methods in the risk assessment process, there is generally
still great reliance on vertebrate test data. Therefore, reliable alternative
testing methods are urgently required to further minimize animal testing
according to the 3R’s principle of replacement, reduction and refinement
[Russell and Burch, 1959].
Bridging the underlying mechanism of endocrine disruption, e.g., by
genistein, with the resulting apical effects is critical. This is, however,
not provided by most current studies, which either focus on a particular
molecular mechanism in defined tissues, in vitro test systems, or on the
resulting adverse outcome in the whole organism. As a first step towards
the development of a testing approach that does not rely on morphological
or reproductive endpoints in adult animals, is the design of short-term
studies that enable the elucidation of the molecular mechanism of action
in non-protected developmental stages.
Fish embryos offer several benefits in this context: First, fish embryos
are almost fully developed by the end of the test, thus allowing effects to
be assessed in a whole organism. Second, fish embryos within the chorion
and early post-hatch are life-stages regarded as non-protected animals ac-
cording to the revised European directive on the protection of animals
used for scientific purposes (Directive 2010/63/EU) [EU, 2010]. Finally,
zebrafish and medaka are fecund all-year spawners with transparent eggs
and a rapid embryogenesis (2d in zebrafish, 7d in medaka), favouring them
for high-throughput and screening applications. Zebrafish embryos allow
a fast 2-day testing procedure, whereas medaka embryos require longer
exposure times. This, in turn, facilitates the investigation of long-term
exposure effects, which are more relevant for endocrine disruption, but are
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impossible to assess in the zebrafish embryos. Moreover, sexual develop-
ment is different in medaka and zebrafish: Zebrafish is an undifferentiated
gonochorist without sex chromosome-related sex determination, and all
zebrafish develop early ovaries prior to the differentiation of testes and
mature ovaries [Maack and Segner, 2004; Takahashi, 1977]. Medaka is a
differentiated gonochorist, with a male heterogametic sex determination,
and testes and ovaries develop directly from the undifferentiated gonad
[Matsuda et al., 2002; Saito and Tanaka, 2009]. These species-specific dif-
ferences in developmental and sexual differentiation imply that medaka and
zebrafish are complementary models for endocrine disruption testing. The
obvious drawback of using embryos as alternative test models is that con-
ventional endocrine disrupting effects, like gonadal malformations or sex
ratio alterations, cannot be assessed in sexually undifferentiated develop-
mental stages. However, this issue can be managed by using suborganismic
test endpoints, which do not rely on sexual development and reproduction.
Transcriptomics promise to be a suitable and sensitive approach to identify
gene targets and regulative pathways affected by endocrine disrupting com-
pounds [Moens et al., 2007; Scholz and Mayer, 2008; Wang et al., 2004,
2010], which can be used as markers or indicators of endocrine activity
of chemicals. Therefore, we conducted microarray experiments with ze-
brafish embryos following a 48h exposure to genistein, in order to analyse
the transcriptomic response to this compound.
The primary aim of the study was to assess the suitability of fish em-
bryos for the detection of estrogenic disruption. We further used two com-
plementary fish species, zebrafish and medaka, to address differences in
species-specific responses and to carve out distinctive advantages for EDC
testing. We chose genistein as a test chemical, firstly, because of its well
documented estrogenic mode of action for fish [Bennetau-Pelissero et al.,
2001; Ng et al., 2006], what we anticipated to facilitate a correlation of fish
embryo results with the estrogenic disrupting effects described for adult
fish, and secondly, because genistein exhibits an interesting endocrine dis-
rupting mode of action as it does not exclusively act estrogenic, but report-
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edly also show estrogen-independent effects [Kim et al., 2009; Sassi-Messai
et al., 2009; Shim et al., 2007]. By using a chemical, which is known for its
estrogenic adverse effects but of a broader endocrine mechanism of action,
we intended to challenge our transcriptomics-based test approach in terms
of its suitability and sensitivity to detect estrogenic disruption.
As a phytoestrogen, genistein can bind to estrogen receptors and ac-
tivate estrogen receptor-dependent pathways [Henley and Korach, 2006;
Sassi-Messai et al., 2009]. It shows a high affinity to the estrogen re-
ceptor b in humans, but indicates no preferences in zebrafish since the
receptor isoforms are more conserved in structure than their mammalian
orthologs [Kuiper et al., 1998; Sassi-Messai et al., 2009]. Besides, genistein
gives evidence to also activate estrogen-independent pathways, including
pro-apoptotic pathways [Kim et al., 2009; Sassi-Messai et al., 2009; Shim
et al., 2007].
With the present study, we aimed at providing substantiating evidence
for the suitability of a fish embryo-based transcriptomics approach to test
for estrogenic disruption. From the results it can be anticipated that this
approach, after a thorough validation with additional estrogenic substances
has been provided, will be seen as a promising alternative for screening and
testing in the context of endocrine disruptor hazard assessment. In sum-
mary, the functional transcriptome analysis identified different genistein-
induced pathways related to processes like pro-apoptotic signalling and the
disruption of brain and nervous system development. Interesting was also
the downregulation of hox genes in zebrafish, since several Hox genes are
known to be estrogen-dependent and to play an important role in embryo-
genesis and the differentiation of certain tissues [Daftary and Taylor, 2006].
Above all, gene expression in both, zebrafish and medaka, clearly indicated
an estrogenic response to genistein exposure. It is therefore suggested that
our approach of combining the fish embryo test with transcriptomics is
promising for the detection and analysis of endocrine disruption.
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5.3 Methods
5.3.1 Fish maintenance and exposure
Adult medaka and zebrafish were maintained in 200 l glass aquaria under
flow-through conditions, with a 14:10 h light:dark photoperiod. Fish were
cultured in activated charcoal and particle-filtered, UV-sterilised tap wa-
ter, entering the aquaria from a 400 l storage tank in which the water was
pre-heated to 26 ± 2C and aerated. Zebrafish were kept in large spawn-
ing groups at a male to female ratio of approximately 2:1; medaka were
separated into smaller spawning groups of six fish by tank dividers at a
male to female ratio of 1:2. Zebrafish eggs were collected in square metal
mesh-covered glass spawning trays and harvested from the aquaria one
hour after light onset. Medaka eggs were striped from the females between
one and two hours after light onset. Before testing, the eggs were rinsed in
ISO (International Organization for Standardization) medium, prepared
according to the Annex 2 of the OECD Guideline 203 (ISO 6341-1982)
[OECD, 1992] and diluted 1:5. Medaka eggs were freed from attachment
filaments using tweezers.
Genistein powder (G6649, Sigma-Aldrich, Munich, Germany) was dis-
solved in acetone (ROTIPURAN R©, purity = 99.8%, p.a., Carl Roth, Karl-
sruhe, Germany) to make up 0.5 mg/l and 1 mg/ml stock solutions for
the zebrafish and the medaka experiments, respectively. Appropriate vol-
umes of the stock were diluted in 2 ml acetone to make test solutions for
each concentration. The test solutions were used to coat 250 ml screw-cap
glass bottles (SCHOTT c©, Mainz, Germany) and the acetone was allowed
to evaporate completely. The bottles were then filled with 200 ml pre-
aerated ISO water and stirred at 26◦C for several hours. A 200 µl aliquot of
each test solution was then transferred to U-bottom 96-well plates (Greiner
Bio-One, Frickenhausen, Germany) and allowed to saturate the walls with
genistein overnight. The solutions in the plates were renewed prior to the
test start. Then, freshly fertilized zebrafish and medaka embryos were
placed into the wells (eggs entered the test solutions no later than 2 hours
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post-fertilization (hpf)) and incubated for 48 hours and 7 days, respec-
tively, at 26◦C ± 1◦C. The test solution was refreshed every 2 days in the
medaka test series. In order to account for any potential effects of residual
acetone after evaporation, a solvent control was included in all tests. The
acetone of the solvent controls was evaporated in the same way as for all
other test compound solutions.
A concentration response relationship for genistein was established for
zebrafish based on lethal and non-lethal morphological defects (see subsec-
tion 5.3.3 and Annex Table B for details) using nine concentrations between
0.97 and 5.22 mg/l, and data evaluated by probit analysis (ToxRat R© Pro-
fessional 2.10, for details, see Figure 5.4-1). Since the microarrays were
performed on embryos after 48h, the concentration-response curve is pro-
vided for this time point only. For medaka, no concentration response
curve could be generated as the limit of solubility was reached at 10 mg/l
of genistein, where only 20% of the embryos were affected. Therefore,
the EC values for medaka were derived from empirical testing. For the
microarray and qPCR tests, embryos were subsequently exposed to the
effective concentrations EC10 and EC20. Accordingly, zebrafish embryos
were exposed to 2.2 mg/l and 2.4 mg/l, medaka embryos to 6 mg/l and
10 mg/l genistein. For the microarrays, four replicates, each comprising of
24 zebrafish embryos, were run in parallel for each treatment, i.e., either
genistein, solvent or ISO-only. For the medaka qPCR test, the same design
was applied as for zebrafish, but with three instead of four replicates per
treatment. After exposure, each replicate group of 24 fish embryos was
pooled together, snap-frozen over dry ice and stored at –80◦C.
5.3.2 Chemical analysis
To confirm the nominal test concentrations of genistein, stock solutions
at the beginning of the test and test solutions (taken from test vessels at
test start and from the 96-well exposure plates at test end) were chemi-
cally analysed. The samples were subjected to GC-MS/MS analysis (Var-
ian 240MS-IonTrap), subsequent to extraction with tert-butylmethylether
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(BME) and derivatization by MSTFA (N-methy-N-(trimethylsilyl) trifluo-
roacetamide) (detailed protocol in Wenzel et al. [2001]).
Chemical analysis could not be conducted on all test solutions used,
therefore concentrations in the figures are depicted as nominal values.
5.3.3 Morphological assessments
The developmental status of the fish embryos (zebrafish and medaka) was
assessed using the inverted microscope system AF6000 from Leica (Wet-
zlar, Germany). Morphological endpoints were recorded after 24 and 48hpf
for zebrafish and after 1, 2, 5 and 7dpf for medaka. The endpoints assessed
are described in the Background Paper on Fish Embryo Toxicity Assays
[Braunbeck and Lammer, 2006] and comprised lethal effects, such as coag-
ulation, no heartbeat or lack of somite development, and sublethal abnor-
malities, e.g. reduced blood flow, formation of edema and malformations
of tail. A detailed list of all morphological endpoints is provided in Annex
Table B.
5.3.4 RNA extraction and reverse transcription
Total RNA was isolated from frozen, pooled embryos by homogenization in
TRIreagent (Sigma-Aldrich, T9424) followed by extraction with chloroform
and ethanol and final purification using RNeasy Mini Spin Columns (QIA-
GEN, Hilden, Germany) according to the manufacturers’ protocols. RNA
was then stored at –80C until analysis. RNA concentrations were measured
by using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific,
Schwerte, Germany). For cDNA synthesis, RNA was treated with DNAse
(Sigma-Aldrich, AMP-D1) and reverse transcribed using SuperScript III
Reverse Transcriptase (Invitrogen, Carlsbad, USA). A negative cDNA con-
trol sample, without added reverse transcriptase, was included in all qPCR
measurements. For the microarray analysis, RNA quality was verified on
an Agilent 2100 Bioanalyser (Agilent Technologies, Santa Clara, USA). All
further processed RNA samples had RNA integrity numbers between 8.8
and 9.8 and a 260/280 absorbance between 1.8 and 2.2.
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5.3.5 Quantitative real-time PCR
Zebrafish microarray data were validated by quantitative PCR using the
iQ5TM5 real-time PCR detection system (BioRad c© , Hercules, USA) and
SYBR R©GreenER qPCR SuperMix (Invitrogen, Carlsbad, USA), with the
primers listed in Annex Table A-1. Only cDNA from the EC20 exposure
were used for the validation. After incubating for 2 min at 50◦C and for
10 min at 95◦C, targets were amplified at 95◦C for 15 s, 59◦C for 30 s and
72◦C for 30 s (40 cycles), together with the two reference genes, β-actin
and rpl13, used to normalize the expression values. Identical RNA samples
were used for the microarrays and the qPCR.
For medaka, qPCR was applied as an alternative to microarrays. Three
biological replicates (24 embryos per replicate) were used for these real-
time qPCR experiments. The expression of 23 genes was analysed in 7 d
old medaka embryos using the Applied Biosystems 7300 Real-time PCR
system with SYBR R©Green qPCR Master Mix. The primers shown in An-
nex Table A-2 were selected from the medaka HPG PCR array collection
developed by Zhang et al. [2008a], which comprise a broad range of genes
involved in the hypothalamic-puitary-gonadal axis. Additional primer sets
were designed using primer-BLAST (NCBI) for target genes found to be
differentially expressed in zebrafish. After incubating for 10 min at 95◦C,
target sequences were amplified at 95◦C for 15 s, 59◦C for 30 s and 72◦C
for 30 s (40 cycles). The data was normalized using two reference genes,
16S rRNA and rpl7.
For both, medaka and zebrafish, 40 ng cDNA were used as starting
template. Two technical replicates and a negative control were integrated
in each experiment. Relative gene expression ratios were calculated by
the comparative Ct method (2∆∆Ct) [Pfaffl, 2001]. For zebrafish data,
a student’s test was used for testing significant differences between the
EC20 conditions and the solvent control. As the medaka qPCR analysis
comprised three conditions (control, EC10 and EC20), one-way ANOVA
with subsequent Dunnett’s multiple comparison test were selected for the
statistical evaluation.
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5.3.6 Microarray analysis
Microarray experiments were carried out using Zebrafish (V2) Gene Ex-
pression Microarrays 4X44K (Agilent Technologies, Santa Clara, USA).
Each array contained 43,604 oligonucleotide probes representing 16,865 dif-
ferent genes (partly in duplicates, and additional non-annotated genes) and
was hybridized with 1.65 cRNA amplified from 500 ng of total RNA accord-
ing to the Agilent one-color microarray hybridization protocol (One-Color
Microarray-Based Gene Expression Analysis, version 5.7, Agilent Tech-
nologies). We carried out cDNA synthesis, cRNA Cy3 labeling, amplifica-
tion and hybridization according to the manufacturer’s protocols (Quick
Amp Labeling Kit; Agilent Technologies). Microarrays were scanned with
the Agilent Microarray Scanner (Agilent Technologies), and data were ex-
tracted using Agilent Feature Extraction Software (Agilent Technologies).
The data were normalized using GeneSpring Software GX (Agilent Tech-
nologies) by setting the raw signal threshold to five, shifting the values of
all probes to the 75th percentile and performing a baseline transformation
to the median for each gene. Flags previously determined by the Agi-
lent Feature Extraction software were then filtered. For statistical evalua-
tion, one-way ANOVA was carried out for each gene, asymptotic p-values
were computed and the Benjamini-Hochberg False Discovery Rate was ap-
plied to correct for multiple testing. The corrected p-value and the fold
change cut-off were set to 0.01 and 2, respectively. Finally, Tukey Honestly
Significant Difference (Tukey HSD) was chosen for post-hoc testing. Dif-
ferentially expressed genes were clustered using the Self Organizing Map
(SOM) algorithm, which uses the K-means calculation to create clusters
of similarly-expressed genes and produce a two-dimensional grid to show
the affinity between clusters. The Manhattan function was chosen for dis-
tance measurement. In the resulting clusters, entities lacking annotations
were removed and excluded from further analysis. The final clusters were
then matched to the KEGG Pathway, Gene Ontology (GO) and InterPro
databases using FatiGO, a web-based tool for functional gene enrichment
analysis, on the babelomics4 platform (http://fatigo.org). To this end,
5.4 Results 113
each cluster was tested for overrepresented genes compared to the rest of
the zebrafish genome, applying Fisher’s exact test and setting the p-value
cut-off to 0.05.
Microarray data have been deposited in the NCBI Gene Expression
Omnibus GEO and can be accessed through GEO Series accession number
(GSE34616).
5.4 Results
5.4.1 Chemical analysis
Chemical analysis of the test solutions from the zebrafish exposure showed
that the genistein stock solution’s actual concentration reached 104% of
the nominal concentration (0.5 mg/ml). The exposure concentrations at
test start were 82% and 104% of the nominal EC10 and EC20 concentrations
(2.2 mg/l and 2.4 mg/l), respectively, and decreased to 76% and 83% of
nominal within the 48h until the end of the test.
The genistein stock solution concentration in the medaka test prior to
test start was 102% of the nominal concentration (1 mg/ml). Test solutions
at test start were not measured, but due to the average loss of 20% of
nominal over 48h in the zebrafish test, a decrease in genistein at a similar
rate was implied for the first two days of the medaka test. After 7 days of
exposure, the genistein exposure concentrations were analysed and showed
a sharp decrease to 19% and 18% (i.e., 1.12 mg/l and 1.4 mg/l) of the
nominal 6 mg/l (EC10) and 10 mg/l (EC20). This drastic decrease of the
concentration could be explained by microbial degradation and adsorption
of genistein to the inner surface of the glass bottle. Since such high losses
of genistein were unanticipated, the stock solutions, of which the EC10 and
EC20 dilutions were prepared in both tests, were not renewed during the
test period. For the 7d medaka test, the replacement of the test solutions
every other day consequently was ineffective in counteracting further losses
of genistein (mainly through adsorption) in the 96-well test plates. As
a result, medaka were exposed to a gradient of genistein concentrations
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ranging from 6 mg/l at test start to 1.12 mg/l at the test end for the EC10
value and, correspondingly, from 10 mg/l to 1.4 mg/l for the EC20 value.
The concentrations in all figures are depicted as nominal.
5.4.2 Morphological defects
In zebrafish embryos, no morphological defects were detected after 24h
exposure up to 2.6 mg/l of genistein. Higher concentrations resulted in
edema, head and tail malformation and reduced spontaneous movement
(Figure 5.4-2). After 48h exposure up to 2.2 mg/l, we observed a reduced
blood circulation as an additional effect. From the concentration response
curve for the cumulative lethal and sublethal morphological effects (Fig 5.4-
1), we derived an EC10 of 2.2 mg/l, an EC20 of 2.4 mg/l and an EC50 of
2.8 mg/l.
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Figure 5.4-1: Concentration response to 48h genistein exposure in zebrafish embryos. Newly
fertilized zebrafish embryos were exposed to 0.97; 1.36; 1.9; 2.2; 2.35; 2.5; 2.66; 3.73; 5.22 mg/l of genistein
for 48 hours post fertilization. The concentration x-axis is logarithmic. The graph shows data points
(black points) depicting the mean±SD percentage number of occurring effects (lethal and non-lethal) in
each concentration, the calculated function (black full line) and the 95% confidence levels (dashed lines),
referring to two replicates comprising 24 individuals each (function and confidence levels were retrieved
by probit analysis, ToxRat R©). Further, the EC50 value is tagged at the concentration axis (5.3.1).
In medaka embryos, the first morphological effects occurred after four
days of exposure. At nominal 10 mg/l of genistein, 20% of exposed medaka
embryos showed morphological defects, including reduced blood circula-
tion, delayed blood vessel development and malformations of the noto-
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chord, tail and head (Figure 5.4-3). It was not possible to determine the
concentration-response relationship because the maximum solubility was
reached at 10 mg/l.
Figure 5.4-2: 48hpf zebrafish
embryos A) of solvent control
and B) exposed to 2.2 mg/l
genistein, showing edema as
well as head and tail deforma-
tion.
A B
edematail
deformation
normal tail
blood clot
normal 
blood flow
Figure 5.4-3: 7dpf medaka em-
bryos A) of solvent control and
B) exposed to 10 mg/l genis-
tein, showing edema as well as
head and tail deformation.
5.4.3 Zebrafish microarray
Zebrafish microarray analysis resulted in the detection of 881 differentially
expressed genes. All genes with a FDR-corrected p-value of less than 0.01
were regarded significant. The subsequent Tukey HSD post-hoc test di-
vided those genes into different groups representing the EC10 (55 genes)
and the EC20 (881 genes) condition, when compared to the solvent and
ISO-water controls. We also identified 36 genes that showed differential
expression when compared to the solvent control and ISO-water control.
A fold change cut-off of 2.0 reduced the number of differentially expressed
genes in the EC10 and EC20 data sets to 20 and 662, respectively (Annex
Tables D-1 and D-2). Nine genes were differentially expressed between the
solvent and ISO-water controls (Annex Table D-3).
SOM clustering identified six clusters in the EC10 group and eight in
the EC20 group. Because each cluster in the EC10 group contained only
116 5. Molecular mechanisms of genistein in fish embryos
1–5 genes, these were merged into one cluster representing the upregulated
genes and another representing the downregulated genes.
EC10 
Cluster Database Accession nr. Term Affected genes 
I GO GO:0032355 response to estradiol stimulus cypa19a1b, vtg1 
II GO GO:0000785 chromatin zgc:110380, zgc:165555 
 
 A
B
C
ClusterClusterEC10 EC20
EC20 
Cluster Database Accession nr. Term Affected genes 
I KEGG dre04115 p53 signalling tp53, casp8, mdm2 
 GO GO:0043280 positive regulation of caspase activity bbc3,tp53 
 InterPro IPR007237 CD20/IgE Fc receptor beta subunit
ms4a17a.1, ms4a17a.4, 
ms4a17a.5 
II GO GO:0032355 response to estradiol stimulus cypa19a1b, vtg1 
IV KEGG dre00260 g ,  t elycine serine and hreonin  pathway cth, tha1 
 KEGG dre00100 steroid biosynthesis  lss, sc4mol 
VII GO GO:0007399 nervous system development 
adcyap1b, atp1b2b, dld, 
fezf2, her3, irx1a, isl1, 
nkx2.2a, pax2a, pou4f2 
 GO GO:0030878 thyroid gland development nkx2.1a, pax2a 
 InterPro IPR018237 
myelin proteolipid protein PLP, 
conserved site 
gpm6aa, plp1a 
 InterPro IPR003022 transcription factor Otx2  otx2, otx5 
VIII InterPro IPR001356 homeobox  crx, meis2.1, otx5, pou4f1, six7, vsx1 
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Figure 5.4-4: Gene clustering and functional analysis of the zebrafish microarray data A
Graphical illustration of gene clusters for the EC10 and EC20 data set (retrieved from four replicates
comprising 24 fish embryos each (5.3.1). Gene clusters (I-II for EC10, left; I-VIII for EC20, right) are
represented in a box-whisker format and plotted on the y-axis according to the log2 fold change (x-axis)
of the genes within each cluster. The vertical line in the boxes shows the median log2 fold change of each
cluster, the whiskers represent the minimum and the maximum value, respectively. The affected GO-
KEGG- and InterPro-categories are listed next to the corresponding gene cluster (note that for the EC20
condition, the figure shows only a selection of categories, the complete set is listed in Annex Table D-4.
B and C show the annotations of the functional categories and the affected genes in the clusters for EC10
(top) and EC20 (bottom). For clustering, all genes were included with a minimal log2 fold change of 2
and a maximal p-value of 0.01. For functional analysis, the p-value for significance was set to 0.05 (5.3.6).
In the EC20 group eight separate clusters were identified (Figure 5.4-
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4). Clusters I, IV and VIII contained relevant regulated endocrine genes,
which could not be assigned to KEGG pathways, GO categories or In-
terPro data (Table 5.1). In addition, four distinct KEGG pathways were
identified that were affected under EC20 conditions (Figure 5.4-4). These
included a strong induction of the p53 signalling pathway, a weaker but
still significant upregulation of steroid biosynthesis and glycine, serine and
threonine metabolism, plus the suppression of DNA replication.
In the EC10 data set, GO analysis revealed upregulated genes involved in
the response to estradiol as well as downregulated genes in the chromatin,
nucleosome and chromosome function category. In the EC20 dataset, the
most strongly upregulated genes grouped under the GO term ’apoptosis’
and many downregulated genes grouped under GO terms relevant for gen-
eral organ morphogenesis and nervous and endocrine system development.
Further annotation provided by InterPro analysis associated genistein reg-
ulated genes with predicted protein domains which are mostly related to
biological functions. No InterPro terms were retrieved from the EC10 data
set, but several were retrieved from the EC20 data set, including home-
obox family proteins and other embryogenesis-related proteins, such as
Mab21-like 2 and transcription factor AP-2 in the downregulated cluster
(Figure 5.4-4).
Table 5.1: Selected endocrine genes, differentially expressed in the EC20 zebrafish microarray data set
(log 2 fold change >2, p-value = 0.01). These genes were not in the significant KEGG, GO or InterPro
categories determined by functional analysis, but they exert important functions in the endocrine system
Cluster Gene
symbol
Description Log2 fold
change
EC 20
Accesion GO association
I lep a leptin a 8.0 up NM001128576 GO:0005179 hormone
activity
IV pth1a parat-
hormone 1a
3.4 up NM212950 GO:0005179 hormone
activity
VIII dio2 deiodinase
type II
3.1 down NM212789 GO:0042446 hormone
biosysnthetic process
GO:0009790 embryo
development
In order to validate the microarray results for selected significantly
changed genes represented in the above identified pathways (vtg1, cyp19a1b,
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sc4mol, pax2a, nkx2.1, hoxa9a, hoxa10b and hoxa11b), their regulation was
confirmed by quantitative PCR. Corresponding to the microarray results,
we found vtg1, cyp19a1b, sc4mol to be upregulated, whereas pax2a, nkx2.1,
hoxa9a, hoxa10b and hoxa11b were downregulated (Figure 5.4-5). Altered
expression was calculated by normalization to the reference genes β-actin
and rpl13, which did not show any exposure-related changes, neither in the
microarray nor in the qPCR analysis.
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Figure 5.4-5: Relative transcript levels of vitellogenin 1 (vtg1 ), aromatase b (cyp19a1b), sterol-C4-
methyl oxidase-like (sc4mol), paired box gene 2 a (pax2a), NK2 homeobox 1 (nkx2.1 ), homeobox a9a
(hoxa9a), homeobox a10b (hoxa10b) and homeobox a11b (hoxa11b) in zebrafish after 48h exposure to 2.4
mg/l genistein (EC20), determined by quantitative PCR. Results represent the mean ± standard error of
the mean (SEM) of the expression ratio and refer to the same RNA samples subjected to the microarray
experiment (5.3.5). Expression ratios were calculated according to the 2∆∆Ct method [Pfaffl, 2001].
Error bars indicate SEM. P-values were determined by student’s t-test and are indicated by asterisks
(*=<0.05,**=<0.01,***<0.001) (5.3.5).
To corroborate the enhancement of apoptosis related genes, we addition-
ally tested and confirmed a concentration dependent increase in apoptotic
cells in the embryos by acridine orange stainings. Methodology and results
are appended on page 132.
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5.4.4 Medaka quantitative real-time PCR
There were significant changes in the expression of seven genes under the
EC20 and one gene under the EC10 condition, respectively (Figure 5.4-6).
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Figure 5.4-6: Relative transcript levels of vitellogenin 1 (vtg1 ), aromatase b (cyp19a1b),
estrogen receptor 2a (esr2a), aromatase a (cyp19a1a), paired box gene 2 a (pax2a), deiodinase
2 (dio2), NK2 homeobox 1 nkx2.1, homeobox a9 (hoxa9a), tumor suppressor protein 53 (tp53),
homeobox a10 (hoxa10b) and homeobox a11(hoxa11b) in medaka after 7d exposure to 6 mg/l
(EC10) and 10 mg/l (EC20) genistein, determined by qPCR. Results represent the mean ±
standard error of the mean (SEM) of the expression ratio of four replicates with each comprising
24 embryos per treatment (5.3.5). Error bars indicate SEM. Expression ratios were calculated
according to the 2∆∆Ct method [Pfaffl, 2001]. P-values were determined by Dunett’s multiple
comparison test and are indicated by asterisks (*=<0.05,**=<0.01,***<0.001)(5.3.5).
As in zebrafish, cyp19a1b and vtg1 were upregulated under the EC20
condition. Dio2 was repressed in the EC10 condition and for pax2a a trend
towards downregulation could be observed, which corresponds to the ze-
brafish EC20 results. Differently to zebrafish, these two genes were upreg-
ulated in the EC20 group of medaka. Also differently regulated was tp53,
which was induced in zebrafish and repressed in medaka. Expression of
nkx2.1 and of the homeobox genes hoxa9a, hoxa10b and hoxa11b remained
unchanged after genistein exposure. Responses observed in medaka only
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involved the estrogen receptor 2a and cyp19a1a.
5.5 Discussion
This paper aimed at providing substantiating data for a fish embryo based
alternative testing strategy suitable for the assessment of estrogenic effects.
This study demonstrated that exposure to estrogens, such as genistein, in-
terfered significantly with multiple molecular pathways in 2- and 7-days old
zebrafish and medaka embryos, respectively, indicating the susceptibility
of fish embryo tests regarding the assessment of estrogenic chemicals.
The p53 signalling pathway was the most severely affected under the
EC20 condition. The consequence of an activation of the tumor suppres-
sor protein TP53 by various stress factors can be either cell cycle arrest
caused by DNA replication blockage or apoptosis [Cox and Lane, 1995;
Klein and King, 2007]. Since the analysis of the GO categories identi-
fied the terms ”positive regulation of apoptosis” and ”positive regulation
of caspase activity” in the same cluster, it was suggested that in the fish
embryos the induction of p53 may be predominantly pro-apoptotic. Since
bbc3 (BCL2 binding component 3) and casp8 (caspase 8) are included in
the same cluster, it is possible that genistein-dependent p53 activation
induces the release of cytochrome c by activation of bbc3, which in turn
activates caspase 3 causing nuclear condensation and fragmentation, as
previously described [Yoon et al., 2000; Ding et al., 2003; Reimertz et al.,
2003; Hong, 2008]. The transcriptional induction of p53, in turn, might
be attributed to the inhibition of topoisomerase II, a crucial enzyme for
DNA replication. This relationship has already been associated with the
apoptotic impact of genistein in mammalian in vitro systems [Ye et al.,
2001; Lo´pez-Lazaro et al., 2007; Schmidt et al., 2008]. Genistein has also
been shown to promote early apoptosis in zebrafish embryos from 15hpf,
suggesting that it acts prior to the onset of somitogenesis [Kim et al.,
2009; Sassi-Messai et al., 2009]. Early apoptosis could induce mortality in
the embryos, but mortality did not increase until 96h [Sassi-Messai et al.,
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2009], which is in agreement with a life cycle study of our department
[Wenzel et al., 2001] that showed a large increase in mortality only after
6d. Although it remains unclear whether apoptosis in fish embryos and
mortality in larvae can both be attributed to the p53 signalling pathway,
the transcriptomic data of the present study provides some indication that
there may be a link between larval mortality [Wenzel et al., 2001] and
early genistein exposure. Additionally, GO analysis showed repression of
genes necessary for the formation of nucleosomes at the EC10, suggest-
ing a pro-apoptotic activity even at low genistein concentrations. Sassi
Messai and colleagues (2009) detected apoptosis at concentrations from
0.68 mg/l via staining of apoptotic cells [Sassi-Messai et al., 2009]. Thus,
in future experiments it would be interesting to determine the minimum
concentration at which apoptosis-related induction is detectable in 48hpf
embryos at gene expression level. It has been shown that apoptosis can
occur in the hindbrain and anterior spinal cord of zebrafish embryos fol-
lowing exposure to genistein [Kim et al., 2009; Sassi-Messai et al., 2009].
This may be reflected by the GO and InterPro data of our study, which
indicated a disruption of genes involved with the regulation of the nervous
system development and the downregulation of Otx family transcription
factors, which are required for brain morphogenesis [Acampora et al., 1999;
Klein and Li, 1999]. Furthermore, InterPro data revealed downregulation
of genes responsible for the formation of the myelin proteolipid protein, the
major component of myelin. All findings together suggest that the predom-
inant effect of genistein was mediated by p53, inducing apoptotic effects
in hindbrain and spinal cord. Acridine orange stainings of control and
genistein-exposed zebrafish embryos verified these findings at the cellular
level (Appendix 5.A-1), showing apoptosis in the brain (data not shown)
and the spinal cord. Since these effects were also seen in exposures with es-
trogen receptor antagonists [Sassi-Messai et al., 2009], we hypothesize that
genistein-mediated induction of p53 signalling may be estrogen-receptor
independent. Regulation of p53 was also identified in medaka. However,
contrary to zebrafish, p53 was downregulated. As the exposure duration
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in medaka embryos was longer than in zebrafish, a negative feedback regu-
lation may be the explanation for this opposing effect, as this was observed
in fish in previous studies [Chen et al., 2005; Chen and Peng, 2009].
The next ranking cluster of upregulated genes in the zebrafish EC20
group was correlated to the GO categories ”response to estradiol stimu-
lus” and ”response to steroid hormone stimulus”, and included the genes
cyp19a1b and vtg1. The upregulated cluster in the EC10 group showed
also enrichment of genes of these categories, and accordingly, these genes
were found to be upregulated in the medaka embryos. CYP19a1 (aro-
matase) catalyzes the conversion of testosterone to estradiol, and there are
two functionally distinct aromatase gene isoforms cyp19a1a and cyp19a1b
in zebrafish, which are expressed predominantly in the ovary and brain,
respectively, at different rates [Fenske and Segner, 2004; Kishida et al.,
2001]. Both isoforms are crucial for gonadal development in fish and dis-
ruption of the aromatase function can cause severe effects on reproduction
[Piferrer et al., 1993; Kitano et al., 2000; Fenske and Segner, 2004], but
only the aromatase 1b is directly responsive to estradiol stimulus [Menuet
et al., 2005; Diotel et al., 2010]. For fish embryos, Kishida et al. [2001]
suggested that cyp19a1b is necessary for central nervous system develop-
ment and thus, represents a reliable marker for testing neurotoxic effects of
xenoestrogens during embryogenesis. Accordingly, cyp19a1b transcription
commences when the central nervous system begins to develop [Kishida
et al., 2001] and is concentrated in radial glial cells, which are impor-
tant for neurogenesis [Tong et al., 2009; Mouriec et al., 2009]. In this
context, the glial cells in the hypothalamus are the predominant area of
cyp19a1b expression in the brain of 48hpf embryos [Menuet et al., 2005].
The synthetic estrogen analogue ethinylestradiol has been shown to induce
cyp19a1b expression additionaly in the preoptic area, which has also been
confirmed for genistein by in situ hybridization [Sassi-Messai et al., 2009;
Chung et al., 2011; Vosges et al., 2012] and more recently in zebrafish
embryos of a cyp19a1b transgenic line in-vivo [Brion et al., 2012]. This
clearly demonstrates the estrogenic mode of action of genistein. The mini-
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mum concentrations reported so far to induce cyp19a1b expression ranged
from approximately 0.5-0.7 mg/l for zebrafish [Sassi-Messai et al., 2009;
Brion et al., 2012]. The induction of aromatase by genistein and 17α-
ethinylestradiol (EE2) in the same celltype (glial cells) and brain area as
well as the presence of estrogen response element (ERE) in the cyp19a1b
gene reflect the estrogen-dependency of cyp19a1b regulation. Since it is
known that cyp19a1b is essential for the regulation of sexual differentia-
tion in fish, a dysregulation by estrogenic substances, such as genistein,
may long-term have severe reproduction- and population-relevant effects.
The first expression of cyp19a1b in response to estrogens [Kishida et al.,
2001] coincides with the onset of estrogen receptor expression [Mouriec
et al., 2009], and the expression of cyp19a1b then increases strongly be-
tween 24 and 48hpf. As the estrogen receptor 1 mRNA (esr1 ) was not
detected in the embryos before 48hpf [Bardet et al., 2002], it is likely that
the estrogen receptor 2a and/or estrogen receptor 2b (Esr2a and Esr2b,
respectively, mRNA of both is expressed by 24hpf) are responsible for reg-
ulating aromatase [Mouriec et al., 2009]. Indeed, in medaka we found esr2a
being upregulated by genistein, implying this form as the active estrogen
receptor at the embryonic stage, which was also described by Chakraborty
et al. [2011]. The identified regulation of esr2 a in medaka only might be at-
tributed to either the longer exposure time or a later developmental stage,
compared to zebrafish. Additionally, sexual differentiation in medaka starts
at a much earlier developmental time point than in zebrafish and thus, also
the differentiation related regulation of gene expression [Maack and Segner,
2003; Kobayashi et al., 2004; Matsuda, 2008; Kondo et al., 2009; Herpin
and Schartl, 2009]. It could therefore be hypothesised that the estrogen re-
ceptors Esr2a and Esr2b are more susceptible in medaka than in zebrafish
embryos. Although we did not detect altered estrogen receptor expres-
sion in zebrafish, an induction of cyp19 by non-genomic estrogen receptor
2a signalling is still plausible, since this mechanism has already been re-
ported to regulate neuronal gene expression particularly in the brain [Beyer
and Raab, 1998; Beyer and Karolczak, 2000; Belcher and Zsarnovszky,
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2001]. The involvement of an estrogen receptor in estrogen signalling in
fish embryos, in turn, indicates that other estrogen-receptor dependent
pathways may also be affected by estrogenic compounds. In this context,
gonadotopin-releasing-hormone (GnRH) neurons are important targets of
steroid hormones and it has indeed been shown recently that the ontogeny
of (GnRH) neurons can be modified in an estrogen-receptor dependent
manner after EE2 exposure [Vosges et al., 2012]. Since GnRH neurons are
also essential regulators of gonadal development and sexual differentiation,
their dysregulation may cause severe reproductive effects in adult fish.
Our data showed that the cyp19a1a isoform was downregulated in medaka,
but not in zebrafish, which is in agreement with Kishida et al. [2001], who
also reported a lack of estrogen-induced response of cyp19a1a in zebrafish
embryos. This is also consistent with data from juvenile and adult zebrafish
[Hinfray et al., 2006] and in vitro experiments in rainbow trout [Pelissero
et al., 1996]. Instead, the downregulation of cyp19a1a by genistein in
medaka was most likely estrogen-independent since there is no evidence
yet that cyp19a1a may be estrogen responsive [Sawyer et al., 2006; Trant
et al., 2001] and there is also no full ERE in its promoter region. Genistein
rather inhibits the aromatase directly by interacting with its active site
[Kao et al., 1998].
Vitellogenin is the yolk precursor protein predominantly expressed in
the female liver, but it can also be induced in male fish in response to ex-
ogenous estrogens and thus, has become the best characterized biomarker
for estrogenic disruption in fish [Sumpter and Jobling, 1995]. Alterations
in vitellogenin 1 ( vtg1 ) expression have been associated with severe repro-
ductive effects such as intersex and impaired gonadal growth [Jobling et al.,
1998; Panter et al., 1998; Jobling et al., 2002]. The induction of vtg1 in fish
by genistein has been reported before [Zhang et al., 2002; Scholz et al., 2004;
Kausch et al., 2008], but the results indicate great variability and seem to
depend on exposure time and concentration. In medaka, exposure to 10
µg/l of genistein for four weeks were sufficient to induce vtg1 expression
in male fish, whereas in adult male zebrafish an induction in liver tissue
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could only been detected at 5 mg/l after seven days. Our data confirm
vtg1 regulation in both effect concentrations for zebrafish and in the EC20
condition for medaka. Muncke and Eggen [2006] observed the induction
of vtg1 expression even already in zebrafish embryos from 24hpf. Accord-
ing to previous studies vitellogenesis in zebrafish is mainly controlled via
Esr1, but Esr2a may also be involved, as it is able to mediate the induc-
tion of the esr1 promoter, and subsequently its expression [Menuet et al.,
2005]. However, Esr1 is most likely not involved in the fish embryo be-
cause, as stated above, it is not yet expressed at this early developmental
stage. Instead, we believe that vtg1 expression involves direct signalling
through Esr2a, as implied by the increased esr2a expression in medaka.
The absence of esr2a regulation in zebrafish suggests that basal estrogen
receptor concentrations may already be present in the embryos and that
only after depletion of these receptors, the estrogenic stimulus manifests
in an upregulation of the corresponding estrogen receptor gene [Arukwe,
2001]. The gene response would then be delayed and likely to be missed
by the short 48h-exposure of zebrafish. Another regulative pathway poten-
tially responsible for the upregulation of vtg1 in the zebrafish embryos is a
calcium-dependent mechanism mediated by the parathormone gene (pth),
which was found strongly upregulated in our study. This correlation has
previously been reported for estradiol by Bevelander et al. [2006]. How-
ever, the exact mechanism by which genistein induced vitellogenin in the
embryos remains to be clarified.
Overall, our results clearly demonstrate that an estrogenic response to
genistein can be detected in fish embryos. Since the response to estra-
diol stimulus was the only biological process being upregulated at EC10
conditions, we conclude that the primary mode of action of genistein was
estrogenic, besides its pro-apoptotic effect. This conclusion is substanti-
ated by the results of another study [Sassi-Messai et al., 2009] that iden-
tified two different pathways, an estrogen receptor-independent induction
of apoptosis and an estrogen receptor-dependent upregulation of cyp19a1b
expression in the brain, through which genistein acts in zebrafish. The
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KEGG analysis confirmed the induction of steroid biosynthesis by genis-
tein, mainly through the genes lss (encoding lanosterol synthase) and
sc4mol (encoding a sterol-C4-methyl oxidase-like enzyme). This suggests
that genistein may stimulate the synthesis of cholesterol, which is a com-
ponent of the plasma membrane as well as a precursor of calcitriol (vita-
min D), bile acid and steroid hormones. Cholesterol synthesis is generally
known to be stimulated by estrogens [Messa et al., 2005], and the induction
of steroid hormone synthesis by genistein in the ovaries of adult medaka
ex vivo has also been documented [Zhang et al., 2003]. Further, since
steroid hormones regulate the development and function of secondary sex
charasteristics in fish [Brantley et al., 1993], it has been proposed that
the gonadal abnormalities observed in a medaka fish study after a 100-day
exposure to 1 mg/l genistein were at least partly caused by disruption of
steroid biosynthesis [Kiparissis et al., 2003]. Thus, our microarray data
clearly corroborate that genistein interferes with steroid biosynthesis, and
longer-term this alteration of steroid biosynthesis genes is likely to affect
normal gonadal development. Besides, steroids play a crucial role in the
development and function of the central nervous system in fish [Arukwe,
2008], and further upregulation of steroidogenesis will therefore also impact
the brain of the embryos. Since our data suggest induction of steroidoge-
nesis occurs via cholesterol synthesis, we hypothesise that the brain of
the embryos is particularly prone to a disruption of steroidogenesis due to
the cholesterol-impermeability of the blood-brain-barrier, which requires
de novo synthesis.
In addition, our microarray results revealed other pathways affected by
genistein, including some regulated by homeobox or Hox genes, which are
key regulators of animal development [Pearson et al., 2005]. The down-
regulation of several developmentally-relevant hox genes (Figure 5.4-4) fits
in with the identified GOs indicating disruption of pattern formation and
morphogenesis and the observed deformations of chorda, tail and head.
The downregulation of hox genes in zebrafish embryos may be caused by
the pro-apoptotic and anti-proliferating activity of genistein. Otherwise,
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certain Hox genes are also known to be regulated by estrogens and to con-
trol the development of female primary sex characteristics [Daftary and
Taylor, 2006; Hewitt et al., 2005]. It has been shown that Hoxa9, Hoxa10
and Hoxa11, which belong to the same HoxA cluster, control the differen-
tiation of the oviduct and the uterine and cervical anlagen in mammalian
embryos [Daftary and Taylor, 2006; Taylor et al., 1997], and dysregulated
expression during development causes reproductive defects and reduced
fertility in adults [Hewitt et al., 2005]. For example, exposure of neona-
tal mice to genistein causes uterine adenocarcinoma [Daftary and Taylor,
2006; Newbold et al., 2001] and it is assumed that this reflects the dysreg-
ulation of Hoxa10 expression in the uterus [Akbas et al., 2007]. Compared
to mammals, teleosts have seven (or even eight in some species) instead of
four Hox clusters, probably due to chromosome doubling following genome
duplication [Amores et al., 1998; Kurosawa et al., 1999]. Thus, genes of
the mammalian HoxA cluster split into two clusters hoxAa and hoxAb in
medaka and zebrafish. In agreement with the mammalian studies, we ob-
served downregulation of hoxa9a, hoxa11b and in particular hoxa10b in
genistein-treated zebrafish but failed to detect any hox gene regulation
in medaka. This difference in the hox gene expression between both fish
species may be a result of their evolutionary distance. In both fish species,
hoxa9, hoxa10 and hoxa11 are expressed in the trunk and in the pectoral
fin bud during embryonic development. Whereas the expression of hoxAa
and hoxAb genes in the pectoral fin bud were shown to be comparable be-
tween medaka and zebrafish, the expression boundaries in the trunk were
slightly shifted [Ahn and Ho, 2008; Takamatsu et al., 2007]. This spa-
tial shift could partially explain the differing expression patterns observed
in medaka and zebrafish. We therefore hypothesize that the different re-
sponses of the hox genes in zebrafish and medaka indicate that it were
mainly the trunk related hox genes that were susceptible to the estrogenic
activity of genistein. Critically, slightly disaligned embryonic stages dur-
ing analysis have to be taken into consideration as a possible cause of the
species specific response in medaka at 7dpf versus the zebrafish at 48hpf,
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in particular due to the temporal regulation of the hox gene expression.
However, if a correlation between hox genes and the sexual development
could be confirmed by further investigations in zebrafish, the regulation of
hox genes may even be considered a useful marker in zebrafish embryos for
the prediction of estrogenic reproductive effects in adult fish.
Finally, GO analysis also revealed the downregulation of genes involved
in endocrine and thyroid development, such as nkx2.1 and pax2a (encoding
transcription factors) and dio2 (encoding type II iodothyronine deiodinase,
which converts thyroxine (T4) to triiodothyronine (T3)). For zebrafish, the
knockout of dio2 and the resulting lack of T3 have shown to disrupt embry-
onic development and pigmentation [Walpita et al., 2009]. Interestingly,
we could not detect pigmentation disorders in our treated zebrafish em-
bryos. It can only be speculated whether the downregulation of dio2 was,
compared to the gene knockout, insufficient to disrupt pigmentation. The
decrease of pax2 and dio2 transcription was consistently found both in ze-
brafish and medaka embryos and this is also consistent with other studies
reporting thyroid-disrupting effects of genistein, such as the downregula-
tion of deiodinase and thyroid peroxidase, reduced thyroid receptor activ-
ity or the disruption of iodide accumulation in vitro [Cody et al., 1986;
Chang and Doerge, 2000; Schmutzler et al., 2007; Walpita et al., 2009].
Contrary to this antithyroidal effect in medaka at the EC10 level, upregu-
lation of pax2 and dio2 was detected at the EC20 level. This indicates a
concentration-dependent effect for medaka and may reflect the apparently
complex etiology of genistein in terms of thyroid disruption. Thyroidal
effects of genistein seem ambiguous, and antithyroidal as well as thyroid
receptor agonistic effects have been reported and long-term thyroidal ef-
fects were not always reproducible [Doerge and Chang, 2002; Schmutzler
et al., 2007; Li et al., 2011]. The cause of the disagreement in the re-
sponse between zebrafish and medaka embryos cannot be clarified by the
present data, but a thyroid disrupting impact of genistein at gene expres-
sion level seemed evident in both species. The key question for our testing
approach, whether an estrogenic chemical generally impacts the thyroid
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activity [Schmutzler et al., 2007], however, cannot be resolved and requires
investigations on further estrogenic chemicals.
5.6 Conclusion
The effects we observed on gene expression patterns in zebrafish and medaka
were largely coherent with findings of other genistein studies [Kim et al.,
2009; Sassi-Messai et al., 2009], which also demonstrated a primarily estro-
genic response and the promotion of apoptosis. Despite the absence of char-
acteristic apical endocrine disrupting effects in fish embryos, we were able
to detect endocrine disrupting molecular effects of genistein even at low
EC10 and EC20 exposure concentrations by using microarray analyses and
quantitative RT-PCR. The combination of the two fish species zebrafish
and medaka in the testing approach proved beneficial because the different
exposure times elicited complementary toxicological effect information. For
medaka, the downregulation of the aromatase isoform cyp19a1a was found
and the estrogen receptor 2a was identified as the likely mediator of the
estrogenic signalling, whereas for zebrafish, a dysregulation of hox genes
was evident. The species-dependent effects on the transcriptome identified
in this study are presumably also related to the different modes of sexual
differentiation of zebrafish (an undifferentiated gonochorist) and medaka
(a differentiated gonochorist). Differences in exposure times and devel-
opmental stages, may, however, have also contributed to species-specific
effects. Consequently, a two-species approach can provide the opportunity
to derive key information on the molecular mechanisms underlying estro-
genic disruption, caused by chemicals like genistein, which can affect sexual
differentiation and reproduction differently in different fish species.
In summary, this study demonstrates that the combination of fish em-
bryo tests with zebrafish and medaka and transcriptomics provides a promis-
ing approach, which can deliver a wealth of mechanistic information about
endocrine disruption in fish. Moreover, if this approach is successfully val-
idated for further estrogens or even chemicals of other endocrine activities,
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confirming endocrine disruption mode-specific patterns in the transcrip-
tome response, then subsets of critical genes suitable for a more practicle
and cost-efficient PCR-based analysis could be extracted. Further valida-
tion of the assay should then be aimed at providing essential data on the
sensitivity of gene expression endpoints to enable a comparison with exist-
ing screening methods for endocrine disruption. After successful validation
a transcriptomics-based assay as proposed by the current study, would then
allow affordable routine measurements alongside the fish embryo test and
could longer term be considered a very valuable alternative testing method
for the assessment of environmental estrogens and considered a useful tool
for EDC screening applications.
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5.A Appendix
5.A.1 Acridine orange staining
Methods Acridine orange (AO) was obtained from Sigma-Aldrich, dis-
solved in H2O for storing as stock solution (2 mg/ml) and the diluted with
ISO water to gain a working solution of 5 mg/L. For staining, vital zebrafish
embryos were dechorionated, incubated in the AO working solution for 30
minutes in the dark and subsequently washed three times with ISO water.
Three independent experiments were performed with each comprising five
embryos per treatment. The staining was assessed using the DMI6000 mod-
ule of the Leica microscope system AF6000. Stack images were retrieved
and subsequently processed and analysed using the ImageJ software 1.46
(U.S. National Institutes of Health, Bethesda, Maryland, USA). Z-stack
images were focused with the plugin “Stack Focuser” to generate full-focus
images (with extended depth of field) and the number of fluorescent par-
ticles, corresponding to apoptotic cells, was assessed for each embryo. For
the purpose of best comparability and for the precision of measurement,
we selected the area between the posterior limit of the yolk sac and the
tail end for quantification of the apoptotic cells. The quantification was
statistically analysed by one way ANOVA with subsequent post hoc testing
(Dunnett’s multiple comparison test).
Results Acridin orange staining showed a concentration-dependent en-
richment of apoptotic cells in genistein-exposed zebrafish embryos (Fig-
ure 5.A-1). Predominantly, apoptosis occurred in the nervous system, as
apoptotic particles were identified in the spinal cord and in the brain (data
not shown).
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Figure 5.A-1: Apoptosis in 48hpf zebrafish embryos after exposure to 2.2 mg/l (EC10) and 2.4 mg/l (EC20)
genistein and solvent control (0.0 mg/l). Apoptotic cells were identified using Acridine orange staining.
The pictures on the left show the concentration-dependent increase of apoptotic cells in the spinal cord.
The graph on the right provides the quantification of apoptotic particles as identified by the analysis of the
particle number using ImageJ. Results represent the mean (horizontal line) ± standard error of the mean
(error bars) as well as individual values (circles) of three independent experiments with each comprising
five embryos per treatment. Statistical analysis was performed using one way ANOVA with subsequent
Dunnett’s multiple comparison test (asterisks illustrate the p-values: **=< 0.01, ***=< 0.001).
Chapter 6
General Discussion and Conclusions
In Germany, the fish embryo toxicity test replaces acute fish test for rou-
tine sewage testing since 2005 and many inter-laboratory studies have been
conducted to confirm a high correlation of acute toxicity values determined
in fish embryos and in adult fish [Lammer et al., 2009]. But the use of fish
embryos is not limited to acute toxicity testing, a variety of further appli-
cations in the context of environmental risk assessment has been proposed
[Scholz and Mayer, 2008]. Such an application is the use of fish embryos for
alternative endocrine disruption testing. Endocrine disruption is a highly
concerned topic in the environmental hazard assessment since it adversely
affects the reproductive system and therefore has population endanger-
ing potency. Currently, testing of endocrine disruption relies on cost- and
time- intensive animal studies and alternative testing strategies are ur-
gently needed. The introduction of a molecular FET-based approach as
such an alternative was targeted by this thesis. To this end, firstly, the
key questions were addressed whether endocrine disruption is detectable
in fish embryos and how the mechanisms of disruption manifest in the
transcriptome. Therefore, embryos of two model fish species for endocrine
disruption, zebrafish and medaka, were exposed to two mode of action
classes of endocrine disruptors, i.e. the estrogenic and anti-androgenic ref-
erence compounds EE2 and flutamide, respectively. After exposure, gene
expression analysis, i.e. microarray analysis and quantitative RT-PCR, un-
covered the molecular embryonic response to the tested compounds. The
utilization of two fish species, differing in embryonic and sexual develop-
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ment, also enabled the elaboration of species and exposure duration spe-
cific effects. Secondly, the thesis aimed at the identification of endocrine
responsive pathways or individual genes which could serve as mode of ac-
tion specific markers for endocrine disruption in fish embryos. For this
purpose, the gene response to further known or suspected estrogenic and
anti-androgenic disruptors was analysed and endocrine features from the
gene response profile of these test compounds were extracted by compar-
ison with the reference compounds. Finally, for zebrafish, the effect of a
prolonged exposure to the posthatch stage of 96h was examined in order
determine the benefits of testing at a later developmental stage. Overall,
this thesis provides new data for the suitability of fish embryos in terms
of alternative endocrine disruption testing and suggests new endpoints for
the assessment of endocrine disruption.
The exposure of fish embryos to the estrogenic reference compound
EE2 resulted in the induction of estrogenic genes and pathways in both
fish species. Importantly, two genes encoding for established estrogenic
biomarkers aromatase b (cyp19a1b) and vitellogenin (vtg1) were induced,
which is in accordance to literature and gives first proof for the suitability
of fish embryos for endocrine disruption testing. Whereas the expression of
these biomarkers was identified in both fish species, the regulation of estro-
gen receptors, i.e. esr2a, was unique to medaka and no estrogen receptor
regulation was identified in zebrafish before 96hpf. Thus, even though an
estrogenic response is detectable in 48hpf embryos, a prolongation of the
test up to 96 hours could be considered whereas the prehatch stage of 7 days
proved sufficient for this purpose in medaka embryos. Also, since different
estrogen receptors were affected by EE2 in the two fish species, a diverg-
ing estrogenic response might be anticipated for medaka and posthatch
zebrafish embryos and should be tested in future studies.
Another pathways affected by EE2 in both fish species were the iso-
prenoid and the related cholesterol synthesis. Three genes associated with
these pathways i.e. mevalonate (diphospho) decarboxylase (mvd), lanos-
terol synthase (lss) and sterol-C4-methyl oxidase-like gene (sc4mol) were
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extracted and their differential expression was validated. The induction of
cholesterol synthesis by EE2 indicates an enhanced steroidogenesis which
eventually might manifest in an enhanced steroid hormone synthesis, how-
ever, this needs to be clarified by further studies. Nevertheless, the isoprenoid-
and cholesterol-related genes appear to be strongly susceptible to EE2 ex-
posure in embryos both fish species and thus are possible test endpoints for
estrogenic disruption. Further, growth and transcription related pathways
were strongly induced upon EE2 exposure in zebrafish. This growth pro-
moting effect of EE2 in early life stages is of particular interest for zebrafish,
since the speed of growing is a known factor for sexual differentiation in ze-
brafish, with faster growing fish preferably developing in females [Lawrence
et al., 2008], and, thus might contribute to altered sex ratios in a popu-
lation. However, although the expression of growth related genes remains
to be analysed in medaka embryos, a previous study by Mizukami-Murata
and Kishi-Kadota [2011] confirmed altered expression of such genes for lar-
val stages of medaka and therefore it is likely that such a response can be
identified in embryonic stages, too. Therefore, the expression of growth
related genes has to be further analysed in future studies as it might serve
as an additional indicator for estrogenic disruption.
Comparing this fish embryo results to studies conducted with larval
stages and adult zebrafish and medaka [Martyniuk et al., 2007; Hoffmann
et al., 2006; Mizukami-Murata and Kishi-Kadota, 2011; Zhang et al., 2002],
much coherence was identified, which is described in detail in chapter 4
and 5. Thus, this thesis provides evidence for the transferability of the
estrogenic gene expression profile of fish embryos to the response in adult
fish.
Next, our results showed that, for both fish species, the response to the
anti-androgen flutamide was discernible from the estrogenic response. This
reflects the mechanistic specificity of the reference substances and also, it
demonstrates the potential of transcriptome analyses in fish embryos to
identify different modes of endocrine action. This potential is even more
underscored by the fact that in adult fish, estrogenic and anti-androgenic
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disruption manifest in similar morphological effects, which are difficult to
distinguish [Scholz and Klu¨ver, 2009].
Exposure to the reference anti-androgen flutamide exposure led to the
regulation of only few pathways in zebrafish embryos, but most of them
were relevant in terms of endocrine disruption. Mainly, those pathways
were related to neuroendocrine processes; in particular, members of the
upper hypothalamic-pituitary-gonadal (HPG) axis (e.g. gh, gnrh3, lhbeta,
npy1r) and kiss receptors were identified in the upregulated gene sets.
Thus, competitive binding of the androgen receptor results in a disruption
of the neuronal part of the HPG axis in embryos. Since only little infor-
mation is available on the impact of anti-androgens on neurotransmitter
activity in fish, these data provide new insights into the mechanisms of
anti-androgens in fish. Further, it is noteworthy that crucial steroid reg-
ulating processes can be apparently affected in early life stages and thus
embryonic data could predict chronic effects in later life stages. The al-
tered expression of neuroendocrine genes therefore exerts a possible marker
function for anti-androgenic mechanisms.
However, established androgenic marker, such as the androgen recep-
tor and cyp11b, which encodes for an enzyme converting testosterone to
11-ketotestosterone, or 3β-hsd, encoding for a steroidogenic enzyme medi-
ating the synthesis of androstenedione, the direct precursor of testosterone,
could be identified in medaka embryos only and not in 48hpf zebrafish em-
bryos. Moreover, medaka showed the downregulation of estrogenic genes
aromatase b and estrogen receptor 2 a, providing further proof for dis-
ruption of the androgen signalling at the prehatch stage. Prolongation
of the zebrafish test to 96hpf resulted in an altered expression of andro-
gen receptor, estrogen receptor 2a and cyp19a1b. Thus, the later stage of
96hpf appears more suitable for detecting androgenic effects in zebrafish
embryos, compared to 48hpf. The prehatch stage of 7dpf in medaka, how-
ever, is sufficient for this purpose. The regulation of the affected genes
in 96hpf zebrafish embryos was different from medaka and moreover, the
androgenic key genes 3β-hsd and cyp11b, were neither affected in the later
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developmental stage in zebrafish, but in medaka only. This implies a dif-
ferent response to anti-androgens in medaka and zebrafish, which might
be caused by either species or exposure time related differences. This data
shows that testing two fish species provides complementary information
and suggests the inclusion of both, zebrafish and medaka, for endocrine
disruption testing in fish embryos.
Given that only little studies have examined the effects of flutamide in
fish at gene expression level, it is difficult to conclude from our fish em-
bryo results to the outcome in adult fish. However, comparison to existing
studies with medaka larvae [Leo´n et al., 2008] and adult fathead minnows
[Filby et al., 2007], showed a similar gene response in embryos and later
developmental stages, indicating the transferability of embryonic results to
later stages. Together, gene expression analysis confirmed the hypothesis
that estrogenic and anti-androgenic disruption is detectable in fish em-
bryos and delivered novel information about the mechanism of action of
the tested reference compounds. Both fish species and test approaches were
suitable in this context. The microarray analysis in zebrafish provided in-
sights in the transcriptome response and delivered indicative pathways for
estrogenic and anti-androgenic disruption. Quantitative RT-PCR (qPCR)
enabled the expression analysis of individual genes, which elicited benefits
of medaka for testing anti-androgenic disruption at the prehatch stage. For
zebrafish, a prolongation of the test up to 96h was suggested for further
testing of anti-androgenic compounds. Also, since complementary infor-
mation was retrieved from the use of both species, a testing strategy based
on both fish species should be considered.
Transcriptome response to non-reference compounds In order to test whether
the estrogenic and anti-androgenic response to the reference compounds
can be identified in non-reference compounds, too, the gene expression pro-
files of a set of compounds, which are known or suspected to be estrogenic
or anti-androgenic, were examined. The selected estrogenic compounds
were BPA, genistein and methylparaben. BPA induced similar pathways
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and genes as EE2 and could be categorized as estrogenic in zebrafish and
medaka embryos. The second estrogenic test compound genistein also
shared many pathways with EE2, however, it simultaneously showed sim-
ilarities to flutamide in the zebrafish microarray results and thus could
not be classified as purely estrogenic. Given that the mode of action of
genistein is known to comprise estrogenic, anti-androgenic, thyroidal and
apoptotic mechanisms, among others, the complexity was apparently re-
flected by the transcriptome response in the zebrafish embryos, which was
the strongest and most divers of all tested compounds. In order to narrow
the focus on the key mechanisms of actions of genistein, a more focused
analysis of the microarray results was chosen. In this context, chapter 5
provides detailed information about the retrieved microarray results for
zebrafish and about additional qPCR data for medaka. The results of the
narrowed analysis and the medaka data showed the regulation of indicative
estrogenic genes, such as upregulation of cyp19a1b, vtg1, estrogen receptor
2a as well as cholesterol synthesis related genes and finally enabled to
classify genistein as predominantly estrogenic in fish embryos.
Methylparaben showed a response contrary to EE2 in zebrafish embryos,
implying an anti-estrogenic mode of action. However, this has to be verified
by comparison to an anti-estrogenic reference compound, which was not
covered within this thesis.
Together, it was possible to extract an estrogenic gene response pattern
and to classify BPA and genistein as predominantly estrogenic. BPA, genis-
tein and EE2 commonly affected pathways related to growth, isoprenoid-
and cholesterol synthesis as well as the induction of estrogenic marker genes
cyp19a1b and vtg1 and, thus, as previously suggested, these pathways are
potential markers for estrogenic disruption in fish embryos. Therefore,
both, 48hpf zebrafish and 7d medaka embryos, proved to be suitable for
detecting the estrogenic impact of endocrine compounds. However, in the
case of a complex test compound such as genistein, both fish species were
needed for a mode-of-action categorization, again underscoring the com-
plementarity of zebrafish and medaka for endocrine disruption testing.
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As non-reference anti-androgens, linuron, propanil and prochoraz were
selected. In zebrafish, linuron and prochloraz induced neuroendocrine
pathways similar to flutamide, confirming the hypothesis of potential marker
function of neuroendocrine genes. Propanil could be classified as anti-
androgenic in zebrafish, although it shared rather unspecific pathways with
flutamide. Further, the tested anti-androgens, and particularly prochloraz,
shared also many pathways with EE2, which prevented a categorization to
a certain mode of action and rather indicated a multiple mode of action,
which is also in line with data from literature [Hofmeister and Bonefeld-
Jørgensen, 2004; Gordon et al., 2004; Salazar et al., 2006; Rime et al.,
2010; Kinnberg et al., 2007; Vinggaard et al., 2002]. Yet, given that the
functional modes of actions of these pesticides, i.e. inhibition of photo-
synthesis or steroidogenesis, are primary not endocrine, it was remarkable
that a response similar to the anti-androgenic reference compound could be
extracted from the zebrafish transcriptome data for linuron and prochlo-
raz. Gene expression analysis of medaka embryos gave even more evidence
for an anti-androgenic disruption. All tested anti-androgens, i.e. linuron,
prochloraz and propanil showed a response comparable to flutamide, down-
regulating gnrhr2, cyp19a1b and the androgenic marker cyp11b and 3β-hsd,
and thus, these genes could be considered markers for anti-androgenic dis-
ruption in medaka embryos. As described above, for zebrafish a more
defined anti-androgenic response is likely to be achieved in 96hpf zebrafish
embryos, which would argue for a prolongation of the test for zebrafish.
Conclusions and perspectives The results of this thesis showed that estro-
genic and anti-androgenic disruption manifest already in the embryonic
life stage of fish. These effects could be detected by means of gene expres-
sion analysis of exposed medaka and zebrafish embryos. Well established
estrogenic and anti-androgenic marker genes as well as further commonly
affected genes or pathways could be identified after exposure to EDCs. In
particular, isoprenoid- and cholesterol synthesis as well as growth related
genes were identified as novel potential marker for estrogenic disruption,
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whereas neuroendocrine genes and common androgenic genes appeared as
targets for anti-androgenic disruption. Together, those genes reflected an
estrogenic and an anti-androgenic response pattern. Moreover, the ob-
tained embryonic gene expression data were generally coherent with the
findings of exposure studies conducted with adult fish, using the same
chemicals. This coherence could be interpreted as a first evidence for a
predictive power of transcriptome-based fish embryo testing approaches.
Albeit the data of this thesis cannot be directly linked to later stage patho-
logical outcomes, e.g. sex reversal, fecundity- or fertility effects, in can
be assumed that disruption of the endocrine system in early developmen-
tal stages impacts the growth, health and eventually the survival rates of
the fish exposed, and ultimately inevitably also affect the survival of fish
populations. Concluding from the results of this thesis, the fish embryo
test could be used as an alternative tool in endocrine disruption testing.
For example, the FET could be included in the screening tier test bat-
tery of the US EPA Endocrine Disruptor Screening Program (EDSP) or
the OECD conceptual framework (CF) for the testing and assessment of
EDCs. Regulatory decisions about endocrine disruptors will have to rely
on weight-of-evidence procedures which are yet to be developed. However,
there are enormous knowledge gaps about the potency and specificity of
endocrine disruptors, and suitable methods for their identification are ur-
gently needed [Kortenkamp et al., 2011]. The fish embryo test in combina-
tion with gene expression analysis could supplement or replace some of the
in-vitro assays or short-term in vivo tests of the current CF. The fish em-
bryo has the full spectrum of metabolism system and endocrine disruption
is detectable at this developmental stage.
Within the testing frameworks, the screening and short-term organism
tests gather information about a chemical and its potential to interact
with steroid receptors or disrupt steroidogenesis or to interfere with repro-
duction in vivo. Evidence for adverse effects is not obtainable from these
tests and is only demonstrated by the top level, higher-tier tests. As de-
scribed in this thesis, most information requirements currently covered by
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the screening and low-tier tests within the CF can equally be satisfied by
the FET and thus, the FET could certainly enhance this level of testing.
The FET can be used as a screening method and moreover, given that the
mode and mechanisms of endocrine action of the tested compound can be
identified at gene expression level, it would merge several of the currently
proposed tests into one assay. The FET has the potential to provide mech-
anistic information currently not covered by the CF (like neuroendocrine
disruption), thus the FET would address one of the key weaknesses of the
current approaches. In terms of practicability, the FET has all the ben-
efits of in vitro tests and can be carried out rapidly and cost-effectively,
and is suitable for higher-throughput applications. The use of fish em-
bryos as an additional test method in the context of a weight of evidence
approach would therefore create an enrichment while at the same time
complying with the 3R’s principle to reduce animal testing according to
the EU-Directive [EU, 2010]. Both, medaka and zebrafish, would be suit-
able fish species for this purpose. However, our data underscore the need to
extend the zebrafish embryo test to the post-hatch eleutheroembryo-stage,
which has previously been highlighted in the OECD fish testing framework
context [OECD, 2012b]. Medaka testing could be limited to the prehatch
stage. We propose that both fish species should be considered as com-
plementary testing models for endocrine disruption. Zebrafish offers rapid
testing and easy handling, whereas medaka allows longer exposure periods
prehatch. Moreover, as medaka is genetically sex determined, sex-specific
effects could be analysed, either by analysing sex specific genes or by us-
ing a mutant fish line (e.g. Qurt strain), which allows a morphological
sex identification. Thus, medaka fish embryos offer several advantages for
endocrine disruption testing.
For a final implementation of a fish-embryo based screening system, ad-
ditional validation studies are certainly still needed. As the next step, a
set of specifically responding genes had to be selected for both species and
their suitability for detection and categorization of endocrine disruption
be verified by testing more estrogenic and anti-androgenic compounds, in
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comparison to suitable negative control chemicals. The subsequent step
would then be to extend the application of the FET approach to addi-
tional endocrine modes of actions, such as androgenic and anti-estrogenic.
Then, a final set of genes, covering the most important endocrine MoAs,
could be used to develop e.g., a gene expression minichip, suitable for a
comprehensive analysis of endocrine MoA specific gene expression.
As a final conclusion from this thesis it should be stated, that the data
presented would provide a valuable basis for the development and imple-
mentation of a transcriptomics based FET approach, which would allow
rapid, animal-test free and cost-effective testing for endocrine disruption.
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A Primer sequences
A.1 Zebrafish primer
Table A-1: Zebrafish primer.*Primer sequences were obtained from Hossain et al. [2008]
Gene Accession Primer Sense Primer Antisense
vtg1 NM001044897 GTCATCAATGAGGATCCAAAGGCCA GCCTCAGCGATCAGTGCACCAT
cyp19a1b NM131642 GCTCCAGACACGCTCTCCAT CATCCTCCAGAGACTGCCTCA
esr2a NM180966 AGAGTCGACTTCAACAGAAC TCTCCTCTGTATCTGCTACC
ar* NM001083123 CACTACGGAGCCCTCACTTGCGGA GCCCTGAACTGCTCCGACCTC
sc4mol BC050163 CCACCGAGCTCTACATCATC AAGAGGGTGGGCATATTCTG
lss NM001083567.1 AGCACACGGGACTGCGGTTGG TCCAGCAGTTTCCCGCCACGT
esr1 NM152959.1 ACAAAGGAATGGAGCACTTA GTGTAGATGGAGGGTTTTTC
cyp11b ENSDARG00000042014 GGCCCATATACAGAGAGCAC GGAAGACTCCTTTGCTGTGT
pax2a NM131184.2 GCAGACCCCTACCTGACGTGGT TTGGGCGTCGCCACTTTTGGTT
nkx2.1 NM131589.1 GAACCCGGAGCCGAGATACCCA CGTCGGGGTTAGATGGATCATGC
hoxa9a NM131532.2 CATCGAGGGGAAACCGGGCG CCGGTCGCGCGTGAGGTAAG
hoxa10b NM131155.1 AAGGGGGTCCACTGGCACCG TCGCCGTCAGCCAGTTAGCTG
hoxa11 NM131147.1 GCGGCAGCAGCAATGGACAAAAG CGGTCAGTGAGGTTGAGCATTCTG
rpl13 NM198143.1 TCTGGAGGACTGTAAGAGGTATGC AGACGCACAATCTTGAGAGCAG
bactin NM131031.1 CGAGCAGGAGATGGGAACC CAACGGAAACGCTCATTGC
A Primer sequences 175
A.2 Medaka primer
Table A-2: Medaka primer. * Primer sequences for genes labelled with asterisks were obtained from
Zhang et al. [2008a]
Gene Accession Primer Sense Primer Antisense
era* D28954 GAGGAGGAGGAGGAGGAGGAG GTGTACGGTCGGCTCAACTTC
erb* AB070901 GCTGGAGGTGCTGATGATGG CGAAGCCCTGGACACAACTG
errg1 EF544135 AAGAGGAGACGCAAGTCATG TTATATGGCTTCTTGGGAGG
ara* AB076399 ACCTGGCTCACTTCGGACAC TCTGACGCCGTACTGCTCTG
cyp19a1a* D82968 CTCTTCCTGGGTGTTCCTGTTG GCTGCTGTCTTGTGCCTCTG
cyp19a1b* AY319970 TCCTGATAACCCTGCTGTCTCG GTTGGTCTGCCTGATGCTGTTC
vtg1* AB064320 ACTCTGCTGCTGTGGCTGTAG AAGGCGTGGGAGAGGAAAGTC
cyp3a* AF105018 GAGATAGACGCCACCTTCC ACCTCCACAGTTGCCTTG
star* DQ988930 TGACAGGTTTGAGAAAGAATG CAATGCGAGAACTTAGAAGG
cyp11b* AB105880 CTAGACGACGTGGCGAAAGACT CCTCTGCTCCTCTTCCTTCTCG
3bhsd* EU159459 GGGCGGGACGAAACTCAG GGAGGCGGTGTGGAAGAC
gnrhr1* AB057675 TCCGACGAGCCGCATCTG GATGAAGCCGACGACGATGAC
gnrhr2* AB057674 GCAGCGGCACAGACATCATC GGACAGCACAATGACCACAGAC
lhr* EF535803 GTGCTACGAAGGCTACGAGATG AGGTCAATGCGGCGGATTTC
npy* EU047761 CTTCCACAGTCAAGTTACAAC TGATCTGCAAGGACGAATG
anxa5* Y11253 CTGATCGTGGCTCTGATGAC CTGCTGAGGTGTTCTGGAAG
lss ENSORLG00000015003 GCAGTGATGCAGGCTCTGAGGCA CAGGCCTTTGTACCCTCCTGCAGT
sc4mol ENSORLG00000007977 TCGATGCCACGCTGGCCGTA TCCGTCTGTGATGCAGCAGGCG
mvd ENSORLG00000009351 GTTCAGTGGATTATGGGAAA TTGTTTGTACGCTAGTTTGC
tp53 NM001104742.1 CCTTATACCAAAAGGCAGAG CTAAGCAAGATGGTGGTCAT
pax2 Z97020 CTTCTCCACCTGTAACCAGC CTGCTGTGTGAAAGCATCTG
dio2 NM001136521.1 CTGACTTCCTGCTGGTTTAC AAAAGTGCTCAGTGAGTTGG
nkx2.1 AY568366 TTTCCGATATCTTGAGTCCC TGCCGGTAAGAAGTGAGAG
hoxa9a NM001104666 CTCTGCACTACAACCCCTT AGATACCGGTTAAAGTGGAA
hoxa10b AB207987.1 GAGTCCAGACAAGCAAGAAA AGTCTGGTGCTTGGTGTAAG
hoxa11b AB207988 GGACAGACACTCAAGAACGA AAGAAGAACTCCCTCTCCAG
16s* S74868 CGATCAACGGACCGAGTTACC AATAGCGGCTGCACCATTAGG
rpl7* DQ118296 GTCGCCTCCCTCCACAAAG AACTTCAAGCCTGCCAACAAC
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B Morphological endpoints
Assessed morphological endpoints for 48hpf zebrafish and 7dpf
medaka embryos (modified after Braunbeck and Lammer [2006])
• Lethal effects
– Coagulation
– Tail not detached
– No somite formation
– No heart-beat
• Non-lethal effects
– Formation of somites
– Development of eyes
– Spontaneous movement
– Heart-beat / blood circulation
– Heart-beat frequency
– Pigmentation
– Formation of edemata
– Malformation of head
– Malformation of tail
– Malformation of heart
– Modified chorda structure
– Yolk deformation
– General growth retardation
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C Entire transcriptome response in 48hpf zebrafish
embryos
C.1 17α-Ethinylestradiol
Table C-1: Entire set of pathways affected by EE2
term description odd’s ra-
tio
adjusted
pvalue
discussed genes
dre04140 Regulation of autophagy -2.807355 0.060950
GO:0006259 DNA metabolic process -1.738365 0.085736
dre04146 Peroxisome -1.216258 0.060950
GO:0030163 protein catabolic process -1.039995 0.060950
GO:0006508 proteolysis -1.021723 0.065131
GO:0006974 response to DNA
damage stimulus
-0.969662 0.069663
GO:0005524 ATP binding -0.704299 0.092147
GO:0006464 protein modification
process
-0.699355 0.069663
GO:0001882 nucleoside binding -0.691595 0.013651
GO:0019538 protein metabolic
process
-0.646737 0.069051
GO:0044267 cellular protein
metabolic process
-0.385341 0.057352
GO:0016787 hydrolase activity -0.368024 0.069051
GO:0009058 biosynthetic process 1.298260 0.069051
GO:0044249 cellular biosynthetic
process
1.299528 0.065485
GO:0006139 nucleobase-containing
compound metabolic
process
1.321056 0.097740
GO:0005634 nucleus 1.326791 0.074280
GO:0003677 DNA binding 1.362416 0.002675
GO:0005515 protein binding 1.377421 0.017885
GO:0009059 macromolecule
biosynthetic process
1.378654 0.000710
GO:0003676 nucleic acid binding 1.426032 0.000760
GO:0016070 RNA metabolic process 1.489290 0.000258
GO:0009889 regulation of
biosynthetic process
1.524245 0.000143
GO:0006351 transcription,
DNA-dependent
1.565829 0.000105
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Continued: Entire set of pathways affected by EE2
term description odd’s ra-
tio
adjusted
pvalue
discussed genes
GO:0045449 regulation of
transcription,
DNA-dependent
1.567058 0.000143
GO:0006355 regulation of
transcription,
DNA-dependent
1.570748 0.000072
GO:0006350 transcription,
DNA-dependent
1.574297 0.002102
GO:0003700 sequence-specific DNA
binding transcription
factor activity
1.627760 0.073119
IPR000694 Anenome neurotoxin 1.654041 0.002102
GO:0043565 sequence-specific DNA
binding
1.677093 0.005989
IPR009057 Homeodomain-like 1.820908 0.000705
IPR001356 Homeobox 1.981976 0.005989
IPR020479 Homeobox, eukaryotic 2.018180 0.000705
IPR017970 Homeobox, conserved
site
2.034857 0.005989
IPR001092 Restriction/modification
DNA-methylase
2.073420 0.005989
IPR011598 Helix-loop-helix
DNA-binding
2.073420 0.001022
IPR000047 Helix-turn-helix motif 2.084086 0.097085
dre03040 Spliceosome 2.150888 0.069051
GO:0048593 camera-type eye
morphogenesis
2.275552 0.086008
IPR001827 Homeobox protein,
antennapedia type,
conserved site
2.632770 0.069051
GO:0009410 response to xenobiotic
stimulus
2.672242 0.064810 vtg1, hsp70l, cyp19a1b,
sult1st5, ahr2, cyp3a65,
cyp1a, sod1
GO:0001503 ossification 2.673862 0.048494
GO:0004950 chemokine receptor
activity
2.724767 0.048494 rxfp3, oprd1b, ccrl1a,
LOC100004625, oprl1,
cxcr7b, kiss1rb, kiss1ra,
LOC571123
Table continues on next page
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Continued: Entire set of pathways affected by EE2
term description odd’s ra-
tio
adjusted
pvalue
discussed genes
GO:0019956 chemokine binding 2.724767 0.060950 rxfp3, oprd1b, ccrl1a,
LOC100004625, oprl1,
cxcr7b, kiss1rb, kiss1ra,
LOC571123
GO:0008299 isoprenoid biosynthetic
process
2.957181 0.052834 ggps1, hmgcs1, hmgcra,
zgc:100824
GO:0008146 sulfotransferase activity 3.048357 0.067596 zgc:113317, sult3st2,
sult2st1
IPR011700 Basic leucine zipper 3.174962 0.067596
IPR008917 Eukaryotic transcription
factor, Skn-1-like,
DNA-binding
3.190505 0.054796
IPR011616 bZIP transcription
factor, bZIP-1
3.259508 0.010987
GO:0019838 growth factor binding 3.278859 0.006898 ctgf, igfbp1b, zgc:85866
GO:0016049 cell growth 3.320855 0.031368 ctgf, igfbp1b, zgc:85866
IPR000837 Fos transforming protein 3.368372 0.003097
GO:0040008 regulation of growth 3.454807 0.003097 ctgf, igfbp1b, zgc:85866
GO:0001558 regulation of cell growth 3.528652 0.002327 ctgf, igfbp1b, zgc:85866
GO:0005520 insulin-like growth
factor binding
3.528652 0.067974 ctgf, igfbp1b, zgc:85866
IPR006208 Cystine knot 3.592205 0.006168 ctgf, zgc:85866
IPR000867 Insulin-like growth
factor-binding protein,
IGFBP
3.626679 0.008534 ctgf, igfbp1b, zgc:85866
dre00900 Terpenoid backbone
biosynthesis
3.807355 0.056513 ggps1, hmgcs1, hmgcra,
dhdds, zgc:100824
GO:0005938 cell cortex 3.807355 0.068906
GO:0030117 membrane coat 3.807355 0.097085
GO:0030118 clathrin coat 3.807355 0.001388
C.2 Flutamide
Table C-2: Entire set of pathways affected by flutamide
term description odd’s ra-
tio
adjusted
pvalue
discussed genes
dre00260 Glycine, serine and
threonine metabolism
-2.112347 0.050690
Table continues on next page
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Continued: Entire set of pathways affected by flutamide
term description odd’s ra-
tio
adjusted
pvalue
discussed genes
IPR013968 Polyketide synthase, KR -1.873624 0.079862
GO:0006519 cellular amino acid
metabolic process
1.815860 0.083236
GO:0005102 receptor binding 1.837300 0.001619 zgc:153219, ins, pth2,
gh1, zgc:173915,
LOC567953, pth1a,
tshb, bmp7a, oxtl,
LOC568912, vip,
gnrh3, calca,
LOC571601, gprc5c,
bmp2a, zgc:73142, hbl4,
ndr1, pomca, hbeta1,
npy
GO:0009165 nucleotide biosynthetic
process
1.842040 0.083236
GO:0006163 purine nucleotide
metabolic process
1.862527 0.083236
GO:0006164 purine nucleotide
biosynthetic process
1.862527 0.083236
GO:0009308 amine metabolic process 1.886211 0.036498
GO:0016820 hydrolase activity,
acting on acid
anhydrides, catalyzing
transmembrane
movement of substances
2.005428 0.060688
GO:0030594 neurotransmitter
receptor activity
2.009463 0.098169 rxfp3, cxcr4a, oprd1b,
zgc:85682, npy4r,
zgc:153417,
LOC100004625, oprl1,
npy1r, LOC561647,
gpr74, cxcr3.1
GO:0006520 cellular amino acid
metabolic process
2.011865 0.024396
IPR000980 SH2 motif 2.206041 0.046363
Table continues on next page
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Continued: Entire set of pathways affected by flutamide
term description odd’s ra-
tio
adjusted
pvalue
discussed genes
GO:0005179 hormone activity 2.208759 0.001619 ins, pth2, gh1,
LOC567953, pth1a,
tshb, oxtl, gnrh3, calca,
trh, zgc:162320, nppcl,
hamp1, lhbeta1, pomcb,
npy
IPR001507 Zona pellucida
sperm-binding protein
2.529897 0.071635 zp2l2,
si:ch211-14a17.7,
si:dkeyp-50f7.2,
zgc:173556, zp3.1,
si:ch211-225p5.3, zp3b,
zp3a.1, LOC555913,
LOC567759,
zgc:171779, zp2.3
GO:0008652 cellular amino acid
biosynthetic process
2.553481 0.078059
IPR017976 Endoglin/CD105 antigen
subgroup
2.668718 0.078170 zp2l2,
si:ch211-14a17.7,
si:dkeyp-50f7.2,
zgc:173556, zp3.1,
si:ch211-225p5.3, zp3b,
zp3a.1
IPR000837 Fos transforming protein 3.139623 0.068716
dre00072 Synthesis and
degradation of ketone
bodies
3.807355 0.078708 hmgcs1, acat1, hmgcl
C.3 Bisphenol A
Table C-3: Entire set of pathways affected by bisphenol A
term description odd’s ratio adjusted
pvalue
GO:0014033 neural crest cell differentiation 1.487992 0.093349
GO:0006626 protein targeting to mitochondrion -2.969447 0.070831
GO:0048666 neuron development 0.883629 0.065532
GO:0019941 modification-dependent protein catabolic pro-
cess
-0.842211 0.017217
GO:0009725 response to hormone stimulus 4.690642 0.055529
Table continues on next page
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Continued: Entire set of pathways affected by BPA
term description odd’s ratio adjusted
pvalue
GO:0006605 protein targeting -1.505978 0.013796
GO:0006412 translation -0.670994 0.015979
GO:0008610 lipid biosynthetic process -2.085857 0.008830
GO:0007368 determination of left/right symmetry -1.008377 0.065689
GO:0006839 mitochondrial transport -1.904487 0.004746
GO:0042446 hormone biosynthetic process -4.011465 0.026957
GO:0006955 immune response 1.293504 0.036037
GO:0007017 microtubule-based process -0.894161 0.063043
GO:0007018 microtubule-based movement -1.313948 0.004181
GO:0006811 ion transport 0.391773 0.080122
GO:0006886 intracellular protein transport -0.692500 0.001470
GO:0016070 RNA metabolic process -0.292776 0.015979
GO:0007186 G-protein coupled receptor signaling pathway 0.382930 0.039750
GO:0055114 oxidation-reduction process 2.046899 0.039998
GO:0008033 tRNA processing -1.584479 0.060400
GO:0006461 protein complex assembly -0.902352 0.001470
GO:0007169 transmembrane receptor protein tyrosine kinase
signaling pathway
1.198339 0.057454
GO:0007166 cell surface receptor signaling pathway 0.461163 0.017196
GO:0006334 nucleosome assembly -1.052835 0.034911
GO:0006333 chromatin assembly or disassembly -0.948134 0.043487
GO:0006139 nucleobase-containing compound metabolic pro-
cess
-0.258463 0.012852
GO:0006397 mRNA processing -1.044421 0.027925
GO:0006396 RNA processing -1.015088 0.000463
GO:0046907 intracellular transport -0.793076 0.000019
GO:0042221 response to chemical stimulus 2.954229 0.007537
GO:0008104 protein localization -0.581950 0.001768
GO:0006352 DNA-dependent transcription, initiation -1.445808 0.090407
GO:0006913 nucleocytoplasmic transport -0.730397 0.038153
GO:0016337 cell-cell adhesion 1.307817 0.040137
GO:0051603 proteolysis involved in cellular protein catabolic
process
-0.900346 0.007028
GO:0051258 protein polymerization -1.656466 0.002440
GO:0015031 protein transport -0.580378 0.001768
GO:0051649 establishment of localization in cell -0.659005 0.000448
GO:0009410 response to xenobiotic stimulus 4.371923 0.055529
GO:0051276 chromosome organization -0.782251 0.029403
GO:0043065 positive regulation of apoptotic process 2.979642 0.060663
Table continues on next page
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Continued: Entire set of pathways affected by BPA
term description odd’s ratio adjusted
pvalue
GO:0008299 isoprenoid biosynthetic process -2.715509 0.068328
GO:0030054 cell junction 0.916452 0.006577
GO:0031226 intrinsic to plasma membrane 0.687427 0.042190
GO:0042995 cell projection -1.070402 0.011295
GO:0045211 postsynaptic membrane 1.7976931 0.000155
GO:0005856 cytoskeleton -0.658250 0.002732
GO:0005694 chromosome -0.786174 0.019602
GO:0005929 cilium -1.830560 0.046790
GO:0043234 protein complex -0.267588 0.028746
GO:0005887 integral to plasma membrane 0.709423 0.040017
GO:0044429 mitochondrial part -1.308955 0.000000
GO:0005886 plasma membrane 0.386954 0.023294
GO:0005783 endoplasmic reticulum 0.465066 0.097013
GO:0070469 respiratory chain -2.504317 0.050479
GO:0005634 nucleus -0.318162 0.000133
GO:0005829 cytosol -0.796570 0.069226
GO:0005739 mitochondrion -1.200449 0.000000
GO:0005737 cytoplasm -0.551424 0.000000
GO:0015630 microtubule cytoskeleton -1.046027 0.017824
GO:0005777 peroxisome -1.454730 0.078509
GO:0030529 ribonucleoprotein complex -1.247352 0.000000
GO:0030288 outer membrane-bounded periplasmic space 1.797429 0.039247
GO:0005840 ribosome -1.173553 0.000148
GO:0016817 hydrolase activity, acting on acid anhydrides -1.053067 0.018422
GO:0046914 transition metal ion binding -0.301153 0.020500
GO:0016818 hydrolase activity, acting on acid anhydrides, in
phosphorus-containing anhydrides
-1.131373 0.017896
GO:0048037 cofactor binding 0.900497 0.029494
GO:0004364 glutathione transferase activity 4.772298 0.000431
GO:0008270 zinc ion binding -0.349885 0.012333
GO:0008138 protein tyrosine/serine/threonine phosphatase
activity
-1.312558 0.065478
GO:0005216 ion channel activity 0.745776 0.003060
GO:0016564 transcription repressor activity 1.893499 0.079774
GO:0050661 NADP binding 2.773784 0.069959
GO:0005230 extracellular ligand-gated ion channel activity 2.202420 0.002429
GO:0003924 GTPase activity -0.829420 0.002777
GO:0042277 peptide binding 1.276522 0.040292
GO:0005102 receptor binding 0.737785 0.032224
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Continued: Entire set of pathways affected by BPA
term description odd’s ratio adjusted
pvalue
GO:0030414 peptidase inhibitor activity 0.822806 0.093475
GO:0019001 guanyl nucleotide binding -0.694283 0.000550
GO:0004879 ligand-activated sequence-specific DNA binding
RNA polymerase II transcription factor activity
1.7976931 0.037542
GO:0005261 cation channel activity 0.666153 0.061207
GO:0004888 transmembrane signaling receptor activity 0.776875 0.000000
GO:0008483 transaminase activity 3.092507 0.052684
GO:0005543 phospholipid binding -0.854941 0.072579
GO:0019838 growth factor binding 1.487992 0.093475
GO:0001882 nucleoside binding -0.525129 0.079774
GO:0017076 purine nucleotide binding -0.569660 0.022466
GO:0008201 heparin binding -3.590287 0.022385
GO:0005525 GTP binding -0.713183 0.000550
GO:0005524 ATP binding -0.634634 0.032224
GO:0015078 hydrogen ion transmembrane transporter activ-
ity
-1.059975 0.037133
GO:0016769 transferase activity, transferring nitrogenous
groups
2.686683 0.076766
GO:0003707 steroid hormone receptor activity 1.7976931 0.096431
GO:0015276 ligand-gated ion channel activity 1.786667 0.001174
GO:0016772 transferase activity, transferring phosphorus-
containing groups
-0.638450 0.099205
GO:0016614 oxidoreductase activity, acting on CH-OH group
of donors
-1.430150 0.060517
GO:0030955 potassium ion binding 1.634652 0.079774
GO:0016616 oxidoreductase activity, acting on the CH-OH
group of donors, NAD or NADP as acceptor
-1.067179 0.036552
GO:0004982 N-formyl peptide receptor activity 1.7976931 0.031653
GO:0004984 olfactory receptor activity 1.485552 0.031653
GO:0005179 hormone activity 1.201560 0.020192
GO:0016765 transferase activity, transferring alkyl or aryl
(other than methyl) groups
5.781008 0.007113
GO:0004303 estradiol 17-beta-dehydrogenase activity -4.417020 0.020617
GO:0015057 thrombin receptor activity 2.199984 0.072579
GO:0003723 RNA binding -0.639179 0.046266
GO:0004970 ionotropic glutamate receptor activity 1.7976931 0.018187
GO:0004872 receptor activity 0.658153 0.000000
GO:0004871 signal transducer activity 0.577220 0.000000
GO:0003735 structural constituent of ribosome -1.115629 0.009308
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Continued: Entire set of pathways affected by BPA
term description odd’s ratio adjusted
pvalue
GO:0005199 structural constituent of cell wall -1.742536 0.090579
GO:0016229 steroid dehydrogenase activity -1.954556 0.022385
GO:0035091 phosphatidylinositol binding -1.014754 0.061207
GO:0001653 peptide receptor activity 1.270153 0.040292
GO:0016874 ligase activity -0.580171 0.080653
GO:0004930 G-protein coupled receptor activity 0.603511 0.002429
GO:0016491 oxidoreductase activity 0.534816 0.051755
GO:0008528 G-protein coupled peptide receptor activity 1.263745 0.040292
GO:0008430 selenium binding -2.479525 0.030302
GO:0016462 pyrophosphatase activity -1.131373 0.017896
GO:0017111 nucleoside-triphosphatase activity -1.115377 0.017896
GO:0016779 nucleotidyltransferase activity -1.039530 0.077458
GO:0016787 hydrolase activity -1.246656 0.069959
GO:0005200 structural constituent of cytoskeleton 1.7976931 0.041898
GO:0004713 protein tyrosine kinase activity 0.580608 0.064476
GO:0004714 transmembrane receptor protein tyrosine kinase
activity
2.315324 0.055074
IPR000504 RNA recognition motif domain -0.974888 0.000154
IPR001163 Like-Sm ribonucleoprotein (LSM) domain 1.7976931 0.038122
IPR016024 Armadillo-type fold -0.641757 0.038122
IPR001683 Phox homologous domain -1.165303 0.074096
IPR018000 Neurotransmitter-gated ion-channel, conserved
site
1.7976931 0.038122
IPR010920 Like-Sm ribonucleoprotein (LSM)-related do-
main
1.7976931 0.038122
IPR000092 Polyprenyl synthetase 1.7976931 0.024927
IPR017975 Tubulin, conserved site -2.206217 0.000552
IPR013026 Tetratricopeptide repeat-containing -0.988846 0.058546
IPR013027 FAD-dependent pyridine nucleotide-disulphide
oxidoreductase
4.129082 0.065481
IPR005225 Small GTP-binding protein domain -0.672100 0.064081
IPR013098 Immunoglobulin I-set 2.267143 0.000805
IPR013753 Ketopantoate reductase ApbA/PanE, C-
terminal
-0.772857 0.027241
IPR000408 Regulator of chromosome condensation, RCC1 -2.281961 0.057944
IPR008280 Tubulin/FtsZ, C-terminal -2.279912 0.000552
IPR003008 Tubulin/FtsZ, GTPase domain -2.462339 0.000545
IPR007110 Immunoglobulin-like 1.060901 0.000038
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Continued: Entire set of pathways affected by BPA
term description odd’s ratio adjusted
pvalue
IPR006649 Like-Sm ribonucleoprotein (LSM) domain,
eukaryotic/archaea-type
1.7976931 0.079712
IPR000158 Cell division protein FtsZ -2.279912 0.000552
IPR001993 Type II secretion system conserved site -1.586540 0.010362
IPR001508 NMDA receptor 1.7976931 0.074145
IPR000826 Formyl/methionyl peptide receptor 1.7976931 0.053379
IPR006029 Neurotransmitter-gated ion-channel transmem-
brane domain
1.7976931 0.038122
IPR010987 Glutathione S-transferase, C-terminal-like 5.586588 0.038536
IPR006073 GTP binding domain -1.907931 0.035200
IPR005101 DNA photolyase, FAD-binding/Cryptochrome,
C-terminal
1.7976931 0.099525
IPR006050 DNA photolyase, N-terminal 1.7976931 0.099525
IPR019781 Germin, manganese binding site -0.661848 0.074096
IPR019734 Tetratricopeptide repeat -0.898168 0.074096
IPR004046 Glutathione S-transferase, C-terminal 6.223281 0.018636
IPR004045 Glutathione S-transferase, N-terminal 6.341153 0.018636
IPR019746 Amyloidogenic glycoprotein, intracellular do-
main, conserved site
-2.462339 0.000545
IPR004057 Epsilon tubulin -2.279912 0.000552
IPR001881 EGF-like calcium-binding 0.917127 0.087150
IPR006210 Epidermal growth factor-like 0.880185 0.053273
IPR006201 Neurotransmitter-gated ion-channel 1.7976931 0.053379
IPR006202 Neurotransmitter-gated ion-channel ligand-
binding
1.7976931 0.038122
IPR006209 EGF 1.086880 0.040717
IPR003961 Fibronectin, type III 1.310279 0.011071
IPR000725 Olfactory receptor 1.461897 0.066991
IPR001806 Small GTPase superfamily -0.569365 0.095555
IPR001827 Homeobox protein, antennapedia type, con-
served site
2.227150 0.003880
IPR002017 Spectrin repeat 1.7976931 0.053273
IPR018316 Tubulin/FtsZ, 2-layer sandwich domain -2.279912 0.000552
IPR002967 Delta tubulin -2.279912 0.000552
IPR001320 Ionotropic glutamate receptor 1.7976931 0.074145
IPR003578 Small GTPase superfamily, Rho type -0.734575 0.053028
IPR003579 Small GTPase superfamily, Rab type -0.718177 0.035671
IPR003577 Interleukin-6 -0.769888 0.025985
IPR002452 Alpha tubulin -2.617529 0.000175
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term description odd’s ratio adjusted
pvalue
IPR002453 Beta tubulin -2.279912 0.000552
IPR002454 Gamma tubulin -2.279912 0.000552
IPR003598 Immunoglobulin subtype 2 1.147611 0.000042
IPR003599 Immunoglobulin subtype 1.141569 0.000030
IPR003596 Immunoglobulin V-set, subgroup 1.377259 0.000057
IPR002067 Mitochondrial carrier protein -1.505978 0.027426
IPR003591 Leucine-rich repeat, typical subtype 1.630594 0.049835
IPR018159 Spectrin/alpha-actinin 1.7976931 0.053273
IPR000217 Tubulin -2.279912 0.000552
IPR017452 GPCR, rhodopsin-like superfamily 0.706427 0.006015
IPR011011 Zinc finger, FYVE/PHD-type -1.274621 0.006243
IPR018108 Mitochondrial substrate/solute carrier -1.586540 0.010362
IPR000276 GPCR, rhodopsin-like, 7TM 0.645902 0.013956
IPR011046 WD40 repeat-like-containing domain -0.668505 0.052366
IPR002113 Adenine nucleotide translocator 1 -1.505978 0.027426
IPR004217 Mitochondrial inner membrane translocase com-
plex, Tim8/9/10/13-zinc finger-like
1.7976931 0.089799
IPR013151 Immunoglobulin 1.558571 0.000645
IPR008978 HSP20-like chaperone -1.669880 0.032078
IPR013684 Mitochondrial Rho-like -0.733387 0.038122
IPR001440 Tetratricopeptide TPR-1 -1.254504 0.031107
IPR008957 Proteinase A inhibitor IA3 domain 1.254141 0.004636
IPR013106 Immunoglobulin V-set 1.164842 0.000268
IPR002893 Zinc finger, MYND-type -2.427729 0.082883
IPR008949 Terpenoid synthase 1.7976931 0.024927
dre04080 Neuroactive ligand-receptor interaction 1.370794 0.015112
dre00480 Glutathione metabolism 4.520993 0.000052
dre04540 Gap junction -1.345393 0.001163
dre04146 Peroxisome -1.039530 0.065283
dre04914 Progesterone-mediated oocyte maturation -1.205866 0.074847
dre01100 Metabolic pathways -0.452910 0.001107
dre00903 Terpenoid backbone biosynthesis 1.7976931 0.059370
dre00900 Terpenoid backbone biosynthesis -1.989333 0.062798
dre00532 Glycosaminoglycan biosynthesis - chondroitin
sulfate
3.872002 0.054351
dre00270 Cysteine and methionine metabolism -1.585715 0.015112
dre00071 Fatty acid metabolism -2.237016 0.009947
dre00072 Synthesis and degradation of ketone bodies 1.7976931 0.065283
dre00980 Metabolism of xenobiotics by cytochrome P450 6.022435 0.001732
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Continued: Entire set of pathways affected by BPA
term description odd’s ratio adjusted
pvalue
dre00982 Drug metabolism - cytochrome P450 6.117833 0.001732
dre00280 Valine, leucine and isoleucine degradation -1.367110 0.013613
dre00650 Butanoate metabolism -1.812317 0.019820
dre04150 mTOR signaling pathway 1.7976931 0.001351
dre03022 Basal transcription factors -1.687895 0.063516
dre00190 Oxidative phosphorylation -1.687393 0.000257
dre03050 Proteasome -1.347943 0.065283
dre00620 Pyruvate metabolism -1.907931 0.011158
dre03040 Spliceosome -1.594393 0.000010
dre00020 Citrate cycle (TCA cycle) -1.588565 0.065283
dre00630 Glyoxylate and dicarboxylate metabolism -2.094283 0.099962
dre04120 Ubiquitin mediated proteolysis -0.897806 0.030304
dre00410 beta-Alanine metabolism -1.742536 0.066171
dre00310 Lysine degradation -1.456362 0.019820
dre00240 Pyrimidine metabolism -1.030141 0.065283
C.4 Genistein
Table C-4: Entire set of pathways affected by genistein
term description odd’s ratio adjusted
pvalue
GO:0048844 artery morphogenesis -2.885973 0.026181
GO:0014033 neural crest cell differentiation -1.801662 5.11E-05
GO:0045449 regulation of transcription, DNA-dependent -1.071522 2.33E-51
GO:0048839 inner ear development -0.744416 0.047509
GO:0008652 cellular amino acid biosynthetic process 1.690341 0.000948
GO:0007275 multicellular organismal development -0.868393 6.66E-37
GO:0045165 cell fate commitment -0.921394 0.005828
GO:0045454 cell redox homeostasis 1.348279 0.000145
GO:0006629 lipid metabolic process 0.800224 1.7E-07
GO:0002682 regulation of immune system process 4.019011 0.066196
GO:0021515 cell differentiation in spinal cord -3.094876 0.022014
GO:0051090 regulation of sequence-specific DNA binding
transcription factor activity
-2.893483 0.00231
GO:0048871 multicellular organismal homeostasis -1.282503 0.012668
GO:0009617 response to bacterium 1.573250 0.015174
GO:0048666 neuron development -0.976066 0.000364
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GO:0019941 modification-dependent protein catabolic pro-
cess
-1.603143 0.015783
GO:0006631 fatty acid metabolic process 1.475654 4.57E-05
GO:0006633 fatty acid biosynthetic process 1.767304 0.000729
GO:0009725 response to hormone stimulus 1.797690 0.098283
GO:0016192 vesicle-mediated transport -0.433997 0.084571
GO:0033333 fin development -0.790720 0.062308
GO:0022008 neurogenesis -1.179681 8.98E-10
GO:0007399 nervous system development -1.275447 2.85E-23
GO:0009607 response to biotic stimulus 2.221174 0.014588
GO:0050790 regulation of catalytic activity 3.554967 0.026561
GO:0006760 folic acid-containing compound metabolic pro-
cess
1.591390 0.096562
GO:0018149 peptide cross-linking 3.539050 0.047835
GO:0050793 regulation of developmental process -1.488888 0.000218
GO:0045664 regulation of neuron differentiation -1.337011 0.020926
GO:0021915 neural tube development -1.380326 0.005828
GO:0009116 nucleoside metabolic process 0.967967 0.087466
GO:0030901 midbrain development -3.229009 0.000257
GO:0009308 amine metabolic process 1.060888 2.53E-09
GO:0030900 forebrain development -2.008256 5.61E-08
GO:0022900 electron transport chain 1.297333 0.042176
GO:0030902 hindbrain development -1.314131 0.000257
GO:0009117 nucleotide metabolic process 0.503324 0.06489
GO:0007389 pattern specification process -0.622019 0.000557
GO:0007242 intracellular signal transduction -0.388098 0.000778
GO:0045494 photoreceptor cell maintenance 1.797690 0.032654
GO:0006606 protein import into nucleus -1.632655 0.032972
GO:0006412 translation 0.926844 7.32E-09
GO:0009880 embryonic pattern specification -1.031543 0.04041
GO:0006508 proteolysis 0.509873 1.37E-05
GO:0009887 organ morphogenesis -0.756277 3.58E-08
GO:0009889 regulation of biosynthetic process -1.019674 1.08E-48
GO:0042742 defense response to bacterium 1.797690 0.062308
GO:0030336 negative regulation of cell migration 1.797690 0.025131
GO:0008610 lipid biosynthetic process 1.031113 2.62E-05
GO:0009239 enterobactin biosynthetic process 1.076091 0.034197
GO:0048881 mechanosensory lateral line system development -4.291284 0.032582
GO:0048884 neuromast development -4.879324 0.015684
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GO:0006725 cellular aromatic compound metabolic process 0.779260 0.001644
GO:0007369 gastrulation -0.638210 0.016522
GO:0007264 small GTPase mediated signal transduction -0.290271 0.083648
GO:0007267 cell-cell signaling -0.957265 0.087083
GO:0007266 Rho protein signal transduction -0.890787 0.098565
GO:0045226 extracellular polysaccharide biosynthetic pro-
cess
2.353324 0.096392
GO:0050767 regulation of neurogenesis -2.046573 0.000335
GO:0050768 negative regulation of neurogenesis -1.590233 0.072754
GO:0050769 positive regulation of neurogenesis -2.326159 0.069359
GO:0000087 M phase of mitotic cell cycle -0.839603 0.04041
GO:0006730 one-carbon metabolic process 0.829296 0.072437
GO:0051056 regulation of small GTPase mediated signal
transduction
-0.993167 0.000632
GO:0006520 cellular amino acid metabolic process 1.247465 5.81E-10
GO:0006519 cellular amino acid metabolic process 1.057478 1.48E-08
GO:0006518 peptide metabolic process 0.867529 0.024207
GO:0006099 tricarboxylic acid cycle 2.619013 0.006221
GO:0048706 embryonic skeletal system development -1.270611 0.099763
GO:0048701 embryonic cranial skeleton morphogenesis -1.270611 0.099763
GO:0009081 branched-chain amino acid metabolic process 1.797690 0.005195
GO:0005975 carbohydrate metabolic process 0.467148 0.000989
GO:0006081 cellular aldehyde metabolic process 2.353324 0.096392
GO:0006950 response to stress 1.256715 0.091734
GO:0006952 defense response 0.602074 0.098422
GO:0006144 purine nucleobase metabolic process 2.130676 0.02804
GO:0010002 cardioblast differentiation -2.808901 0.049282
GO:0010001 glial cell differentiation -1.305498 0.067022
GO:0046688 response to copper ion 1.610927 0.089943
GO:0019752 carboxylic acid metabolic process 1.194075 5.21E-15
GO:0042309 homoiothermy -1.842482 0.000896
GO:0006541 glutamine metabolic process 1.591390 0.096562
GO:0009266 response to temperature stimulus -1.150928 0.002058
GO:0009060 aerobic respiration 1.990393 0.012668
GO:0006270 DNA replication initiation -4.970340 1.13E-06
GO:0019882 antigen processing and presentation 1.339249 0.088147
GO:0006959 humoral immune response 3.652864 0.057226
GO:0007017 microtubule-based process -0.571638 0.065868
GO:0006813 potassium ion transport -0.608328 0.044498
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GO:0007018 microtubule-based movement -0.812715 0.023167
GO:0006066 alcohol metabolic process 0.668290 0.000278
GO:0009056 catabolic process 0.572362 1.31E-09
GO:0015671 oxygen transport 1.797693 0.087466
GO:0006260 DNA replication -1.882404 1.8E-05
GO:0006261 DNA-dependent DNA replication -3.231909 3.9E-05
GO:0006563 L-serine metabolic process 2.996479 0.048589
GO:0009395 phospholipid catabolic process 1.797693 0.005195
GO:0006164 purine nucleotide biosynthetic process 0.453367 0.097809
GO:0006694 steroid biosynthetic process 1.484088 0.000534
GO:0006796 phosphate-containing compound metabolic pro-
cess
-0.384406 0.000186
GO:0007178 transmembrane receptor protein ser-
ine/threonine kinase signaling pathway
-0.980559 0.032347
GO:0007179 transforming growth factor beta receptor signal-
ing pathway
-2.247498 0.009534
GO:0006979 response to oxidative stress 2.882964 0.000317
GO:0048066 developmental pigmentation -1.423359 0.049222
GO:0048545 response to steroid hormone stimulus 4.019011 0.066196
GO:0007186 G-protein coupled receptor signaling pathway -1.084019 3.53E-11
GO:0043687 post-translational protein modification -0.420099 2.29E-05
GO:0055114 oxidation-reduction process 0.769003 4.98E-10
GO:0008037 cell recognition -1.344852 0.072736
GO:0048514 blood vessel morphogenesis -0.682329 0.038903
GO:0009952 anterior/posterior pattern specification -0.893548 0.001131
GO:0008033 tRNA processing 2.228457 5.9E-06
GO:0006470 protein dephosphorylation -0.755021 0.052502
GO:0007059 chromosome segregation -1.995792 0.038273
GO:0007155 cell adhesion -0.587918 0.002956
GO:0048925 lateral line system development -4.003411 0.043841
GO:0007156 homophilic cell adhesion -1.346913 0.00086
GO:0048048 embryonic eye morphogenesis -1.996978 0.001407
GO:0021953 central nervous system neuron differentiation -2.671181 0.00109
GO:0009966 regulation of signal transduction -0.661712 0.001158
GO:0007067 mitosis -0.795287 0.070665
GO:0007160 cell-matrix adhesion -1.005823 0.092565
GO:0006468 protein phosphorylation -0.595493 7.54E-07
GO:0006464 cellular protein modification process -0.350045 0.000166
GO:0007166 cell surface receptor signaling pathway -0.646925 7.37E-11
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GO:0043627 response to estrogen stimulus 4.529963 0.066196
GO:0060041 retina development in camera-type eye -0.843741 0.023332
GO:0048592 eye morphogenesis -1.010379 0.004218
GO:0048593 camera-type eye morphogenesis -1.073640 0.028684
GO:0048598 embryonic morphogenesis -0.858545 2.42E-07
GO:0016050 vesicle organization -2.352168 0.070665
GO:0031076 embryonic camera-type eye development -1.755227 0.011299
GO:0048589 developmental growth -1.345538 0.013851
GO:0042127 regulation of cell proliferation -1.556969 0.034238
GO:0001708 cell fate specification -1.373006 0.018141
GO:0042254 ribosome biogenesis 1.768721 2.6E-05
GO:0006334 nucleosome assembly -1.629801 0.000891
GO:0006333 chromatin assembly or disassembly -1.636416 0.000104
GO:0016042 lipid catabolic process 1.298037 0.009073
GO:0001501 skeletal system development -0.824210 0.003863
GO:0050931 pigment cell differentiation -1.554164 0.038833
GO:0000278 mitotic cell cycle -0.781187 0.033624
GO:0040008 regulation of growth 1.706322 0.023256
GO:0021536 diencephalon development -1.936388 0.00012
GO:0043009 chordate embryonic development -0.850763 0.000737
GO:0048568 embryonic organ development -0.828279 0.005828
GO:0043010 camera-type eye development -0.703844 0.007573
GO:0006397 mRNA processing -0.850573 0.012721
GO:0006396 RNA processing 0.524665 0.029634
GO:0021522 spinal cord motor neuron differentiation -3.318211 0.013488
GO:0006108 malate metabolic process 1.797690 0.074196
GO:0048562 embryonic organ morphogenesis -1.609821 0.001262
GO:0016568 chromatin modification -1.259460 0.000656
GO:0006013 mannose metabolic process 2.353324 0.096392
GO:0008219 cell death 0.778988 0.017215
GO:0044262 cellular carbohydrate metabolic process 0.970650 0.039597
GO:0006364 rRNA processing 1.969644 0.000399
GO:0042221 response to chemical stimulus 0.943731 0.002075
GO:0007219 Notch signaling pathway -1.291087 0.005828
GO:0032355 response to estradiol stimulus 4.529963 0.066196
GO:0016310 phosphorylation -0.409409 0.000311
GO:0016311 dephosphorylation -0.636759 0.073858
GO:0021592 fourth ventricle development 1.797690 0.097809
GO:0035270 endocrine system development -1.391564 0.002163
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GO:0051301 cell division -0.744932 0.032347
GO:0042246 tissue regeneration -1.701780 0.022533
GO:0021575 hindbrain morphogenesis -2.071718 0.034739
GO:0008202 steroid metabolic process 1.114151 0.003951
GO:0008203 cholesterol metabolic process 1.797690 0.031216
GO:0030097 hemopoiesis -0.670224 0.081504
GO:0006355 regulation of transcription, DNA-dependent -1.546408 2.29E-48
GO:0006915 apoptotic process 0.772317 0.023008
GO:0006259 DNA metabolic process -0.614005 0.034739
GO:0006917 induction of apoptosis 1.869765 0.072678
GO:0006351 transcription, DNA-dependent -1.506204 1.05E-46
GO:0006350 transcription, DNA-dependent -1.032412 5.41E-50
GO:0000902 cell morphogenesis -0.842067 0.001954
GO:0016331 morphogenesis of embryonic epithelium -1.255384 0.066634
GO:0016126 sterol biosynthetic process 1.797690 0.001899
GO:0016125 sterol metabolic process 2.941896 0.003886
GO:0007601 visual perception -1.051308 0.046392
GO:0007600 sensory perception -0.878400 0.007311
GO:0051216 cartilage development 1.797690 0.002185
GO:0009790 embryo development -0.758740 1.43E-09
GO:0009653 anatomical structure morphogenesis -0.704708 1.21E-10
GO:0030154 cell differentiation -0.819798 7E-12
GO:0030163 protein catabolic process 0.542280 1.69E-06
GO:0042074 cell migration involved in gastrulation -0.706685 0.057515
GO:0016337 cell-cell adhesion -1.054554 0.001052
GO:0009451 RNA modification 1.700595 0.007613
GO:0042471 ear morphogenesis -1.476208 0.005755
GO:0042472 inner ear morphogenesis -1.527572 0.004257
GO:0043085 positive regulation of catalytic activity 4.831357 0.00222
GO:0042063 gliogenesis -1.200059 0.088705
GO:0043280 positive regulation of cysteine-type endopepti-
dase activity involved in apoptotic process
2.968663 0.007999
GO:0030182 neuron differentiation -1.131861 9.95E-08
GO:0007626 locomotory behavior -1.204738 0.091508
GO:0001568 blood vessel development -0.678059 0.023255
GO:0042981 regulation of apoptotic process 3.156683 0.056997
GO:0045995 regulation of embryonic development 1.797690 0.059457
GO:0001764 neuron migration -1.723961 0.038903
GO:0001570 vasculogenesis -1.842435 0.005828
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GO:0001654 eye development -0.715071 0.00172
GO:0009409 response to cold -1.965482 0.000186
GO:0016481 negative regulation of transcription, DNA-
dependent
-1.274872 0.011299
GO:0009410 response to xenobiotic stimulus 1.764817 0.050595
GO:0001944 vasculature development -0.734548 0.011606
GO:0007417 central nervous system development -1.550595 2.32E-15
GO:0007418 ventral midline development -2.289014 0.046373
GO:0007423 sensory organ development -0.725666 0.000117
GO:0050808 synapse organization -1.841445 0.073601
GO:0007420 brain development -1.472801 1.14E-12
GO:0007422 peripheral nervous system development -1.849915 0.006238
GO:0030030 cell projection organization -0.839951 0.001649
GO:0043039 tRNA aminoacylation 1.359604 0.00098
GO:0051276 chromosome organization -0.920369 1.76E-06
GO:0008283 cell proliferation -0.874182 0.067192
GO:0048699 generation of neurons -1.707598 3.79E-09
GO:0060026 convergent extension -0.898434 0.034197
GO:0050819 negative regulation of coagulation 2.815789 0.001461
GO:0045941 positive regulation of transcription, DNA-
dependent
-1.441806 0.058672
GO:0043065 positive regulation of apoptotic process 4.319771 0.004499
GO:0001522 pseudouridine synthesis 1.842602 0.097473
GO:0008299 isoprenoid biosynthetic process 1.591390 0.096562
GO:0050826 response to freezing -1.842482 0.000896
GO:0016477 cell migration -0.824758 0.000613
GO:0031018 endocrine pancreas development -2.129519 0.019891
GO:0009405 pathogenesis 1.797690 0.087466
GO:0031226 intrinsic to plasma membrane -0.598184 0.041932
GO:0005615 extracellular space 1.298742 0.001643
GO:0000502 proteasome complex 3.047425 0.000118
GO:0009986 cell surface 1.797690 0.072718
GO:0005694 chromosome -0.748674 0.000885
GO:0005887 integral to plasma membrane -0.615536 0.041932
GO:0044429 mitochondrial part 0.812681 0.000844
GO:0045263 proton-transporting ATP synthase complex,
coupling factor F(o)
1.996948 0.041932
GO:0008287 protein serine/threonine phosphatase complex -2.254401 0.041932
GO:0005886 plasma membrane -0.480965 0.000566
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GO:0070469 respiratory chain 2.395506 0.027643
GO:0015629 actin cytoskeleton -1.215107 0.098108
GO:0005829 cytosol 0.963596 0.001009
GO:0005739 mitochondrion 0.857755 3.28E-07
GO:0015630 microtubule cytoskeleton -0.667614 0.025941
GO:0005777 peroxisome 1.533148 0.041932
GO:0005839 proteasome core complex 2.855886 0.000844
GO:0033177 proton-transporting two-sector ATPase com-
plex, proton-transporting domain
1.437941 0.041932
GO:0005578 proteinaceous extracellular matrix 2.728998 0.057689
GO:0042613 MHC class II protein complex 1.797690 0.041932
GO:0031012 extracellular matrix 2.693780 0.057689
GO:0030529 ribonucleoprotein complex 0.532357 0.003752
GO:0005840 ribosome 1.398098 7.51E-07
GO:0019956 chemokine binding 1.206354 0.058431
GO:0048037 cofactor binding 1.050313 4.02E-10
GO:0008047 enzyme activator activity -0.811577 0.026756
GO:0050662 coenzyme binding 1.026910 2.64E-07
GO:0050660 flavin adenine dinucleotide binding 1.408997 5.54E-05
GO:0008667 2,3-dihydro-2,3-dihydroxybenzoate dehydroge-
nase activity
0.856247 0.049022
GO:0030414 peptidase inhibitor activity 2.131534 0.008234
GO:0017040 ceramidase activity 1.797690 0.022904
GO:0004672 protein kinase activity -0.587454 2.26E-06
GO:0004674 protein serine/threonine kinase activity -0.589809 1.34E-05
GO:0004675 transmembrane receptor protein ser-
ine/threonine kinase activity
-1.701238 0.091218
GO:0004091 carboxylesterase activity 0.870100 0.088991
GO:0004879 ligand-activated sequence-specific DNA binding
RNA polymerase II transcription factor activity
-1.539992 2.06E-05
GO:0004896 cytokine receptor activity -2.186454 0.041444
GO:0003810 protein-glutamine gamma-glutamyltransferase
activity
3.539050 0.026029
GO:0004887 thyroid hormone receptor activity -1.527980 0.009391
GO:0004888 transmembrane signaling receptor activity -0.752898 6.41E-11
GO:0003700 sequence-specific DNA binding transcription
factor activity
-1.751533 2.43E-47
GO:0016769 transferase activity, transferring nitrogenous
groups
1.334133 0.025097
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GO:0003707 steroid hormone receptor activity -1.358094 0.001672
GO:0003708 retinoic acid receptor activity -1.316141 0.058469
GO:0016627 oxidoreductase activity, acting on the CH-CH
group of donors
1.051158 6.94E-05
GO:0005085 guanyl-nucleotide exchange factor activity -0.940276 0.049022
GO:0005083 small GTPase regulator activity -0.537569 0.090504
GO:0005003 ephrin receptor activity -2.339144 0.06551
GO:0016773 phosphotransferase activity, alcohol group as ac-
ceptor
-0.404021 0.000621
GO:0046983 protein dimerization activity 1.784029 0.010496
GO:0016772 transferase activity, transferring phosphorus-
containing groups
-0.270584 0.013951
GO:0009982 pseudouridine synthase activity 1.842602 0.074515
GO:0016615 malate dehydrogenase activity 1.797690 0.087956
GO:0016614 oxidoreductase activity, acting on CH-OH group
of donors
1.006327 5.17E-05
GO:0003854 3-beta-hydroxy-delta5-steroid dehydrogenase
activity
1.660878 0.020552
GO:0016616 oxidoreductase activity, acting on the CH-OH
group of donors, NAD or NADP as acceptor
0.956445 0.000266
GO:0005179 hormone activity 1.462356 0.010175
GO:0046873 metal ion transmembrane transporter activity -0.515293 0.019661
GO:0016765 transferase activity, transferring alkyl or aryl
(other than methyl) groups
2.250236 5.54E-05
GO:0003995 acyl-CoA dehydrogenase activity 2.354212 0.003601
GO:0016746 transferase activity, transferring acyl groups 0.550327 0.076098
GO:0016651 oxidoreductase activity, acting on NADH or
NADPH
1.616161 0.013951
GO:0003735 structural constituent of ribosome 1.385432 6.01E-06
GO:0022832 voltage-gated channel activity -0.844487 0.001696
GO:0005199 structural constituent of cell wall -1.796681 0.064201
GO:0016874 ligase activity 0.395311 0.037497
GO:0003743 translation initiation factor activity 0.835290 0.06768
GO:0042802 identical protein binding 1.359893 0.042292
GO:0016866 intramolecular transferase activity 1.363936 0.020552
GO:0003954 NADH dehydrogenase activity 1.702227 0.082171
GO:0020037 heme binding 0.737553 0.040296
GO:0016788 hydrolase activity, acting on ester bonds 0.366057 0.048561
GO:0008528 G-protein coupled peptide receptor activity 1.640490 1.03E-07
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GO:0003774 motor activity -0.843741 0.030913
GO:0008430 selenium binding 1.533148 0.029876
GO:0016798 hydrolase activity, acting on glycosyl bonds 0.858523 0.003253
GO:0005021 vascular endothelial growth factor-activated re-
ceptor activity
-0.953035 0.053782
GO:0016884 carbon-nitrogen ligase activity, with glutamine
as amido-N-donor
3.038030 0.013985
GO:0019239 deaminase activity 1.230311 0.042135
GO:0008831 dTDP-4-dehydrorhamnose reductase activity 2.353324 0.070518
GO:0003777 microtubule motor activity -1.245189 0.039007
GO:0043565 sequence-specific DNA binding -1.885669 9.19E-47
GO:0005099 Ras GTPase activator activity -1.884499 0.008849
GO:0005097 Rab GTPase activator activity -1.766451 0.019136
GO:0005096 GTPase activator activity -1.065792 0.005845
GO:0016876 ligase activity, forming aminoacyl-tRNA and re-
lated compounds
1.296753 0.001092
GO:0005212 structural constituent of eye lens 3.220678 0.004714
GO:0016810 hydrolase activity, acting on carbon-nitrogen
(but not peptide) bonds
0.991189 0.001418
GO:0016811 hydrolase activity, acting on carbon-nitrogen
(but not peptide) bonds, in linear amides
1.237983 0.008907
GO:0001614 purinergic nucleotide receptor activity 2.345928 8.33E-05
GO:0005496 steroid binding 0.709078 0.088985
GO:0005506 iron ion binding 0.734867 0.02151
GO:0004364 glutathione transferase activity 2.535842 0.033244
GO:0005125 cytokine activity 1.114879 0.088719
GO:0016829 lyase activity 0.985103 0.000278
GO:0008137 NADH dehydrogenase (ubiquinone) activity 1.702227 0.082171
GO:0005216 ion channel activity -0.629831 0.001092
GO:0016564 transcription repressor activity -1.282539 0.058431
GO:0004252 serine-type endopeptidase activity 1.675278 0.001322
GO:0016563 transcription activator activity -1.225543 0.079246
GO:0042277 peptide binding 1.550708 2.16E-07
GO:0005244 voltage-gated ion channel activity -0.835003 0.002079
GO:0016853 isomerase activity 0.649553 0.05319
GO:0016301 kinase activity -0.388947 0.000439
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GO:0016712 oxidoreductase activity, acting on paired donors,
with incorporation or reduction of molecular
oxygen, reduced flavin or flavoprotein as one
donor, and incorporation of one atom of oxygen
1.005678 0.023429
GO:0008373 sialyltransferase activity -1.656555 0.066401
GO:0005262 calcium channel activity -1.306801 0.035937
GO:0005261 cation channel activity -0.755912 0.001523
GO:0030594 neurotransmitter receptor activity -1.030477 6.94E-05
GO:0005267 potassium channel activity -0.777485 0.012767
GO:0005549 odorant binding 3.285068 0.00658
GO:0005550 pheromone binding 2.996479 0.036354
GO:0008236 serine-type peptidase activity 1.539452 0.001144
GO:0008233 peptidase activity 0.783688 9.47E-10
GO:0008234 cysteine-type peptidase activity 1.151450 0.005039
GO:0008237 metallopeptidase activity 1.985915 0.000244
GO:0008483 transaminase activity 1.295166 0.078498
GO:0008484 sulfuric ester hydrolase activity 2.440174 0.088631
GO:0004298 threonine-type endopeptidase activity 2.855886 0.001371
GO:0005544 calcium-dependent phospholipid binding 2.441920 0.000263
GO:0004497 monooxygenase activity 0.621218 0.03023
GO:0005543 phospholipid binding 1.430499 0.001439
GO:0005529 carbohydrate binding 1.759787 0.059647
GO:0005524 ATP binding -0.165099 0.098208
GO:0005344 oxygen transporter activity 1.797690 0.060302
GO:0016705 oxidoreductase activity, acting on paired donors,
with incorporation or reduction of molecular
oxygen
0.865397 0.060075
GO:0015078 hydrogen ion transmembrane transporter activ-
ity
0.971573 0.005055
GO:0015077 monovalent inorganic cation transmembrane
transporter activity
0.773685 0.008941
GO:0004989 octopamine receptor activity 1.797690 0.039645
GO:0004707 MAP kinase activity -1.344852 0.087799
GO:0015276 ligand-gated ion channel activity -0.811019 0.024541
GO:0030955 potassium ion binding -1.525944 0.067407
GO:0004977 melanocortin receptor activity 1.323347 0.00486
GO:0004982 N-formyl peptide receptor activity -1.701100 0.044566
GO:0004984 olfactory receptor activity 1.883551 0.000176
GO:0004983 neuropeptide Y receptor activity 2.297984 0.000164
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GO:0004175 endopeptidase activity 1.697580 2.16E-09
GO:0004177 aminopeptidase activity 1.438240 0.011418
GO:0030170 pyridoxal phosphate binding 1.331526 0.001205
GO:0004866 endopeptidase inhibitor activity 1.453653 0.006694
GO:0015057 thrombin receptor activity 1.493774 0.058431
GO:0004867 serine-type endopeptidase inhibitor activity 1.321659 0.088631
GO:0004965 G-protein coupled GABA receptor activity 1.702227 0.082171
GO:0004966 galanin receptor activity -2.254401 0.027401
GO:0031402 sodium ion binding 1.562393 0.079537
GO:0004970 ionotropic glutamate receptor activity -2.030885 0.079455
GO:0004872 receptor activity -0.618760 1.61E-12
GO:0004857 enzyme inhibitor activity 1.263018 0.000272
GO:0004859 phospholipase inhibitor activity 2.815789 0.001323
GO:0031418 L-ascorbic acid binding -1.659721 0.036828
GO:0031419 cobalamin binding 2.121334 0.078498
GO:0051536 iron-sulfur cluster binding 1.431017 0.001698
GO:0004952 dopamine receptor activity -2.303285 0.028245
GO:0004197 cysteine-type endopeptidase activity 1.167587 0.000266
GO:0004198 calcium-dependent cysteine-type endopeptidase
activity
1.948654 0.009429
GO:0030246 carbohydrate binding 0.550081 0.093799
GO:0016229 steroid dehydrogenase activity 1.081286 0.044248
GO:0030247 polysaccharide binding 1.653692 0.088631
GO:0035091 phosphatidylinositol binding 1.117404 0.081158
GO:0001653 peptide receptor activity 1.645819 1.03E-07
GO:0008168 methyltransferase activity 0.662807 0.003997
GO:0015035 protein disulfide oxidoreductase activity 2.354212 0.003601
GO:0004022 alcohol dehydrogenase (NAD) activity 1.013387 0.033867
GO:0004602 glutathione peroxidase activity 2.996479 0.036354
GO:0004527 exonuclease activity 0.985882 0.074756
GO:0004601 peroxidase activity 2.775853 0.001439
GO:0004950 chemokine receptor activity 1.206354 0.058431
GO:0004747 ribokinase activity 2.456728 0.088985
GO:0004930 G-protein coupled receptor activity -0.943171 1.95E-10
GO:0008170 N-methyltransferase activity 1.136464 0.088985
GO:0008173 RNA methyltransferase activity 1.996948 0.037497
GO:0004518 nuclease activity 0.923969 0.036782
GO:0045028 G-protein coupled purinergic nucleotide recep-
tor activity
2.322239 0.000116
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GO:0016491 oxidoreductase activity 0.771297 1.02E-15
GO:0004222 metalloendopeptidase activity 1.797690 0.001408
GO:0008188 neuropeptide receptor activity -1.330994 5.17E-05
GO:0004553 hydrolase activity, hydrolyzing O-glycosyl com-
pounds
0.963593 0.001785
GO:0008289 lipid binding 0.938472 0.000626
GO:0004721 phosphoprotein phosphatase activity -0.682043 0.026756
GO:0004722 protein serine/threonine phosphatase activity 1.797690 0.039645
GO:0004725 protein tyrosine phosphatase activity -0.680859 0.086252
GO:0050825 ice binding -1.842482 0.0016
GO:0004812 aminoacyl-tRNA ligase activity 1.257335 0.001523
GO:0004536 deoxyribonuclease activity 2.308374 0.049701
GO:0003682 chromatin binding -1.571006 0.009712
GO:0004713 protein tyrosine kinase activity -0.619262 2.26E-06
GO:0004714 transmembrane receptor protein tyrosine kinase
activity
-1.124095 0.001815
GO:0005201 extracellular matrix structural constituent -2.822759 0.014192
IPR000504 RNA recognition motif domain -0.964652 1.93E-07
IPR011598 Helix-loop-helix DNA-binding -1.862295 6.24E-10
IPR001630 cAMP response element binding (CREB) pro-
tein
2.974052 0.038384
IPR018097 EGF-like calcium-binding, conserved site -0.984929 0.023503
IPR008145 Guanylate kinase/L-type calcium channel -1.884499 0.023503
IPR008144 Guanylate kinase -1.964000 0.068236
IPR018081 Anaphylatoxin 1.797690 0.026842
IPR006703 AIG1 1.797690 0.031899
IPR018073 Proteinase inhibitor I25, cystatin, conserved site 1.797690 0.093802
IPR006711 Hox9, N-terminal activation domain 1.797690 0.050181
IPR000536 Nuclear hormone receptor, ligand-binding, core -1.322188 0.01004
IPR004087 K Homology -1.230452 0.039264
IPR004088 K Homology, type 1 -1.672751 0.04914
IPR001660 Sterile alpha motif domain -1.228321 0.027624
IPR016035 Acyl transferase/acyl hydro-
lase/lysophospholipase
2.823916 0.028921
IPR001671 Melanocortin/ACTH receptor 1.323347 0.010595
IPR007863 Peptidase M16, C-terminal 3.689694 0.070558
IPR016027 Nucleic acid-binding, OB-fold-like -1.984953 0.027473
IPR001128 Cytochrome P450 1.168820 0.070558
IPR001134 Netrin domain 2.627544 0.027427
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IPR016017 GDNF/GAS1 1.797690 0.03807
IPR009100 Acyl-CoA dehydrogenase/oxidase 2.248655 0.038873
IPR011510 Sterile alpha motif, type 2 -1.191543 0.055843
IPR000020 Anaphylatoxin/fibulin 4.751605 0.026842
IPR000024 Phosphofructokinase domain -1.829307 0.026749
IPR017112 Homeobox, Hox9 1.797690 0.050181
IPR016449 Potassium channel, inwardly rectifying, Kir -2.826309 0.000593
IPR000047 Helix-turn-helix motif -2.513236 4.67E-37
IPR000949 ELM2 domain -2.394506 0.093535
IPR001606 ARID/BRIGHT DNA-binding domain 1.797690 0.007329
IPR018039 Intermediate filament protein, conserved site -1.973357 0.027231
IPR000562 Fibronectin, type II, collagen-binding 4.944317 0.007823
IPR001611 Leucine-rich repeat -0.597341 0.040145
IPR001614 Myelin proteolipid protein PLP -3.586766 0.001776
IPR000566 Lipocalin/cytosolic fatty-acid binding protein
domain
1.678040 0.047317
IPR007087 Zinc finger, C2H2 -0.867640 3.1E-10
IPR001628 Zinc finger, nuclear hormone receptor-type -1.439307 0.008828
IPR001627 Semaphorin/CD100 antigen -1.319505 0.05152
IPR002219 Protein kinase C-like, phorbol es-
ter/diacylglycerol binding
-1.479599 0.000961
IPR017972 Cytochrome P450, conserved site 0.892968 0.06326
IPR017973 Cytochrome P450, conserved site 0.942001 0.03816
IPR017976 Endoglin/CD105 antigen subgroup 2.351055 0.068197
IPR017970 Homeobox, conserved site -2.691880 2.7E-52
IPR002225 3-beta hydroxysteroid dehydrogenase/isomerase 1.660878 0.089456
IPR017995 Homeobox protein, antennapedia type -2.141776 4.86E-06
IPR003380 Transforming protein Ski -2.957114 0.028286
IPR013019 MAD homology, MH1 -2.822759 0.030192
IPR013027 FAD-dependent pyridine nucleotide-disulphide
oxidoreductase
1.797690 0.000459
IPR013032 EGF-like region, conserved site -0.578681 0.042136
IPR017956 AT hook, DNA-binding motif -2.926062 0.002879
IPR013787 S100/CaBP-9k-type, calcium binding, subdo-
main
-4.542725 0.052784
IPR003349 Transcription factor jumonji, JmjN -2.764514 0.086338
IPR003347 Transcription factor jumonji/aspartyl beta-
hydroxylase
-1.659721 0.07298
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IPR002290 Serine/threonine- / dual-specificity protein ki-
nase, catalytic domain
-0.597529 3.41E-05
IPR013069 BTB/POZ -0.745036 0.083582
IPR002286 P2 purinoceptor 2.221525 0.001331
IPR013091 Phospholipase A2, active site -1.041550 0.086735
IPR013098 Immunoglobulin I-set -0.776477 0.003164
IPR004965 Paralemmin 1.797690 0.075313
IPR009048 Alpha-macroglobulin, receptor-binding 2.879535 0.05328
IPR009071 High mobility group, superfamily -2.171767 6.23E-09
IPR009072 Histone-fold -0.955686 0.094537
IPR001926 Pyridoxal phosphate-dependent enzyme, beta
subunit
3.689694 0.070558
IPR001523 Paired box protein, N-terminal -3.503350 0.00115
IPR008266 Tyrosine-protein kinase, active site -1.075039 0.010343
IPR008271 Serine/threonine-protein kinase, active site -0.557857 0.007352
IPR009057 Homeodomain-like -2.334554 3.05E-51
IPR016137 Regulator of G protein signalling superfamily -1.245189 0.093537
IPR007123 Gelsolin domain 1.843097 0.088963
IPR007122 Gelsolin 2.248655 0.038873
IPR001254 Peptidase S1/S6, chymotrypsin/Hap 2.693955 0.002311
IPR006620 Prolyl 4-hydroxylase, alpha subunit -1.659721 0.07298
IPR009003 Peptidase cysteine/serine, trypsin-like 2.742201 0.001659
IPR015424 Pyridoxal phosphate-dependent transferase,
major domain
1.178890 0.076613
IPR007110 Immunoglobulin-like -0.524934 0.019934
IPR016129 Peptidase C14, ICE, catalytic subunit p20, ac-
tive site
1.797690 0.087325
IPR006638 Elongator protein 3/MiaB/NifB 1.797690 0.093802
IPR001965 Zinc finger, PHD-type -2.071326 1.13E-10
IPR001245 Serine-threonine/tyrosine-protein kinase cat-
alytic domain
-0.641816 7.1E-06
IPR011651 Notch ligand, N-terminal -4.217075 0.000735
IPR000483 Cysteine-rich flanking region, C-terminal -0.871273 0.060175
IPR000169 Peptidase, cysteine peptidase active site 1.392723 0.01004
IPR003879 Butyrophylin-like 1.069515 0.034921
IPR003073 Orphan nuclear receptor, NURR type -4.404200 0.097652
IPR003072 Orphan nuclear receptor, NOR1 type -2.038241 0.046723
IPR003070 Orphan nuclear receptor -1.964000 0.068236
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IPR011249 Metalloenzyme, LuxS/M16 peptidase-like,
metal-binding
3.689694 0.070558
IPR003078 Retinoic acid receptor -2.211180 0.097652
IPR000152 EGF-type aspartate/asparagine hydroxylation
site
-0.940843 0.046723
IPR011616 bZIP transcription factor, bZIP-1 2.875753 0.005186
IPR003025 Transcription factor Otx -6.489015 0.008905
IPR007197 Radical SAM 1.797690 0.04046
IPR002314 Aminoacyl-tRNA synthetase, class II (G/ H/ P/
S), conserved domain
1.797690 0.093802
IPR001509 NAD-dependent epimerase/dehydratase 1.363936 0.089456
IPR001507 Zona pellucida sperm-binding protein 2.479169 0.037847
IPR006108 3-hydroxyacyl-CoA dehydrogenase, C-terminal 3.438183 0.078354
IPR011626 A-macroglobulin complement component 2.879535 0.05328
IPR011625 Alpha-2-macroglobulin, N-terminal 2 2.879535 0.05328
IPR000837 Fos transforming protein 3.120870 0.005186
IPR006680 Amidohydrolase 1 -2.866015 0.093673
IPR000426 Proteasome, alpha-subunit, N-terminal domain 1.797690 0.008828
IPR000195 Rab-GAP/TBC domain -1.766451 0.05222
IPR015880 Zinc finger, C2H2-like -0.946328 1.1E-10
IPR006025 Opioid neuropeptide precursor 2.473957 0.021429
IPR005542 PBX 1.797690 0.075146
IPR013847 POU -3.100505 5.48E-32
IPR011700 Basic leucine zipper 2.538767 0.008725
IPR010982 Lambda repressor-like, DNA-binding -2.811349 7.01E-05
IPR002347 Glucose/ribitol dehydrogenase 1.092119 0.00303
IPR002343 Paraneoplastic encephalomyelitis antigen -1.506271 0.030718
IPR006030 Neurotransmitter-gated ion-channel transmem-
brane domain
-1.898278 0.049416
IPR000910 High mobility group, HMG1/HMG2 -2.281109 5.08E-09
IPR000135 High mobility group, HMG1/HMG2, subgroup -2.285019 2.03E-06
IPR002391 Annexin, type IV 2.933899 0.002161
IPR002392 Annexin, type V 3.375156 0.007174
IPR012336 Thioredoxin-like fold 1.043781 0.000683
IPR003893 Iroquois-class homeodomain protein -4.978018 3.18E-09
IPR000104 Antifreeze protein, type I -1.842482 0.003917
IPR016044 Filament -1.793409 0.011302
IPR016040 NAD(P)-binding domain 1.113001 3.22E-07
IPR019786 Zinc finger, PHD-type, conserved site -2.328318 5.35E-09
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IPR019787 Zinc finger, PHD-finger -2.358395 1E-10
IPR016050 Proteasome, beta-type subunit, conserved site 2.395506 0.081034
IPR001208 Mini-chromosome maintenance, DNA-
dependent ATPase
-4.277127 1.8E-05
IPR006092 Acyl-CoA dehydrogenase, N-terminal 2.823916 0.028921
IPR006091 Acyl-CoA oxidase/dehydrogenase, central do-
main
2.130676 0.08126
IPR001599 Alpha-2-macroglobulin 2.879535 0.05328
IPR009075 Acyl-CoA dehydrogenase/oxidase C-terminal 1.797690 0.016018
IPR004044 K Homology, type 2 -2.822759 0.030192
IPR014778 Myb, DNA-binding -1.214051 0.06608
IPR019742 Alpha-2-macroglobulin, conserved site 3.285068 0.036294
IPR004827 Basic-leucine zipper domain 1.957532 0.096337
IPR004020 Pyrin 3.689694 0.070558
IPR014756 Immunoglobulin E-set -1.269518 0.016527
IPR013851 Transcription factor Otx, C-terminal -6.489015 0.008905
IPR013854 Transcription factor AP-2, C-terminal -4.561720 0.00129
IPR001353 Proteasome, subunit alpha/beta 2.855886 0.003164
IPR001356 Homeobox -2.552173 2.72E-54
IPR002401 Cytochrome P450, E-class, group I 0.782934 0.092006
IPR002403 Cytochrome P450, E-class, group IV 0.877330 0.055843
IPR011333 BTB/POZ fold -0.777485 0.059201
IPR013201 Proteinase inhibitor I29, cathepsin propeptide 2.305646 0.034735
IPR001395 Aldo/keto reductase 1.988626 0.083147
IPR014025 Glutaredoxin subgroup 1.797690 0.04046
IPR001881 EGF-like calcium-binding -0.769466 0.022178
IPR006210 Epidermal growth factor-like -0.625988 0.064859
IPR000719 Protein kinase, catalytic domain -0.615015 1.75E-05
IPR000315 Zinc finger, B-box 1.011126 0.025263
IPR003935 Lens fibre membrane intrinsic protein 1.797690 0.076613
IPR006574 SPRY-associated 1.485451 0.040424
IPR006209 EGF -0.721182 0.050103
IPR000327 POU-specific -3.578270 1.54E-05
IPR000324 Vitamin D receptor -1.439307 0.008828
IPR007237 CD20-like 5.347552 8.42E-05
IPR003961 Fibronectin, type III -0.948456 0.000742
IPR003962 Fibronectin, type III -1.347602 0.000654
IPR003954 RNA recognition motif domain, eukaryote -0.904487 0.053567
IPR000725 Olfactory receptor 1.865108 0.000574
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IPR018252 Annexin repeat, conserved site 2.441920 0.00145
IPR017350 Caspase, interleukin-1 beta convertase 3.438183 0.078354
IPR003979 Tropoelastin 1.797690 0.075146
IPR000742 Epidermal growth factor-like, type 3 -1.192297 0.082621
IPR000747 Homeobox engrailed -3.457733 0.038231
IPR001818 Peptidase M10, metallopeptidase 5.135229 0.04986
IPR018237 Myelin proteolipid protein PLP, conserved site 1.797690 0.000154
IPR005818 Histone H1/H5 -3.811482 0.001615
IPR005819 Histone H5 -3.474225 0.003333
IPR001827 Homeobox protein, antennapedia type, con-
served site
-2.707789 3.6E-07
IPR000372 Leucine-rich repeat-containing N-terminal -0.990568 0.024012
IPR006180 3-hydroxyacyl-CoA dehydrogenase, conserved
site
3.438183 0.078354
IPR015919 Cadherin-like -1.287807 0.008411
IPR006176 3-hydroxyacyl-CoA dehydrogenase, NAD bind-
ing
3.438183 0.078354
IPR002909 Cell surface receptor IPT/TIG -2.577093 0.037999
IPR005467 Signal transduction histidine kinase, core 1.797690 0.03807
IPR006195 Aminoacyl-tRNA synthetase, class II 1.797690 0.008828
IPR018502 Annexin repeat 2.441920 0.00145
IPR004358 Signal transduction histidine kinase-related pro-
tein, C-terminal
1.797690 0.03807
IPR011778 Hydantoinase/dihydropyrimidinase -3.713572 0.023956
IPR018525 Mini-chromosome maintenance, conserved site -4.970340 6.07E-06
IPR018933 Netrin module, non-TIMP type 2.476064 0.08945
IPR002957 Keratin, type I -1.963638 0.004927
IPR002972 Prostaglandin D synthase 3.285068 0.036294
IPR002975 Fungal G-protein, alpha subunit -1.759741 0.097305
IPR001300 Peptidase C2, calpain, catalytic domain 1.948654 0.043493
IPR013521 Potassium channel, inwardly rectifying, Kir,
conserved region 2
-2.219835 0.005768
IPR003585 Neurexin/syndecan/glycophorin C -2.799484 0.023956
IPR001310 Histidine triad (HIT) protein 1.797690 0.093802
IPR002049 EGF-like, laminin -0.958560 0.043871
IPR002450 von Ebner’s gland protein/ Bos/Can allergen 3.689694 0.070558
IPR001314 Peptidase S1A, chymotrypsin-type 1.797690 0.000361
IPR003598 Immunoglobulin subtype 2 -0.614916 0.01004
IPR003599 Immunoglobulin subtype -0.556244 0.016521
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IPR003596 Immunoglobulin V-set, subgroup -0.681811 0.020656
IPR003594 ATPase-like, ATP-binding domain -1.436783 0.080162
IPR003591 Leucine-rich repeat, typical subtype -0.741719 0.018931
IPR002477 Peptidoglycan binding-like 5.828566 0.044635
IPR000694 Anenome neurotoxin -0.873387 1.41E-15
IPR001491 Thrombomodulin -1.982963 0.056559
IPR001092 Restriction/modification DNA-methylase -1.862295 6.24E-10
IPR001791 Laminin G domain -1.924501 0.031568
IPR000679 Zinc finger, GATA-type -2.200066 0.047296
IPR000668 Peptidase C1A, papain C-terminal 2.017373 0.024943
IPR001487 Bromodomain -1.843426 0.001696
IPR001774 Delta/Serrate/lag-2 (DSL) protein -3.993867 0.00107
IPR014891 DWNN domain 6.724402 0.02138
IPR003619 MAD homology 1, Dwarfin-type 1.797690 0.007352
IPR003613 U box domain 1.588479 0.017442
IPR001753 Crotonase, core 1.797690 0.055369
IPR001751 S100/Calbindin-D9k, conserved site -4.409130 0.057616
IPR000611 Neuropeptide Y receptor 2.285635 0.000402
IPR000210 BTB/POZ-like -0.883297 0.026112
IPR003268 Potassium channel, inwardly rectifying, Kir1.1 -3.076781 0.001156
IPR017441 Protein kinase, ATP binding site -0.544724 0.001877
IPR017442 Protein kinase, ATP binding site -0.622062 1.62E-05
IPR001005 SANT domain, DNA binding -1.325196 0.032478
IPR020479 Homeobox, eukaryotic -2.467517 1.55E-33
IPR020478 AT hook-like -1.596696 0.053228
IPR001723 Steroid hormone receptor -1.322188 0.01004
IPR020068 Frizzled domain -2.116820 0.021429
IPR020067 Frizzled domain -2.011707 0.015221
IPR001728 Thyroid hormone receptor -1.479058 0.037363
IPR020471 Aldo/keto reductase subgroup 2.681930 0.022368
IPR020474 G-protein beta WD-40 repeat -0.550721 0.08072
IPR000248 Angiotensin II receptor -2.092994 0.010432
IPR011028 Wiscott-Aldrich syndrome, C-terminal -1.245189 0.093537
IPR018111 K Homology, type 1, subgroup -1.291155 0.02772
IPR017853 Glycoside hydrolase, superfamily 1.292019 0.005454
IPR018114 Peptidase S1/S6, chymotrypsin/Hap, active site 2.625818 0.00513
IPR017452 GPCR, rhodopsin-like superfamily -1.696324 1.32E-10
IPR011011 Zinc finger, FYVE/PHD-type -1.302876 6.1E-06
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IPR006821 Intermediate filament head, DNA-binding do-
main
-3.364531 0.000563
IPR011009 Protein kinase-like domain -0.595767 1.75E-05
IPR018359 Bromodomain, conserved site -2.577093 0.037999
IPR018352 Orange subgroup -2.772589 0.00143
IPR008930 Terpenoid cylases/protein prenyltransferase
alpha-alpha toroid
3.095492 0.031502
IPR008936 Rho GTPase activation protein -1.594679 0.08126
IPR008927 6-phosphogluconate dehydrogenase, C-terminal-
like
2.592624 0.036294
IPR000276 GPCR, rhodopsin-like, 7TM -1.810007 1.94E-11
IPR011038 Calycin-like 1.678040 0.047317
IPR008917 Eukaryotic transcription factor, Skn-1-like,
DNA-binding
2.735799 0.005186
IPR002126 Cadherin -1.452394 0.001877
IPR002110 Ankyrin repeat -0.645684 0.021778
IPR002109 Glutaredoxin 1.797690 0.008828
IPR002818 ThiJ/PfpI 1.797690 0.093802
IPR013164 Cadherin, N-terminal -2.213029 0.001659
IPR013151 Immunoglobulin -0.678093 0.01004
IPR001408 G-protein alpha subunit, group I -2.116248 0.083561
IPR003650 Orange -2.571786 0.003035
IPR003656 Zinc finger, BED-type predicted -0.787622 0.030561
IPR003654 Paired-like homeodomain protein, OAR -3.046169 0.000116
IPR003659 Plexin/semaphorin/integrin -1.191543 0.055843
IPR008985 Concanavalin A-like lectin/glucanase -1.675406 0.023956
IPR002198 Short-chain dehydrogenase/reductase SDR 1.050531 0.003611
IPR001464 Annexin 2.441920 0.00145
IPR013129 Transcription factor jumonji -2.822759 0.030192
IPR013111 EGF, extracellular -1.002402 0.05152
IPR008957 Proteinase A inhibitor IA3 domain -0.776477 0.003164
IPR013106 Immunoglobulin V-set -0.537350 0.092051
IPR008047 Mini-chromosome maintenance complex protein
4
1.797690 0.000311
IPR002165 Plexin -1.884499 0.023503
IPR002890 Alpha-2-macroglobulin, N-terminal 2.815835 0.030606
IPR008946 Nuclear hormone receptor, ligand-binding -1.322188 0.01004
dre04330 Notch signaling pathway -1.767561 3.75E-05
dre00340 Histidine metabolism 1.797690 0.025545
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dre00480 Glutathione metabolism 1.186740 0.032461
dre04080 Neuroactive ligand-receptor interaction -1.109071 0.006163
dre00250 Alanine, aspartate and glutamate metabolism 1.612498 0.005718
dre00053 Ascorbate and aldarate metabolism 2.051191 0.094321
dre00052 Galactose metabolism 1.274298 0.084034
dre00910 Nitrogen metabolism 1.583005 0.037678
dre04146 Peroxisome 1.220770 0.00432
dre03010 Ribosome 1.954130 3.75E-05
dre00511 Other glycan degradation 1.295166 0.059089
dre04142 Lysosome 1.703414 1.14E-08
dre04914 Progesterone-mediated oocyte maturation -1.096129 0.005734
dre04916 Melanogenesis -0.713194 0.067133
dre00330 Arginine and proline metabolism 1.266520 0.009058
dre00260 Glycine, serine and threonine metabolism 1.948663 0.00232
dre00062 Fatty acid elongation 1.834149 0.037678
dre00670 One carbon pool by folate 2.121909 0.0234
dre00903 Terpenoid backbone biosynthesis 2.900709 0.001495
dre00900 Terpenoid backbone biosynthesis 2.354212 0.004959
dre00534 Glycosaminoglycan biosynthesis - heparan sul-
fate
-1.423359 0.072648
dre00520 Amino sugar and nucleotide sugar metabolism 1.963952 2.83E-06
dre00531 Glycosaminoglycan degradation 1.939261 0.043976
dre04350 TGF-beta signaling pathway -0.714274 0.066818
dre00360 Phenylalanine metabolism 1.428527 0.061236
dre00270 Cysteine and methionine metabolism 1.296830 0.008657
dre00071 Fatty acid metabolism 1.632986 0.002833
dre00072 Synthesis and degradation of ketone bodies 1.797690 0.020704
dre00980 Metabolism of xenobiotics by cytochrome P450 1.786432 0.006344
dre03030 DNA replication -2.075181 0.000386
dre00982 Drug metabolism - cytochrome P450 1.295166 0.059089
dre00280 Valine, leucine and isoleucine degradation 2.540186 1.16E-08
dre00450 Selenocompound metabolism 1.177305 0.076823
dre00650 Butanoate metabolism 1.493567 0.023609
dre00970 Aminoacyl-tRNA biosynthesis 2.285911 0.000689
dre03020 RNA polymerase 1.464086 0.077719
dre00190 Oxidative phosphorylation 2.219431 4.44E-11
dre03430 Mismatch repair -2.116820 0.009246
dre00770 Pantothenate and CoA biosynthesis 2.121334 0.059089
dre00380 Tryptophan metabolism 1.783700 0.003834
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dre03050 Proteasome 2.831267 6.98E-07
dre03420 Nucleotide excision repair 1.797690 0.037678
dre01040 Biosynthesis of unsaturated fatty acids 1.919523 0.013629
dre00620 Pyruvate metabolism 1.055072 0.048744
dre03040 Spliceosome -0.981349 0.000169
dre00020 Citrate cycle (TCA cycle) 1.191730 0.073668
dre00630 Glyoxylate and dicarboxylate metabolism 1.437342 0.099458
dre04621 NOD-like receptor signaling pathway -1.057614 0.054041
dre04623 Cytosolic DNA-sensing pathway 1.974858 0.014127
dre04020 Calcium signaling pathway 1.053165 0.090389
dre04520 Adherens junction -1.428693 0.037678
dre04120 Ubiquitin mediated proteolysis -0.943149 0.076686
dre00230 Purine metabolism 0.877756 0.002833
dre04320 Dorso-ventral axis formation -2.030885 0.077683
dre00030 Pentose phosphate pathway 2.332833 0.040462
dre04012 ErbB signaling pathway -0.788755 0.07941
dre00410 beta-Alanine metabolism 2.729680 0.000131
dre00640 Propanoate metabolism 2.192881 0.000195
dre00310 Lysine degradation 1.136464 0.067018
dre04110 Cell cycle -1.057764 0.000117
dre00240 Pyrimidine metabolism 0.910557 0.025196
dre04310 Wnt signaling pathway -0.738351 0.011551
dre04210 Apoptosis 0.836528 0.032461
dre04115 p53 signaling pathway 2.804544 0.000601
dre00040 Pentose and glucuronate interconversions 1.939261 0.043976
dre00590 Arachidonic acid metabolism 1.584795 0.037071
C.5 Linuron
Table C-5: Entire set of pathways affected by linuron
term description odd’s ratio adjusted
pvalue
GO:0045449 regulation of transcription, DNA-dependent 0.296972 0.0092319
GO:0045165 cell fate commitment 2.426748 0.0228534
GO:0045454 cell redox homeostasis -1.38744 0.0155560
GO:0006629 lipid metabolic process -0.58516 0.0154271
GO:0006631 fatty acid metabolic process -1.01383 0.0997320
GO:0009116 nucleoside metabolic process -1.24497 0.0870542
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GO:0009308 amine metabolic process -0.64259 0.0340032
GO:0009889 regulation of biosynthetic process 0.286875 0.0108879
GO:0007229 integrin-mediated signaling pathway -1.37667 0.0746872
GO:0000087 M phase of mitotic cell cycle 1.06137 0.0929158
GO:0006520 cellular amino acid metabolic process -0.66861 0.0506374
GO:0006519 cellular amino acid metabolic process -0.58746 0.0690567
GO:0006096 glycolysis -1.67088 0.0003120
GO:0005975 carbohydrate metabolic process -0.62841 0.0000601
GO:0019752 carboxylic acid metabolic process -0.80783 0.0001758
GO:0006072 glycerol-3-phosphate metabolic process -1.61336 0.0870542
GO:0006071 glycerol metabolic process -1.57642 0.0230786
GO:0009060 aerobic respiration -1.50458 0.0661182
GO:0007010 cytoskeleton organization -0.69864 0.0243041
GO:0006066 alcohol metabolic process -0.9944 0.0000004
GO:0009056 catabolic process -0.43408 0.0002331
GO:0006163 purine nucleotide metabolic process -0.58243 0.0959605
GO:0016070 RNA metabolic process 0.414417 0.0013932
GO:0007186 G-protein coupled receptor signaling pathway 0.730182 0.0000042
GO:0043687 post-translational protein modification 0.287348 0.0555511
GO:0055114 oxidation-reduction process -0.80745 0.0000000
GO:0048048 embryonic eye morphogenesis 1.79769 0.0859405
GO:0007165 signal transduction 0.312446 0.0180628
GO:0006869 lipid transport -1.61521 0.0031064
GO:0007166 cell surface receptor signaling pathway 0.36411 0.0085845
GO:0006464 cellular protein modification process 0.243855 0.0954065
GO:0016052 carbohydrate catabolic process -1.42411 0.0003120
GO:0006334 nucleosome assembly -5.13684 0.0684905
GO:0006333 chromatin assembly or disassembly -4.86858 0.0684905
GO:0001501 skeletal system development -0.83466 0.0193157
GO:0000278 mitotic cell cycle 0.888071 0.0983634
GO:0006006 glucose metabolic process -1.62834 0.0000788
GO:0006396 RNA processing 0.79196 0.0303126
GO:0006108 malate metabolic process -3.17805 0.0172836
GO:0019318 hexose metabolic process -1.10356 0.0005240
GO:0048562 embryonic organ morphogenesis 1.79769 0.0193157
GO:0044262 cellular carbohydrate metabolic process -0.75637 0.0005199
GO:0042221 response to chemical stimulus -0.68498 0.0030927
GO:0035162 embryonic hemopoiesis -1.66426 0.0363867
GO:0006355 regulation of transcription, DNA-dependent 0.279739 0.0311605
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GO:0006351 transcription, DNA-dependent 0.289835 0.0192435
GO:0006350 transcription, DNA-dependent 0.328959 0.0021540
GO:0051216 cartilage development -0.99536 0.0300244
GO:0030036 actin cytoskeleton organization -1.04449 0.0040015
GO:0030041 actin filament polymerization -1.78311 0.0878442
GO:0031032 actomyosin structure organization -1.33442 0.0193157
GO:0015031 protein transport -0.34027 0.0954065
GO:0050819 negative regulation of coagulation 1.79769 0.0690567
GO:0001666 response to hypoxia -2.26315 0.0020067
GO:0000159 protein phosphatase type 2A complex 1.79769 0.0527858
GO:0009331 glycerol-3-phosphate dehydrogenase complex -2.88196 0.0107700
GO:0005794 Golgi apparatus -0.60439 0.0217459
GO:0005694 chromosome -4.37986 0.0541127
GO:0044429 mitochondrial part -0.78086 0.0232787
GO:0008287 protein serine/threonine phosphatase complex 2.173897 0.0216200
GO:0005581 collagen -3.42142 0.0057789
GO:0070469 respiratory chain -1.94601 0.0514262
GO:0000151 ubiquitin ligase complex 0.822239 0.0839302
GO:0005739 mitochondrion -0.82379 0.0004874
GO:0043296 apical junction complex -1.04954 0.0131832
GO:0005911 cell-cell junction -0.73533 0.0552399
GO:0005578 proteinaceous extracellular matrix -1.47785 0.0025644
GO:0031012 extracellular matrix -1.50045 0.0025016
GO:0005212 structural constituent of eye lens -3.64587 0.0031275
GO:0016810 hydrolase activity, acting on carbon-nitrogen
(but not peptide) bonds
-0.64337 0.0952581
GO:0016813 hydrolase activity, acting on carbon-nitrogen
(but not peptide) bonds, in linear amidines
-1.9005 0.0989598
GO:0008324 cation transmembrane transporter activity -0.30455 0.0956472
GO:0004634 phosphopyruvate hydratase activity -2.77179 0.0795910
GO:0019956 chemokine binding 1.518157 0.0660326
GO:0001614 purinergic nucleotide receptor activity 0.980257 0.0472942
GO:0016820 hydrolase activity, acting on acid anhydrides,
catalyzing transmembrane movement of sub-
stances
-0.70591 0.0791988
GO:0005496 steroid binding -0.62243 0.0816286
GO:0048037 cofactor binding -0.72621 0.0004266
GO:0005506 iron ion binding -0.64998 0.0020515
GO:0005507 copper ion binding -1.83472 0.0893588
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GO:0005509 calcium ion binding -0.67996 0.0000033
GO:0004368 glycerol-3-phosphate dehydrogenase activity 1.79769 0.0398415
GO:0016829 lyase activity -0.70625 0.0315965
GO:0016830 carbon-carbon lyase activity -1.08871 0.0747613
GO:0008270 zinc ion binding 0.322513 0.0006537
GO:0008047 enzyme activator activity 0.898197 0.0766943
GO:0050662 coenzyme binding -0.72537 0.0073950
GO:0050660 flavin adenine dinucleotide binding -0.86625 0.0660326
GO:0003924 GTPase activity -0.74576 0.0088743
GO:0051287 NAD binding -1.03092 0.0658929
GO:0042277 peptide binding 1.015213 0.0002055
GO:0016849 phosphorus-oxygen lyase activity 1.79769 0.0931006
GO:0004386 helicase activity 1.013585 0.0398415
GO:0030414 peptidase inhibitor activity -0.66361 0.0689662
GO:0019001 guanyl nucleotide binding -0.53374 0.0102502
GO:0004674 protein serine/threonine kinase activity 0.361726 0.0660326
GO:0008601 protein phosphatase type 2A regulator activity 1.79769 0.0490637
GO:0030594 neurotransmitter receptor activity 1.242682 0.0001682
GO:0008233 peptidase activity -0.3864 0.0256922
GO:0008234 cysteine-type peptidase activity -0.76049 0.0599774
GO:0016211 ammonia ligase activity 1.79769 0.0398415
GO:0004888 transmembrane signaling receptor activity 0.442306 0.0032720
GO:0005544 calcium-dependent phospholipid binding -2.1495 0.0151455
GO:0005543 phospholipid binding -0.7141 0.0769784
GO:0019838 growth factor binding -1.56295 0.0893588
GO:0005525 GTP binding -0.53852 0.0102502
GO:0005524 ATP binding 0.321027 0.0430661
GO:0016705 oxidoreductase activity, acting on paired donors,
with incorporation or reduction of molecular
oxygen
-0.69585 0.0733761
GO:0015078 hydrogen ion transmembrane transporter activ-
ity
-1.14319 0.0008202
GO:0003993 acid phosphatase activity -2.41118 0.0989598
GO:0015077 monovalent inorganic cation transmembrane
transporter activity
-1.18929 0.0001453
GO:0016627 oxidoreductase activity, acting on the CH-CH
group of donors
-0.88649 0.0097277
GO:0005083 small GTPase regulator activity 0.687973 0.0490637
GO:0004707 MAP kinase activity 1.79769 0.0556967
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GO:0016615 malate dehydrogenase activity -3.17805 0.0113928
GO:0016614 oxidoreductase activity, acting on CH-OH group
of donors
-1.10606 0.0009055
GO:0004974 leukotriene receptor activity 1.79769 0.0490637
GO:0016616 oxidoreductase activity, acting on the CH-OH
group of donors, NAD or NADP as acceptor
-1.02399 0.0048747
GO:0004983 neuropeptide Y receptor activity 1.446263 0.0022896
GO:0030170 pyridoxal phosphate binding -0.96628 0.0518410
GO:0003995 acyl-CoA dehydrogenase activity -2.67536 0.0131486
GO:0004869 cysteine-type endopeptidase inhibitor activity -1.67428 0.0454785
GO:0004866 endopeptidase inhibitor activity -0.74223 0.0523280
GO:0003723 RNA binding 0.701017 0.0007399
GO:0004966 galanin receptor activity 1.79769 0.0424138
GO:0016651 oxidoreductase activity, acting on NADH or
NADPH
-1.22004 0.0599774
GO:0004970 ionotropic glutamate receptor activity 2.291014 0.0606703
GO:0004872 receptor activity 0.288601 0.0138496
GO:0004871 signal transducer activity 0.275786 0.0097277
GO:0004857 enzyme inhibitor activity -0.807 0.0055343
GO:0004859 phospholipase inhibitor activity -2.18869 0.0343661
GO:0003735 structural constituent of ribosome -0.56742 0.0664645
GO:0004952 dopamine receptor activity 2.434396 0.0284331
GO:0004197 cysteine-type endopeptidase activity -0.9906 0.0490637
GO:0004946 bombesin receptor activity 1.79769 0.0893353
GO:0001653 peptide receptor activity 1.094292 0.0001682
GO:0015035 protein disulfide oxidoreductase activity -2.35635 0.0660326
GO:0004022 alcohol dehydrogenase (NAD) activity -1.04407 0.0816286
GO:0004950 chemokine receptor activity 1.518157 0.0660326
GO:0016868 intramolecular transferase activity, phospho-
transferases
-1.9005 0.0989598
GO:0004935 adrenergic receptor activity 1.79769 0.0556967
GO:0004930 G-protein coupled receptor activity 0.894616 0.0000147
GO:0003899 DNA-directed RNA polymerase activity 1.725797 0.0514604
GO:0045028 G-protein coupled purinergic nucleotide recep-
tor activity
1.056674 0.0396363
GO:0016491 oxidoreductase activity -0.92273 0.0000000
GO:0008528 G-protein coupled peptide receptor activity 1.081881 0.0001682
GO:0008188 neuropeptide receptor activity 1.633976 0.0001682
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GO:0004553 hydrolase activity, hydrolyzing O-glycosyl com-
pounds
-0.69868 0.0826386
GO:0008289 lipid binding -0.73588 0.0001453
GO:0004356 glutamate-ammonia ligase activity 1.79769 0.0398415
GO:0016798 hydrolase activity, acting on glycosyl bonds -0.69781 0.0660326
GO:0003779 actin binding -0.59878 0.0832920
GO:0003677 DNA binding 0.400203 0.0000030
GO:0005201 extracellular matrix structural constituent -2.52032 0.0360158
GO:0005096 GTPase activator activity 0.987469 0.0766943
IPR000504 RNA recognition motif domain 0.868506 0.0004380
IPR016024 Armadillo-type fold 0.706402 0.0051682
IPR009100 Acyl-CoA dehydrogenase/oxidase -2.57986 0.0846335
IPR018056 Kringle, conserved site 1.79769 0.0812356
IPR018059 Deoxyribonuclease I, active site 1.79769 0.0812356
IPR007087 Zinc finger, C2H2 0.594889 0.0051682
IPR017976 Endoglin/CD105 antigen subgroup 2.499075 0.0812356
IPR002232 5-Hydroxytryptamine 6 receptor 1.79769 0.0812356
IPR017997 Vinculin 1.763982 0.0812356
IPR000001 Kringle 1.79769 0.0812356
IPR001965 Zinc finger, PHD-type 1.248945 0.0104057
IPR000169 Peptidase, cysteine peptidase active site -1.37709 0.0773343
IPR001507 Zona pellucida sperm-binding protein 2.617139 0.0657803
IPR015880 Zinc finger, C2H2-like 0.645489 0.0051682
IPR013847 POU -0.80585 0.0855918
IPR000929 Dopamine receptor 1.79769 0.0571493
IPR002391 Annexin, type IV -2.57986 0.0846335
IPR013806 Kringle-like fold -2.57986 0.0846335
IPR012336 Thioredoxin-like fold -1.32395 0.0001863
IPR004001 Actin, conserved site 1.79769 0.0571493
IPR004000 Actin-like -2.35769 0.0241260
IPR016040 NAD(P)-binding domain -0.97204 0.0038784
IPR019786 Zinc finger, PHD-type, conserved site 1.445863 0.0165138
IPR019787 Zinc finger, PHD-finger 1.265851 0.0190350
IPR006092 Acyl-CoA dehydrogenase, N-terminal 1.79769 0.0571493
IPR006090 Acyl-CoA oxidase/dehydrogenase, type 1 1.79769 0.0312092
IPR006091 Acyl-CoA oxidase/dehydrogenase, central do-
main
-2.57986 0.0846335
IPR006089 Acyl-CoA dehydrogenase, conserved site 1.79769 0.0812356
IPR013201 Proteinase inhibitor I29, cathepsin propeptide -2.76256 0.0425590
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IPR000315 Zinc finger, B-box 1.178697 0.0356883
IPR003958 Transcription factor CBF/NF-Y/archaeal his-
tone
6.086615 0.0557277
IPR000330 SNF2-related 2.323627 0.0463595
IPR018252 Annexin repeat, conserved site -2.1495 0.0773343
IPR018247 EF-Hand 1, calcium-binding site -0.7883 0.0009230
IPR018249 EF-HAND 2 -0.85593 0.0002731
IPR018248 EF-hand -0.91784 0.0003245
IPR000749 ATP:guanido phosphotransferase -3.61912 0.0880701
IPR005818 Histone H1/H5 -7.0861 0.0095716
IPR005819 Histone H5 -5.8117 0.0465279
IPR002038 Osteopontin -3.70187 0.0784257
IPR018502 Annexin repeat -2.1495 0.0773343
IPR002048 Calcium-binding EF-hand -0.90091 0.0002117
IPR000694 Anenome neurotoxin 0.501507 0.0177110
IPR000668 Peptidase C1A, papain C-terminal 1.79769 0.0849939
IPR001774 Delta/Serrate/lag-2 (DSL) protein 1.79769 0.0698720
IPR000611 Neuropeptide Y receptor 1.420147 0.0241260
IPR001005 SANT domain, DNA binding 2.498126 0.0917668
IPR011024 Gamma-crystallin-related -4.10938 0.0000000
IPR001064 Beta/gamma crystallin -4.10938 0.0000000
IPR017452 GPCR, rhodopsin-like superfamily 1.1983 0.0000065
IPR011011 Zinc finger, FYVE/PHD-type 1.182223 0.0051682
IPR020457 Zinc finger, B-box, chordata 1.933888 0.0059349
IPR000276 GPCR, rhodopsin-like, 7TM 1.084415 0.0000413
IPR003656 Zinc finger, BED-type predicted 1.363385 0.0611206
IPR001464 Annexin -2.1495 0.0773343
IPR013684 Mitochondrial Rho-like -0.67791 0.0849939
IPR013107 Acyl-CoA dehydrogenase, type 2, C-terminal 1.79769 0.0312092
dre04330 Notch signaling pathway 1.450033 0.0100231
dre00250 Alanine, aspartate and glutamate metabolism -1.8108 0.0043610
dre04810 Regulation of actin cytoskeleton -0.49906 0.0787683
dre04540 Gap junction -1.24164 0.0963690
dre00053 Ascorbate and aldarate metabolism -2.72689 0.0751441
dre00860 Porphyrin and chlorophyll metabolism -1.57647 0.0787683
dre03018 RNA degradation 1.232318 0.0204793
dre00051 Fructose and mannose metabolism -1.83472 0.0490745
dre04146 Peroxisome -1.14932 0.0409185
dre04144 Endocytosis -0.52094 0.0787683
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dre03010 Ribosome -0.97592 0.0740629
dre00510 N-Glycan biosynthesis -1.30708 0.0743111
dre04142 Lysosome -0.97668 0.0060879
dre04910 Insulin signaling pathway -0.68461 0.0677391
dre00330 Arginine and proline metabolism -1.85356 0.0000116
dre04530 Tight junction -1.10536 0.0557779
dre00903 Terpenoid backbone biosynthesis -2.00932 0.0399846
dre00520 Amino sugar and nucleotide sugar metabolism -1.07212 0.0805004
dre00360 Phenylalanine metabolism -2.19231 0.0127876
dre00071 Fatty acid metabolism -1.76929 0.0121034
dre00072 Synthesis and degradation of ketone bodies 1.79769 0.0331230
dre04260 Cardiac muscle contraction -1.84339 0.0000006
dre00562 Inositol phosphate metabolism -1.56804 0.0775604
dre03440 Homologous recombination 2.210831 0.0743111
dre00280 Valine, leucine and isoleucine degradation -2.04655 0.0005333
dre00400 Phenylalanine, tyrosine and tryptophan biosyn-
thesis
-3.3953 0.0135546
dre00650 Butanoate metabolism -1.2885 0.0395013
dre00970 Aminoacyl-tRNA biosynthesis -2.26069 0.0962517
dre00190 Oxidative phosphorylation -1.81565 0.0000000
dre00010 Glycolysis / Gluconeogenesis -1.98108 0.0000000
dre00620 Pyruvate metabolism -2.02588 0.0000213
dre03040 Spliceosome 1.585618 0.0002426
dre00020 Citrate cycle (TCA cycle) -1.65055 0.0027877
dre00630 Glyoxylate and dicarboxylate metabolism -1.98207 0.0332209
dre00230 Purine metabolism -0.77312 0.0331230
dre04320 Dorso-ventral axis formation 2.365263 0.0332209
dre00030 Pentose phosphate pathway 1.79769 0.0000022
dre00410 beta-Alanine metabolism -2.03462 0.0751441
dre00640 Propanoate metabolism -1.9062 0.0032221
dre04510 Focal adhesion -0.59571 0.0331230
C.6 Methylparaben
Table C-6: Entire set of pathways affected by methylparaben
term description odd’s ratio adjusted
pvalue
GO:0007596 blood coagulation -1.408441 0.027613
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GO:0006796 phosphate-containing compound metabolic pro-
cess
1.095916 0.088286
GO:0043687 post-translational protein modification 1.292421 0.025212
GO:0055114 oxidation-reduction process -0.876986 0.000014
GO:0006869 lipid transport -1.812210 0.074712
GO:0006468 protein phosphorylation 1.560031 0.074712
GO:0006464 cellular protein modification process 1.324408 0.005241
GO:0016310 phosphorylation 1.438071 0.060997
GO:0044267 cellular protein metabolic process 1.168533 0.001611
GO:0042060 wound healing -1.294283 0.027613
GO:0009409 response to cold 1.646356 0.097590
GO:0005694 chromosome 1.374631 0.010225
GO:0048471 perinuclear region of cytoplasm 3.281382 0.033404
GO:0005829 cytosol 1.000490 0.059835
GO:0042612 MHC class I protein complex 3.820070 0.052475
GO:0005624 membrane fraction 4.082477 0.003234
GO:0005212 structural constituent of eye lens -3.053015 0.081579
GO:0005506 iron ion binding -0.824738 0.007052
GO:0005507 copper ion binding -1.402850 0.092967
GO:0016830 carbon-carbon lyase activity -1.858814 0.037062
GO:0004252 serine-type endopeptidase activity -1.050206 0.061242
GO:0008667 2,3-dihydro-2,3-dihydroxybenzoate dehydroge-
nase activity
-1.210033 0.087140
GO:0030414 peptidase inhibitor activity -1.090565 0.011573
GO:0004672 protein kinase activity 1.543391 0.043139
GO:0004674 protein serine/threonine kinase activity 1.799479 0.040355
GO:0016712 oxidoreductase activity, acting on paired donors,
with incorporation or reduction of molecular
oxygen, reduced flavin or flavoprotein as one
donor, and incorporation of one atom of oxygen
-1.456758 0.007052
GO:0008236 serine-type peptidase activity -0.954376 0.087140
GO:0004497 monooxygenase activity -1.001585 0.019427
GO:0001882 nucleoside binding 0.817409 0.002933
GO:0017076 purine nucleotide binding 0.885725 0.057453
GO:0005524 ATP binding 0.847821 0.002933
GO:0016705 oxidoreductase activity, acting on paired donors,
with incorporation or reduction of molecular
oxygen
-1.932906 0.000167
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GO:0003700 sequence-specific DNA binding transcription
factor activity
-0.627379 0.012908
GO:0016773 phosphotransferase activity, alcohol group as ac-
ceptor
0.829187 0.061242
GO:0016772 transferase activity, transferring phosphorus-
containing groups
0.640286 0.087140
GO:0016614 oxidoreductase activity, acting on CH-OH group
of donors
-0.888804 0.049484
GO:0016616 oxidoreductase activity, acting on the CH-OH
group of donors, NAD or NADP as acceptor
-1.013490 0.031143
GO:0004866 endopeptidase inhibitor activity -1.177843 0.008419
GO:0004867 serine-type endopeptidase inhibitor activity -1.213867 0.043551
GO:0004872 receptor activity 0.416448 0.055251
GO:0004871 signal transducer activity 0.455648 0.019427
GO:0004857 enzyme inhibitor activity -0.890603 0.048517
GO:0031418 L-ascorbic acid binding -3.042970 0.010992
GO:0030246 carbohydrate binding -0.933306 0.049484
GO:0030247 polysaccharide binding -1.907689 0.036889
GO:0010181 FMN binding -2.886002 0.024077
GO:0004022 alcohol dehydrogenase (NAD) activity -1.511635 0.026347
GO:0008171 O-methyltransferase activity -3.605471 0.042546
GO:0004518 nuclease activity -0.924151 0.090444
GO:0016491 oxidoreductase activity -0.759137 0.000012
GO:0020037 heme binding -0.977339 0.014015
GO:0016788 hydrolase activity, acting on ester bonds -0.429361 0.072405
GO:0008289 lipid binding -0.989948 0.024077
GO:0016887 ATPase activity 1.380772 0.007144
GO:0030145 manganese ion binding -1.866790 0.065394
GO:0004812 aminoacyl-tRNA ligase activity 1.721776 0.072405
GO:0043565 sequence-specific DNA binding -0.612090 0.039079
GO:0004713 protein tyrosine kinase activity 1.459641 0.074989
GO:0016876 ligase activity, forming aminoacyl-tRNA and re-
lated compounds
1.721776 0.072405
IPR001128 Cytochrome P450 -1.194770 0.070705
IPR001680 WD40 repeat 0.858510 0.009877
IPR018039 Intermediate filament protein, conserved site -2.798758 0.091820
IPR017986 WD40-repeat-containing domain 0.924386 0.009877
IPR017972 Cytochrome P450, conserved site -1.427681 0.024449
IPR017973 Cytochrome P450, conserved site -1.275084 0.070705
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IPR017970 Homeobox, conserved site -0.812442 0.070705
IPR012224 Peptidase S1A, coagulation factor
VII/IX/X/C/Z
-6.128081 0.066445
IPR001254 Peptidase S1/S6, chymotrypsin/Hap -1.369154 0.092004
IPR006620 Prolyl 4-hydroxylase, alpha subunit -2.473357 0.092004
IPR009003 Peptidase cysteine/serine, trypsin-like -1.320191 0.092282
IPR005123 Oxoglutarate/iron-dependent oxygenase -2.502671 0.064296
IPR002397 Cytochrome P450, B-class -1.375941 0.070705
IPR016044 Filament -2.557440 0.001196
IPR019782 Germin, manganese binding site 0.912357 0.010699
IPR019781 Germin, manganese binding site 0.877712 0.012430
IPR001212 Somatomedin B domain -3.828696 0.074616
IPR001356 Homeobox -0.861588 0.092004
IPR002401 Cytochrome P450, E-class, group I -1.194770 0.070705
IPR002403 Cytochrome P450, E-class, group IV -1.275084 0.070705
IPR002957 Keratin, type I -2.748827 0.000740
IPR002972 Prostaglandin D synthase 4.059276 0.037981
IPR001314 Peptidase S1A, chymotrypsin-type -1.394559 0.092004
IPR001073 Complement C1q protein -1.454978 0.099595
IPR020479 Homeobox, eukaryotic -1.022369 0.024449
IPR018170 Aldo/keto reductase, conserved site -2.942392 0.092282
IPR020471 Aldo/keto reductase subgroup -2.942392 0.092282
IPR020472 G-protein beta WD-40 repeat 0.870016 0.055803
IPR018114 Peptidase S1/S6, chymotrypsin/Hap, active site -1.369154 0.092004
IPR020436 Somatomedin B, chordata -3.828696 0.074616
IPR011046 WD40 repeat-like-containing domain 0.870699 0.009877
IPR008068 Cytochrome P450, E-class, group I, CYP2B-like -2.328712 0.070705
IPR008069 Cytochrome P450, E-class, group I, CYP2D-like -1.560519 0.070705
IPR008983 Tumour necrosis factor-like -1.368379 0.099595
dre03010 Ribosome 2.890070 0.002181
dre00260 Glycine, serine and threonine metabolism 1.768124 0.065508
dre00520 Amino sugar and nucleotide sugar metabolism -1.617768 0.034149
dre00350 Tyrosine metabolism 2.554615 0.085467
dre00500 Starch and sucrose metabolism -1.955955 0.067480
dre00380 Tryptophan metabolism 1.931877 0.085467
dre03050 Proteasome 1.772366 0.026303
dre00760 Nicotinate and nicotinamide metabolism 2.998484 0.065508
dre00030 Pentose phosphate pathway -1.668081 0.080288
dre00100 Steroid biosynthesis 2.852641 0.085467
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GO:0048839 inner ear development 0.946122 0.0776958
GO:0008652 cellular amino acid biosynthetic process 3.593754 0.0025296
GO:0007275 multicellular organismal development -0.32641 0.0064267
GO:0006629 lipid metabolic process 0.942296 0.0000383
GO:0006631 fatty acid metabolic process 1.349724 0.0084646
GO:0006633 fatty acid biosynthetic process 1.423979 0.0476442
GO:0016192 vesicle-mediated transport 0.88432 0.0132921
GO:0007399 nervous system development -0.61116 0.0064267
GO:0009308 amine metabolic process 1.291312 0.0003739
GO:0009117 nucleotide metabolic process 0.758245 0.0941145
GO:0006508 proteolysis 0.952404 0.0757793
GO:0009889 regulation of biosynthetic process -0.25743 0.0862219
GO:0008610 lipid biosynthetic process 1.373108 0.0000383
GO:0009239 enterobactin biosynthetic process 1.645696 0.0089172
GO:0006725 cellular aromatic compound metabolic process 1.387507 0.0017227
GO:0007268 synaptic transmission 1.923431 0.0606131
GO:0006520 cellular amino acid metabolic process 1.553941 0.0000609
GO:0006519 cellular amino acid metabolic process 1.444555 0.0000609
GO:0006518 peptide metabolic process 1.65402 0.0045868
GO:0019752 carboxylic acid metabolic process 1.525554 0.0000001
GO:0007015 actin filament organization 1.79769 0.0776958
GO:0007017 microtubule-based process -1.21693 0.0555894
GO:0006812 cation transport 0.553668 0.0203149
GO:0006811 ion transport 0.549345 0.0083190
GO:0009059 macromolecule biosynthetic process -0.21825 0.0968852
GO:0006066 alcohol metabolic process 1.109181 0.0052104
GO:0009056 catabolic process 0.363201 0.0299015
GO:0015672 monovalent inorganic cation transport 0.56519 0.0968852
GO:0006163 purine nucleotide metabolic process 0.937912 0.0317646
GO:0006164 purine nucleotide biosynthetic process 0.890933 0.0615771
GO:0006694 steroid biosynthetic process 1.33685 0.0563156
GO:0006796 phosphate-containing compound metabolic pro-
cess
-0.45408 0.0594251
GO:0006886 intracellular protein transport 0.663637 0.0026932
GO:0007186 G-protein coupled receptor signaling pathway -0.42693 0.0660158
GO:0043687 post-translational protein modification -0.36625 0.0555894
Table continues on next page
C Entire transcriptome response in 48hpf zebrafish embryos 221
Continued: Entire set of pathways affected by propanil
term description odd’s ratio adjusted
pvalue
GO:0055114 oxidation-reduction process 0.6453 0.0012291
GO:0006865 amino acid transport 2.752717 0.0348206
GO:0007154 cell communication -0.22246 0.0766602
GO:0007155 cell adhesion -0.49391 0.0944142
GO:0007156 homophilic cell adhesion -1.25987 0.0993149
GO:0007165 signal transduction -0.26864 0.0299015
GO:0006468 protein phosphorylation -0.47443 0.0337788
GO:0007166 cell surface receptor signaling pathway -0.38424 0.0299015
GO:0006464 cellular protein modification process -0.40422 0.0594251
GO:0048589 developmental growth -1.42894 0.0993149
GO:0046907 intracellular transport 0.60597 0.0026932
GO:0042221 response to chemical stimulus 1.176743 0.0246542
GO:0006810 transport 0.364719 0.0011302
GO:0016310 phosphorylation -1.02072 0.0800776
GO:0008104 protein localization 0.51027 0.0078012
GO:0035162 embryonic hemopoiesis 1.400668 0.0848694
GO:0008202 steroid metabolic process 1.935698 0.0252178
GO:0030097 hemopoiesis 0.993514 0.0976279
GO:0006352 DNA-dependent transcription, initiation -2.42473 0.0152593
GO:0006914 autophagy 2.903542 0.0700201
GO:0006350 transcription, DNA-dependent -0.25233 0.0944142
GO:0016125 sterol metabolic process 2.662953 0.0744928
GO:0030154 cell differentiation -0.44897 0.0317646
GO:0030163 protein catabolic process 0.364002 0.0776958
GO:0042471 ear morphogenesis 1.188514 0.0776958
GO:0042472 inner ear morphogenesis 1.188514 0.0776958
GO:0015031 protein transport 0.565735 0.0026932
GO:0051649 establishment of localization in cell 0.52735 0.0078012
GO:0043039 tRNA aminoacylation 2.241732 0.0003739
GO:0008299 isoprenoid biosynthetic process 3.506456 0.0002944
GO:0030117 membrane coat 1.664842 0.0008525
GO:0030118 clathrin coat 1.742785 0.0070400
GO:0044429 mitochondrial part 1.093719 0.0009418
GO:0005634 nucleus -0.28889 0.0035049
GO:0005739 mitochondrion 1.075455 0.0629522
GO:0005737 cytoplasm 0.388258 0.0003442
GO:0005578 proteinaceous extracellular matrix -4.18454 0.0287681
GO:0031012 extracellular matrix -4.14086 0.0287681
GO:0005768 endosome 1.698647 0.0461079
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GO:0008324 cation transmembrane transporter activity 0.476974 0.0355004
GO:0016820 hydrolase activity, acting on acid anhydrides,
catalyzing transmembrane movement of sub-
stances
1.112711 0.0869803
GO:0048037 cofactor binding 1.368629 0.0000532
GO:0005509 calcium ion binding -0.82804 0.0352357
GO:0016830 carbon-carbon lyase activity 2.241104 0.0886994
GO:0050662 coenzyme binding 1.543565 0.0000532
GO:0008667 2,3-dihydro-2,3-dihydroxybenzoate dehydroge-
nase activity
1.645696 0.0079976
GO:0051287 NAD binding 1.895793 0.0262312
GO:0042277 peptide binding -0.70804 0.0519330
GO:0004672 protein kinase activity -0.90623 0.0344200
GO:0004674 protein serine/threonine kinase activity -1.53218 0.0328823
GO:0016301 kinase activity -1.46152 0.0700938
GO:0008373 sialyltransferase activity 1.592979 0.0755079
GO:0005549 odorant binding 1.79769 0.0498457
GO:0008236 serine-type peptidase activity 0.724287 0.0654840
GO:0008233 peptidase activity 0.97969 0.0211269
GO:0008234 cysteine-type peptidase activity 1.915758 0.0297115
GO:0004888 transmembrane signaling receptor activity -0.55731 0.0078065
GO:0005544 calcium-dependent phospholipid binding -2.6312 0.0869803
GO:0005543 phospholipid binding 1.108125 0.0539470
GO:0019825 oxygen binding 1.897013 0.0612545
GO:0015075 ion transmembrane transporter activity 0.516345 0.0036873
GO:0015077 monovalent inorganic cation transmembrane
transporter activity
0.912274 0.0447677
GO:0016627 oxidoreductase activity, acting on the CH-CH
group of donors
1.579276 0.0007030
GO:0022891 substrate-specific transmembrane transporter
activity
0.497764 0.0036873
GO:0016773 phosphotransferase activity, alcohol group as ac-
ceptor
-1.20579 0.0216217
GO:0016772 transferase activity, transferring phosphorus-
containing groups
-1.30177 0.0730645
GO:0016614 oxidoreductase activity, acting on CH-OH group
of donors
1.771493 0.0000532
GO:0016616 oxidoreductase activity, acting on the CH-OH
group of donors, NAD or NADP as acceptor
1.895619 0.0000410
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GO:0004175 endopeptidase activity 1.124008 0.0215092
GO:0031402 sodium ion binding 1.57098 0.0447677
GO:0004872 receptor activity -0.33823 0.0255073
GO:0004871 signal transducer activity -0.50409 0.0344200
GO:0022857 transmembrane transporter activity 0.5023 0.0036873
GO:0004197 cysteine-type endopeptidase activity 2.34352 0.0053461
GO:0035091 phosphatidylinositol binding 1.320261 0.0344200
GO:0001653 peptide receptor activity -0.74807 0.0447677
GO:0016874 ligase activity 1.190768 0.0005397
GO:0015171 amino acid transmembrane transporter activity 3.074355 0.0818678
GO:0005044 scavenger receptor activity -5.10344 0.0449539
GO:0004930 G-protein coupled receptor activity -0.61577 0.0255073
GO:0016491 oxidoreductase activity 0.671898 0.0000303
GO:0008528 G-protein coupled peptide receptor activity -0.73636 0.0492928
GO:0008188 neuropeptide receptor activity -0.97337 0.0975860
GO:0004553 hydrolase activity, hydrolyzing O-glycosyl com-
pounds
2.652766 0.0402620
GO:0015297 antiporter activity 1.979199 0.0578944
GO:0016798 hydrolase activity, acting on glycosyl bonds 2.589295 0.0402620
GO:0003677 DNA binding -0.28782 0.0222732
GO:0004812 aminoacyl-tRNA ligase activity 2.123745 0.0005397
GO:0016787 hydrolase activity 0.354607 0.0344200
GO:0004713 protein tyrosine kinase activity -0.56675 0.0174584
GO:0004714 transmembrane receptor protein tyrosine kinase
activity
-1.2253 0.0636429
GO:0016876 ligase activity, forming aminoacyl-tRNA and re-
lated compounds
2.123745 0.0005397
IPR011598 Helix-loop-helix DNA-binding -2.09057 0.0594600
IPR001190 Speract/scavenger receptor -5.79746 0.0378467
IPR001199 Cytochrome b5 3.76799 0.0733147
IPR002293 Amino acid/polyamine transporter I 3.76799 0.0733147
IPR000169 Peptidase, cysteine peptidase active site 2.879408 0.0048888
IPR010987 Glutathione S-transferase, C-terminal-like 2.036376 0.0321085
IPR002347 Glucose/ribitol dehydrogenase 1.170852 0.0611867
IPR016040 NAD(P)-binding domain 1.577782 0.0002441
IPR004841 Amino acid permease domain 3.186587 0.0601496
IPR002933 Peptidase M20 1.79769 0.0772204
IPR002957 Keratin, type I -2.18517 0.0278279
IPR002972 Prostaglandin D synthase 1.79769 0.0611867
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IPR003560 2,3-dihydro-2,3-dihydroxybenzoate dehydroge-
nase
1.645696 0.0772204
IPR001092 Restriction/modification DNA-methylase -2.10936 0.0594600
IPR000668 Peptidase C1A, papain C-terminal 3.861221 0.0001446
IPR001753 Crotonase, core 3.310078 0.0611867
IPR017448 Speract/scavenger receptor-related -5.79746 0.0378467
IPR018376 Enoyl-CoA hydratase/isomerase, conserved site 1.79769 0.0611867
IPR017452 GPCR, rhodopsin-like superfamily -1.1578 0.0611867
IPR000276 GPCR, rhodopsin-like, 7TM -1.18881 0.0611867
IPR003656 Zinc finger, BED-type predicted -1.27423 0.0262487
IPR002198 Short-chain dehydrogenase/reductase SDR 1.116971 0.0611867
dre04710 Circadian rhythm - mammal 3.36251 0.0514462
dre04540 Gap junction -1.59085 0.0347604
dre04142 Lysosome 1.973179 0.0000000
dre00511 Other glycan degradation 3.457917 0.0499575
dre00260 Glycine, serine and threonine metabolism 3.195262 0.0549450
dre01100 Metabolic pathways 0.728048 0.0000001
dre00900 Terpenoid backbone biosynthesis 3.218672 0.0001974
dre00520 Amino sugar and nucleotide sugar metabolism 3.148521 0.0024908
dre00531 Glycosaminoglycan degradation 3.71737 0.0327146
dre00071 Fatty acid metabolism 3.076827 0.0001576
dre04260 Cardiac muscle contraction 1.294015 0.0328038
dre00980 Metabolism of xenobiotics by cytochrome P450 2.151729 0.0726910
dre03320 PPAR signaling pathway 2.025534 0.0184649
dre00140 Steroid hormone biosynthesis 2.84122 0.0834190
dre00600 Sphingolipid metabolism 1.850572 0.0293231
dre00280 Valine, leucine and isoleucine degradation 2.539919 0.0002536
dre00450 Selenocompound metabolism 3.01884 0.0978393
dre00650 Butanoate metabolism 3.343844 0.0083316
dre00970 Aminoacyl-tRNA biosynthesis 2.212185 0.0091632
dre03022 Basal transcription factors -2.34442 0.0154033
dre00290 Valine, leucine and isoleucine biosynthesis 3.843096 0.0386600
dre04370 VEGF signaling pathway 1.1503 0.0978526
dre00380 Tryptophan metabolism 1.658298 0.0233910
dre00604 Glycosphingolipid biosynthesis - ganglio series 2.92651 0.0906388
dre00603 Glycosphingolipid biosynthesis - globo series 4.374789 0.0162979
dre01040 Biosynthesis of unsaturated fatty acids 2.748393 0.0301350
dre04020 Calcium signaling pathway -1.71059 0.0029859
dre00030 Pentose phosphate pathway 2.034479 0.0644934
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dre00410 beta-Alanine metabolism 2.845374 0.0287122
dre00640 Propanoate metabolism 2.508703 0.0526369
dre00310 Lysine degradation 2.987332 0.0718835
dre00100 Steroid biosynthesis 3.950466 0.0024908
dre00591 Linoleic acid metabolism 3.247074 0.0611275
C.8 Prochloraz
Table C-8: Entire set of pathways affected by prochloraz
term description odd’s ratio adjusted
pvalue
GO:0014033 neural crest cell differentiation -1.65125 0.0123743
GO:0045449 regulation of transcription, DNA-dependent 0.295099 0.0969384
GO:0008652 cellular amino acid biosynthetic process 3.146683 0.0000652
GO:0007275 multicellular organismal development -0.23231 0.0889889
GO:0030509 BMP signaling pathway -2.76701 0.0123743
GO:0007399 nervous system development -0.42176 0.0889889
GO:0009308 amine metabolic process 1.101012 0.0000240
GO:0007242 intracellular signal transduction -0.36065 0.0889889
GO:0006412 translation 1.127591 0.0000211
GO:0009887 organ morphogenesis -0.42223 0.0889889
GO:0009889 regulation of biosynthetic process 0.301316 0.0739286
GO:0009239 enterobactin biosynthetic process 2.188159 0.0170212
GO:0006725 cellular aromatic compound metabolic process 1.729489 0.0170212
GO:0007369 gastrulation -0.71945 0.0889889
GO:0051056 regulation of small GTPase mediated signal
transduction
1.79769 0.0028642
GO:0006520 cellular amino acid metabolic process 1.368872 0.0000012
GO:0006519 cellular amino acid metabolic process 1.105938 0.0000344
GO:0006518 peptide metabolic process 2.123384 0.0203097
GO:0006457 protein folding 0.894276 0.0703033
GO:0019752 carboxylic acid metabolic process 1.51818 0.0000000
GO:0009060 aerobic respiration 1.79769 0.0715661
GO:0009058 biosynthetic process 0.398853 0.0000525
GO:0009059 macromolecule biosynthetic process 0.338998 0.0057556
GO:0009056 catabolic process 0.315041 0.0965423
GO:0006974 response to DNA damage stimulus 1.184818 0.0674905
Table continues on next page
226 7. Annex
Continued: Entire set of pathways affected by prochloraz
term description odd’s ratio adjusted
pvalue
GO:0006796 phosphate-containing compound metabolic pro-
cess
-0.44366 0.0053807
GO:0007178 transmembrane receptor protein ser-
ine/threonine kinase signaling pathway
-2.51069 0.0047741
GO:0016070 RNA metabolic process 0.380465 0.0057556
GO:0007186 G-protein coupled receptor signaling pathway -0.592 0.0267828
GO:0043687 post-translational protein modification -0.44091 0.0051945
GO:0055114 oxidation-reduction process 0.753828 0.0000356
GO:0009953 dorsal/ventral pattern formation -1.0638 0.0388926
GO:0007059 chromosome segregation 1.79769 0.0767802
GO:0007154 cell communication -0.31045 0.0022134
GO:0007155 cell adhesion -0.65501 0.0107016
GO:0009966 regulation of signal transduction -0.87955 0.0053807
GO:0007165 signal transduction -0.34454 0.0013513
GO:0007160 cell-matrix adhesion -1.83563 0.0314220
GO:0006468 protein phosphorylation -0.58905 0.0015686
GO:0006464 cellular protein modification process -0.37555 0.0103899
GO:0007166 cell surface receptor signaling pathway -0.62828 0.0015486
GO:0048598 embryonic morphogenesis -0.51373 0.0889889
GO:0016055 Wnt receptor signaling pathway -0.94072 0.0889889
GO:0001501 skeletal system development -0.81244 0.0889889
GO:0006139 nucleobase-containing compound metabolic pro-
cess
0.298462 0.0174931
GO:0040008 regulation of growth 2.354144 0.0589221
GO:0048262 determination of dorsal/ventral asymmetry -2.67142 0.0222651
GO:0016568 chromatin modification -1.17807 0.0965423
GO:0006807 nitrogen compound metabolic process 0.379223 0.0003100
GO:0042221 response to chemical stimulus 1.691107 0.0047504
GO:0016310 phosphorylation -0.48356 0.0053807
GO:0006355 regulation of transcription, DNA-dependent 0.368804 0.0231230
GO:0006915 apoptotic process 0.753711 0.0739286
GO:0006351 transcription, DNA-dependent 0.358533 0.0249365
GO:0000902 cell morphogenesis -0.92391 0.0331839
GO:0044249 cellular biosynthetic process 0.406221 0.0000525
GO:0009790 embryo development -0.40706 0.0889889
GO:0009653 anatomical structure morphogenesis -0.43493 0.0222651
GO:0042981 regulation of apoptotic process 0.906611 0.0809218
GO:0043039 tRNA aminoacylation 1.670647 0.0057556
GO:0060026 convergent extension -1.31439 0.0388926
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GO:0016477 cell migration -0.85808 0.0260649
GO:0043234 protein complex -1.02612 0.0033353
GO:0005886 plasma membrane -1.01755 0.0335340
GO:0005634 nucleus 0.20573 0.0790900
GO:0015629 actin cytoskeleton -1.00829 0.0935562
GO:0005739 mitochondrion 0.95941 0.0000481
GO:0005737 cytoplasm 0.425802 0.0000009
GO:0005578 proteinaceous extracellular matrix -1.32712 0.0076549
GO:0012505 endomembrane system -0.71843 0.0353110
GO:0031012 extracellular matrix -1.23162 0.0076549
GO:0030529 ribonucleoprotein complex 1.104167 0.0000481
GO:0005840 ribosome 1.673877 0.0000009
GO:0000166 nucleotide binding -0.21091 0.0780337
GO:0048037 cofactor binding 1.409954 0.0109632
GO:0004364 glutathione transferase activity 1.79769 0.0947269
GO:0003913 DNA photolyase activity 2.765805 0.0942908
GO:0016829 lyase activity 1.389105 0.0050334
GO:0016830 carbon-carbon lyase activity 1.644641 0.0385842
GO:0008047 enzyme activator activity -1.24807 0.0270060
GO:0050662 coenzyme binding 1.009411 0.0356408
GO:0008667 2,3-dihydro-2,3-dihydroxybenzoate dehydroge-
nase activity
1.698961 0.0532303
GO:0004672 protein kinase activity -0.61775 0.0014462
GO:0004674 protein serine/threonine kinase activity -0.61984 0.0038492
GO:0004675 transmembrane receptor protein ser-
ine/threonine kinase activity
1.79769 0.0780337
GO:0016301 kinase activity -0.49206 0.0017908
GO:0016712 oxidoreductase activity, acting on paired donors,
with incorporation or reduction of molecular
oxygen, reduced flavin or flavoprotein as one
donor, and incorporation of one atom of oxygen
1.853444 0.0007722
GO:0030594 neurotransmitter receptor activity 0.827486 0.0390594
GO:0051082 unfolded protein binding 1.196872 0.0270060
GO:0008083 growth factor activity 1.79769 0.0053261
GO:0004888 transmembrane signaling receptor activity -0.819 0.0008913
GO:0004497 monooxygenase activity 1.077742 0.0216123
GO:0001882 nucleoside binding -0.30186 0.0171354
GO:0005524 ATP binding -0.33845 0.0076034
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GO:0016705 oxidoreductase activity, acting on paired donors,
with incorporation or reduction of molecular
oxygen
1.113714 0.0173573
GO:0003700 sequence-specific DNA binding transcription
factor activity
0.333881 0.0615014
GO:0003702 RNA polymerase II transcription factor activity 1.534665 0.0942908
GO:0016627 oxidoreductase activity, acting on the CH-CH
group of donors
0.91074 0.0253729
GO:0005085 guanyl-nucleotide exchange factor activity 1.79769 0.0873825
GO:0005083 small GTPase regulator activity -1.12649 0.0071077
GO:0016773 phosphotransferase activity, alcohol group as ac-
ceptor
-0.52996 0.0017908
GO:0016772 transferase activity, transferring phosphorus-
containing groups
-0.41155 0.0071077
GO:0016616 oxidoreductase activity, acting on the CH-OH
group of donors, NAD or NADP as acceptor
0.88411 0.0942908
GO:0004983 neuropeptide Y receptor activity 0.929533 0.0764475
GO:0005179 hormone activity 1.198326 0.0093673
GO:0030170 pyridoxal phosphate binding 1.094268 0.0942908
GO:0016765 transferase activity, transferring alkyl or aryl
(other than methyl) groups
2.076547 0.0019647
GO:0003995 acyl-CoA dehydrogenase activity 2.180701 0.0945744
GO:0004872 receptor activity -1.0356 0.0007710
GO:0004871 signal transducer activity -0.8188 0.0018226
GO:0003735 structural constituent of ribosome 1.631252 0.0000820
GO:0004198 calcium-dependent cysteine-type endopeptidase
activity
2.07352 0.0657760
GO:0005044 scavenger receptor activity -1.9793 0.0134239
GO:0004930 G-protein coupled receptor activity -0.84575 0.0116614
GO:0016491 oxidoreductase activity 0.823161 0.0003807
GO:0020037 heme binding 0.914829 0.0855464
GO:0008188 neuropeptide receptor activity 1.002446 0.0439566
GO:0003774 motor activity -1.58506 0.0093673
GO:0004812 aminoacyl-tRNA ligase activity 1.645763 0.0053261
GO:0043565 sequence-specific DNA binding 0.512191 0.0172720
GO:0016780 phosphotransferase activity, for other substi-
tuted phosphate groups
1.79769 0.0947269
GO:0004713 protein tyrosine kinase activity -0.67615 0.0011818
GO:0005096 GTPase activator activity -1.66452 0.0114830
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GO:0016876 ligase activity, forming aminoacyl-tRNA and re-
lated compounds
1.645763 0.0053261
IPR001128 Cytochrome P450 1.52694 0.0115244
IPR000047 Helix-turn-helix motif 1.460852 0.0000051
IPR001190 Speract/scavenger receptor 1.79769 0.0183443
IPR017972 Cytochrome P450, conserved site 1.75835 0.0058388
IPR017973 Cytochrome P450, conserved site 1.65261 0.0075214
IPR017970 Homeobox, conserved site 1.037967 0.0004269
IPR017995 Homeobox protein, antennapedia type 2.610215 0.0000264
IPR002290 Serine/threonine- / dual-specificity protein ki-
nase, catalytic domain
-0.64121 0.0087147
IPR001279 Beta-lactamase-like 1.79769 0.0140625
IPR009068 S15/NS1, RNA-binding 1.79769 0.0824930
IPR008271 Serine/threonine-protein kinase, active site -0.78262 0.0206974
IPR009057 Homeodomain-like 0.650966 0.0187932
IPR001245 Serine-threonine/tyrosine-protein kinase cat-
alytic domain
-0.67745 0.0056008
IPR010987 Glutathione S-transferase, C-terminal-like 1.738775 0.0948332
IPR002347 Glucose/ribitol dehydrogenase 2.193798 0.0816851
IPR002397 Cytochrome P450, B-class 1.493442 0.0636541
IPR012336 Thioredoxin-like fold 1.056291 0.0378375
IPR016040 NAD(P)-binding domain 1.426794 0.0749596
IPR006089 Acyl-CoA dehydrogenase, conserved site 3.097371 0.0912371
IPR004827 Basic-leucine zipper domain -2.48255 0.0442524
IPR004826 Basic leucine zipper domain, Maf-type -4.512 0.0442524
IPR001356 Homeobox 0.868134 0.0014430
IPR002401 Cytochrome P450, E-class, group I 1.556919 0.0115244
IPR002403 Cytochrome P450, E-class, group IV 1.54417 0.0140625
IPR000719 Protein kinase, catalytic domain -0.66693 0.0056008
IPR001827 Homeobox protein, antennapedia type, con-
served site
2.414321 0.0004913
IPR000694 Anenome neurotoxin -0.45827 0.0581455
IPR017448 Speract/scavenger receptor-related 1.79769 0.0183443
IPR017442 Protein kinase, ATP binding site -0.63553 0.0124457
IPR020479 Homeobox, eukaryotic 1.427536 0.0000075
IPR017452 GPCR, rhodopsin-like superfamily -0.9774 0.0824930
IPR011009 Protein kinase-like domain -0.62371 0.0072229
IPR000276 GPCR, rhodopsin-like, 7TM -0.98552 0.0824930
IPR008068 Cytochrome P450, E-class, group I, CYP2B-like 2.588964 0.0205276
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IPR008067 Cytochrome P450, E-class, group I, CYP2A-like 2.407791 0.0140625
IPR008069 Cytochrome P450, E-class, group I, CYP2D-like 1.834099 0.0205276
IPR002198 Short-chain dehydrogenase/reductase SDR 2.139494 0.0816851
dre00340 Histidine metabolism 1.890622 0.0802800
dre00480 Glutathione metabolism 1.380801 0.0654632
dre00053 Ascorbate and aldarate metabolism 1.79769 0.0688674
dre00860 Porphyrin and chlorophyll metabolism 1.816951 0.0564376
dre04146 Peroxisome 1.314259 0.0119796
dre03010 Ribosome 1.602135 0.0140588
dre04340 Hedgehog signaling pathway -1.28556 0.0907868
dre00260 Glycine, serine and threonine metabolism 2.480714 0.0017579
dre01100 Metabolic pathways 0.70131 0.0000046
dre00900 Terpenoid backbone biosynthesis 2.808293 0.0620687
dre00534 Glycosaminoglycan biosynthesis - heparan sul-
fate
-2.97433 0.0678365
dre00130 Ubiquinone and other terpenoid-quinone
biosynthesis
2.765805 0.0654632
dre04350 TGF-beta signaling pathway -2.31676 0.0330395
dre00071 Fatty acid metabolism 1.895185 0.0340716
dre00072 Synthesis and degradation of ketone bodies 4.366969 0.0052733
dre00980 Metabolism of xenobiotics by cytochrome P450 3.08815 0.0000758
dre00982 Drug metabolism - cytochrome P450 2.228247 0.0151482
dre00280 Valine, leucine and isoleucine degradation 2.952652 0.0000007
dre00350 Tyrosine metabolism 1.79769 0.0907868
dre00450 Selenocompound metabolism 1.785693 0.0654632
dre00650 Butanoate metabolism 2.562068 0.0013314
dre00970 Aminoacyl-tRNA biosynthesis 2.586652 0.0005693
dre00290 Valine, leucine and isoleucine biosynthesis 4.366969 0.0052733
dre00770 Pantothenate and CoA biosynthesis 2.402702 0.0884216
dre00380 Tryptophan metabolism 2.091419 0.0672144
dre03420 Nucleotide excision repair 3.866212 0.0994723
dre00620 Pyruvate metabolism 2.516667 0.0597974
dre00410 beta-Alanine metabolism 1.890622 0.0802800
dre00310 Lysine degradation 1.52889 0.0884216
dre04510 Focal adhesion -1.11615 0.0031386
dre04110 Cell cycle -0.90926 0.0907868
dre00830 Retinol metabolism 1.851239 0.0194541
dre04115 p53 signaling pathway 1.499161 0.0330395
dre00591 Linoleic acid metabolism 2.402702 0.0884216
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dre00590 Arachidonic acid metabolism 1.998254 0.0748870
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Table D-1: Differentially expressed genes in the genistein EC10 data set compared to the solvent control
data set of the narrowed zebrafish microarray study (log2 fold change >2, p-value <0.01) (chapter 5)
gene sym-
bol
description accession
nr.
log2 fold
change
EC10
regu-
lation
Q90YN8BRARE Vitellogenin 1,
partial (23%)
TC310806 3.6072705 up
cyp19a1b cytochrome P450, family 19,
subfamily A, polypeptide 1b
NM131642 6.7385383 up
Q2CRI1ECTHA (Q2CRI1) Rare
lipoprotein A, partial (5%)
TC320817 4.3404484 down
NM199552 H1 histone family,
member 0
TC336779 3.1874058 down
zgc:152982 zgc:152982 NM001076711 11.124624 up
Solute carrier family 2, facilitated
glucose transporter member 7
(Glucose transporter type
7)(GLUT-7)
ENSDART
00000112141
2.451616 up
Q90YN8BRARE Vitellogenin 1,
partial (22%)
TC350829 4.756492 up
bbc3 BCL2 binding component 3 , NM001045472 3.2554438 up
zgc:110380 zgc:110380 NM001017660 2.1361663 down
vtg1 vitellogenin 1 NM001044897 7.174794 up
zgc:77060 zgc:77060 NM001002218 6.637477 down
zgc:165555 zgc:165555 NM001098761 5.955553 down
LOC561766 PREDICTED: monocarboxylate
transporter 7-like (LOC561766),
mRNA
XM685174 2.397228 down
vrk2 vaccinia related kinase 2 (vrk2),
mRNA
NM201170 2.0537143 up
fabp2 fatty acid binding protein 2,
intestinal (fabp2), mRNA
NM131431 2.037342 down
zgc:123272 zgc:123272 NM001037413 2.0267937 up
Q90YN8BRARE Vitellogenin 1,
partial (18%)
TC344218 6.4599056 up
LOC794484 hypothetical protein LOC794484 NM001115120 2.0097404 up
LOC100007289PREDICTED: similar to
transmembrane protein 16G
isoform NGEP long
XM001345751 2.5457695 up
D Genistein gene enrichment analysis 233
Table D-2: Differentially expressed genes in the genistein EC20 data set compared to the solvent control
data set of the focused zebrafish microarray study (log2 fold change>2, p-value<0.01) (chapter 5)
gene
symbol
description accession
nr.
log2 fold
change
EC20
regu-
lation
pbx3b pre-B-cell leukemia transcription
factor 3b (pbx3b), transcript
variant 2
NM131616 2.840022 down
si:dkey-
21o22.1
hypothetical protein LOC564348
[Source:R[EFSeq peptide; Acc: NP
001025357]
ENSDART
00000066972
9.010674 up
mcm4 MCM4 minichromosome
maintenance deficient 4, mitotin
(S. cerevisiae) (mcm4)
NM198913 2.085782 down
zgc:165628 zgc:165628 (zgc:165628) NM001099260 3.299352 down
taldo1 transaldolase 1 (taldo1), transcript
variant 1
NM199687 2.421284 up
zgc:64012 zgc:64012 (zgc:64012) NM214761 14.36169 up
zgc:153738 cDNA clone IMAGE:5601013,
partial cds.
BC055163 2.219074 up
insig1 insulin induced gene 1 (insig1) NM199869 1.559553 up
Q90YN8 BRARE (Q90YN8)
Vitellogenin 1, partial (23%)
TC310806 5.099284 up
zgc:114037 zgc:114037 (zgc:114037) NM001031826 2.044877 down
dld deltaD (dld) NM130955 1.943427 down
CT730011 ZF mu cDNA clone ZF
mu 256g05 5’ sequence
CT730011 2.430764 down
mdkb midkine-related growth factor b
(mdkb)
NM131716 1.700208 down
upb1 ureidopropionase, beta (upb1) NM199616 4.241656 up
c3b complement component c3b (c3b) NM131243 4.26495 up
cyp19a1b cytochrome P450, family 19,
subfamily A, polypeptide 1b
(cyp19a1b)
NM131642 3.467675 up
si:ch211-
81a5.8
si:ch211-81a5.8 (si:ch211-81a5.8) NM001044935 2.539134 up
nkx2.2a NK2 transcription factor related 2a
(nkx2.2a)
NM131422 2.195475 down
zgc:153151 zgc:153151 (zgc:153151) NM001045365 3.888244 up
rab32 RAB32, member RAS oncogene
family (rab32)
NM201332 1.987075 up
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symbol
description accession
nr.
log2 fold
change
regu-
lation
9531707 ZF34 cDNA clone 3407427
sequence
EB944368 2.043374 down
scfd2 sec1 family domain containing 2
(scfd2)
NM001013564 8.412213 up
zgc:158291 zgc:158291 (zgc:158291) NM001080058 2.346244 down
LOC793563 Novel protein similar to vertebrate
Aortic aneurysm, familial thoracic
1 (AAT1)
[Source:UniProtKB/TrEMBL; Acc:
B0S5Z4]
ENSDART
00000081859
2.038342 up
slc5a1 solute carrier family 5
(sodium/glucose cotransporter),
member 1 (slc5a1)
NM200681 5.556535 up
prph plasticin mRNA, complete cds. U89709 2.215932 down
hamp1 hepcidin antimicrobial peptide 1
(hamp1)
NM205583 3.652097 up
cyp3c1 cytochrome P450, family 3,
subfamily c, polypeptide 1 (cyp3c1)
NM212673 1.735935 up
zgc:65861 zgc:65861 (zgc:65861) NM199552 2.50451 down
DKEY-
77F17.4
PREDICTED: novel
immunoglobulin I-set domain
containing protein (LOC797969)
XM001338382 1.780523 up
zgc:103752 zgc:103752 (zgc:103752) NM001005594 2.299094 down
zgc:136279 zgc:136279 (zgc:136279) NM001040381 2.67076 up
wu:fj68b05 AGENCOURT 11031645 NCI
CGAP ZKid1 cDNA clone
IMAGE:6805944 5’ sequence
CA787617 2.074844 up
zgc:92621 zgc:92621 (zgc:92621) NM001002701 5.215403 down
Q2CRI1 ECTHA (Q2CRI1) Rare
lipoprotein A, partial (5%)
TC320817 2.599401 down
zgc:110847 [Source:RefSeq peptide;
Acc: NP 001014318]
ENSDART
00000053963
2.136758 up
si:ch211-
210c8.6
PREDICTED: wu:fc47e12
(wu:fc47e12)
XM687383 1.679621 up
zgc:77234 zgc:77234 (zgc:77234) NM205671 2.337017 up
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symbol
description accession
nr.
log2 fold
change
regu-
lation
si:dkey-
85n7.4
Novel protein similar to vertebrate
ankyrin repeat and SOCS
box-containing 2 Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q5RIH6]
ENSDART
00000026088
1.762201 up
tcap cDNA clone IMAGE:7281444. BC095167 3.014534 up
Q2U4W4 ASPOR (Q2U4W4)
Predicted protein, partial (5%)
TC326851 2.356208 down
FDR306-P00036-DEPE-R M14
FDR306 cDNA clone
FDR306-P00036-BR M14 3’
sequence
EH609141 32.2102 up
FDR103-P00060-DEPE-F J14
FDR103 cDNA clone
FDR103-P00060-BR J14 5’
sequence
EH453265 2.17794 down
AGENCOURT 30542903 NIH ZGC
19 cDNA clone IMAGE:7430324 5’
sequence
CO935066 4.205873 down
cDNA clone IMAGE:7156068. BC139611 2.354661 down
gadd45bl growth arrest and
DNA-damage-inducible, beta like
(gadd45bl)
NM001012386 4.334255 up
vsx1 visual system homeobox 1
homolog, chx10-like (vsx1)
NM131333 3.620865 down
AL728946 embryonic inner ear
subtracted cDNA cDNA clone
BN0AA104ZG10 5’ sequence
AL728946 3.368198 down
brn1.2 brain POU domain gene 1.2
(cDNA clone IMAGE:6972273),
partial cds.
BC067685 2.294233 down
zgc:100814 zgc:100814 (zgc:100814) NM001003999 1.536339 up
NM 199552 H1 histone family,
member 0 (exp=-1; wgp=0;
cg=0), complete
TC336779 4.305323 down
zgc:77614 zgc:77614 (cDNA clone
MGC:174458 IMAGE:7000776),
complete cds.
BC153610 4.141603 up
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ptgs2b prostaglandin-endoperoxide
synthase 2b (ptgs2b)
NM001025504 3.185861 up
si:dkey-
147f23.1
LOC100004228 protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q1ECW0]
ENSDART
00000086334
2.050505 up
AL730448 embryonic inner ear
subtracted cDNA cDNA clone
BN0AA113ZC01 5’ sequence
AL730448 2.600857 down
nr1h5 nuclear receptor subfamily 1, group
H, member 5 (nr1h5)
NM001123241 2.13778 up
tph1b tryptophan hydroxylase 1b (tph1b) NM001001843 3.019964 down
AGENCOURT 17185647 NIH ZGC
4 cDNA clone IMAGE:7088899 5’
sequence
CK362605 2.028496 down
LOC559012 Novel protein similar to vertebrate
transglutaminase 2 (C polypeptide,
protein-glutamine-gamma-
glutamyltransferase) (TGM2)
[Source:UniProtKB/TrEMBL; Acc:
A3KQ87]
ENSDART
00000080312
2.433381 up
zgc:123218 zgc:123218 (zgc:123218) NM001037117 5.128684 up
Protein FAM19A1 Precursor
(Chemokine-like protein TAFA-1)
[Source:UniProtKB/Swiss-Prot;
Acc: Q7Z5A9]
ENSDART
00000090117
2.754939 down
evlb Enah/Vasp-like b (evlb) NM205633 1.903424 down
Q676M3 9HYST (Q676M3)
Cytochrome b (Fragment), partial
(5%)
TC360041 2.106876 down
Q561Z0 BRARE (Q561Z0) Mdm2
protein, partial (38%)
TC338262 10.25166 up
zgc:103438 zgc:103438 (zgc:103438) NM001006036 6.336216 up
zgc:110549 zgc:110549 (zgc:110549) NM001017566 2.746738 down
mdm2 transformed 3T3 cell double
minute 2 homolog (mouse) (mdm2)
NM131364 8.971011 up
CT686559 ZF mu cDNA clone ZF
mu 152h07 5’ sequence
CT686559 2.362308 up
eml1 echinoderm microtubule associated
protein like 1 (eml1)
NM001076583 4.604507 down
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si:ch211-
170d8.2
si:ch211-170d8.2 (si:ch211-170d8.2) NM001113624 1.794468 down
Q6NYR5 BRARE (Q6NYR5)
Ctsla protein, partial (66%)
TC318791 1.79014 up
CT649588 ZF mu cDNA clone ZF
mu 131f09 5’ sequence
CT649588 2.324452 down
meis1 myeloid ecotropic viral integration
1 (cDNA clone MGC:73029
IMAGE:4145050), complete cds.
BC060891 1.830481 down
plp1a proteolipid protein 1a (plp1a) NM175576 3.444263 down
zgc:85843 zgc:85843 (zgc:85843) NM212944 1.546413 up
AGENCOURT 15592374 NIH ZGC
4 cDNA clone IMAGE:7012986 5’
sequence
CF550670 2.50344 down
wu:fj48a08 9722264 ZF35 cDNA clone 3428039
sequence
EB954416 1.890283 down
Interferon-stimulated gene 20 kDa
protein (EC
3.1.13.1)(Promyelocytic leukemia
nuclear body-associated protein
ISG20)(Estrogen-regulated
transcript 45 protein)
[Source:UniProtKB/Swiss-Prot;
Acc: Q96AZ6]
ENSDART
00000112896
5.419394 up
zgc:174863 zgc:174863 (zgc:174863) NM001114571 3.059115 up
LOC553422 protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q6DGH4]
ENSDART
00000066045
2.599757 down
zgc:101840 zgc:101840 (zgc:101840) NM001005968 1.658881 down
zgc:112315 zgc:112315 (zgc:112315) NM001020678 2.962781 up
pmpcb peptidase (mitochondrial
processing) beta (pmpcb), nuclear
gene encoding mitochondrial
protein
NM001012496 1.608535 up
zgc:152982 zgc:152982 (zgc:152982) NM001076711 8.247036 up
Q8UWD0 TETNG (Q8UWD0)
Lambda-recombinase-like protein
(Fragment), partial (3%)
TC356663 2.685269 up
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b2m beta-2-microglobulin (b2m),
transcript variant 1
NM131163 3.114969 up
Novel protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
B0R100]
ENSDART
00000113314
12.32983 down
pvalb7 parvalbumin 7 (pvalb7) NM205574 2.051425 up
lnx1 ligand of numb-protein X 1 (lnx1) NM001075113 7.806558 up
clu clusterin (complement lysis
inhibitor, SP-40,40, sulfated
glycoprotein 2,
testosterone-repressed prostate
message 2, apolipoprotein J) (clu)
NM200802 6.409255 up
dla deltaA (dla) NM130954 2.196928 down
thnsl2 threonine synthase-like 2 (S.
cerevisiae) (thnsl2)
NM001037566 4.816927 up
ldb3b LIM domain binding 3b (ldb3b) NM199858 1.613054 up
zgc:110152 zgc:110152 (zgc:110152) NM001017853 6.303769 up
tpp1 tripeptidyl peptidase I (tpp1) NM001128798 1.763254 up
atp1b2b ATPase, Na+/K+ transporting,
beta 2b polypeptide (atp1b2b)
NM131838 2.416442 down
crfb12 cytokine receptor family member
B12 (crfb12)
NM001040353 1.878843 up
LOC794635 PREDICTED: similar to
complement C4-2 (LOC794635)
XM001334604 2.490833 up
foxg1 forkhead box G1 (foxg1) NM131067 1.794696 down
LOC558956 cDNA clone IMAGE:7441397. BC151911 63.84703 up
foxq2 forkhead box Q2 (foxq2) NM001104941 4.008474 down
atoh2a atonal homolog 2a (atoh2a) NM131816 2.583319 down
AGENCOURT 21025520 NIH ZGC
8 cDNA clone IMAGE:7243821 5’
sequence
CN173854 4.919968 down
gnb3l guanine nucleotide binding protein
(G protein), beta polypeptide 3,
like (gnb3l)
NM001002437 9.21528 down
zgc:92518 zgc:92518 (zgc:92518) NM001002361 2.235576 up
zgc:110459 zgc:110459 (zgc:110459) NM001020596 3.705505 up
LOC565309 PREDICTED: similar to es1
protein (LOC565309)
XM688586 3.644651 up
zgc:112294 zgc:112294 (zgc:112294) NM001020677 2.641648 down
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wu:fb15e04 wu:fb15e04 (cDNA clone
IMAGE:8008341), partial cds.
BC124740 1.762003 down
meis2.1 myeloid ecotropic viral integration
site 2.1 (meis2.1)
NM130910 3.325953 down
psap prosaposin (psap) NM131883 1.901143 up
LOC571584 PREDICTED: similar to
Macrophage receptor MARCO
(Macrophage receptor with
collagenous structure) (Scavenger
receptor class A member 2)
(LOC571584)
XM695188 1.723622 up
mmp2 matrix metalloproteinase 2 (mmp2) NM198067 3.632407 up
LOC559157 PREDICTED: similar to
mKIAA0868 protein (LOC559157)
XM001919279 2.369082 down
arhgap11a Rho GTPase activating protein
11A (arhgap11a)
NM213316 2.248307 down
vrk2 vaccinia related kinase 2 (vrk2) NM201170 7.531027 up
sox14 SRY-box containing gene 14
(sox14)
NM001037680 2.671679 down
HUAC002425 Gene product with
similarity to Rat P8 Homo sapiens
(exp=0; wgp=1; cg=0), partial
(38%)
TC309424 3.092431 up
oxtl oxytocin-like (oxtl) NM178291 3.228138 down
si:ch211-
127b11.1
si:ch211-127b11.1
(si:ch211-127b11.1)
NM001114488 2.577287 up
cx44.2 connexin 44.2 (cx44.2) NM131810 2.106306 up
Q58XP5 BRARE (Q58XP5)
Fibronectin 1b, partial (10%)
TC324369 4.538744 up
Novel protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q5RGX9]
ENSDART
00000079429
2.062903 up
parp3 poly (ADP-ribose) polymerase
family, member 3 (parp3)
NM200501 6.582803 up
igfbp1a insulin-like growth factor binding
protein 1a (igfbp1a)
NM173283 3.484126 up
LOC559800 PREDICTED: similar to
arylsulfatase J (LOC559800)
XM683173 4.499584 up
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ornithine decarboxylase antizyme
inhibitor [Source:RefSeq peptide;
Acc: NP 001017568]
ENSDART
00000056101
2.525176 up
zgc:162999 zgc:162999 (zgc:162999) NM001089552 6.859685 down
tmx3 thioredoxin-related transmembrane
protein 3 (tmx3)
NM001020557 5.863276 down
CT704749 ZF mu cDNA clone ZF
mu 192o08 3’ sequence
CT704749 30.59956 up
gnat2 guanine nucleotide binding protein
(G protein), alpha transducing
activity polypeptide 2 (gnat2)
NM131869 2.607925 up
zgc:136930 zgc:136930 (zgc:136930) NM001039819 1.73239 down
fc86a05.y1 Zebrafish WashU
MPIMG EST cDNA clone
IMAGE:3728240 5’ sequence
AI965034 2.964225 down
rspo1 R-spondin homolog (Xenopus
laevis) (rspo1)
NM001002352 12.0356 up
paired box 3 [Source:RefSeq
peptide; Acc: NP 571352]
ENSDART
00000014350
1.512306 down
junb jun B proto-oncogene (junb) NM213556 3.567484 up
cbwd COBW domain containing (cbwd) NM213253 1.628843 up
LOC565454 PREDICTED: similar to ischemia XM688733 15.45804 up
pfkfb4l 6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase 4, like
(pfkfb4l)
NM198816 2.92108 down
zgc:152916 zgc:152916 (zgc:152916) NM001045418 2.528024 up
LOC100004563PREDICTED: hypothetical
LOC100004563 (LOC100004563)
XM001337068 3.092821 up
zgc:153270 zgc:153270 (zgc:153270) NM001045386 3.154017 down
O55566 NPVLS (O55566) P12,
partial (22%)
TC327743 2.018382 up
LOC565873 PREDICTED: similar to
Centrosomal protein of 152 kDa
(Cep152) (LOC565873)
XM689135 3.241815 up
tnfrsf1a tumor necrosis factor receptor
superfamily, member 1a (tnfrsf1a)
NM213190 2.194939 up
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Transcription factor COE1
(O/E-1)(OE-1)(Early B-cell factor)
[Source:UniProtKB/Swiss-Prot;
Acc: Q9UH73]
ENSDART
00000100508
3.680702 down
zgc:92647 zgc:92647 (zgc:92647) NM001002434 2.278939 up
LOC100005846PREDICTED: similar to
engulfment and cell motility 1
(LOC100005846)
XM001338913 2.141861 down
zgc:86661 zgc:86661 (zgc:86661) NM001002059 1.717278 down
Q90YN8 BRARE (Q90YN8)
Vitellogenin 1, partial (22%)
TC350829 6.814847 up
cadm2a cell adhesion molecule 2a (cadm2a) NM200664 2.090716 down
zgc:172061 zgc:172061 (zgc:172061) NM001111182 3.66439 up
bbc3 BCL2 binding component 3 (bbc3) NM001045472 13.52474 up
gpd1 glycerol-3-phosphate
dehydrogenase 1 (soluble) (gpd1)
NM214753 2.19029 up
slc25a27 solute carrier family 25, member 27
(slc25a27), nuclear gene encoding
mitochondrial protein
NM200341 2.267124 up
zgc:110158 zgc:110158 (zgc:110158) NM001020567 2.21891 down
zgc:103631 nuclear receptor subfamily 2 group
E member 3 (nr2e3) mRNA,
partial cds.
EF010863 2.915477 down
wnt4a wingless-type MMTV integration
site family, member 4a (wnt4a)
NM001040387 1.90556 up
zgc:154020 zgc:154020 (zgc:154020) NM001077607 6.802491 up
zgc:172321 zgc:172321 (zgc:172321) NM001114316 2.076709 down
b2h01z1.r1 10am (morning) eye EE203377 2.241395 down
fosl1 FOS-like antigen 1 (fosl1) NM001161552 7.95123 up
Q6XZH1 BRARE (Q6XZH1) POU
domain transcription factor
Brn3b-l (Pou4f2/Brn-3b), complete
TC306191 2.457573 down
Novel protein similar to vertebrate
t-complex testis expressed 1
(Tctex1) Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q1LYB4]
ENSDART
00000105444
2.780945 up
zgc:110113 zgc:110113 (zgc:110113) NM001017574 3.024087 down
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Q4SIR3 TETNG (Q4SIR3)
Chromosome 21 SCAF14577, whole
genome shotgun sequence, partial
(35%)
TC311240 1.814369 down
kif23 kinesin family member 23 (cDNA
clone MGC:109838
IMAGE:2640039), complete cds.
BC096779 1.973305 down
pax2b paired box gene 2b (pax2b) NM131640 2.388834 down
olig2 oligodendrocyte lineage
transcription factor 2 (olig2)
NM178100 2.400188 down
zgc:136410 zgc:136410 (zgc:136410) NM001040294 2.056381 up
impdh2 IMP (inosine monophosphate)
dehydrogenase 2 (impdh2)
NM201464 1.865849 up
zgc:110380 zgc:110380 (zgc:110380) NM001017660 4.686218 down
AGENCOURT 22778561 NIH ZGC
9 cDNA clone IMAGE:7276248 5’
sequence
CN502918 2.98628 down
zgc:123214 zgc:123214 (zgc:123214) NM001039990 1.912544 down
gbx1 gastrulation brain homeobox 1
(gbx1)
NM174861 2.850579 down
ankk1 ankyrin repeat and kinase domain
containing 1 (ankk1)
NM001130665 1.857009 up
zgc:86915 zgc:86915 (zgc:86915) NM001002092 2.486419 up
ZFT223 Zebrafish Testis cDNA 5’
sequence
BM141359 1.868252 down
s100t S100 calcium binding protein T
(s100t)
NM001013495 2.493735 down
zgc:73377 zgc:73377 (zgc:73377) NM200810 1.837131 down
zgc:100906 zgc:100906 (zgc:100906) NM001003517 1.666043 down
AGENCOURT 22826682 NIH ZGC
9 cDNA clone IMAGE:7279555 5’
sequence
CN507190 1.804395 down
zgc:109988 zgc:109988 (zgc:109988) NM001020546 4.390405 down
si:dkey-
260n20.1
si:dkey-260n20.1 (si:dkey-260n20.1) NM001044899 3.600446 down
zgc:165502 zgc:165502 (zgc:165502) NM001098772 2.361815 up
il4r interleukin 4 receptor (il4r) NM001013282 2.831853 up
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LOC100003493PREDICTED: similar to E3
ubiquitin-protein ligase MARCH9
(Membrane-associated RING finger
protein 9) (Membrane-associated
RING-CH protein IX)
(MARCH-IX) (LOC100003493)
XM001339809 2.418277 down
zgc:123272 zgc:123272 (zgc:123272) NM001037413 6.784892 up
LOC100151346PREDICTED: similar to
Thrombospondin-1
(LOC100151346)
XM001920227 1.953692 up
zgc:172288 zgc:172288 (zgc:172288) NM001113601 2.915557 down
si:rp71-
10d23.3
si:rp71-10d23.3 (si:rp71-10d23.3) NM001089376 3.235846 down
socs3b suppressor of cytokine signaling 3b
(socs3b)
NM213304 4.858039 up
zgc:100994 zgc:100994 (zgc:100994) NM001003607 1.889239 down
si:dkey-
22o20.1
si:dkey-22o20.1 (si:dkey-22o20.1) NM001015066 2.046101 down
ccng1 cyclin G1 (ccng1) NM199481 2.859598 up
LOC563369 LOC563369 protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
A9JRH5]
ENSDART
00000079091
2.842611 down
zgc:77060 zgc:77060 (zgc:77060) NM001002218 2.936883 down
mycl1a v-myc myelocytomatosis viral
oncogene homolog 1, lung
carcinoma derived (avian) a
(mycl1a)
NM212937 2.059384 down
wu:fj48e09 PREDICTED: wu:fj48e09
(wu:fj48e09)
XM682101 1.787042 down
Novel protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q5RH86]
ENSDART
00000053241
3.054919 up
vtg1 vitellogenin 1 (vtg1) NM001044897 10.5897 up
AGENCOURT 25049891 NIH ZGC
4 cDNA clone IMAGE:7289460 5’
sequence
CN832327 6.288389 down
PREDICTED: similar to
chromosome 17 open reading frame
27 (LOC563001)
XM001920043 41.65926 up
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calca calcitonin/calcitonin-related
polypeptide, alpha (calca)
NM001002471 1.795029 up
zgc:153307 zgc:153307 (zgc:153307) NM001045457 7.24355 up
Q6NY34 BRARE (Q6NY34)
Zgc:76977, partial (24%)
TC329901 1.717059 down
cDNA clone IMAGE:7163810. BC167968 3.91295 down
LOC571790 PREDICTED: similar to predicted
protein (LOC571790)
XM695417 4.100358 up
hmgb1 high-mobility group box 1 (hmgb1) NM199555 1.759219 down
nrxn2a neurexin 2a (nrxn2a) NM001079970 2.494598 down
gtpbp1l GTP binding protein 1, like
(gtpbp1l)
NM001024811 6.786969 up
zgc:63667 zgc:63667 (zgc:63667) NM200479 2.197664 up
si:ch211-
135f11.1
Novel protein similar to vertebrate
centaurin delta 2 (CENTD2)
Fragment
[Source:UniProtKB/TrEMBL; Acc:
A2CEC9]
ENSDART
00000089682
2.123409 up
hmgb3a high-mobility group box 3a
(hmgb3a)
NM001122836 1.743755 down
slc5a5 solute carrier family 5 (sodium
iodide symporter), member 5
(slc5a5)
NM001089391 3.423302 up
agxt alanine-glyoxylate aminotransferase
(agxt)
NM213162 2.267075 down
desm desmin (desm) NM130963 2.204668 up
si:dkey-
183c2.4
si:dkey-183c2.4 (si:dkey-183c2.4) NM001030156 2.843344 up
irf9 interferon regulatory factor 9 (irf9) NM205710 2.817157 up
Q9NAU0 MYTED (Q9NAU0) Foot
protein-3 variant16, partial (14%)
TC347224 50.63246 up
fos v-fos FBJ murine osteosarcoma
viral oncogene homolog (fos)
NM205569 9.187773 up
zgc:171644 zgc:171644 (zgc:171644) NM001102621 2.321549 up
lyrm1 LYR motif containing 1 (lyrm1) NM001002506 5.205381 up
ghdcl GH3 domain containing like (ghdcl) NM001089358 2.002084 up
tfap2a transcription factor AP-2 alpha
(tfap2a)
NM176859 1.880292 down
foxq1 forkhead box Q1 (foxq1) NM212907 2.233388 down
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zgc:152944 Zgc:152944 protein
[Source:UniProtKB/TrEMBL; Acc:
A8WFS2]
ENSDART
00000086765
2.466078 up
cDNA clone IMAGE:6034066. BC139699 3.774332 up
pcdh1g18 protocadherin 1 gamma 18
(pcdh1g18)
NM001024117 2.303174 down
rpl28l cDNA clone IMAGE:7075690, ****
WARNING: chimeric clone ****.
BC155108 9.273444 up
zgc:153588 zgc:153588 (zgc:153588) NM001077290 2.021562 down
barhl2 BarH-like 2 (barhl2) NM205740 2.889248 down
cDNA clone IMAGE:9007145. BC150401 14.94087 up
zgc:162216 zgc:162216 (zgc:162216) NM001089475 2.363389 up
Q58EH9 BRARE (Q58EH9)
LOC572000 protein (Fragment),
partial (97%)
TC327964 1.92011 up
gpm6aa glycoprotein M6Aa (gpm6aa) NM213200 2.440137 down
LOC100006777PREDICTED: similar to
protocadherin 10a (LOC100006777)
XM001345397 4.844011 down
Novel protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
B7ZD03]
ENSDART
00000002858
2.213133 up
zgc:153911 zgc:153911 (zgc:153911) NM001077315 3.189559 up
rdh12l retinol dehydrogenase 12, like
(rdh12l)
NM001009912 2.643136 up
ndrg1l N-myc downstream regulated gene
1, like (ndrg1l)
NM200692 2.218066 down
her8.2 hairy-related 8.2 (her8.2) NM001166166 2.121473 down
tmem206 transmembrane protein 206
(tmem206)
NM200457 2.889606 up
zgc:113646 zgc:113646 (zgc:113646) NM001014347 3.696069 down
zgc:85969 zgc:85969 (zgc:85969) NM212914 2.878946 down
wu:fb01b03 wu:fb01b03 (wu:fb01b03) NM001142583 2.161795 up
fezf2 FEZ family zinc finger 2 (fezf2) NM131636 2.110458 down
zgc:162509 zgc:162509 (zgc:162509) NM001083816 6.146155 up
LOC798510 PREDICTED: similar to Uncx4.1
(LOC798510)
XM001336529 2.168253 down
zgc:136871 zgc:136871 (zgc:136871) NM001040379 4.669031 up
Q90YN8 BRARE (Q90YN8)
Vitellogenin 1, partial (31%)
TC318183 4.476497 up
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Q1ZXB1 DICDI (Q1ZXB1) CCHC
zinc finger domain-containing
protein, partial (5%)
TC333177 2.062032 up
sb:cb8 STR00010 segmentation stage
cDNA library cDNA clone CB8 5’
sequence
BI325077 1.864307 down
nr2f1a nuclear receptor subfamily 2, group
F, member 1a (cDNA clone
MGC:65769 IMAGE:6800668),
complete cds.
BC056574 2.121188 down
NM 001031121 synaptobrevin-like
1 Gallus gallus (exp=-1; wgp=0;
cg=0), partial (6%)
TC317349 5.509369 up
zgc:113362 zgc:113362 (zgc:113362) NM001014310 2.076337 up
zgc:162509 zgc:162509 (cDNA clone
IMAGE:6901284), partial cds.
BC090678 3.935078 up
pacsin1 protein kinase C and casein kinase
substrate in neurons 1 (pacsin1)
NM001033728 1.776781 down
psap prosaposin (cDNA clone
MGC:77888 IMAGE:6996846),
complete cds.
BC063994 1.989779 up
otx2 orthodenticle homolog 2 (otx2) NM131251 2.104085 down
zgc:110131 zgc:110131 (zgc:110131) NM001017568 3.241329 up
zgc:136439 zgc:136439 (zgc:136439) NM001040372 2.182732 up
si:dkey-
202c5.1
hypothetical protein LOC560234
[Source:RefSeq peptide; Acc: NP
001124247]
ENSDART
00000100063
3.210784 down
Q9I9L7 BRARE (Q9I9L7) Caspase
a, complete
TC306290 2.339875 up
Novel protein containing multiple
sushi domains (SCR repeat)
[Source:UniProtKB/TrEMBL; Acc:
A8E7E2]
ENSDART
00000056813
2.197207 up
lbr lamin B receptor (lbr) NM001002720 1.70111 down
zgc:162327 zgc:162327 (zgc:162327) NM001089482 2.840914 up
atf3 activating transcription factor 3
(atf3)
NM200964 2.880291 up
gpr98 G protein-coupled receptor 98
(gpr98)
NM001001845 1.895159 down
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LOC100004709PREDICTED: similar to
retinoblastoma-binding protein 6
(LOC100004709)
XM001923560 9.295895 up
zgc:92704 zgc:92704 (cDNA clone MGC:92704
IMAGE:7075077), complete cds.
BC076184 2.410702 down
irge4 immunity-related GTPase family,
e4 (irge4)
NM001083032 6.02139 up
si:dkey-
177p2.5
AGENCOURT 86331607 NIH ZGC
32 cDNA clone IMAGE:8746289 5’
sequence
EE303400 1.530479 up
Q6DC61 BRARE (Q6DC61)
Zgc:101017, partial (16%)
TC310630 3.893344 up
irx4a iroquois homeobox protein 4a
(irx4a)
NM205698 2.568908 down
Q5BLI5 BRARE (Q5BLI5)
Im:7144703 protein (Fragment),
complete
TC324961 2.140974 down
LOC557892 hypothetical LOC557892 (cDNA
clone IMAGE:7407213), partial cds.
BC122334 2.563219 up
dpf1 D4, zinc and double PHD fingers
family 1 (dpf1)
NM001030204 2.240372 down
fab28d06.y1 Zebrafish SJD 15 day
embryo cDNA clone
IMAGE:5904443 5’ sequence
BQ615615 1.952438 down
lss lanosterol synthase
(2,3-oxidosqualene-lanosterol
cyclase) (lss)
NM001083567 2.256622 up
Q485A8 COLP3 (Q485A8)
DNA-binding response regulator,
partial (6%)
TC330380 3.220941 up
gadd45al growth arrest and
DNA-damage-inducible, alpha like
(gadd45al)
NM200576 8.091406 up
EPS8-like 3 [Source:RefSeq
peptide; Acc: NP 956655]
ENSDART
00000099515
1.889503 up
ctssb.1 cathepsin S, b.1 (ctssb.1) NM001024409 4.411412 up
zgc:103663 zgc:103663 (zgc:103663) NM001007362 2.43952 down
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LOC100004175PREDICTED: similar to
cyclin-dependent kinase inhibitor
1C (p57, Kip2) (LOC100004175)
XM001337160 1.719364 down
ms4a17a.4 membrane-spanning 4-domains,
subfamily A, member 17A.4
(ms4a17a.4)
NM001102638 40.75822 up
AGENCOURT 17422356 NIH ZGC
4 cDNA clone IMAGE:7116765 5’
sequence
CK398403 3.585746 down
zgc:92851 zgc:92851 (zgc:92851) NM001002493 2.737301 up
LOC556254 cDNA clone IMAGE:7428827. BC142821 1.616362 down
nxph1 neurexophilin 1 (nxph1) NM001002733 2.48868 down
si:dkey-
76b14.4
Novel protein (Sb:cb26)
[Source:UniProtKB/TrEMBL; Acc:
B8JKW4]
ENSDART
00000024624
2.145756 up
zgc:77262 zgc:77262 (zgc:77262) NM205654 1.656688 down
zgc:158394 zgc:158394 (zgc:158394) NM001079990 1.61213 down
PREDICTED: misc RNA
(LOC100149048), partial miscRNA
XR044978 2.435209 up
LOC563252 PREDICTED: similar to
core-binding factor, runt domain,
alpha subunit 2, translocated to, 3,
transcript variant 1 (LOC563252)
XM681892 2.149425 down
Novel protein similar to vertebrate
type 1 tumor necrosis factor
receptor shedding aminopeptidase
regulator (ARTS-1) Fragment
[Source:UniProtKB/TrEMBL; Acc:
A2BGQ9]
ENSDART
00000098527
1.616658 up
LOC100001286PREDICTED: similar to
26-29kD-proteinase CG8947-PA
(LOC100001286)
XM001337464 4.892555 up
crfb1 cytokine receptor family member
b1 (crfb1)
NM001079681 2.265306 up
zgc:171595 zgc:171595 (zgc:171595), transcript
variant 1
NM001110114 2.028055 up
fn1b fibronectin 1b (fn1b) NM001013261 4.769491 up
LOC571928 PREDICTED: similar to
sarcalumenin (LOC571928)
XM695573 2.032102 up
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Q4RVQ9 TETNG (Q4RVQ9)
Chromosome 9 SCAF14991, whole
genome shotgun sequence, partial
(6%)
TC355381 1.729297 down
Novel protein containing multiple
sushi domains (SCR repeat)
Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q1L928]
ENSDART
00000105633
3.35832 up
fuca1 fucosidase, alpha-L- 1, tissue
(fuca1)
NM212740 1.457756 up
Q5U3R6 BRARE (Q5U3R6)
Zgc:101711, partial (5%)
TC344118 3.742431 down
Q4S816 TETNG (Q4S816)
Chromosome 9 SCAF14710, whole
genome shotgun sequence, partial
(29%)
TC328507 2.966337 down
Q6DH50 BRARE (Q6DH50)
Zgc:92647, partial (50%)
TC344258 2.572673 up
rem1 rad and gem related GTP binding
protein 1 (rem1)
NM201174 1.882541 down
si:dkey-
25f3.3
si:dkey-25f3.3 (si:dkey-25f3.3) NM001044875 2.845126 up
Q91275 9PERO (Q91275)
Complement regulatory plasma
protein, partial (5%)
TC331566 2.112585 up
fli1a friend leukemia integration 1a
(fli1a)
NM131348 1.697059 down
si:ch73-
131e21.5
similar to Rab1-prov protein
(cDNA clone IMAGE:7014230),
containing frame-shift errors.
BC122309 2.338195 up
gata3 GATA-binding protein 3 (gata3) NM131211 1.811766 down
AL716675 embryonic inner ear
subtracted cDNA cDNA clone
BN0AA020ZH10 5’ sequence
AL716675 2.414084 down
si:ch211-
196f5.2
si:ch211-196f5.2 (si:ch211-196f5.2) NM001044802 5.664277 up
zgc:110377 zgc:110377 (zgc:110377) NM001020588 2.687899 up
foxi1 forkhead box I1 (foxi1) NM181735 4.155761 up
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Q8JHX6 BRARE (Q8JHX6)
Insulin-like growth factor binding
protein-1, partial (47%)
TC362165 6.178889 up
tkt transketolase (tkt) NM198070 1.958974 up
zgc:77466 zgc:77466 (zgc:77466) NM212908 2.440017 down
NM 001011715 transforming acidic
coiled coil 2 Takifugu rubripes
(exp=-1; wgp=0; cg=0), partial
(7%)
TC344339 1.818672 down
LOC793976 PREDICTED: similar to Tctex1
domain containing 4 (LOC793976)
XM001333821 1.976477 up
foxn4 forkhead box N4 (foxn4) NM131099 2.140034 down
LOC567411 LOC567411 protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
A3KPA9]
ENSDART
00000103502
2.755861 down
nkx2.1a NK2 homeobox 1a (nkx2.1a) NM131589 2.561558 down
Q5U3U9 BRARE (Q5U3U9)
Zgc:101613, partial (28%)
TC343915 2.190491 up
LOC557884 PREDICTED: similar to
monocarboxylate transporter 3
(LOC557884)
XM681038 3.467849 up
wu:fd58b11 AGENCOURT 20195611 NIH ZGC
14 cDNA clone IMAGE:7228781 5’
sequence
CN014967 4.815255 up
zgc:123271 zgc:123271 (zgc:123271) NM001037401 2.179702 up
rhbdl3 rhomboid, veinlet-like 3
(Drosophila) (rhbdl3)
NM001017556 2.066552 down
lmo3 LIM domain only 3 (lmo3) NM001020739 3.522356 down
zgc:122979 zgc:122979 (zgc:122979) NM001037574 3.747888 down
LOC568188 Novel protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q5RIY9]
ENSDART
00000061500
2.113756 up
zgc:92355 zgc:92355 (zgc:92355) NM001007311 1.768827 down
ctnna2 cDNA clone IMAGE:7057261,
containing frame-shift errors.
BC131855 1.847291 down
mtmr1a myotubularin related protein 1a
(mtmr1a)
NM001020721 2.292314 down
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AGENCOURT 17063100 NIH ZGC
9 cDNA clone IMAGE:7073300 5’
sequence
CK354570 5.850845 down
CT670730 ZF mu cDNA clone ZF
mu 169i05 5’ sequence
CT670730 2.545192 up
Q6P603 BRARE (Q6P603)
Annexin A2a, partial (33%)
TC351695 2.841164 up
irx1a iroquois homeobox protein 1, a
(irx1a), transcript variant 1
NM207184 2.289815 down
nao45g08.y1 Zebrafish Posterior
segment. Unnormalized (nao)
cDNA clone nao45g08 5’ sequence
DN893839 18.5781 up
Tyrosine-protein kinase STYK1
(EC
2.7.10.2)(Serine/threonine/tyrosine
kinase 1)(Novel oncogene with
kinase domain)(Protein
PK-unique)
[Source:UniProtKB/Swiss-Prot;
Acc: Q6J9G0]
ENSDART
00000061477
1.706181 up
zgc:91912 zgc:91912 (zgc:91912) NM001002176 2.301868 up
sesn2 sestrin 2 (sesn2) NM001079975 2.206161 up
crygn1 crystallin, gamma N1 (crygn1) NM001007784 4.514085 up
si:ch211-
199m3.4
Novel protein Fragment [
Source:UniProtKB/TrEMBL; Acc:
Q5RH81]
ENSDART
00000038535
2.555957 up
sesn3 sestrin 3 (sesn3) NM213519 2.741694 up
PREDICTED: similar to
follistatin-like 5 (LOC100148398)
XM001920110 1.84759 down
Q5C6Y2 SCHJA (Q5C6Y2)
SJCHGC07590 protein (Fragment),
partial (16%)
TC344059 2.780379 down
fstb follistatin b (fstb), transcript
variant 2
NM001109831 2.010921 up
wu:fj23a05 wu:fj23a05 (wu:fj23a05) NM001100074 1.863378 up
AGENCOURT 20636429 NIH ZGC
17 cDNA clone IMAGE:7235256 5’
sequence
CN023754 1.766161 up
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rab36 RAB36, member RAS oncogene
family (rab36)
NM001079660 2.114886 up
sc4mol sterol-C4-methyl oxidase-like
(sc4mol)
NM213353 2.152164 up
si:dkey-
12h3.1
si:dkey-12h3.1 (si:dkey-12h3.1) NM001122760 3.88578 down
tnni2b.1 troponin I, skeletal, fast 2b.1
(tnni2b.1), transcript variant 2
NM001017587 2.026225 up
mcm5 MCM5 minichromosome
maintenance deficient 5 (S.
cerevisiae) (mcm5)
NM178436 2.536613 down
zgc:103710 zgc:103710 (cDNA clone
MGC:153510 IMAGE:7015114),
complete cds.
BC122311 2.713349 up
h1fx H1 histone family, member X
(h1fx)
NM199276 5.332916 down
zgc:165617 zgc:165617 (zgc:165617) NM001098739 2.033055 down
nots nothepsin (nots) NM131804 2.841338 up
tfap2b transcription factor AP-2 beta
(tfap2b), transcript variant 2
NM001024665 4.238251 down
zgc:101843 zgc:101843 (zgc:101843) NM001008594 4.068479 down
zgc:162551 zgc:162551 (zgc:162551) NM213637 2.397062 down
zgc:101715 zgc:101715 (zgc:101715) NM001004633 2.408843 up
si:dkeyp-
50f7.2
si:dkeyp-50f7.2 (si:dkeyp-50f7.2),
transcript variant 2
NM212718 1.879791 up
mcm6 MCM6 minichromosome
maintenance deficient 6, mitotin
(S. cerevisiae) (mcm6)
NM001082849 1.895562 down
zgc:77806 zgc:77806 (zgc:77806) NM205691 2.266782 up
zgc:85900 zgc:85900 (zgc:85900) NM213260 1.892598 down
cDNA clone IMAGE:7061170. BC154833 19.47098 up
zgc:110010 zgc:110010 (zgc:110010) NM001020554 1.820296 up
rs1 retinoschisis (X-linked, juvenile) 1
(rs1)
NM001003438 5.211627 down
spon2b spondin 2b, extracellular matrix
protein (spon2b)
NM131008 1.94966 down
CT680825 ZF mu cDNA clone ZF
mu 269e10 5’ sequence
CT680825 1.794144 down
neurod neurogenic differentiation (neurod) NM130978 3.874979 down
Table continues on next page
D Genistein gene enrichment analysis 253
Continued: Differentially expressed genes in the genistein EC20 data set
gene
symbol
description accession
nr.
log2 fold
change
regu-
lation
cyp3c1l2 cytochrome P450, family 3,
subfamily c, polypeptide 1 like, 2
(cyp3c1l2)
NM001007400 1.85737 up
zgc:153753 zgc:153753 (zgc:153753) NM001076654 3.377168 down
FDR202-P00045-DEPE-F H13
FDR202 cDNA clone
FDR202-P00045-BR H13 5’
sequence
EH552414 8.451053 up
barhl1.1 PREDICTED: BarH-like 1.1
(barhl1.1)
XM677740 3.286312 down
zgc:101897 zgc:101897 (zgc:101897) NM001007372 2.290856 up
glb1l galactosidase, beta 1-like (glb1l) NM001122856 1.88358 up
tspan18b tetraspanin 18b (tspan18b) NM001002439 2.055865 down
arl3l1 ADP-ribosylation factor-like 3, like
1 (arl3l1)
NM200693 4.836941 down
nkx1.2lb NK1 transcription factor related
2-like,b (nkx1.2lb)
NM213548 2.390768 down
zgc:109991 zgc:109991 (zgc:109991) NM001024402 3.787951 up
dpysl4 dihydropyrimidinase-like 4 (cDNA
clone IMAGE:7086117), complete
cds.
BC115083 1.954538 down
cth cystathionase (cystathionine
gamma-lyase) (cth)
NM212604 2.079831 up
uo:ion001 uo:ion001 mRNA, 3’ UTR. FJ392612 2.027128 up
LOC557301 naa11e05.y1 Zebrafish whole eye.
Unnormalized (naa) cDNA clone
naa11e05 5’ sequence
DN857240 5.430602 up
zgc:175106 zgc:175106 (zgc:175106) NM001111190 2.720306 down
barhl1.2 BarH-like 1.2 (barhl1.2) NM001017712 2.526787 down
atoh2b atonal homolog 2b (atoh2b) NM131817 3.427445 down
Q5XJ31 BRARE (Q5XJ31)
Zgc:103755, partial (8%)
TC329650 3.037384 down
Q90YN8 BRARE (Q90YN8)
Vitellogenin 1, partial (18%)
TC344218 9.609266 up
complement component 9
[Source:RefSeq peptide; Acc: NP
001019606]
ENSDART
00000115273
2.573164 up
klf11a Kruppel-like factor 11a (klf11a) NM001044941 4.282402 down
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ptgs2a prostaglandin-endoperoxide
synthase 2a (ptgs2a)
NM153657 1.767471 up
c9 complement component 9 (c9) NM001024435 2.090966 up
enkur C10orf63 protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q7ZWE8]
ENSDART
00000042478
2.256079 up
fezf1 FEZ family zinc finger 1 (fezf1) NM001114348 2.386744 down
AGENCOURT 55088342 NIH ZGC
7 cDNA clone IMAGE:7992334 5’
sequence
DR720639 10.3323 up
LOC561242 PREDICTED: similar to
KIAA1946 (LOC561242)
XM684648 1.786981 down
zgc:103752 AGENCOURT 15135819 NIH ZGC
7 cDNA clone IMAGE:6996819 5’
sequence
CF265463 2.315661 down
pou4f1 POU domain, class 4, transcription
factor 1 (pou4f1)
NM201285 3.102408 down
Q9ER82 MOUSE (Q9ER82) Sr528
protein (Fragment), partial (12%)
TC325602 2.013934 down
zgc:112161 zgc:112161 (zgc:112161) NM001020655 2.01717 down
cAMP-regulated phosphoprotein 21
(ARPP-21)(Thymocyte
cAMP-regulated phosphoprotein)
[Source:UniProtKB/Swiss-Prot;
Acc: Q9UBL0]
ENSDART
00000051724
3.273945 up
mmp13 matrix metalloproteinase 13
(mmp13)
NM201503 2.970017 up
zgc:123339 zgc:123339 (zgc:123339) NM001037695 1.989707 up
pax6a paired box gene 6a (pax6a) NM131304 1.875292 down
Q3ZBV2 BOVIN (Q3ZBV2)
DEAD (Asp-Glu-Ala-As) box
polypeptide 19B, partial (95%)
TC313080 3.00737 up
six7 sine oculis homeobox homolog 7
(six7)
NM131354 3.892548 down
AGENCOURT 21608431 NIH ZGC
19 cDNA clone IMAGE:7254510 5’
sequence
CN329377 2.078972 down
si:ch211-
147d7.2
si:ch211-147d7.2 (si:ch211-147d7.2) NM001045392 3.150237 up
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LOC794484 hypothetical protein LOC794484
(LOC794484)
NM001115120 2.151194 up
epb41 erythrocyte membrane protein
band 4.1 (elliptocytosis 1,
RH-linked) (epb41)
NM175084 1.645485 down
zgc:158347 zgc:158347 (zgc:158347) NM001082998 5.329737 up
bag3 BCL2-associated athanogene 3
(bag3)
NM001003533 2.716873 up
Novel zinc finger protein
[Source:UniProtKB/TrEMBL; Acc:
A8E7H6]
ENSDART
00000084035
1.771127 down
LOC566268 PREDICTED: similar to Regulator
of G-protein signaling 4
(LOC566268)
XM689538 6.115727 up
zgc:77366 zgc:77366 (zgc:77366) NM212645 1.76764 down
zgc:162229 zgc:162229 (zgc:162229) NM001089522 2.35348 up
AJ938034 legumin-like protein
Lupinus albus (exp=-1; wgp=0;
cg=0), partial (5%)
TC317514 3.308047 down
zgc:174888 zgc:174888 (zgc:174888) NM001113584 1.978205 up
Dynein heavy chain 5, axonemal
(Axonemal beta dynein heavy
chain 5)(Ciliary dynein heavy chain
5) [Source:UniProtKB/Swiss-Prot;
Acc: Q8TE73]
ENSDART
00000079294
2.042003 up
DKEY-
76K16.5
PREDICTED: similar to Glycine
N-acyltransferase-like protein
(Acyl-CoA:glycine
N-acyltransferase-like) (AAc-like)
(LOC566887)
XM690171 2.881575 up
zgc:153441 zgc:153441 (zgc:153441) NM001045455 3.034934 down
zgc:55318 zgc:55318 (zgc:55318) NM199804 1.979706 down
pvalb8 parvalbumin 8 (pvalb8) NM182937 1.661748 down
zgc:112060 zgc:112060 (zgc:112060) NM001017653 3.105098 up
gfap glial fibrillary acidic protein (gfap) NM131373 1.997895 down
DKEY-
204H11.5
hypothetical protein LOC798290
(LOC798290)
NM001100061 5.47052 up
oc90 otoconin 90 (oc90) NM001080192 3.652037 up
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LOC100007289PREDICTED: similar to
transmembrane protein 16G
isoform NGEP long
(LOC100007289)
XM001345751 23.16996 up
Protein strawberry notch homolog
2 [Source:UniProtKB/Swiss-Prot;
Acc: Q9Y2G9
ENSDART
00000056032
2.261062 up
LOC563713 cDNA clone IMAGE:7421679. BC142868 4.726114 up
LOC553422 PREDICTED: misc RNA
(LOC553422), miscRNA
XR029573 2.239211 down
Q4KME9 BRARE (Q4KME9)
Prps1a protein, partial (33%)
TC342429 1.43421 down
Si:rp71-61h23.4 protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q6PHE3]
ENSDART
00000100473
1.863537 up
si:dkey-
52k20.12
si:dkey-52k20.12 (cDNA clone
IMAGE:7450319), partial cds.
BC152528 5.641156 down
zgc:77058 zgc:77058 (zgc:77058) NM212900 1.669892 down
CT717482 ZF mu cDNA clone ZF
mu 296e12 3’ sequence
CT717482 3.355204 down
tfap2e transcription factor AP-2 epsilon
(tfap2e)
NM200821 2.671612 down
LOC799904 III-FBPL precursor (LOC799904) NM001083874 1.471663 up
Q6GL23 XENTR (Q6GL23)
Protein phosphatase 1, regulatory
(Inhibitor) subunit 3C, partial
(6%)
TC355273 1.396927 down
irx6a Iroquois homeobox protein 6aIrx6a
protein
[Source:UniProtKB/TrEMBL; Acc:
Q503Z8]
ENSDART
00000045628
2.263668 down
zgc:92069 zgc:92069 (zgc:92069) NM001002376 2.1111 up
dld D.rerio mRNA for DeltaD protein. Y11760 2.099319 down
gata2a GATA-binding protein 2a (gata2a) NM131233 1.717751 down
col10a1 collagen, type X, alpha 1 (col10a1) NM001083827 4.216383 down
AGENCOURT 16623472 NIH ZGC
7 cDNA clone IMAGE:7053987 5’
sequence
CK027604 2.910254 down
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LOC795748 PREDICTED: similar to RING
finger protein 169 (LOC795748)
XM001335976 4.638896 up
bhlhe23 basic helix-loop-helix family,
member e23 (bhlhe23)
NM001030133 5.614885 down
ZF201-P00005-DEPE-F E20
GISZF201 cDNA clone
IMAGE:7168318 5’ sequence
CK708867 1.630971 up
LOC563713 cDNA clone IMAGE:7429367. BC122185 4.545731 up
Q7ZZT0 BRARE (Q7ZZT0) Low
density lipoprotein receptor, partial
(3%)
TC345258 2.011971 up
si:rp71-
39b20.7
Novel protein similar to vertebrate
angiopoietin-like 4 (ANGPTL4,
im:7144703) Fragment
[Source:UniProtKB/TrEMBL; Acc:
B0S6G2]
ENSDART
00000052062
2.227887 down
si:dkeyp-
110g5.2
si:dkeyp-110g5.2 (si:dkeyp-110g5.2) NM001123285 3.165429 up
sox1a SRY-box containing gene 1a
(sox1a)
NM001002483 1.871442 down
Q8IMS9 DROME (Q8IMS9)
CG31439-PA, partial (4%)
TC359727 3.21958 up
Novel protein containing multiple
sushi domains (SCR repeat)
[Source:UniProtKB/TrEMBL; Acc:
A8E7E2]
ENSDART
00000079311
2.35639 up
zgc:162825 zgc:162825 (zgc:162825) NM001089526 3.416338 down
FDR306-P00004-DEPE-F K05
FDR306 cDNA clone
FDR306-P00004-BR K05 5’
sequence
EH579759 2.230879 down
15478255 ZF40 cDNA clone
4214679 sequence
EB974833 5.564903 down
zgc:163061 zgc:163061 (zgc:163061) NM001089531 2.348149 down
phlda3 pleckstrin homology-like domain,
family A, member 3 (phlda3)
NM001002455 10.37068 up
zgc:101876 zgc:101876 (zgc:101876) NM001005963 2.156437 up
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Q6JCT3 9HEMI (Q6JCT3)
Cytochrome b (Fragment), partial
(5%)
TC344169 1.831662 down
nfia nuclear factor I/A (nfia) NM001079962 5.265885 down
rasl11b RAS-like, family 11, member B
(rasl11b)
NM200140 4.170151 up
magi1 membrane associated guanylate
kinase, WW and PDZ domain
containing 1 (magi1)
NM001007063 2.056976 down
npl N-acetylneuraminate pyruvate
lyase (dihydrodipicolinate
synthase) (npl)
NM207051 1.722737 up
PREDICTED: similar to
LOC569044 protein
(LOC100148147)
XM001919173 13.29995 up
LOC100004940PREDICTED: similar to TAFI95
(LOC100004940)
XM001344082 5.769952 up
zgc:112992 zgc:112992 (zgc:112992) NM001017909 2.677306 down
AGENCOURT 21027210 NIH ZGC
8 cDNA clone IMAGE:7251715 5’
sequence
CN174007 2.052561 down
atp2b1b ATPase, Ca++ transporting,
plasma membrane 1b (atp2b1b)
NM001135631 4.383395 down
zgc:73144 zgc:73144 (zgc:73144) NM200729 1.908823 down
Uncharacterized protein C20orf26
[Source:UniProtKB/Swiss-Prot;
Acc: Q8NHU2]
ENSDART
00000115217
2.179847 up
slc16a9b solute carrier family 16
(monocarboxylic acid
transporters), member 9b
(slc16a9b)
NM001003552 2.737366 down
ms4a17a.1 membrane-spanning 4-domains,
subfamily A, member 17A.1
(ms4a17a.1)
NM001017783 12.5578 up
her3 hairy-related 3 (her3) NM131080 2.360123 down
zgc:86757 zgc:86757 (zgc:86757) NM001002133 2.606165 up
zgc:65788 zgc:65788 (zgc:65788) NM199603 2.100553 up
hk2 hexokinase 2 (hk2) NM213066 1.974619 up
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slc8a4b solute carrier family 8
(sodium/calcium exchanger),
member 4b (slc8a4b)
NM001123240 2.735473 up
FDR202-P00045-DEPE-F F24
FDR202 cDNA clone
FDR202-P00045-BR F24 5’
sequence
EH552377 3.007585 up
cx39.9 connexin 39.9 (cx39.9) NM212826 1.756971 up
6943921 KZ69 cDNA clone 2727824
sequence
EB790629 3.026774 up
prom1b prominin 1 b (prom1b) NM198071 2.624134 down
chondroitin sulfate proteoglycan 5
(neuroglycan C) [Source:RefSeq
peptide; Acc: NP 001038357]
ENSDART
00000104393
3.250224 down
polm polymerase (DNA directed), mu
(polm)
NM200248 1.957528 up
LOC100007672PREDICTED: hypothetical
LOC100007672 (LOC100007672)
XM001346031 2.733261 down
ctbp1 C-terminal binding protein 1
(ctbp1)
NM131714 1.813711 down
abca12 Novel protein similar to vertebrate
ATP-binding cassette, sub-family
A (ABC1) family Fragment
[Source:UniProtKB/TrEMBL; Acc:
B0UYK5]
ENSDART
00000109197
1.767246 up
zgc:153102 zgc:153102 (zgc:153102) NM001077310 3.959853 down
arl13a ADP-ribosylation factor-like 13A
(arl13a)
NM200818 5.874757 down
Filamin-C (Gamma-
filamin)(Filamin-2)(Protein
FLNc)(Actin-binding-like
protein)(ABP-L)(ABP-280-like
protein)
[Source:UniProtKB/Swiss-Prot;
Acc: Q14315]
ENSDART
00000046218
1.725416 up
LOC792603 PREDICTED: similar to pol
polyprotein (LOC792603)
XM001332108 4.450485 up
zgc:153749 zgc:153749 (zgc:153749) NM001077727 2.079011 up
isl1 islet1 (isl1) NM130962 1.904897 down
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otx5 orthodenticle homolog 5 (otx5) NM181331 3.473275 down
bmp2b bone morphogenetic protein 2b
(bmp2b)
NM131360 1.895248 up
wu:fc83e05 wu:fc83e05 (wu:fc83e05) NM001127519 1.945707 down
zgc:103625 zgc:103625 (zgc:103625) NM001004669 5.64478 down
pax2a paired box gene 2a (pax2a) NM131184 2.127791 down
cDNA clone IMAGE:7286037. BC153962 2.481944 up
zgc:110200 zgc:110200 (zgc:110200) NM001017825 3.135527 up
AGENCOURT 16618662 NIH ZGC
7 cDNA clone IMAGE:7052357 5’
sequence
CK028289 1.622265 up
gpm6bb glycoprotein M6Bb (gpm6bb) NM001013334 1.713486 down
zgc:114180 zgc:114180 (zgc:114180) NM001030248 4.149353 down
socs3a suppressor of cytokine signaling 3a
(socs3a)
NM199950 5.309525 up
mcm2 MCM2 minichromosome
maintenance deficient 2, mitotin
(S. cerevisiae) (mcm2)
NM173257 2.142594 down
rcv1 recoverin (rcv1) NM199964 2.620092 down
LOC567847 PREDICTED: similar to
complement C3-H1 (LOC567847)
XM691154 2.458484 up
si:ch211-
210h11.4
si:ch211-210h11.4
(si:ch211-210h11.4)
NM001159984 1.490156 down
ms4a17a.5 membrane-spanning 4-domains,
subfamily A, member 17A.5
(ms4a17a.5)
NM001004629 8.215281 up
zgc:66106 zgc:66106 (zgc:66106) NM199992 2.083605 down
mxtx1 mix-type homeobox gene 1 (mxtx1) NM131560 8.888673 up
si:dkey-
46k9.12
LOC569187 protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q6GML5]
ENSDART
00000033902
3.326087 up
her4.2 hairy-related 4.2 (her4.2) NM131090 1.876455 down
si:dkey-
22i16.3
si:dkey-22i16.3 (si:dkey-22i16.3) NM001145556 5.798974 down
tnfaip6 tumor necrosis factor,
alpha-induced protein 6 (tnfaip6)
NM001040243 2.674105 up
cthl cystathionase (cystathionine
gamma-lyase), like (cthl)
NM001005400 1.966644 up
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LOC553492 PREDICTED: hypothetical protein
LOC553492 (LOC553492)
XM001920878 3.514522 up
zgc:92034 zgc:92034 (zgc:92034) NM001004605 2.396996 down
gng2 guanine nucleotide binding protein
(G protein), gamma 2 (gng2)
NM001044318 2.036635 down
tlr3 toll-like receptor 3 (tlr3) NM001013269 2.822704 up
dachshund c [Source:RefSeq
peptide; Acc: NP 001038701]
ENSDART
00000018827
1.680497 down
her13 hairy-related 13 (her13) NM001017901 2.314575 down
dio2 deiodinase, iodothyronine, type II
(dio2)
NM212789 3.123466 down
zgc:91850 zgc:91850 (zgc:91850) NM001003472 5.970573 up
zgc:162184 zgc:162184 (zgc:162184) NM001089383 3.168924 up
lep leptin (lep) NM001128576 12.48402 up
zgc:171945 zgc:171945 (zgc:171945) NM001109701 2.162161 up
si:dkey-
52h23.1
si:dkey-52h23.1 (cDNA clone
IMAGE:4786389), partial cds.
BC060943 1.80542 down
six6b sine oculis-related homeobox 6b
(six6b)
NM001020585 2.037629 down
CH211-
233A1.7
gastrin-releasing peptide-like
(LOC559978)
NM001161350 1.675771 down
abl2 v-abl Abelson murine leukemia
viral oncogene homolog 2 (abl2)
NM001122705 6.764296 up
zgc:153034 zgc:153034 (zgc:153034) NM001076637 3.147945 up
cyp24a1l cytochrome P450, family 24,
subfamily A, polypeptide 1, like
(cyp24a1l)
NM001089458 4.259962 up
Q6DGV1 BRARE (Q6DGV1)
Zgc:92761, complete
TC303710 2.798158 down
fam49a family with sequence similarity 49,
member A (fam49a)
NM001003606 2.114187 down
sulf2 sulfatase 2 (sulf2) NM200936 1.875447 down
zgc:92164 zgc:92164 (zgc:92164) NM001004554 1.859956 down
zgc:101699 zgc:101699 (zgc:101699) NM001007430 5.335932 up
AGENCOURT 16391933 NIH ZGC
7 cDNA clone IMAGE:7038117 5’
sequence
CF997540 2.520208 down
zgc:55773 zgc:55773 (zgc:55773) NM200175 2.552156 up
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si:dkey-
234p10.2
si:dkey-234p10.2 (si:dkey-234p10.2) NM001083091 2.044958 up
meis2.2 myeloid ecotropic viral integration
site 2.2 (meis2.2)
NM131896 2.55656 down
Q9R161 MOUSE (Q9R161) Zinc
finger protein ZFP235, partial
(27%)
TC357200 1.681407 down
Q4SNA9 TETNG (Q4SNA9)
Chromosome 8 SCAF14543, whole
genome shotgun sequence, partial
(3%)
TC335015 1.958912 down
LOC559993 PREDICTED: similar to THAP
domain containing, apoptosis
associated protein 1 (LOC559993)
XM683384 2.273461 up
adcyap1b adenylate cyclase activating
polypeptide 1b (adcyap1b)
NM214715 1.984346 down
DR AOV FL09 C08 adult ovary
full-length (TLL) cDNA sequence
CO350313 2.260837 down
LOC553441 LOC553441 protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q1JQ25]
ENSDART
00000024869
1.818509 up
DR 5WM FL06 B04 5-week-old
gonad (TLL) cDNA 5’ sequence
EV603514 2.692009 down
s100s Novel protein similar to vertebrate
S100 calcium binding protein
family (Zgc:91995)
[Source:UniProtKB/TrEMBL; Acc:
A5WW32]
ENSDART
00000053397
1.896597 down
Q3P8R2 PARDE (Q3P8R2) ABC
transporter precursor, partial (5%)
TC344624 5.844225 down
zgc:112165 zgc:112165 (zgc:112165) NM001020656 3.089113 up
lmo1 LIM domain only 1 (lmo1) NM173219 2.190716 down
b3gat2 beta-1,3-glucuronyltransferase 2
(glucuronosyltransferase S)
(b3gat2)
NM001003454 1.793451 down
zgc:158829 zgc:158829 (zgc:158829) NM001080602 3.476528 down
zgc:114196 zgc:114196 (zgc:114196) NM001025546 4.520169 down
mab21l1 mab-21-like 1 (mab21l1) NM152974 2.266604 down
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sim2 single-minded homolog 2
(Drosophila) (sim2)
NM131836 2.685351 down
gpm6ab glycoprotein M6Ab (gpm6ab) NM214687 2.049761 down
klf4 Kruppel-like factor 4 (klf4) NM131723 2.985775 down
robo2 roundabout homolog 2 (robo2) NM131633 3.610844 down
cyp4 cytochrome P450, family 4 (cyp4) NM199216 2.650347 up
sp5l Sp5 transcription factor-like (sp5l) NM194371 3.548322 down
stc2 stanniocalcin 2 [Source:RefSeq
peptide; Acc: NP 001014827]
ENSDART
00000079215
2.513381 up
1510304A COUP transcription
factor. Homo sapiens (exp=-1;
wgp=0; cg=0), partial (10%)
TC346240 3.065604 down
fx46f03.y1 Zebrafish SJD 15 day
embryo cDNA clone
IMAGE:5626493 5’ sequence
BM532803 2.354975 down
casp8 caspase 8, apoptosis-related
cysteine peptidase (casp8)
NM131510 7.109197 up
tp53 tumor protein p53 (tp53) NM131327 5.643098 up
crx cone-rod homeobox (crx) NM152940 4.981849 down
jun v-jun sarcoma virus 17 oncogene
homolog (avian) (jun)
NM199987 1.831376 up
pth1a parathyroid hormone 1a (pth1a) NM212950 3.476991 up
zgc:109965 zgc:109965 (zgc:109965) NM001033747 4.44103 down
LOC564267 PREDICTED: similar to
extracellular matrix protein 1
(LOC564267)
XM687611 2.284671 up
lingo1b leucine rich repeat and Ig domain
containing 1b (lingo1b)
NM001004576 1.788592 down
zgc:162707 UPF0524 protein C3orf70 homolog
B [Source:UniProtKB/Swiss-Prot;
Acc: A3KNX6]
ENSDART
00000088199
2.015701 down
Q4V8Z2 BRARE (Q4V8Z2)
LOC407677 protein (Fragment),
complete
TC339636 1.956112 down
ccdc113 coiled-coil domain containing 113
(ccdc113)
NM001006061 2.149235 up
cfb complement factor B (cfb) NM131338 2.453206 up
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otx2 orthodenticle homolog 2 (cDNA
clone MGC:136535
IMAGE:8124372), complete cds.
BC115165 2.183106 down
nr2f1a nuclear receptor subfamily 2, group
F, member 1a (nr2f1a)
NM131180 2.467893 down
zgc:153395 zgc:153395 (zgc:153395) NM001045421 2.073412 down
pcp4l1 naa39b07.y2 Zebrafish whole eye.
Unnormalized (naa) cDNA clone
naa39b07 5’ sequence
DN859471 2.460079 down
pde11a1 PREDICTED: phosphodiesterase
11A (pde11a)
XM692475 3.425471 down
Q90YN8 BRARE (Q90YN8)
Vitellogenin 1, partial (28%)
TC343157 13.26806 up
PREDICTED: similar to zinc
finger protein 648 (LOC556911)
XM679845 1.793368 up
LOC100000377FDR202-P00029-DEPE-F B03
FDR202 cDNA clone
FDR202-P00029-BR B03 5’
sequence
EH546362 2.05815 up
c6 complement component 6 (c6) NM200638 4.279199 up
Q2HUF2 MEDTR (Q2HUF2)
Transposase, IS4, partial (30%)
TC358023 4.897356 down
LOC792676 similar to N-myc-interactor (Nmi)
(N-myc and STAT interactor)
(cDNA clone IMAGE:7212495),
partial cds.
BC142759 2.211511 up
gsna gelsolin a (gsna) NM001012312 1.79254 up
LOC100151479PREDICTED: similar to urea
transporter UT-C (LOC100151479)
XM001921024 3.594171 up
LOC558876 PREDICTED: similar to
LOC794117 protein (LOC558876)
XM682152 4.783338 up
prdm8b PR domain containing 8b (prdm8b) NM001105105 2.616708 down
zgc:65909 zgc:65909 (zgc:65909) NM200532 2.206905 up
rbpms2 RNA binding protein with multiple
splicing 2 (rbpms2)
NM200259 1.923222 down
Q90YN8 BRARE (Q90YN8)
Vitellogenin 1, partial (16%)
TC349183 5.644599 up
Table continues on next page
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Continued: Differentially expressed genes in the genistein EC20 data set
gene
symbol
description accession
nr.
log2 fold
change
regu-
lation
naa02h10.y1 Zebrafish whole eye.
Unnormalized (naa) cDNA clone
naa02h10 5’ sequence
DN856546 1.719359 down
zgc:175091 zgc:175091 (zgc:175091) NM001111226 2.527972 up
chrna4 cholinergic receptor, nicotinic,
alpha 4 (chrna4)
NM001048063 1.621261 down
wu:fd08b07 fd08b07.x1 Zebrafish WashU
MPIMG EST cDNA clone
IMAGE:3730261 3’ sequence
AI957916 14.67315 up
timp2b tissue inhibitor of
metalloproteinase 2b (timp2b)
NM213296 6.997766 up
wu:fc56h05 PREDICTED: wu:fc56h05
(wu:fc56h05)
XM679958 2.188644 down
zgc:158340 zgc:158340 (zgc:158340) NM001079657 4.107515 down
si:dkey-
91f15.6
si:dkey-91f15.6 (si:dkey-91f15.6) NM001045047 2.428101 down
mab21l2 mab-21-like 2 (mab21l2) NM152975 2.122781 down
Armadillo repeat-containing
protein 4
[Source:UniProtKB/Swiss-Prot;
Acc: Q5T2S8]
ENSDART
00000077453
2.438734 up
hspb1 heat shock protein,
alpha-crystallin-related, 1 (hspb1)
NM001008615 1.744415 up
Q4SE83 TETNG (Q4SE83)
Chromosome undetermined
SCAF14625, whole genome
shotgun sequence. (Fragment),
partial (84%)
TC309983 4.973845 up
si:dkey-
145p14.5
Si:dkey-145p14.5 protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q5BJ03]
ENSDART
00000020798
5.591256 up
ptprn2 receptor PTP-like protein IA-2beta
mRNA, partial cds.
AF190145 2.042903 down
ms4a17a.11 membrane-spanning 4-domains,
subfamily A, member 17A.11
(ms4a17a.11)
NM001017670 3.651293 up
AGENCOURT 30544823 NIH ZGC
19 cDNA clone IMAGE:7436084 5’
sequence
CO924904 4.05785 down
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Continued: Differentially expressed genes in the genistein EC20 data set
gene
symbol
description accession
nr.
log2 fold
change
regu-
lation
es1 es1 protein (es1) NM131039 5.920426 up
Q4RV39 TETNG (Q4RV39)
Chromosome 15 SCAF14992, whole
genome shotgun sequence, partial
(44%)
TC314653 2.407382 down
pcp4l1 Purkinje cell protein 4 like 1
(pcp4l1)
NM001161488 2.509559 down
DKEY-
27P23.3
UPF0722 protein C11orf88
homolog (LOC566423)
NM001100021 2.304593 up
fl55h06.x1 Sugano Kawakami
zebrafish DRA cDNA clone
IMAGE:3817955 3’ sequence
BG303456 7.153785 up
mmp9 matrix metalloproteinase 9 (mmp9) NM213123 7.350886 up
dmbx1a Diencephalon/mesencephalon
homeobox protein 1-A (Paired
homeobox protein 1)
[Source:UniProtKB/Swiss-Prot;
Acc: Q8JI10]
ENSDART
00000017173
2.715202 down
FDR306-P00011-DEPE-F L20
FDR306 cDNA clone
FDR306-P00011-BR L20 5’
sequence
EH582293 13.40648 up
AGENCOURT 17185568 NIH ZGC
4 cDNA clone IMAGE:7088918 5’
sequence
CK362545 1.95451 down
tnrc4 trinucleotide repeat containing 4
(tnrc4)
NM131494 2.254162 down
cdkn1bl cyclin-dependent kinase inhibitor
1b, like (cdkn1bl)
NM001013268 2.021378 up
LOC795197 PREDICTED: similar to CUG-BP-
and ETR-3-like factor 3 (CELF-3)
(Bruno-like protein 1)
(RNA-binding protein BRUNOL-1)
(ELAV-type RNA-binding protein
1) (ETR-1) (Trinucleotide
repeat-containing gene 4 protein)
(LOC795197)
XM001335280 2.26264 down
fgf2 fibroblast growth factor 2 (fgf2) NM212823 5.778863 up
Table continues on next page
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Continued: Differentially expressed genes in the genistein EC20 data set
gene
symbol
description accession
nr.
log2 fold
change
regu-
lation
tmem35 zgc:110832 (cDNA clone
MGC:110832 IMAGE:7152951),
complete cds.
BC091856 3.138422 down
bhlhb3l basic helix-loop-helix domain
containing, class B, 3 like (bhlhb3l)
NM001039107 1.761058 up
kctd15l potassium channel tetramerisation
domain containing 15, like
(kctd15l)
NM001006012 2.713107 down
ivns1abpb influenza virus NS1A binding
protein b (ivns1abpb)
NM201483 1.64476 down
wu:fb81h03 PREDICTED: wu:fb81h03
(wu:fb81h03)
XM689244 1.692216 up
lhx1a LIM homeobox 1a (lhx1a) NM131216 2.670706 down
foxj1b forkhead box J1b (foxj1b) NM001008648 3.380022 up
trpv4 transient receptor potential cation
channel, subfamily V, member 4
(trpv4)
NM001042730 1.753835 up
cDNA clone IMAGE:6034273. BC124617 2.864668 up
CH211-
45M15.1
hypothetical protein LOC556137
(LOC556137)
NM001044796 5.269604 down
zgc:153921 zgc:153921 (zgc:153921) NM001076767 6.230609 up
rrm2b ribonucleotide reductase M2 b
(rrm2b)
NM001007163 1.599953 up
zgc:136396 zgc:136396 (zgc:136396) NM001040291 1.889285 up
optc opticin (optc) NM001003583 3.662445 up
ft15b08.y1 Zebrafish neuronal
cDNA clone IMAGE:5081438 5’
sequence
BI864124 1.973343 down
AGENCOURT 17114339 NIH ZGC
4 cDNA clone IMAGE:7089281 5’
sequence
CK361229 2.284212 down
CR015 HUMAN (Q96N68) Protein
C18orf15, partial (10%)
TC361618 2.325112 down
eng2a engrailed 2a (eng2a), transcript
variant 1
NM131044 1.89809 down
acss3 Novel protein Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q1LWR6]
ENSDART
00000077670
1.755765 up
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gene
symbol
description accession
nr.
log2 fold
change
regu-
lation
LOC100001518PREDICTED: similar to POU
domain, class 6, transcription
factor 2 (Retina-derived POU
domain factor 1) (RPF-1)
(LOC100001518)
XM001341460 2.746899 down
LOC794759 PREDICTED: similar to sorting
nexin 20, transcript variant 2
(LOC794759)
XM001922883 1.986314 down
wdr16 WD repeat domain 16 (wdr16) NM001020639 2.43943 up
stap2a signal transducing adaptor family
member 2a (stap2a)
NM198808 2.389278 down
hif1an hypoxia-inducible factor 1, alpha
subunit inhibitor (hif1an)
NM201496 2.499234 down
PREDICTED: similar to
flavoprotein oxidoreductase
MICAL2 (LOC569564)
XM001922215 1.922072 up
prtga protogenin homolog a (Gallus
gallus) (prtga)
NM001045030 2.684242 up
aox1 Novel protein similar to vertebrate
aldehyde oxidase 1 (AOX1)
Fragment
[Source:UniProtKB/TrEMBL; Acc:
Q1LVZ9]
ENSDART
00000043711
2.048454 up
zgc:123120 zgc:123120 (zgc:123120) NM212693 2.117955 up
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Table D-3: Differentially expressed genes in the solvent control data set compared to the ISO water control
data set of the narrowed zebrafish microarray study (log2 fold change>2, p-value<0.01) (chapter 5)
gene sym-
bol
description accession
nr.
log2 fold change regu-
lation
c1qb Danio rerio complement component
1, q subcomponent, B chain (c1qb),
mRNA
NM 001003482 6.3 down
si:ch211-
244h7.6
Danio rerio si:ch211-244h7.6,
mRNA
NM 001045169 2.1 down
zgc:153921 Danio rerio zgc:153921, mRNA NM 001076767 2.2 down
si:dkey-
162b3.6
Danio rerio zgc:113361 NM 001161361 2 up
zgc:123333 Danio rerio zgc:123333 NM 001037388 2.1 up
zgc:113361 Danio rerio zgc:113361 NM 001014312 3.3 up
Table D-4: Affected KEGG, GO and InterPro terms in the genistein EC20 condition. Gene clusters
were built from the EC20 data set and subjected to single enrichment analysis, which included searching
the KEGG, GO and InterPro databases for overrepresented pathways. All significant pathways (p-
value≤0.05) are listed (chapter 5)
data-
base
cluster accession term affected genes
KEGG I dre04115 p53 signalling tp53, casp8, mdm2
III dre00260 glycine, serine and threonin
pathway
cth, tha1
dre00100 steroid biosynthesis lss, sc4mol
GO I GO:0043065 positive regulation of apoptosis bbc3, casp8, tp53
GO:0043280 positive regulation of caspase ac-
tivity
bbc3, tp53
II GO:0032355 response to estradiol stimulus cypa19a1b, vtg1
GO:0048545 response to steroid hormone
stimulus
cypa19a1b, vtg1
IV GO:0009617 response to bacterium cfb,tlr3,tnfrsf1a
VI GO:0007399 nervous system development dla, dld, dmbx1a, fezf1,
olig2, otx2, plp1a,
sox14
VII GO:0001654 eye development adcyap1b, irx1a,
mab21l2, mcm2, pax2a
GO:0007399 nervous system development adcyap1b, atp1b2b, dld,
fezf2, her3, irx1a, isl1,
nkx2.2a, pax2a, pou4f2
GO:0048699 generation of neurons atp1b2b, dld, fezf2,
her3, irx1a, isl1,
nkx2.2a
Table continues on next page
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Continued: Affected KEGG, GO and InterPro terms in the genistein EC20 data set
data-
base
cluster accession term affected genes
GO:0007423 sensory organ development adcyap1b, atp1b2b,
irx1a, mab21l2, mcm2,
pax2a
GO:0009887 organ morphogenesis atp1b2b, dld, gng2,
irx1a, mab21l2,
nkx2.2a, pax2a
GO:0042471 ear morphogenesis atp1b2b, irx1a, pax2a
GO:0048598 embryonic morphogenesis atp1b2b, irx1a,
mab21l2, nkx2.2a,
pax2a
GO:0045165 cell fate commitment dld, isl1, pax2a
GO:0006261 DNA-dependent DNA-
replication
mcm2, mcm4, mcm5
GO:0030878 thyroid gland development nkx2.1a, pax2a
GO:0035270 endocrine system development nkx2.1a, nkx2.2a,
pax2a
Inter-
pro
I IPR007237 CD20/IgE Fc receptor beta sub-
unit
ms4a17a.1, ms4a17a.4,
ms4a17a.5
III IPR000837 fos transforming protein atf3, si:ch211-147d7.2,
zgc:92851
IPR006730 PA26 p53-induced protein (ses-
trin)
sesn2, sesn3
IV IPR001597 aromatic amino acid beta-
eliminating lyase/threonine
aldolase
cth, tha1
VI IPR009057 homeodomain-like irx1a, irx4a, irx6a, isl1,
meis2.1, nkx2.1a,
nkx2.2a, pax2a, pax2b,
pou4f2, six6b
IPR004962 mab-21-like 2 mab21l1, mab21l2
IPR001208 DNA-dependent ATPase MCM mcm2, mcm4, mcm5
VII IPR009057 homeodomain-like barhl1.2, barhl2,
dmbx1a, gbx1, lhx1a,
meis2.2, nkx1.2lb, otx2,
otx5, pax2b, pbx3b,
pou4f1, zgc:158291
IPR018237 myelin proteolipid protein PLP,
conserved site
gpm6aa, plp1a
Table continues on next page
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Continued: Affected KEGG, GO and InterPro terms in the genistein EC20 data set
data-
base
cluster accession term affected genes
IPR013854 transcription factor AP-2, C-
terminal
tfap2b, tfap2e
IPR003022 transcription factor Otx2 otx2, otx5
VIII IPR001356 homeobox crx, meis2.1, otx5,
pou4f1, six7, vsx1
IPR013854 transcription factor AP-2, C-
terminal
tfap2b, zgc:114196
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